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Aromatic L-Amino Acid Decarboxylase (AADC) is the enzyme responsible for the 
synthesis of two essential neurotransmitter dopamine and serotonin from L-Dopa 
and L-hydroxytryptophan. AADC owes its specific catalytic activity to the 
chemistry of its cofactor, pyrydoxal-5’-phosphate (PLP). Almost 20 years ago, the 
crystal structure of a mammalian holoAADC (porcine, sharing 90% of sequence 
identity) was solved and the availability of its 3D structure paved the way to 
structural studies. Moreover, 10 years later, human apoAADC structure was 
published, shedding light on the conformational rearrangement occurring on the 
apo enzyme upon addition of PLP.  
Importantly, apo and holoAADC structures provided crucial insights for the 
comprehension of the pathogenicity of a number of AADC deficiency associated 
variants. AADC deficiency (OMIM#608643) is a rare autosomal recessive inborn 
disease due to missense mutations in the AADC gene. Patients bearing these 
mutations show mild to severe phenotypes, whose destiny is often fatal. Due to the 
rarity of the disease and to the heterogeneous response to the treatments, 
medications are not often satisfactory.  
In the past years, some efforts on human recombinant AADC pathogenic variants 
have tried to provide support to the research on AADC deficiency by means of 
biochemical and biophysical approaches determining the impact of the amino acid 
substitutions on the enzyme features.  
Here, a further contribution to the comprehension of the AADC deficiency is 
provided. The crystal structure of human holoAADC has been solved under 
different conditions, both in its native and ligand bound form. The combination of 
crystallographic studies, molecular dynamics simulations (MD) and site directed 
mutagenesis uncovered novel aspects of the AADC structure-function relationship. 
Moreover, the characterization of 21 novel identified pathogenic variants (spread 
on each AADC domain, N-terminal, Large and C-terminal Domains) led to the 
widening of the range of enzymatic phenotypes associated to AADC deficiency. 
The proposed combination of biochemical and kinetic studies permitted to 
determine correlations between structural and functional signals. Enzymatic 
phenotypes span from variants characterized by a mild phenotypes to variants 
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(mainly located at the NTD-CTD interface) whose dramatic structural defects lead 
to a catalytic incompetence. In addition, MD simulations and in solutions data point 
out a critical role for the loop3 element that contains the essential catalytic residue 
Tyr332. A group of variants affecting loop3 has been identified as catalytically 
incompetent and their structural features have been dissected thanks also to the 
solving of the crystal structure of pathogenic variant L353P, which constitutes the 
first solved structure of an AADC variant.  
Altogether, this study on human AADC provides new elements for the 
comprehension of the structure-function relationship of AADC with a particular 
focus on protein dynamics and mobility. Lastly, structural details might represent 
the basis for both the designing of novel specific inhibitors and for a better 
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Chapter 1. PYRIDOXAL 5’-PHOSPHATE ENZYMES AND a-
DECARBOXYLASES 
 
A. Vitamers B6 
 
Pyridoxal 5’-phosphate (PLP) is the derivative of Pyridoxal (PL) which is a vitamer 
of vitamin B6. Vitamin B6 is a generic term which refers to three interconvertible 
pyridine compounds called vitamers (PL together with pyridoxamine -PM and 
pyridoxine -PN) which differ in the chemical group present at the 4’ position and 
in their three phosphorylated forms (PLP, PMP and PNP respectively). While 
microorganisms and plants are able to perform a de novo synthesis of PLP, in 
humans this anabolic pathway does not exist. Nonetheless, vitamin B6 can be found 
in many foods, including meat, milk products, potatoes, beans, nuts and several 
fruits and vegetables 1. In addition, once obtained from diet and absorbed in the 
intestine, vitamers B6 can be recycled through a “salvage pathway” involving 
phosphorylation steps (catalysed by pyridoxal kinase, PLK; EC2.7.1.35) and 
oxidation steps of PNP and PMP (thanks to pyridox(am)ine phosphate oxidase, 
PNPOx; EC1.4.3.5) and several different phosphatases that altogether yield to PLP, 
the catalytically active form of vitamin B6 (Figure 1) 2,3.  
 
 
Fig. 1. The structure of free B6 vitamers and PLP salvage pathway. Adapted from 4. 
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PL coming from diet is cleared by the liver, phosphorylated and secreted into the 
circulatory blood system where is tightly bound to a lysine residue of albumin 5. 
The delivery of PLP to the peripheral tissues and in particular to the blood-brain-
barrier (BBB) is combined with activity of membrane associated alkaline 
phosphatases. Once entered into the target cell, PL is finally re-phosphorylated by 
PLK 6. 
 
B. PLP-dependent enzymes 
 
Vitamin B6, in its biologically active form of PLP, plays a primary role acting as a 
cofactor for a large number of essential enzymes arguably making it the most 
versatile organic cofactor in all organisms 7–11. The catalytic versatility of this 
cofactor is well represented by the genomic data reported by Percudani & Peracchi 
in 12. Figure 2 illustrates 145 PLP-dependent activities as set of enzyme families 
and superfamilies classified in accordance with the Enzyme Nomenclature 
Committee of the International Union of Biochemistry and Molecular Biology (EC; 
http://www.chem.qmul.ac.uk/iubmb/enzyme/).  
 
Fig. 2. Catalytic versatility of PLP-dependent enzymes. The Enzyme Commission (EC) 
identifies an enzyme activity using a four-digit number, where the first digit indicates the 
general class of the catalyzed reaction (1, oxidoreductases; 2, transferases; 3, hydrolases; 4, 
lyases; 5, isomerases; 6, synthetases). Of six general classes, five include pyridoxal phosphate 
(PLP)-dependent enzymes. The catalytic diversity within enzyme families and superfamilies 
can be illustrated by a set of concentric pie charts 13. Here, we show the distribution of the 
145 PLP-dependent activities that have been classified so far. Sectors are colored according 
to EC classes. The circles, from inner to outer, represent the first, second, third and fourth 
levels in the EC hierarchy. The structure of PLP is shown in the center of the graph. Adapted 
from 12. 
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The PLP-dependent enzymes belong to five (1, oxidoreductases; 2, transferases; 3, 
hydrolases; 4, lyases; 5, isomerases) out of seven enzyme classes, performing 
essential reactions in metabolism of amino acids and amines. In addition to this, 
despite their incredible functional variety, all these proteins have been initially 
grouped into five structural families 11,14. It is a common opinion that PLP-
dependent enzymes, sharing similar structure and sequence and catalysing different 
reactions, represent a remarkable example of divergent evolution.  
 
C. Classification and families of PLP-dependent enzymes 
 
The traditional classification of the PLP-dependent enzymes was initially proposed 
in 1995 on the basis of amino acid sequence comparisons and structural 
informations published therefore 14. This classification has been updated in 1998 
by Jansonius et al., and by Denessiou and Schneider 8,11,15. Subsequently it has been 
expanded in 2009 16.  
The actual seven structural superfamilies called ‘fold type’ I to VII are also 
associated with the name of the prototype enzyme (Table 1). Fold type I is the most 
common superfamily and includes aminotransferases (except for aminotransferase 
class IV), a-decarboxylases of groups II and III 14,17, and some enzymes performing 
a-, b- or g-elimination 18.  
 
Table 1.  The fold type superfamily of PLP-dependent enzymes 
 
Superfamily Prototype enzyme   
Fold type I Aspartate aminotransferase 
Proposed by 8,11,14,15 
Fold type II Tryptophan synthase 
Fold type III Alanine racemase and eukaryotic ornithine decarboxylase 
Fold type IV D-amino acid aminotransferase 
Fold type V Glycogen phosphorylase family 
Fold type VI D-lysine-5,6-aminomutase 
Added by 16 
Fold type VII Lysine 2,3-aminomutase 
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Since the topic of the present thesis regards an a-decarboxylases belonging to fold 
type I, table 2 lists a classification of the a-decarboxylases in different groups based 
on evolutionary extent of conservation of their amino-acid sequence in association 
to the group of folding 19.  
 
Table 2. PLP-dependent a-decarboxylases. Adapted from 19. 
 
Decarboxylase group Superfamily Enzyme members 
Group I Fold type I Glycine decarboxylase (EC 1.4.4.2) 
Group II Fold type I 
Glutamate decarboxylase (EC 4.1.1.15) 
Histidine decarboxylase (EC 4.1.1.22) 
Aromatic-L-amino-acid decarboxylase (EC 4.1.1.28) 
Cysteine sulfinic acid decarboxylase (EC 4.1.1.29) 
Group III Fold type I 
prokaryotic Ornithine decarboxylase (EC 4.1.1.17) 
Lysine decarboxylase (EC 4.1.1.18) 
Arginine decarboxylase (EC 4.1.1.19) 
Group IV Fold type III 
eukatyotic Ornithine decarboxylase (EC 4.1.1.17) 
Arginine decarboxylase (EC 4.1.1.19) 
Diaminopimelate decarboxylase (EC 4.1.1.20) 
 
At the beginning of the new century the structural features of group II PLP-
dependent a-decarboxylases have attracted particular attention starting from the 
first crystal structure of a member of this family, i.e. Sus scrofa Aromatic L-Amino 
Acid Decarboxylase (AADC) in 2001 20 (among other PLP-dependent 
decarboxylases belonging to different evolutionary groups, only ornithine 
decarboxylase 21, and dialkylglycine decarboxylase 22 were solved at that time). 
 
D. Group II a-decarboxylases overall topology 
 
Common features of the a-decarboxylases belonging to the fold type I are those of 
(i) presenting a glycine-rich motif upstream from the PLP-bound lysine residue and 
(ii) showing a conserved aspartate residue interacting with the cofactor pyridine 
nitrogen 14,19. A deep and comprehensive bioinformatics analysis of the deposited 
structures of the mammalian a-decarboxylases listed in table 3 has been carried out 
by Paiardini et al 23.  
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Table 3. PLP-dependent a-decarboxylases belonging to group II 23.  
 
Enzyme Substrates Products Sequencea Structuresb 
AADC 
L-Dopa; Dopamine; P20711 1JS3c, 1JS6c, 3RBF, 
3RBL, 3RCH 5-hydroxy-L-Tryprophan Serotonin (DDC_HUMAN) 

















a accession code on UniProtKB 
b accession code on ProteinDataBank 
c AADC from Sus scrofa (90% sequence identity with the human enzyme) 
d GAD65/67 chimaera 
 
In the review, the authors provide details on the structure-function relationships of 
AADC, histidine decarboxylases (HDC), the two isoforms of glutamate 
decarboxylase (GAD65 and GAD67) and cysteine sulfinic acid decarboxylase 
(CSAD) highlighting, at the same time, overall common features and key 
differences responsible for substrate specificity. These enzymes maintained a 
number of structural features in common with fold type I PLP-dependent enzymes. 
Some of these features regard for example their conserved quaternary structure as 
structural and functional dimeric enzymes 8, and that they maintain all the seventeen 
structurally conserved regions and the positioning of key residues for the cofactor 
binding 23. Moreover, a peculiar feature of human group II decarboxylases is the 
presence of a highly flexible loop at the active site which is crucial for the 





Fig. 3. Structural superposition of AADC, HDC, GAD67, GAD65 and CSAD. In the 
case of AADC, the Sus scrofa structure was used. The N-terminal, large and C-terminal 
domains are represented in green, cyan and pink, respectively. Chain B is represented as 
grey cartoons and surface. Adapted from 23. 
 
Each dimer is composed of three distinct domains (Figure 3) called: N-terminal 
domain (NTD, residues 1-85 in AADC), large domain (LD, residues 86-360 in 
AADC), C-terminal domain (CTD,  also called ‘small domain’ and comprising 
residues 361-486 in AADC). Moreover, among a number of unstructured loops 
belonging to the various domains, three have been identified to participate to the 
active site architecture and named loop1 (amino acids 66-84) loop2 (amino acids 
100-110) and loop3 (amino acids 323-354). As firstly described by Burkhard et al 
20, the LD contains the PLP binding site and its architecture consists in seven-
stranded mixed β-sheet (β-barrel) surrounded by eight α-helices in a typical α/β 
fold. CTD comprises a four-stranded antiparallel β-sheets and three helices. NTD 
represents a distinctive tract of group II decarboxylases and is composed of two 
parallel helices linked by an extended strand. Moreover, the two helices of one 
monomer form a clamp to the neighbouring subunit with each helix aligning 
antiparallel with the equivalent one of the cognate monomer forming an extended 
four helix bundle network (Figure 4). The intricate organization between these 
helices leads to the extension of the monomer-monomer interface, and in the case 




Fig. 4. Structural organization of the N-terminal domain of AADC and dimer 
interface 24. Organization of the 12 helices cluster that arises from the domain swapping of 
the N-terminal domain which is peculiar of the Group II decarboxylases. These helices are 
organized as an extended four helix bundle network and build the dimer interface. Colour 
code: blue-NTD; yellow-LD; red-CTD. The capital letters used after the helix number 
denote the domain to which each helix belongs (i.e., α-1N-NTD, α-1L-LD, α-1C-CTD).  
 
E. Group II α-decarboxylases active site 
 
AADC, HDC, GAD65, GAD67 and CSAD exhibit conserved residues interacting 
with the cofactor (Table 4).  
The active site of these homologous enzymes is buried in the dimer and at the 
monomer-monomer interface with the majority of the residues interacting with PLP 
belonging to one subunit. The cofactor binds to an evolutionarily invariant e-amino 
group of a lysine residue through a Schiff base linkage. The protonated nitrogen of 
PLP is stabilized by the carboxylate group of an aspartate residue (already 
mentioned as conserved in fold type I enzymes), via an electrostatic interaction. 
The pyridine ring of PLP is further stabilized through a well conserved histidine or 
arginine forming a base-stacking on its re face and a hydrophobic interaction with 
a conserved alanine residue on its si face. A conserved threonine residue stabilizes 
the oxygen atom in position 3 of PLP via a hydrogen bond. Finally, the phosphate 
group of PLP is anchored to the protein moiety through an extended hydrogen bond 
network (Figure 5A).   
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 Table 4. Residues of group II decarboxylases interacting with PLP and substrate 23. 
 
  Cofactor   Ligand 




AADC1 K303 D271 T246 H192 A273 
S147, A148, 
S149,   H192 T82, I101, 
N300, H302 H302 
HDC K305 D273 T248 H194 A275 
V150, S251, 
N302,   H194 Y81, L102, 
S354 S354 
GAd672 K396 D364 T339 H282 A306 
G243, A244, 
N393,   R558 S183, N203, F205 H295, G447 
GAD653 K405 D373 T348 H291 A375 
G252, A253, 
N402,   R567 S192, N212, F214 H404, G456 
CSAD4 K305 D273 T248 H191 A275 
G152, S153, 
N302,   R466 F94, S114, 
H304, G357 Y116 
 
1 AADC structure from Sus scrofa 
2, 3 GAD67 and GAD65 have been solved in complex with the reaction product GABA 






Fig. 5. Homologous residues of group II PLP-dependent α-decarboxylases interacting with 
cofactor and comparison of AADC and HDC active sites 23. A) residues are represented as white 
sticks, PLP is represented as cyan balls and sticks. B) AADC active site, C) HDC active site in 
presence of carbiDopa and HME respectively. Residues are labelled according to PDB numbering 
and shown as white sticks. Ligands are shown as cyan ball-and-sticks.  
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F. AADC and HDC binding to ligands 
 
Porcine AADC and human HDC have been crystallised both in the ligand-free form 
and in complex with their respective ligands carbiDopa 20 and histidine methyl ester 
(HME) 26. In particular, both compounds place the α-carboxylate group 
approximately orthogonal to the plane of the PLP pyridine ring according with the 
Dunathan’s hypothesis 27, thus these structures provide precious insights into the 
binding mode of the substrate and into the reaction specificity of these enzymes. 
The comparison of the crystal structure of the enzymes bound to carbiDopa and 
HME shows at the same time, a highly similar conformation of the respective 
external aldimines and key differences responsible for substrate specificity (figure 
5B, C).  
CarbiDopa binds to AADC through its hydrazine group thus forming a hydrazone 
linkage mimicking the external aldimine 28,29. His192 and three structural water 
molecules interact with the α-carboxylate moiety of the compound and Thr82 side 
chain makes a hydrogen bond with one hydroxyl group of the catechol ring. The 
second hydroxyl group of carbiDopa interacts with the phosphate moiety of PLP 
and with His302. In HDC, the imidazole ring of HME points toward the si face of 
the PLP-HME complex and makes two hydrogen bonds with the main chain of 
Tyr81 and a structural water molecule. Interestingly, the latter and second water 
molecule occupies the same position of the two hydroxyl groups of the catechol 
ring of carbiDopa in AADC. The discriminant residue that confers substrate 
specificity has been suggested to be Ser354 of HDC 26. In fact, in AADC this 
residue consists in a glycine residue that permits to accommodate the six-membered 
ring of the catechol substrate into an enlarged pocket. The S354G mutation in HDC 
resulted in a decreased affinity for histidine and an acquired ability to bind and 
catalyse the decarboxylation of L-Dopa 26.  
 
G. Active site mobile catalytic loop of group II α-decarboxylases 
 
As mentioned before, a distinctive structural feature of the human group II 
decarboxylases is the presence of a highly flexible element generally called 




Fig. 6. Multiple sequence alignment of group II PLP-dependent α-decarboxylases. A) 
Sequences were taken from the NCBI website (https://www.ncbi.nlm.nih.gov/) and aligned 
with Clustal Omega alignment (http://www.ebi.ac.uk/Tools/msa/clustalo/). Amino acid one-
letter code is used. Dashes represent insertions and deletions. Invariant positions are indicated 
with *. Mobile catalytic loop is circled with a dashed line when electron density map is 
missing. Conserved catalytic tyrosine is indicated. B) CL residues are reported for each 
enzyme.  
 
Despite its highly disordered structure, it is clearly assigned in the electron density 
map of HDC, CSAD and GAD67 (pdb: 4e1o, 2jis and 2okj) while it lacks of the 
coordinates in the structures of AADC and GAD65 (pdb: 1js6 and 2okk). The 
solved structures show that the loop is located at the dimer interface and extends 
towards the active site of the other monomer ‘closing’ the active site. The mobility 
of this loop has been associated with an important catalytic role 30–32. Several 
studies have shown that this loop is more prone to the cleavage of proteases in the 
ligand-free form of the enzyme whereas it is somehow protected from proteolysis 
when the substrate/ligand is bound at the active site 30,33. Taken together, structural 
and mechanistic data suggest that in the native form the catalytic loop adopts an 
‘open’ and more solvent exposed conformation that is prone to the proteolytic 
attack, while upon binding of the substrate/inhibitor the CL becomes more rigid, 
less susceptible to the cleavage and occludes the active site cleft shielding it from 
the solvent. The identified tryptic site is a conserved positively charged residue, 
identified to be Lys334 in AADC, Arg336 in HDC, Lys431 in GAD64 and Lys440 
in GAD67 (even if no tryptic data are available on CSAD, according to its amino 
acid sequence it shows a conserved lysine residue in position 341 analogue with 
those of GAD56 and GAD67) 25,26,31,32,34,35. Moreover, structural analysis together 
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with site direct mutagenesis (Tyr®Phe) in AADC, GAD and HDC suggest that a 
conserved residue of tyrosine belonging to the CL acts as proton donor to the 
carbanionic quinonoid intermediate (formed upon release of CO2) (Figure 6) 
26,31,35. Once the substrate/inhibitor is bound, the tyrosine residue moves in close 
proximity to the PLP-stacking histidine residue that induces a decrease of the pKa 
of the tyrosine favoring the protonation of the negatively charged Cα atom of the 
catalytic intermediate. AADC CL (residues 328-339 in the pk-holo enzyme) 
constitutes the ‘X-ray invisible’ part of the element called loop3 (mentioned 
before).  
 
H. Open conformation of the human  apo enzymes AADC and 
GAD65 
 
In 2011, Giardina et al published the first crystal structure of an apo- form of the 
group II a-decarboxylases, human AADC 24. Until that moment, in vitro 
biochemical and biophysical analysis clearly pointed out the existence of some 
conformational differences between holo and apo enzymes 3,36–38. Human 
apoAADC, in its crystal form, appears to exist in an unexpected ‘open’ 
conformation compared with the compact and ‘closed’ porcine holo form. In the 
absence of bound PLP, the dimer subunits move up to 20 Å apart and the active 
sites become solvent-exposed (with a solvent accessible surface area increased of 







Fig. 7. Human apoAADC in its crystallographic open conformation 24. Surface and 
cartoon representation of the human apoAADC structure in the open conformation. The 
domain organization of one monomer is highlighted using different colors (blue - NTD; 
yellow - LD; Red - CTD) while the other monomer is shown in white. The structure of the 
porcine holoAADC (pdb id: 1js6) in the closed conformation is shown for comparison in the 
same orientation; the three domains are colored differently for clarity (purple - NTD; green - 
LD; orange - CTD). 
 
Globally, the fold of each domain is essentially unchanged in the holo and 
apoAADC meaning that the achievement of the open conformation occurs through 
a rigid body quaternary rearrangement of the dimer. The active site and 
hydrophobic regions become solvent exposed and the two interconnected N-
terminal domains remain the only interfaced part of the open-dimer (figure 7). The 
dimeric enzyme has been compared with an ‘open bivalve shell’ that can close upon 
coenzyme binding and the extended four helix bundle network of NTD acts as a 
‘hinge’. 
The mechanism of this gross conformational change and its structural determinants 
have been proposed. In fact, some intermediate structures were solved by soaking 
the crystals of the apo protein in solution with different PLP concentrations. These 
structures trapped the active site in different conformations with increasing PLP 
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occupancy (0, 0.5, 1.5) but never acquiring the catalytically competent complete 
holo form. Once compared with that of the already published porcine holoAADC, 
the authors proposed a morphing process occurring upon PLP addition to the apo 
enzyme 24. In the apo-to-holo transition a crucial role has been attributed to loop1 
(residues 66-84) that, once PLP has bound to Lys303 in the open structure, triggers 
the rearrangement to the closed conformation by transmitting the change sub 
sequentially to loop2 (residues 100-110) and in turn to loop3 (which contains the 
CL). Notably, loop2 and loop3 are not visible in the electron density of both 
subunits of the apoAADC, meaning that these are mobile or unstructured in absence 
of PLP.  
More recently, another apo structure of PLP-dependent group II decarboxylases 
was published by Kass et al. 25. In this study the authors coupled in silico analysis 
with small-angle X-ray scattering and limited proteolysis to describe the 
conformational opening of holo-GAD65. Using the origami analogy, they 
illustrated the mechanism of dimer opening. Their data indicate that GAD65 is 
more dynamic and flexible than GAD67 and much more susceptible to proteolytic 
cleavage (at the CL, NTD and CTD) and that a conformational change in GAD65 
occurs when PLP is released. Kass el al. postulate that for both GAD and AADC 
the apo-to-holo transition ‘unlikely depends solely on the CL conformation’ but 




Chapter 2. AADC STRUCTURE-FUNCTION RELATIONSHIP 
 
I. PLP chemistry in catalysis 
 
As already mentioned in chapter 1, the ubiquitous PLP-dependent enzymes account 
on one hand a limited number of different scaffolds, called fold types, and on the 
other hand a very wide variety of catalysed reactions, in particular, reactions 
involved in the metabolism of amino acid and amines. The heteroaromatic 
pyridinium ring of the PLP carries a strong electron withdrawing capability that 
enables the coenzyme to stabilize and delocalize the electrons of the α- or β- 
carbanionic intermediate called quinonoid, facilitating the wide variety of the 




Fig. 8. Catalytic intermediates and versatility of PLP-catalyzed reactions. From 23  
 
Once the external aldimine is appropriately located, the protein environment 
confers the reaction specificity. In the PLP-dependent enzymes, the aldehyde group 
of the cofactor is invariably bound to the e-amino group of a lysine residue forming 
a Schiff base structure commonly referred as ‘internal aldimine’. The internal 
aldimine is converted into the ‘external aldimine’ when the C4’ of the cofactor ads 
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to  the α-amino group of the substrate amino acid. This multistep process is called 
‘transaldimination’ and proceeds through a geminal diamine in which both enzyme 
and substrate amino groups are bound to C4’ (figure 8). Once the external aldimine 
is formed, the course of the reaction depends on which of the three substituents in 
Cα is lost, according to the Dunathan’s hypothesis 27: (i) elimination of CO2 (α-
decarboxylation), (ii) deprotonation (transamination, racemization, b- or g-
elimination) and (iii) elimination of the side chain of the substrate amino acid (α-
synthesis and aldol cleavage) (figure 8). Once the α-substituent has left, a coplanar 
structure between the substrate and the cofactor is formed, called quinonoid 
intermediate (with the exception of PLP-dependent phosphorylases that use PLP in 
an acid-base chemistry on sugar substrates 41). The destiny of each intermediate 
depends on the polypeptide chain and the residues forming the active site cleft.  
 
J. AADC α-decarboxylation and side reactions 
 
As for all group II α-decarboxylases, in AADC the mechanism of α-
decarboxylation proceeds by a re-protonation of the Cα to form the amine product 
(re-protonation mediated by Tyr332 of the CL, as described in chapter 1g) 31. 
Finally, after a second transaldimination reaction, the aromatic amine (dopamine or 
serotonin) is released from the active site with the concomitant reconstitution of the 
internal aldimine (figure 9A). The comprehension of the mechanistic details of 
AADC catalysis have been initially undertaken on the pig 42 and rat 43 enzymes 
since the human recombinant form has been obtained solely in 2011 44. In these 
investigations, the use of non-natural ligands has been a useful approach to dissect 




Fig. 9. A) Decarboxylation reaction od L-Dopa and B) Pictet-Spengler cyclization of 
PLP and L-Dopa. Adapted from 45,46. 
 
Given the inherent high reactivity of the PLP, it is common among PLP-dependent 
enzymes the possibility to catalyse side-reactions that could sometimes be 
physiologically significant. D-aromatic amino acids are AADC substrates for a 
half-transamination reaction 30. The products of this reaction, reviewed in 47, are an 
α-keto acid as result of the hydrolysis of the ketimine resulting from the re-
protonation of the quinonoid intermediate and the PMP cofactor form that 
dissociates from the enzyme, leaving it inactive in the apo form.  
Reactions with molecular oxygen have been reported in the past twenty years to 
occur in ADDC and other group II α-decarboxylases (recently reviewed by our 
group 48). The unexpected AADC reactivity with molecular oxygen has been 
described to occur both in presence of the aminic products dopamine and serotonin 
49,50 and with other substrates like L-α-methylDopa and D-tryptophan methyl ester 
50 (see figure 10). This reaction consists in an oxidative deamination that leads to 
the release of the amino group as ammonia and the oxidation of the Cα forming a 
carbonyl compound (aldehydic/ketonic product). It has been suggested that the 
produced aromatic compound, (such as dihydroxyphenyl acetaldehyde, DOPAL, 
from dopamine 51) represents a strong biological active signal 48.  
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Finally, a Pictet-Spengler condensation has been described to occur between the 
aromatic ring of the  substrate and PLP leading to the formation of a cyclic covalent 
adduct that irreversibly inactivates the enzyme 30,44. This reaction has been firstly 
described to occur concomitantly with AADC half transamination in presence of 
D-substrate (D-5-hydroxytryptophan and D-Dopa) or in the nicked AADC treated 
with trypsin 30. All together these results indicate that an inefficient control of PLP 
reactivity due to a mispositioning of the coenzyme or to a non-natural substrate or 
to an unproductive ‘closure’ of the active site may lead to the formation of an 
unproductive external aldimine that is released as a cyclic substrate-PLP adduct 30.  
 
 
Fig. 10. AADC natural substrates, products, analogues and inhibitors. Dopamine (3,4 
dihydroxyphenethylamine), L-Dopa (L-3,4-dihydroxyphenylalanine), DME (Dopa methyl 
ester), serotonin (5-hydroxytryptamine), L-5-HTP (L-5-hydroxytryptophan), carbiDopa (L-
α-methyl-α-hydrazino-3,4-dihydroxyphenylpropionic acid, MK 485), benserazide 
(trihydroxybenzylhydrazine seryl derivative, Ro-4-4602). 
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K. Kinetic and spectroscopic features of holo and apoAADC 
 
Human AADC is a homodimeric enzyme where each monomer is composed by 480 
residues with a molecular weight of 53926 Da (no disulphide bridges are present, 
despite the numerous cysteine residues). The protein shows a slight acidic nature 
having a pI equal to 6.76.  
The available functional analysis of human AADC is resumed in table 5, in 
comparison with those of the recombinant porcine enzyme 52.  
 
Table 5. Kinetic parameters of human and porcine ADDC for the decarboxylation of L-Dopa and 
L-5-HTP. Human kinetic parameters have been calculated in 100 mM potassium phosphate, pH 7.4 
while porcine has been analyzed in 50 mM hepes, pH 7.5.  
 
Enzyme L-aa kcat (s-1) Km (mM) kcat/Km (s-1mM-1) 
Human 44 L-Dopa 7.6 ± 0.1 0.11 ± 0.01 69.1 ± 10 
Porcine 52 L-Dopa 4.3 ± 0.2 0.07 ± 0.005 61.4 ± 7 
Human a L-5-HTP 0.63 ± 0.02 0.029 ± 0.006 21.7 ± 4.5 
Porcine 52 L-5-HTP 1.9 ± 0.3 0.15 ± 0.01 13.3 ± 1.7 
  
a calculated during the PhD program, still not published. 
 
The catalytic features have been evaluated by measuring the kinetic parameters for 
the decarboxylation of natural substrates L-Dopa and L-5-hydroxytryptophan under 
steady state conditions. The catalytic efficiency of the two enzymes toward L-Dopa 
is similar. Notably, activity data of human AADC toward L-5HTP have been 
determined in this PhD thesis and can be found in table 5. 
Moreover, the apparent equilibrium dissociation constant for PLP has been 
calculated to be 43 ± 12 nM for the human enzyme and 44 ± 13 mM for the porcine 
one, indicating a consistent high affinity for the coenzyme 44,53.  
Structure/function relationships of AADC have been obtained by means of 
spectroscopic and structural studies originally on both the naturally occurring and 
the recombinant purified pig kidney and rat liver enzymes 30,43,49,51–57 and later on 
the recombinant purified human AADC 24,44,58–60. ApoAADC lacks of absorbance 
in the visible region, while the holo enzyme is characterised by two absorbance 
bands peaking at 335 nm and 420 nm, associated with positive dichroic signals at 
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the same wavelengths (Figure 11A ). These two visible bands have been associated 
with two ionization states of the internal aldimine. In fact, the Schiff base formed 
between PLP and Lys303 exists as a tautomeric equilibrium between an enolimine 
and a ketoenamine tautomer (Figure 11B), peaking respectively at 335 nm and 420 
nm 59.  
 
Fig. 11. Spectroscopic features of human apo and holoAADC. A) Near UV-visible 
circular dichroism spectra of apo and holoAADC together with holoAADC visible 
absorbance spectrum (inset). Tautomeric equilibrium is indicated as ratio between 335 nm 
and 420 nm bands, B) chemical representation of the enolimine and ketoenamine species 
generating the absorbance band in the visible range and peaking at 335 nm and 420 nm, 
respectively, C) intrinsic fluorescence spectra of apo and holoAADC obtained upon 
excitation at 280 nm, D) CD spectra of apo and holoAADC recorded in the far-UV region.  
 
In the near-UV region, holoAADC presents a positive dichroic band at 280 nm 
while the apoAADC presents a band at the same wavelength but with a decreased 
magnitude, suggesting some structural changes in the microenvironment of 
aromatic amino acids. Secondary structure signals recorded in the far-UV region 
consist in intense negative dichroic signals relative in particular to the abundant a-
helical content (Figure 11D). Upon excitation at 280 nm, the buried environment 
of the aromatic residues produces an emission spectrum with a lmax of emission at 
around 330 nm, due to an energy transfer effects to the imine-pyridine system 
(figure 11C).   
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L. AADC inhibition and regulation 
 
The inhibition of AADC has been object of long research, starting from the 
identification of  carbiDopa and benserazide in 1970s, to the more recent structure 
based virtual screening of novel molecules 58,61. In addition, also plant-derived and 
natural-derived compounds have been tested for AADC activity inhibition 61. Most 
of the efforts in the finding of AADC specific inhibitors are focused on the 
treatment of Parkinson’s disease (PD).  
PD is neurodegenerative disease consisting in a motor system disorder mainly due 
to a progressive loss of dopamine-producing cells in the substantia nigra in the 
midbrain. The severe phenotype of PD is mainly characterized by tremor at rest, 
slowness of movement, and rigidity associated with other non-motor symptoms. At 
present while no cure exist for PD, a number of palliatives reduces the disease 
symptoms 62. Drug treatments aim to replenish dopamine levels at the CNS and 
since dopamine is enable to cross the BBB, L-Dopa was approved by FDA for the 
PD treatment in 1970. The common therapy relies on the co-administration of L-
Dopa - which represent the gold standard in PD treatment - with peripheral 
inhibitors (not crossing the BBB) of AADC that prevent L-Dopa degradation by 
peripheral enzyme and thus increasing its bioavailability for central nervous system 
(CNS) uptake. 
CarbiDopa (L-α-methyl-α-hydrazino-3,4-dihydroxyphenylpropionic acid, MK 
485) together with benserazide (trihydroxybenzylhydrazine seryl derivative, Ro-4-
4602), are the only two AADC inhibitors actually used as drugs. While carbiDopa 
is a per se AADC powerful irreversible inhibitor 29, benserazide behaves as a poor 
inhibitor 29, but is rapidly bioactivated to 2,3,4-triydroxybenzylhydrazine 28 (figure 
10). However, both inhibitors have been shown to react also with free PLP, 
generating hydrazone-derivatives inhibitors for PLK 63, and also for many other 
PLP-dependent enzymes, such as kynureninase and kynurenine aminotransferase 
64. 
Among the chemical compounds tested as AADC inhibitors (but still not used as 
drugs) there are various α-derivative substrates that act via suicide mechanism by 
alkylating the enzyme. α-chloromethyl-, α-fluoromethyl-, α-vinyl- and α-acetylenic 
derivative of L-Dopa are reported in 52. Other compounds consist in the 
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phosphopyridoxyl aromatic amino acid Schiff base analogs 65 and substrate analogs 
(such as green tea polyphenols (-)-epigallocatechin-3-gallate, EGCG, and (-)-
epicatechin-3-gallate, ECG) 66. The KD values reported for these compounds range 
between 10-2 and 10-6 M. A more promising AADC inhibitor, called Amb2470350, 
has been identified through a virtual screening approach and the in vitro analysis 
measured a Ki of 500 nM 58. Interestingly this leading compound was predicted not 
to cross the BBB, not to bind free PLP (since it does not contain a hydrazinic group) 
and to reversibly inhibit AADC.  
A putative modulator role has been associated to the paracatalytic reaction of 
AADC with α-methylDopa. In fact, the oxidative-deaminated product 3,4-
dihydroxyphenylacetone behaves as a site direct affinity label forming a covalent 
adduct at the active site and irreversibly inactivating the enzyme 50. Moreover, also 
the carbonyl compounds generated by the oxidative deamination of serotonin 
(and/or its aldehyde) act as mechanism-based inhibitor 49. In addition to the 
mentioned AADC inhibition, evidence for AADC activity modulation by drugs that 
act on dopamine receptor and other neurotransmitter receptors suggest to consider 
these drugs a potent adjuvant when developing strategies for L-Dopa treatment 
augmentation (these aspects are widely reviewed in 67).  
 
M. Biology of AADC 
 
AADC was first identified in extracts from mammalian kidney in 1938, thus 80 
years ago 68. However, despite its crucial physiological role, the knowledge on its 
regulation is, till now, fragmented, partial or not mechanistically detailed. For this 
reason, AADC has classically been regarded as a post-translational unregulated 
enzyme. Even if no information is found in the official online resource for the 
notation of protein post-translational modifications (PTMs) i.e. biochemically 
validated data and mass spectrometry data (PhosphoCitePlus®, 69), some evidences 
of AADC regulations came from literature.  
Until now, no PTMs sites have been identified for human AADC, even if its 
primary structure contains a number of recognition motifs for phosphorylation by 
PKA, PKC, Ca-CM PKII, and proline-directed protein kinase 70. Moreover, its 
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amino acid sequence shares some conserved residues that have been identified to 
be ubiquitynated (Lys205, Lys207) 71 and acetylated (Gln383, Lys443) 72 in mouse 
and rat AADC respectively. Despite this, evidence for a regulated activity mediated 
by phosphorylation (in mouse AADC) comes from 73 and 74. More recent data on 
the mouse enzyme have been reported in vitro on the recombinant and 
immunoprecipitated AADC 41,75. The main finding in these works is that the 
enzymatic activity increases up to 70 % once phosphorylated by PKA 75, and that 
the Vmax and Km are increased of ~ 30-60 % respectively when AADC is 
phosphorylated by cyclic guanosine monophosphate/protein kinase G 
(cGMP/PKG) 41. In neither of the cases the authors identified the phosphorylation 
site. The activation effect carried by phosphorylation has also been reported by 
Tehranian et al. 76. In their work the authors described a functional direct interaction 
between AADC and α-synuclein in rat striatum. The effect of this interaction would 
be a reduction in the AADC phosphorylation level (probably by activation of a 
phosphatase) and a concomitant inhibition of AADC activity 76.  
In addition to the proposed interaction with α-synuclein, human AADC has been 
suggested to take part of a functional protein complex involving dopamine 
synthesis and its transport into the synaptic vesicles 77. Cartier et al identified an 
interaction between the vesicular monoamine transporter-2 (VMAT2) and both 
tyrosine hydroxylase (TH) and AADC indicating that dopamine synthesis occurs at 
the synaptic vesicle membrane 77. Taken together these data suggest that the 
activation of neuronal AADC by drugs that increase phosphorylation could be a 
novel and promising approach to the treatment not only of PD but also of other 
pathological conditions where catecholamine homeostasis is impaired, such as 
AADC deficiency (see chapter 4). Anyway, at present, no data are available on the 





Chapter 3. AADC IN HUMAN METABOLISM 
 
AADC is the enzyme at the crossroad of two monoamine biosynthetic 
pathways. AADC converts L-Dopa and L-5HTP into the neurotransmitters 
dopamine and serotonin, respectively. Moreover, dopamine is the precursor of 
monoamines norepinephrine and epinephrine, also known as noradrenaline and 




Fig. 12. Summary scheme of the biosynthesis and breakdown of serotonin and the 
catecholamines (dopamine, norepinephrine and epinephrine), and melatonin 
synthesis. Cofactors (BH4, PLP, Cu, vitamin C) and methyldonor (SAM) are positioned 
on the lines relative to the respective enzyme reactions. Dashed arrows do not show 
intermediate steps. BH4: tetrahydrobiopterin; COMT: catechol O-methyl transferase; CSF: 
cerebrospinal fluid; Cu: cupper; DβH: dopamine beta hydroxylase; DOPAC: 
dihydroxyphenylacetic acid; 5-HIAA: 5-hydroxyindoleacetic acid; L-5-HTP: L-5-
hydroxytryptophan; HVA: homovanillic acid; L-Dopa: 3,4-dihydroxyphenylalanine; 
MAO: monoamine oxidase; MHPG: 3-methoxy 4-hydroxyphenylglycol; 3-OMD: 3-O-
methyldopa (=3-methoxytyrosine); PH: phenylalanine hydroxylase; SAM: s-
adenosylmethionine; TH: tyrosine hydroxylase; TPH: tryptophan hydroxylase; VLA: 
vanillactic acid.  
 
This enzyme owes its name to the ability to decarboxylate, although with much less 
efficiency, also other aromatic L-amino acids such as tyrosine, tryptophan and 
phenylalanine to the corresponding amines tyramine, tryptamine and 
phenethylamine, known as trace amines. Biochemically, their regulation is quite 
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similar, with similar proteins regulating synthesis, storage, release, uptake and 
metabolism. Monoamines and their products are metabolised by the same set of 
enzymes, mainly by monoamine oxidases (MAO-A/B), aldehyde dehydrogenase 
(ALDH), catechol-O-methyl transferase (COMT) (Figure 12). Final products of 
their breakdown are homovanillic acid (HVA) from dopamine, and 5-
hydroxyindoleacetic acid (5-HIAA) from serotonin. The levels of these metabolites 
are measured in clinical research, as first line of the analysis to diagnose possible 
pathological states.  
Despite the convergence of dopamine and serotonin metabolic pathways on AADC, 
this enzyme is not considered rate-limiting for the neurotransmitter synthesis. The 
rate-limiting enzymes in dopamine and serotonin synthesis are tyrosine 
hydroxylases (TH) and tryptophan hydroxylase (TPH) respectively. AADC 
assumes a rate limiting role in those pathological conditions with aberrant 
dopamine production such as Parkinson’s disease and the AADC deficiency 46,61. 
In the following paragraphs the main aspects regarding dopamine and serotonin 
synthesis are discussed, as well as the pathological states in which dopamine 
homeostasis is involved.  
 
N. Dopaminergic system  
 
There are only ∼ 200000 dopaminergic neurons on each side of human brain 78,  
and the cell bodies of these neurons are confined to a few relatively small brain 
areas (retrorubral field, RRF, substantia nigra pars compacta, ventral tegmental 
area, posterior hypothalamus, arcuate nucleus, zona incerta, and periventricular 
nucleus) 79,80. However, their axons project to many other brain areas playing 
important roles in neuromodulation, such as roles in motor control, motivation, 
reward, cognitive function, maternal, and reproductive behaviours 81. There are two 
main groups of dopamine-producing cells called substantia nigra (SN) and ventral 
tegmental area (VTA). SN neurons project the so-called nigrostriatal dopamine 
pathway to the striatum and VTA neurons project the mesolimbic and mesocortical 
pathways to the nucleus accumbens and to the prefrontal cortex respectively 80,82 
(Figure 13A).   
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Fig. 13. Representation of midbrain dopaminergic (A) and serotonergic (B) neurons 
organization and projections in CNS. SN: substantia nigra; VTA: ventral tegmental area.   
 
In particular:  
- nigrostriatal pathway mediates motor function and learning of new motor 
skills. Hyperactivity of dopamine in this pathway can lead to dystonia, 
parkinsonian symptoms and hyperkinetic movements such as dyskinesias 83.  
- mesolimbic pathway is the site of the rewards circuit and mediates pleasure. 
Hyperactivity of dopamine in the mesolimbic pathway mediates positive 
psychotic symptoms and aggression 83 
- mesocortical pathway regulate cognition, executive functioning as well as 
emotions. Decreased dopamine in the mesocortical pathway may lead to 
schizophrenia 83. 
Once released from presynaptic terminals, dopamine can be removed from the 
synaptic cleft by the dopamine active transporter (DAT) and stored again into the 
vesicles through VMAT2 until a new action potential triggers its release through 
exocytosis. Tissue-specific response is mediated upon binding to post-synaptic 
specific G-coupled receptors (GPCRs), expressed in both peripheral and central 
nervous system, that mediate the signal transduction. Dopamine can bind to five 
distinct but closely related post-synaptic receptors (D1-D5). These receptors are 
divided into two major groups: D1-like family receptor comprises D1 and D5 
receptors, whereas the D2, D3 and D4 receptors are members of the D2-like family 
84,85. In the brain, GPCRs are expressed at a high level of density in those area where 
the SN and VTA neurons are projected i.e striatum, the nucleus accumbens, the 
olfactory bulb, frontal cortex among others 84.  
 37 
Since dopamine does not cross the BBB, dopaminergic signalling in the brain is 
functionally separated from peripheral dopamine actions 86. Peripheral dopamine 
secreting tissues are located in the adrenal medulla, peripheral sympathetic nerves 
and in those cells that actively take up L-Dopa. In the periphery, dopamine acts as 
autocrine/paracrine factor regulating the olfaction, retinal processes, cardiovascular 
functions, immune system, renal functions and is also involved in hormonal 
regulation and sympathetic regulation 85,87–90. Moreover, dopamine can be absorbed 
from food in digestive system and interestingly, up to ~ 95 % of plasma dopamine 
circulates in a detoxified sulfo-conjugated form 91, while free-dopamine 
concentration in human plasma is normally very low, about 0.1 nmol/L 92. 
Dopamine signalling is crucial for maintaining a number physiological processes 
and an unbalanced activity may eventually be involved in the progression of 
neurodegenerative diseases such as Parkinson’s disease and Huntington’s diseases, 
and in the nervous system such as schizophrenia, attention deficit hyperactivity 
disorder, addiction and Tourette’s syndrome 81,84. Targeting dopamine receptors 
with specific agonists and antagonists still is the opportunity to influence 
dopaminergic transmission and dopamine-dependent functions by enhancing or 
blocking the signal transduction. 
 
O. Serotonergic system  
 
Since its isolation in the 40’s, serotonin was supposed to be the vasoconstrictor 
substance contained in platelets 93. In 1957, Brodie & Shore proposed the role of 
serotonin as neurotransmitter since it was demonstrated the localization of serotonin 
receptors in specific areas of the vertebrate brain 94,95. Only in 1972, Christenson et 
al, demonstrated that a single enzyme, namely AADC, is responsible for the 
decarboxylation of both L-Dopa and 5-hydroxytryptophan (L-5-HTP) (initially 
supposed to be Dopa Decarboxylase and Tryptophan Decarboxylase respectively) 
96. 
Serotonin acts as an important neurotransmitter in the central nervous system 
(CNS) and a critical hormone in the peripheral tissues 97, and since it does not cross 
the BBB, each pool of serotonin has distinct functions 98. Accordingly, in 
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vertebrate, tryptophan hydroxylase (TPH) is encoded by two different genes 
generating two different enzymes: TPH1, which is expressed in the periphery, and 
TPH2 expressed mainly in the brain. Only 5% of the total body serotonin acts as 
neurotransmitter regulating however multiple physiological roles: behaviour, 
learning, appetite and glucose homeostasis 98–100. Serotonin exerts its effects in 
target cells through at least fourteen identified specific receptors mainly belonging 
to the G-protein coupled superfamily 101. The re-uptake of extracellular serotonin 
occurs through the serotonin transporters (SERT), member of the class of the 
monoamine transporter, that removes the neurotransmitter from the synaptic cleft. 
Within the CNS, serotonin is synthesized and stored in the presynaptic neurones 
(serotonergic neurons, as well as pineal gland and dopaminergic neurons). Nine 
groups of cell bodies, called raphe nuclei, have been isolated in the midbrain. They 
have both ascending and descending pathways projecting their axons to the 
forebrain and spinal cord respectively (Figure 13B). 
Availability of serotonin in the peripheral tissues is determined by both local 
production (pancreatic b cells, adipocytes and osteoclasts 101) and by free-serotonin 
in the blood. In fact, the 95 % of serotonin is produced in the peripheral organs, 
where it can acts locally or enter into the blood circulation and being stored by 
platelets. In fact, only 2 % of the blood serotonin is free and can act as hormone 102. 
Decreased serotonin levels are associated with several diseases and disturbs 103. 
Consequently a number of drugs are available to help bringing serotonin back to 
physiological levels. Serotonin homeostasis is altered in major depressive disorders 
such as mood disorder, anxiety disorder, schizophrenia, addiction, attention deficit 
hyperactivity disorder and autism 103. The most diffused and specific class of drug 
is that of the selective serotonin reuptake inhibitors (SSRIs) that specifically bind 





Chapter 4. A GENETIC DISEASE OF AROMATIC L-AMINO ACID 
DECARBOXYLASE: AADC DEFICIENCY 
 
P. AADC deficiency: an overview, from incidence to diagnosis and 
therapy 
 
AADC deficiency (AADCd, OMIM #608643) is caused by mutations on the AADC 
gene (short arm of chromosome 7 between positions 12.2 and 12.1) that can be 
present in both  homozygosis or compound heterozygosis. AADCd is inherited in 
an autosomal recessive manner and the age of onset is typically neonatal/infancy. 
AADCd is classified as very rare disorder since the estimated worldwide prevalence 
is <1/106 according to the Orphanet Epidemiological data 
(www.orpha.net/consor/cgi-bin/index). To date, ~ 130 patients have been identified 
worldwide, but the total number seems to be under-estimated 104–107. A total of 82 
AADC mutations are listed in the locus-specific database (BIOMDB available at: 
http://biopku.org/home/pnddb.asp). This current variant list includes 58 missense, 
6 frame-shift, 9 splice-site, 1 in-frame, 3 complex and 2 nonsense variants. To date, 
123 confirmed patients with AADC deficiency have been diagnosed 107. Due to the 
rarity of the AADCd and to the heterogeneous phenotype and response to the 
treatments, to date no univocal guidelines exist. Many efforts have been made, and 
in 2013 the International Working Group on Neurotransmitter Relater Disorder 
(iNTD) has been founded and proposed new guidelines of therapy 104.  
AADCd is typically detected through detailed clinical assessment and a number of 
diagnostic tests, starting from the most common symptoms identification. When the 
diagnosis is clinically suspected, cerebrospinal fluid (CSF) analysis of 
neurotransmitters should be undertaken, in order to detect the characteristic 
reduction of homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA) and 
3-methoxy 4-hydroxyphenylglycol (MHPG) together with an increasing of L-
Dopa, L-5-HTP, 3-O-methyldopa (3-OMD) and vanillactic acid (VLA) (see Figure 
14).  
Furthermore, AADC enzymatic activity can be measured in plasma, confirming a 
decreased or lost enzymatic activity, and finally, AADC genetic sequencing can be 
performed to definitely confirm the diagnosis 108. AADCd was first reported by 
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Hyland et al. nearly 30 years ago in male monozygotic twins 109,110. Their findings 
demonstrated that both dopamine and serotonin synthesis were affected in central 
and peripheral nervous systems (as well as norepinephrine and epinephrine), 
consistent with a deficiency of AADC. Treatment with a monoamine oxidase 
inhibitor, dopamine agonist and pyridoxine resulted in a striking improvement 109. 
The parents were asymptomatic heterozygous. In the following decades the number 
of diagnosed patients increased, thanks to the growing literature about this disease, 
with a prevalence in certain Asian population 104, especially in Taiwan and Japan 
111, due to an early emergence of a founder splice point variant mutation 111,112.  
The range of AADCd symptoms and the variability in clinical manifestation are 
consequences of the deficiency of the four neurotransmitters dopamine, 
epinephrine, norepinephrine and serotonin (Table 6). 
 
Table 6. Typical signs and symptoms reported in patients with AADC deficiency. Adapted from 107. 
  
Common Less common Non-neurologic 
Hypokinesia Epileptic seizures Short stature 
Hypotonia (proximal) Sleep disturbance Diarrhea 
Hypertonia (proximal) Irritability Constipation 
Oculogyric crises Dysphoria Feeding difficulties 
Developmental delay Autism-like symptoms Nasal congestion 
Ptosis Temperature instability Gastroesophageal reflux 
Excessive sweating   Hypoglycemia 
Dystonia     
 
Generally, AADCd should be considered as an early-onset parkinsonism. 
Deficiencies in dopamine result in altered cognitive function, voluntary movements 
and can impact emotional state. Reduced levels of epinephrine and norepinephrine 
can affect mood, attention, normal sleep patterns, cognition and stress hormone 
levels 107. Altered serotonin levels affect a number of basal functions, including 
mood, sleep, memory/learning and bloody temperature as well as cardiovascular 
and endocrine function 108. While most patients present a severe phenotype with 
early onset hypotonia, oculogyric crises, ptosis, dystonia, hypokinesia, impaired 
development and autonomic dysfunction 108, a few patients with milder disease 
course are known 113. In these cases, initial symptoms evolve to become dystonia–
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parkinsonism in adulthood. Complications linked to many different aspects of this 
disease may lead, in some cases, to vegetative state and premature death 108.  
There is currently no cure for AADCd. Current medications help the treatments of 
the signs and symptoms of the disease. Whether or not a treatment works, may 
depend on the exact nucleotide substitution and the enzymatic phenotype. First-
choice medication could include any one or combination of the following 104: (i) 
dopamine receptor agonists (such as bromocriptine, pramipexole, or ropinirole) to 
mimic the effect of dopamine by activating postsynaptic dopamine receptors, (ii) 
monoamine oxidase inhibitors (such as selegiline or tranylcypromine) in order to 
avoid dopamine, serotonin and norepinephrine further breaking down, (iii) 
pyridoxine (vitamin B6) and PLP to keep AADC saturated with its coenzyme and 
optimize residual enzyme activity (Figure 14).  
 
 
Fig. 14. Alteration of neurotransmitters level in AADC deficiency and current 
treatment options. Abbreviations: AADC: Aromatic L-Amino Acid Decarboxylase; 
DA: dopamine; DAT: dopamine transporter; VMAT2: vesicular monoamine transporter-
2; MAO: monoamine oxidase.  
 
Other treatments may depend on the symptoms of each individual patient 108. These 
treatment options include: (i) anticholinergic agents to treat movement disorders, 
(ii) seizure medication, (iii) melatonin to treat sleep disturbances, (iv) selective 
serotonin reuptake inhibitors. In few cases the use of L-Dopa in combination with 
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pyridoxine has been reported to lead to positive effects only in those patients whose 
mutations has impact on the substrate binding at the enzyme active site (i.e G102S, 
R160W, R347Q 78,114). Globally, the response to the treatment of AADCd is often 
disappointing, in fact, only a small subset of patients shows a good response to 
dopamine agonists 113, and often, patients show no or poor response 108. Side effects 
have been reported for almost every drug used, and are listed in 104. For most 
patients, treatment response still cannot be predicted.  
Since AADCd is a genetic disease it makes sense to consider therapies that use gene 
addition or repair to correct and mitigate the effects of the involved genetic lesions. 
Promising and clinical studies in humans are currently underway 106. Gene therapy, 
aimed at targeting to the brain the human AADC gene, was originally developed for 
treating PD patients 115. Gene transfer aimed at treating AADCd has been firstly 
performed by Hwu et al. in 2012 in four patients in Taiwan with modest but 
promising results 116. Gene therapy for AADCd is today under development in 
Taiwan, Japan and also USA and Europe 106,117,118.  
The crucial step in changing the natural history of AADCd in patients still consists 
in the ability to identify this disorder after its initial presentation and before the 
onset of brain damage.  
 
Q. AADC deficiency – A molecular investigation 
 
In the past years, molecular investigations on the AADC protein have been 
undertaken with the aim to provide a better comprehension of the molecular aspects 
of AADCd by determining the impact of the amino acid substitutions on the enzyme 
structure and function. In 2011 Montioli et al. published the first in vitro 
biochemical investigation of four AADC pathogenic variants 44. Until now, a 
number of studies on the recombinant purified homodimeric enzymes are available 
44,60,119,120. More recently, after the emergence of heterozygous genotypes, also 
heterodimeric enzymes have been obtained, mimicking both the homozygous and 
heterozygous patients respectively and expanding the spectrum of enzymatic 
phenotypes associated with AADCd 121,122. 
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Table 7 lists the kinetic parameters and coenzyme binding affinity of the 
homodimeric pathogenic variants characterized up to 2019. The picture, emerged 
in almost a decade after the publication of the human apoAADC crystal structure 
24, revealed that the majority of the mutations led to amino acid substitutions of 
residues belonging to regions involved in the apo-to-holo transition 119. A 
correlation between the structural and functional effects of these missense 
substitutions has been proposed and a role for loop1 region has been suggested 119. 
In addition, some catalytically inactive variants showing no gross structural 
alteration and located close to the active site have been pointed out to play a crucial 
role in the catalysis 44,120. In some cases, the biochemical characterization of the 
pathogenic variants permitted to propose therapeutic promptings based on the in 
vitro determined functional properties 44,60,119.  
 
Table 7. Reported kinetic parameters for L-Dopa of all homodimeric recombinant 
AADC pathogenic variants from 2011 to 2019.  
 
Enzyme kcat  Km  kcat/Km KD(PLP)  references 
(s-1) (mM) (sec-1mM-1) (nM) 
WT 7.6 ± 0.1 0.11 ± 0.01 70.6 ± 8.4 43 ± 12 
44 
G102S 1.2 ± 0.1 1.2 ± 0.1 1.0 ± 0.2 61.7 ± 9.2 
F309L 0.37 ± 0.03 3.8 ± 1.0 0.10 ± 0.03 360 ± 118 
S147R 0.0090 ± 0.0002 0.12 ± 0.01 0.076 ± 0.008 846 ± 63 
A275T 1.4 ± 0.04 0.35 ± 0.03 4 ± 0.4 7200 ± 1200 
T79M 3.5 ± 0.2 0.46 ± 0.07 7.6 ± 1.2 100 ± 13 
119 
H70T 0.34 ± 0.02 0.69 ± 0.09 0.49 ± 0.07 510 ± 90 
H72Y 0.20 ± 0.01 1.38 ± 0.23 0.14 ± 0.02 2145 ± 409 
Y79C 0.32 ± 0.01 3.98 ± 0.37 0.080 ± 0.007 487 ± 110 
P81L 0.50 ± 0.01 0.19 ± 0.02 2.6 ± 0.5 390 ± 63 
A110Q 0.015 ± 0.01 3.6 ± 0.4 0.004 ± 0.002 829 ± 60 
R347Q 0.087 ± 0.005 0.49 ± 0.08 0.16 ± 0.06 54 ± 10 
L38P n.d. n.d. n.d. 460 ± 58 
P47H 1.70 ± 0.06 0.60 ± 0.05 2.8 ± 0.2 100 ± 24 
L408I 0.78 ± 0.06 1.78 ± 0.26 0.44 ± 0.07 105 ± 33 
R412W 1.45 ± 0.05 0.27 ± 0.03 5.37 ± 0.61 84 ± 23 
R447H 0.38 ± 0.02 0.79 ± 0.13 0.41 ± 0.07 1010 ± 160 
R462P 0.40 ± 0.01 0.25 ± 0.03 1.60 ± 0.19 544 ± 50 
G123R 3.30 ± 0.14 0.74 ± 0.07 4.46 ± 0.45 101 ± 13 
S250F 2.1 ± 0.1 0.22 ± 0.04 9.3 ± 1.7 62 ± 24 
R285W 2.08 ± 0.08 0.16 ± 0.03 13.0 ± 2.5 335 ± 39 
F309A 0.47 ± 0.03 4.8 ± 0.6 0.097 ± 0.013 225 ± 26 
R347G 0.016 ± 0.001 0.64 ± 0.13 0.025 ± 0.05 178 ± 14 120 
R358H 0.030 ± 0.001 4.9 ± 0.4 0.0061 ± 0.0005 1300 ± 100 121 R160W 1.12 0.07 1.95 ± 0.25 0.6 ± 0.08 560 ± 60 
A91V 0.0083 ± 0.0007 0.15 ± 0.01 0.055 ± 0.009 782 ± 47 122 C410G 4.4 ± 0.2 0.27 ± 0.04 16.3 ± 2.4 1070 ± 19 
 
n.d not detectable 
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The AADCd management still presents a number of still not addressed challenging 
questions: (i) is there a rational behind the heterogeneity of the medication 
response? (ii) what are the molecular bases of each clinic phenotype? (iii) is there 
an approach to get a more effective therapeutic intervention? (iv) is it possible to 
cluster the patients on the basis of their enzymatic phenotype? 
In order to provide a contribution in addressing all these challenges, the present 
thesis aims at expanding the knowledge of the enzymatic phenotypes associated 
with the AADCd by characterizing 20 novel identified pathogenic variants (Table 
8) in their homodimeric form. 
 
Tabel 8. New reported AADC homozygous or hemizygous variants from 2014 to 2020.  
 
New variant Reference Note 
Y20del p.c  - 
E25K p.c - 
V60A 44 Hemizygous, the other allele produces a protein that ends prematurely at 248 amino acids, with no formation of the active site 
H70Y 123 119 Homozygous, reported incorrectly as H70T 
H70R/W71del p.c - 
F77L www.bioku.org/pnd/home.asp - 
G96R 107 Hemizygous, the other allele produces a protein that ends prematurely at 248 amino acids, with no formation of the active site 
W105C p.c - 




P210L 124 Hemizygous, the other allele has a mutation leading to a premature stop codon 
L222P 124 Homozygous 
F237S 113 Hemizygous, the other allele has a mutation leading to a premature stop codon 
F251S 125 Hemizygous, the other allele produces a protein that ends prematurely at 248 amino acids, with no formation of the active site 
W267R R. Pons, p.c R. Pons, personal communication 
C281W p.c - 
E283A 126 Hemizygous, the other allele produces a protein that ends prematurely at 248 amino acids, with no formation of the active site 
P330L p.c - 
L353P 126 Hemizygous, the other allele produces a protein that ends prematurely at 248 amino acids, with no formation of the active site 
M362T p.c - 
R453C 127 Homozygous, reported incorrectly as R375C 
 
p.c personal communication 
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MATERIALS AND METHODS 
 
Materials 
PLP, L-Dopa, D-Dopa, dopamine, dopa methylester (DME), carbiDopa, 
hydroxylamine hydrochloride, isopropyl-β-D-thiogalactopyranoside (IPTG), 
trinitrobenzenesulfonic acid (TNB), phenylmethylsulfonyl fluoride (PMSF), 
trichoroacetic-acid (TCA), protease inhibitor cocktail (P8849), were purchased 
from Sigma. Anti AADC monoclonal antibody (8E8) and mouse IgG kappa binding 




AADC variants were obtained by mutating the template DNA on the pDDChis 
vector as previously described 44. Each mutagenesis reaction has been performed 
using the Quick-Change II kit (Agilent technologies) using the appropriate 
oligonucleotides (summarized in the table below) and their complements. All 
mutations were confirmed by DNA sequence analysis of the whole ORF. S193A 
plasmid was kindly provided by Prof. Robert S. Phillips at the University of Georgia 




































Expression and purification of AADC variants 
E. coli BL21 (DE3) cells were transformed by heat shock at 42 °C with the desired 
construct and grown in 4.5 L of Luria–Bertani (LB) broth in presence of ampicillin 
(100 mg/ml). The cultures were grown at 37 °C to an OD600nm of 0.4–0.6, and 
expression was induced with 0.1 mM IPTG for 15 h at 30 °C. Cells were harvested 
and resuspended in 20 mM sodium phosphate buffer pH 7.4, containing 0.5 M 
NaCl, 20 mM imidazole, 50 μM PLP, 0.5 mM PMSF and protease inhibitor 
cocktail. Lysozyme was then added to a concentration of 0.2 mg/ml and the culture 
was incubated for 30 min at room temperature. After a freeze thaw, leupeptin and 
pepstatin (both at 1 μg/ml concentration) were added and the suspension was 
centrifuged at 16,000 g for 30 min. The crude cellular lysate was loaded on a 
HisPrep FF 16/10 column (GE Healthcare) equilibrated with 20 mM sodium 
phosphate buffer pH 7.4, containing 0.5 M NaCl and 20 mM imidazole. AADC was 
eluted with a linear gradient (0–100% in 200 ml) of the same buffer containing 500 
mM imidazole. After addition of 100 μM PLP, the protein solution was 
concentrated and imidazole and unbound coenzyme were removed by extensive 
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washing with 100 mM potassium phosphate buffer pH 7.4, using Amicon Ultra 15 
concentrators (Millipore). The enzymes concentration was determined using an εM 
of 1.42 . 105 M−1 cm−1 at 280 nm. PLP content was determined by releasing the 
coenzyme in 0.1 M NaOH using εM of 6600 M−1 cm−1 at 388 nm 44.  
 
Size-exclusion liquid chromatography 
Size-exclusion liquid chromatography was applied as further purification step. 
Samples were loaded on a Superdex 200 (10/300) (GE Healthcare) column 
equilibrated with 100 mM potassium phosphate buffer pH 7.4, on an Akta FPLC 
system (GE Healthcare). The run was performed using the same buffer at a flow 
rate of 0.3 ml/min with detection at 280 nm. 
 
Crystallization 
Crystallization conditions for WT h-holoAADC were screened at 21 °C by hanging 
drop vapor diffusion method using commercial crystallization kit (Molecular 
Dimension, MemGold2TM). Small crystals were obtained under the preliminary 
conditions of 0.1 M Tris pH 8.5, 44% PEG200, by mixing 1 µl of protein solution 
(holoAADC 20 mg/mL in 50 mM Hepes pH 7.4) with 1 µl of reservoir. In order to 
obtain bigger crystals, we further optimized the conditions by changing the buffer, 
pH and increasing the amount of protein by mixing 1.5 µl of protein solution with 
0.5 µl of reservoir. Best crystals were obtained in the four conditions 0.1 M Hepes 
pH 7.5, 40% PEG 200; 0.1 M Hepes pH 8.5, 40% PEG 200; 0.1 M Tris pH 8.0, 
50% PEG 200; 0.1 M Tris pH 9.0, 46% PEG 200. Crystal grew in 2–6 days under 
all conditions.  
Crystals of holoAADC with 1 equivalents of carbiDopa per monomer were 
obtained by mixing 1.5 µl of protein solution (holoAADC 20 mg/mL in 50 mM 
Hepes pH 7.4, 2mM carbiDopa) with 0.5 µl. of  0.1 M Hepes pH 7.5, 48% PEG 
200; 0.1 M Tris pH 8.0, 42% PEG 200; 0.1 M Tris pH 8.5, 42% PEG 200; 0.1 M 
Tris pH 9.0, 42% PEG 200.  
Crystals of holoL353P were grown at 21 °C by hanging drop vapor diffusion 
method my mixing 1.5 µl of protein solution (20 mg/mL in 50 mM Hepes pH 7.4) 
with 0.5 µl of reservoir (0.1 M Tris pH 8.0, 40% PEG 200).  
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Data Collection, Phasing and Refinement 
The diffraction data were collected from crystals frozen at 100°K after a brief 
immersion in a mixture of 80% of the mother liquor and 20% glycerol. 
The data used for refinement of all the crystal structures were collected on the 
XRD2 beamline of the Elettra Synchrotron in Trieste. The data were indexed, 
integrated, reduced and converted to structure factors using the programs 
MOSFLM 128 and the CCP4 software suite 129. 
The high resolution structure of WT h-holoAADC at pH 8.0 in Tris buffer was 
solved using the molecular replacement method as implemented in the program 
Molrep 130. The search probe used was the available model to 2.8 Å resolution 
without LLP, PLP and solvent molecules (pdb: 3rch). All the other crystal forms 
were modeled into difference Fourier maps phased by the refined WT h-holoAADC 
pH 8.0 structure. 
The final refinement of the nine crystal forms of AADC was carried out initially 
using the program REFMAC 131 and, in a second stage, with the program 
Phenix.refine 132. 
The models were built using the program Coot 133 and finally subjected to a final 
round of TLS refinement. The ligands in the co-crystals were modelled into 
difference Fourier maps phased by the refined, unliganded structure. Solvent 
molecules were added to the models in the final stages of refinement according to 
hydrogen-bond criteria and only if their b-factors refined to reasonable values and 
if they improved the R free.  
The diffraction data and refinement statistics of all the models are summarized in 
Table 9. All solved structures have not been deposited yet. 
Modelling of the loops 
To obtain complete structures of the enzyme on the apo and holoAADC, we 
performed molecular modeling using available crystal structures as templates. 
ApoAADC was modeled against available crystal structure (pdb: 3rbl) using 
Modeller v9.21 134. One hundred models for the apo structure were generated and 
assessed through DOPE 135 and GA341 136 scores. The best model was chosen 
according these scores and visual observation to avoid crossing loops. The same 
modelling protocol was applied to model the holo enzyme against the solved crystal 
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structure (structure 1 of table 9). However because Modeller wasn’t able to 
correctly model the loops, we used Swissmodel 137 instead, which allowed us to 
obtain a better model. Once the holo state was modeled, the Lysin-Pyridoxal 
phosphate was manually introduced in the structure on position 303 of both chains. 
Lysin-Pyridoxal phosphate parametrization 
The topology parameters of the zwitterionic form of Lys303-PLP (LLP) complex 
were generated using antechamber package of the AMBER20 tools 134. The atomic 
partial charges were computed according to the bcc scheme 135 and the AMBER 
atom types were assigned. Then, the residue library and parameters forcefield were 
prepared according to the ff99SB force field. Finally, the topology files were 
converted to GROMACS’ compatible files using the ACPYPE tool 138.  
 
MD Simulations 
All atom MD simulations of the apo and holo states of the enzyme were carried out 
using the GROMACS program, version 2019  . For the holo state simulation, LLP 
parameters were manually included into the force-field. Water, described with the 
TIP3P water model 136, and ion molecules (0.154 M of Na+/Cl- to mimic 
physiological conditions) were added to complete the systems. Each system was 
then equilibrated through a complete workflow: steepest descents minimization of 
5000 steps, NVT equilibration of 100 ps, NPT equilibration of 100 ps, and MD 
production under the NPT ensemble for 300 ns at room temperature.  
All calculations were performed within a GPU node available by the computational 
platform from the “Centro Piattaforme Tecnologiche” of the University of Verona. 
 
Bioinformatic analysis and Molecular graphics 
Human AADC sequence (EC: 4.1.1.28) was aligned with 75 homologues sequences 
retrieved from Uniref-90 database by the homolog search algorithm PSI-BLAST 
and aligned using Multiple Sequence Alignment software CLUSTALW on 
ConSurf server (http://consurf.tau.ac.il). A conservation score (9 = highly 
conserved, 1 = highly variable) was attributed to each residue. Structural analysis, 
measurements and figures of the human holoAADC structure (structure 1 in table 
9) was carried out using Pymol 2.2.3 (The The PyMOL Molecular Graphics 
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System, Version 2.0 Schrödinger, LLC). Dimeric AADC has been obtained by 
generating the symmetric mate of the crystallographic monomer. BindProfX was 
used to predict changes in binding affinity upon mutations in the form of ΔΔG 
(change in free energy of binding) values. The algorithm combines the FoldX 
physics-based potential with the conservation scores from pairs of protein-protein 
interaction surfaces sequence profiles.  
 
Determination of solubility level of the AADC variants 
E. coli has been used as a model for the expression study of the pathogenic AADC 
variants. Chemical competent bacteria were transformed with the proper 
mutagenized plasmid as described in the expression and purification section. 
Cultures were grown even in the absence or in the presence of 50 μM exogenous 
PLP and 1 ml of each culture was processed following the same procedure 
described above. After lysis, samples were treated with DNase (10 U) at room 
temperature for 30 min. The whole cell extract was separated by centrifugation at 
13,200 rpm, 10 min, 4 °C. Total protein content in the crude cellular lysate was 
quantified and 15 μg of total protein was run on a 12% (w/w) SDS-PAGE gel. 
Proteins from the gel were transferred on a nitrocellulose membrane by a Mini 
Trans-Blot cell (Bio-Rad). Membrane was blocked with a 5% (w/w) milk solution 
at 37 °C for 1 h and, after the washing steps, it was incubated with a 1:200 (v/v) 
diluted anti-AADC monoclonal antibody solution over night at 4 °C. Membrane 
was then washed and then incubated with a 1:4000 (v/v) anti-mouse secondary 
antibody solution for 1 h at 25 °C. Blotted proteins were detected and quantified 
with ECL (Millipore), using the ChemiDoc XRS Imaging System (Bio-Rad, 
Hercules, CA). Quantification of the band was obtained with ImageJ software (Fiji). 
 
Apoenzyme preparation and coenzyme binding affinity measurements 
Apoenzyme was obtained by incubating 5 μΜ holoenzyme with 10 mM 
hydroxylamine in 0.5 M potassium phosphate buffer pH 6.8 at 25 °C for 3 h. The 
solution was then loaded on a Desalting 26/10 column (GE Healthcare) pre-
equilibrated with 0.5 M potassium phosphate buffer pH 6.8 and eluted at 1 mL/min. 
The eluted enzyme was then concentrated on an Amicon Ultra 15 concentrators 
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(Millipore) and washed with 100 mM potassium phosphate buffer pH 7.4. The 
equilibrium apparent dissociation constant for PLP, KD(PLP), was determined by 
measuring the quenching of the intrinsic fluorescence of 0.1 μM AADC apoenzyme 
incubated in the presence of PLP at concentrations ranging from 0.005 to 20 μM 
for 3 h at 25 °C (in the dark) in 100 mM potassium phosphate buffer pH 7.4. 
The data were fitted to the following equation: 
 
𝑌 = 𝑌MAX
[𝐸]𝑡 + [𝑃𝐿𝑃]𝑡 + 𝐾𝐷(𝑃𝐿𝑃) − 2([𝐸]𝑡 + [𝑃𝐿𝑃]𝑡 + 𝐾𝐷(𝑃𝐿𝑃))2 − 4[𝐸]𝑡[𝑃𝐿𝑃]𝑡
2[𝐸]𝑡  
 
where [E]t and [PLP]t represent the total concentrations of the enzyme and PLP, 
respectively, Y refers to the intrinsic quenching changes at a PLP concentration, 
and Ymax refers to the fluorescence changes when all enzyme molecules are 
complexed with coenzyme. Curves fitting was performed using Prism, 8.4.0, 
(GraphPad ®). 
 
Enzyme activity assays 
The decarboxylase activity was measured by a stopped spectrophotometric assay 
140,141. Each variant enzyme (at appropriate concentration) was incubated for 1 h 
under saturating PLP concentration (10 μM) and different L-Dopa concentrations 
in a final volume of 250 μL in 100 mM potassium phosphate buffer pH 7.4 for a 
time within which a linear product formation is observed. The reaction was then 
stopped by heating at 100 °C for 2 min. TNB (1 ml of a 4.3 mM solution) and 
toluene (1.5 ml) were added and the extraction of trinitrophenyl-derivative was 
carried out at 42 °C for 45 min with continuous shaking. The concentration of 
trinitrophenyl-derivative in the toluene layer was quantified using prepared 
calibration curve of absorbance at 340 nm as a function of trinitrophenyl-derivative 
concentration 141. In the case of variants losing the PLP during the reaction with L-
Dopa (Y20del, Y20A, Y20S, H70R/W71del, W105C, A110E, S193D, S193E, 
P330L, R347Q, L353P) kinetic parameters were determined at the HPLC. Each 
enzyme was incubated in presence of 100 μM PLP and different L-Dopa 
concentrations in a final volume of 225 μL in 100 mM potassium phosphate buffer 
pH 7.4 for a time within which a linear product formation is observed. The reaction 
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was quenched with 25 μL of a 100 % TCA solution. Proteins were precipitated in 
ice and removed by centrifugation. Supernatants were analyzed by HPLC as 
described 49,50 using a Gemini C18 column (150 Å~ 4.6 mm, Phenomenex, CA, 
USA) on a Jasco PU-2080 Plus HPLC system equipped with a UV-1570 detector 
set at 295 nm. Samples were eluted in 50 mM potassium phosphate, pH 2.35, at a 
flow rate of 1 mL/min. Standard curves of dopamine peak area were prepared with 
commercially available dopamine. The kinetic parameters were determined by 
fitting the data obtained with the Michaelis-Menten equation using Prism, 8.4.0, 
(GraphPad ®).  
 
Spectroscopic measurements 
All spectral measurements were acquired in 100 mM potassium phosphate, pH 7.4, 
at 25 °C. CD measurements were recorded with a Jasco J-710 spectropolarimeter 
at a scan speed of 50 nm/min with a bandwidth of 2 nm at a protein concentration 
of 1–5 μM. Thermal denaturation was performed by monitoring the CD signal at 
222 nm of 4 μM enzyme on a 25–90 °C linear temperature gradient, with a 
temperature slope of 1 °C/min. 100 μM of exogenous PLP was added to the 
holoenzymes. Analysis of the external aldimine spectral modifications has been 
carried out on a Jasco V-550 spectrophotometer at a protein concentration of 10 μM 
in absence or in presence of saturating concentration (2 μM) for all variants, and 20 
μM for G96R and G146R) of substrates L-Dopa, DME, carbiDopa. Pictet Spengler 
adduct has been obtained by incubating PLP and L-Dopa and the corresponded 
HPLC peak has been collect, desalted, lyophilized. PMP profile was obtained by 
commercially available compound.  
 
HPLC analysis of coenzyme modification and dopamine formation 
Catalytically inactive AADC variants were incubated at 10 μM protein 
concentration with 2 mM L-Dopa in 100 mM potassium phosphate buffer, pH 7.4 
at 25 °C. Concentration-time curves were followed by withdrawing aliquots at time 
intervals and quenching the reaction by adding trichloroacetic acid to a final 
concentration of 10% (v/v). Proteins were then precipitated in ice and removed by 
centrifugation. Supernatants were analyzed by HPLC as described 49,50, using a 
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GeminiC18 column (150 Å~ 4.6 mm, Phenomenex, CA, USA) and performed on a 
Jasco PU-2080 Plus HPLC system equipped with a UV-1570 detector set at 295 
nm. Samples were eluted in 50 mM potassium phosphate, pH 2.35, at a flow rate of 
1 mL/min. Standard curves of peak area as a function of coenzyme or cyclic adducts 
concentration were prepared with commercially available PLP and coenzyme 
adducts obtained by synthesis. 
 
NMR experiments 
Before NMR analysis, the HPLC-purified compounds were exchanged in water, 
lyophilized and re-dissolved in D2O. All the NMR spectra were recorded at 298 K 
on a 600 MHz Bruker AVIII HD spectrometer equipped with a TCI cryogenic 
probe. For the acquisition we used a spectral width of 20 ppm, an acquisition time 
of 1.36 s, 32,000 data points and 128 or 256 scans. NMR data were processed with 
Topspin 3.2. PLP and PMP peak assignments were confirmed by comparing the 
chemical shifts of the 1D 1H NMR spectra with those from reference spectra 
deposited in the Biological Magnetic Resonance Data Bank (BMRB). The 1H NMR 
peak assignments to the Pictet-Spengler adduct were verified by comparing the 
chemical shifts with previously reported resonances 30, and supported by 2D 
correlation NMR experiment (TOCSY). 
 
DLS measurements 
DLS measurements were obtained on a Zetasizer Nano ZS instrument (Malvern), 
using disposable ZEN0112 polystyrene cuvettes. Setting used for particle size 
measurements was the following: solvent refractive index 1.330, viscosity 0.8872 
cP, protein refractive index 1.450, protein absorption 0.001, temperature 25 °C, 
equilibration 2 min, measurement angle 173° backscatter, analysis model multiple 
narrow modes. Samples were prepared at 3-4 µM protein concentration in 100 mM 
potassium phosphate, pH 7.4 (with additional 100 µM PLP for the holo forms) and 
filtered using a 0.02 µm Anotop 10 filter (Whatman). The reported sizes are based 
on 20 measurements, each consisting of 12-18 runs. Particle size for each sample is 
indicated as mean ± standard error of means (SEM). The results were compared 
using Student’s t-test between holoWT and holo variants and between apoWT and 
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apo variants *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Aggregation 
study was performed with a constant 90° scattering angle and a 633 nm wavelength 
laser. Protein samples were prepared at 4 μM concentration under physiological 
conditions (58 mM potassium phosphate, pH 7.4 at 37 °C). 100 µM PLP was added 
to samples relative to holo forms. The buffer was filtered a 0.02 µm immediately 
before the use. 
 
Limited proteolysis experiments 
Limited proteolysis were performed by incubating  0.54 mg/mL AADC with trypsin 
at the final E/S ratio of 1:100 (w/w) in 100 mM potassium phosphate, pH 7.4 at 25 
°C, with the addition of 100 μM PLP for the holoAADC samples. Time points were 
taken within 1 h of incubation and compared with AADC sample in absence of 
trypsin. At each time point, the reaction was boiled in SDS sample buffer to stop 
trypsin activity. The digestion products were separated by SDS/PAGE, and gels 
were stained with Coomassie blue. The gels were scanned, and peak profiles were 
obtained for the bands using National Institutes of Health IMAGE J software. All 
species were calculated as percentage of the undigested band and were graphed 
against time. Monomer disappearance where fitted to a one phase exponential 
function. N-terminal cleavage initial rate was estimated by analyzing the 
appearance of the nicked monomer (51.5 kDa species) with a linear fit.  
 
Identification of the tryptic sites by LC-MS  
A solution containing 0.54 mg/mL of WT and variants AADC has been digested 
with trypsin at 1:100 (w/w) in 100 mM potassium phosphate, pH 7.4 at 25 °C, with 
the addition of 100 μM PLP for the holoAADC samples. Digestion was quenched 
after 30 min by adding specific trypsin inhibitor at the ratio 1:2 (w/w). Reaction 
mixture was then analyzed and desalted by RP-HPLC (Agilent, mod. 1200, Santa 
Clara, Ca, USA) with a Jupiter C4 column (4.6 mm x 250 mm, 5 μm; Phenomenex, 
CA, USA). Peptides peaks were eluted with a gradient of water and acetonitrile, 
containing 0.1 % of trifluoroacetic acid: from 5 to 38 % in 5 min and from 38 to 43 
% in 15 minutes at 226 nm. Peptide identity was assessed with a Xevo® G2-XS 
ESI-Q-TOF mass spectrometer (Waters Corporation, Milford, Massachusetts, 
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USA) in positive mode. The capillary potential was set at 1.5 kV. The source 
temperature was at 100°C. Mass values were determined at a resolution >35.000 
and an accuracy <5 ppm. Mass spectra were analyzed by the Mass-Lynx 4.1 
software (Waters).  
 
Microfluidic Modulation Spectroscopy 
Wilde type AADC and L353P variant were prepared in the apo and holo form at 
the protein concentration of 0.5 mg/mL in 100mM potassium phosphate, pH 7.4 
with the addition of 100 µM PLP for the holoenzymes. Samples with matched 
buffers were prepared in pairs in 96-well plates. Microfluidic Modulation 
Spectroscopy (MMS) measurements were made using an automated AQS3Pro 
system from RedShiftBio, collecting differential absorption spectra between 
sample and reference pairs. The system provides highly-sensitive and reproducible 
IR spectra encompassing the amide I band, used for protein secondary structure 
analysis (1590 - 1710 cm-1). Measurements are made using a Y-shaped microfluidic 
cell in combination with a tunable quantum cascade laser (QCL) and a 
thermoelectric cooled HgCdTe (TEC-MCT) detector. Protein sample and reference 
are alternately flowed through the flow cell with pathlength 24.9 μm at 1 Hz, using 
dry compressed air at a positive pressure of 5 psi to record differential absorption 
spectra with a spacing of 4 cm-1. Subtraction of reference from sample spectra in 
real time due to modulation results in cancellation of any laser output variance and 
prevents the influence of absorbing components in this range, such as that of water. 
Flow cell and needle cleaning was performed as part of the measurements, and 
system cleanliness was measured between samples to ensure no contamination. 
Differential absorption spectra were deconvoluted to provide secondary structure 
information automatically as part of the measurement, using inbuilt AQS3 delta 
analytics software. Analysis was performed using gaussian curve fitting, based on 
the model described in 142. 
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AIMS OF THE THESIS 
 
Many efforts have been made in the past years for elucidating the structural and 
functional features of human AADC. Biochemical and biophysical approaches 
contributed to the dissection of the mechanistic aspects of its catalysis. However, 
some pieces of the puzzle regarding AADC are still missing.  
The first part of this thesis aims to provide additional structural details on the WT 
AADC. The objectives regard: 
• determining the crystal structure of human holoAADC in its native and 
ligand bound form and as a function of pH, in order to unravel structural 
determinants for the achievement of the structurally competent state; 
• analyzing the differences between the apo and holoAADC by means of 
molecular dynamics simulation highlighting region flexibility, protein 
mobility and domains crosstalk/communication; 
• providing in solution data to validate structural data by means of 
biochemical and biophysical techniques (limited proteolysis, spectroscopy, 
kinetics, site directed mutagenesis). 
The second part aims to expand the knowledge of the enzymatic phenotypes 
associated with the AADC deficiency. To this, the following objectives were 
pursued:   
• Cloning, expressing and purifying both artificial and novel pathogenic 
AADC variants; 
• Performing a biochemical characterization of the variants, possibly 
correlating different parameters and clustering the variants on the basis of 
their structural and/or functional defects; 
• Obtaining the crystal structure of a pathogenic variant and combining in 
silico and in solution data. 
Final aim of the present study consists in expanding the AADC structure-function 
relationship by correlating the new results of the WT protein with those obtained 
from the pathogenic and rationally designed variants possibly mapping the 
functional and structural effects of the mutations on the different protein regions 
and creating predictive models for future analysis.  
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This approach will lead to better understand the molecular basis of AADCd and 
provide useful tools for the improvement of severity prediction as well as to give 







Part 1. NOVEL INSIGHTS ON AADC STRUCTURE-FUNCTION 
RELATIONSHIP 
 
1. Overall spatial structure of human holoAADC  
 
While the apo human crystal structure of AADC has been solved in 2011 24, the 
only holo structure available until now is that of pig 20. Even if this is a good model 
of the human holo (89% sequence identity), the resolution of the human counterpart 
is desirable. 
Human holoAADC (h-holoAADC) crystal structure has been obtained at pH 7.5 by 
Molecular Replacement (MR) method at 1.90 Å resolution in collaboration with 
Prof. Massimiliano Perduca at the University of Verona (Table 9).  
While the porcine holoAADC exists as homodimer in the asymmetric unit like other 
group II a-decarboxylases (such as GAD67, HDC, CSAD), h-holoAADC exists as 
monomer in the asymmetric unit. The backbone atoms of h-holoAADC at pH 7.5 
superposes to chainA of pk-holoAADC (pdb: 1js6) with a Root Mean Square 
Deviation (RMSD) of 0.356 Å and with chainB with a RMSD of 0.347 Å. These 















pH 7.5 pH 8.0 pH 8.5 pH 9.0 pH 8.0 pH 8.5 pH 9.0 pH 7.5 pH 8.0 
Space group P6122 P6122 P6122 P6122 P6122 P6122 P6122 P6122 P6122 
Structure 1 2 3 4 5 6 7 8 9 
a (Å) 107.17 106.98 107.14 107.23 107.39 107.12 107.40 107.39 107.25 
b (Å) 107.17 106.98 107.14 107.23 107.39 107.12 107.40 107.39 107.25 
c (Å) 218.98 218.49 219.14 219.14 219.11 218.92 219.17 218.97 219.19 
a 90.0 90 90 90.0 90.0 90.0 90.0 90.0 90.0 
b 90.0 90 90 90.0 90.0 90.0 90.0 90.0 90.0 
g 120.0 120 120 120.0 120.0 120.0 120.0 120.0 120.0 
Molecules in 
the 1 1 1 1 1 1 1 1 1 asymmetric 
unit 
Resolution 
range (Å) 85.45 - 1.90 
85.30 – 










2.84 48.17 - 2.05 
Observed 
reflections 341,933 361,504 526,391 305,21 447,404 235,952 405,605 107,44 455,055 
Independent 
reflections 59,247 62,715 54,173 43,448 51,277 27,751 47,724 18,359 47,57 
Multiplicity 5.8 (6.0) 5.8 (5.9) 9.7 (9.9) 7.0 (7.0) 8.7 (9.0) 8.5 (8.3) 8.5 (8.1) 5.9 (5.9) 9.6 (9.7) 
Rmerge (%) 10.6 (47.4) 8.2 (48.4) 11.8 (49.9) 10.7 (49.8) 11.2 (48.2) 14.8 (49.7) 12.4 (48.7) 16.3 (50.9) 6.3 (53.0) 








(100.0) 98.8 (99.5) 
100.0 








refinement 59,121 62,62 54,04 43,414 51,155 27,73 47,585 18,281 47,502 
Rcryst (%) 19.05 17.85 18.07 17.53 17.06 17.89 16.71 19.90 18.47 
Rfree (%) 
(test set 5%) 21.54 20.06 19.26 19.76 19.40 20.92 20.32 23.24 20.44 
Protein 
atoms 3,667 3,559 3,64 3,553 3,636 3,636 3,642 3,553 3,556 
Ligand atoms 28 48 28 48 57 57 44 59 41 
Water 








0.527 1.173 0.618 0.850 0.869 0.578 1.196 0.874 0.654 
Planar 




0.041 0.068 0.044 0.053 0.051 0.042 0.076 0.048 0.042 
Average B 
factor (Å2) 24.59 30.60 28.87 31.11 29.72 40.43 31.48 33.99 34.76 
Protein 
atoms 24.28 30.29 28.68 30.87 29.34 40.16 31.26 33.93 34.45 
Ligand atoms 29.38 38.91 29.76 42.42 44.43 62.61 38.12 43.63 46.85 
Solvent 
atoms 28.57 34.08 32.00 32.82 32.59 38.23 34.06 31.83 37.40 
 
* The values in parentheses refer to the highest resolution shells. 
a Rmerge = ΣhΣi | Iih – <Ih> / ΣhΣi <Ih> where <Ih> is the mean intensity of the i observations of reflection h.  
b Rcryst = Σ | |Fobs| - |Fcalc| | / Σ |Fobs|, where |Fobs| and |Fcalc| are the observed and calculated structure factor amplitudes, 
respectively. Summation includes all reflections used in the refinement. 
c Rfree = Σ | |Fobs| - |Fcalc| | / Σ |Fobs|, evaluated for a randomly chosen subset of 5% of the diffraction data not included in 
the refinement.  





Fig. 15. Crystal structure of porcine and human holoAADC. Novel human holoAADC 
(represented as cartoon, colored: cyan) aligned to pk-holoAADC (cartoon, green, pdb: 1js6) 
shows the typical Fold type 1, group II a-decarboxylases organization. A) PLP (represented 
as yellow spheres) is bound to the conserved Lys303 of each LD. The two mammalian 
enzymes display identical overall topology in terms of high order secondary structure content 
as well as domain organization. B) Two LDs (green colored surface) of each monomer are 
faced, in a tightly closed bivalve conformation, the NTDs (cyan colored surface) are strictly 
intertwined forming a single stable interconnected structure. The CTDs (magenta colored 
surface) of each monomer are located at the opposite side of the molecule. Dimeric human 
enzyme has been obtained by generating symmetric mate to the crystallographic monomer 
using PyMol. 
 
Once the dimeric form of human holoAADC is generated by adding the symmetric 
mate, the overall structures of human and porcine AADC have been superposed 
(Figure 15). The NTD, LD and CTD are recognizable with regions 1-85, 86-360 
and 361-486 respectively. The N-terminal helices (helix-1 (residues 1-25), helix-2 
(residues 37-41) and helix-3 (residues 56-64)) of each monomer are strictly 
intertwined. The H1-loop-H2 is facing the CTD, in particular helix-16 (aa 416-431), 
on the same monomer. On the opposite side helix-3 drives the correct positioning 
of loop1 (aa 66-84). Each LD forms mainly water-mediated electrostatic 
interactions with the juxtaposed LD of the second monomer also mediated by some 
residues (Ile101 and Phe103) of loop2 (aa 100-110) and the whole loop3 (aa 323-
357) (Figure 16). As in the porcine structure the region corresponding to the CL is 





Fig. 16. Essential AADC unstructured regions called loop1, loop2 and loop3. A) 
Crystallographic monomer of human AADC (white) presents the characteristic functionally 
unstructured regions (represented as cartoon and ribbons) named loop1 (red), loop2 (green) 
and loop3 (blue). (B) While loop1 (residues 66-84) is sandwiched between NTD and CTD 
of the same monomer (white), loop2 and loop3 extend to the active site of the second 
monomer (gray). 
 
The structure obtained here completes the sequence of an open asymmetric bivalve 
that acquires symmetry upon closure, and reaches a symmetric and final 
conformation (Figure 17).  
 
 
Fig. 17. Novel human holoAADC completes the last frame of the apo reconstitution 
movie. The transition from the open apo structure to the closed holo one has been described 
as a morphing process consisting in an increasing PLP occupancy that drives the bivalve 
closure 24. ApoAADC structure used correspond to the following id: no PLP occupancy pdb: 




2. Active site of native and ligand bound human holoAADC 
 
AADC active site is mainly composed by residues of one monomer, with a few 
residues belonging to loop2 (Ile101’, Phe103’ (the prime ‘ denotes residues coming 
from the neighboring subunit) and loop3 (Leu353’, Gly354’) of the second 
monomer (Figure 18A).  
 
Fig. 18. View of the AADC active site in presence and in absence of Parkinson’s disease 
associated inhibitor carbiDopa.  A) Lys303-PLP monomer is shown in white, facing 
monomer is shown in gray. Structural water molecules are represented as spheres and colored 
in red.  B) Lys303 monomer is colored in cyan, while facing monomer in shown in magenta. 
Panels C and D shows the hydrogen bond network stabilizing PLP and carbiDopa, together 
with structural water molecules.  
 
 
As described in 20, a salt bridge between Asp271 side chain and protonated pyridine 
nitrogen of the cofactor stabilizes the PLP that forms a Schiff base with Lys303. 
PLP ring is further stabilized by His192 and Ala273 by stacking interactions. In 
addition, the cofactor phosphate group is anchored to the protein through an 
extended hydrogen bond network in which several residues (Ser147, Ala148, 
Ser149, Asn300, His302) and, as a novelty with respect to the pig structure 20, three 
water molecules are present (Figure 18A). While Ile101’ and Phe103’, involved in 
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hydrophobic interactions with the substrate catechol ring, do not participate in polar 
interactions, Leu353’ and Gly354’ backbones contact a water molecule A (WatA) 
that acts as bridge between loop3 and PLP. Water molecule B (WatB) is interacting 
with His192 side chain and molecule C (WatC) is shared between phosphate group 
of PLP and His302. 
The spatial structure of human AADC solved in complex with carbiDopa at pH 7.5 
at 2.84 Å shows the inhibitor forming a hydrazone linkage that mimics the external 
aldimine enzyme-substrate intermediate. Figure 18B shows the penetration of the 
catechol ring in the active site cleft generated by residues Thr82, Ile101’, Phe103’ 
and Tyr79. Carboxylate group of carbiDopa interacts with the imidazole ring of 
His192 still stacking the pyridine ring, while the 3’ and 4’ catechol hydroxyl groups 
of the inhibitor contact Thr82 and His302 respectively (Figure 18B).  
The superposition of human holoAADC solved at pH 7.5 in the absence and 
presence of carbiDopa reveals new details. In the absence of carbiDopa, loop3 
keeps Leu353’ in proximity to the phosphate moiety contacting WatA, as 
mentioned, and WatB is hydrogen bonded to His192. In this conformation, Arg355’ 
is turned in the opposite direction lying on a backward position. Once the PLP-
carbiDopa complex is formed, the carboxylate group of the ligand is positioned at 
2.3 Å from where WatB was placed and replaces it in interacting with His192. 
Loop3 undergoes a gross rearrangement, since Leu353’ and Gly354’ are displaced 
and become invisible in the electron density map. Interestingly, Arg355’ undergoes 
a 90° rotation, moving forward in proximity to the PLP and interacting with WatA’ 
that replaced WatA (Figure 19). WatC is placed in the same position in both 
structures. Altogether, this could represent a model of the catalytically competent 
conformation possibly favoring the rearrangement of CL and the positioning of 





Fig. 19. Proposed conformational change occurring at the AADC active site at pH 7.5 
when carbiDopa is bound.  Ribbon and sticks representation of the Leu353 and Arg355 
rearrangement. Ligand free monomer A is shown in white and loop3 is shown in gray. Ligand 
bound enzyme is shown in cyan. Water  molecules are shown in red. In absence of carbiDopa, 
Leu353 and PLP are interacting with structural water molecule A while His192 with water 
molecule B. In this active site conformation Arg355 lies on a backward position.  Once ligand 
is bound, the carboxylate group of carbiDopa substitutes molecule B in interacting with His192 
and molecule A’ replaces molecule A. Loop3 is rearranged, Arg355 is moved into a forward 
conformation interacting with molecule A’. Once displaced from the active site Leu353 
electron density is missing. 
 
Overall, the human AADC architecture of the active site solved at physiological pH 
confirms the known cofactor binding mode of this class of PLP a-decarboxylases 
23, and reveals new structural elements possibly implicated in catalysis. 
 
3. Effect of pH on AADC monomer-monomer interface: sensitivity of 
loop3 
 
Given the modifications in terms of crystallographic water molecules as well as 
loop3 residues visible in the transition from the internal aldimine to PLP-carbiDopa 
complex, we decided to undertake an investigation of the pH effect on AADC active 
site at first of the native unliganded form and then in complex with carbiDopa. 
Human structures obtained at different pH values have been superposed to the 
porcine one (pdb: 1js6) obtained at pH 6.5 20. Although the structures share identical 
overall topology (Figure 20A), they reveal slight structural alterations at the dimer 
interface, i.e at the active site and on loop2 and loop3. AADCpH7.5 aligns to 
AADCpH8.0 with a RMSD of 0.140 Å, to AADCpH8.5 with RMSD of 0.100 Å, to 
AADCpH9.0 with RMSD of 0.143 Å indicating a global good similarity.   
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Fig. 20. View of the AADC active site under different pH values. A) Human structures 
solved at pH 7.5, 8.0, 8.5, 9.0 (colored cyan, purple, yellow, pink, respectively) are 
superposed to the porcine holoAADC solved at pH 6.5 (green, pdb: 1js6) without showing 
any relevant topological differences. B) While the PLP is similarly bound Lys303, active site 
differences come from surrounding structural water molecules. C) Major differences of the 
active site residues are mainly visible on those residues belonging to loop2 and loop3 (Ile101, 
Phe103, Lue353, Gly354) and Thr82. In particular, Leu353 and Pro352 are missing at pH 8.0 
and 9.0.  
 
An insight into the active site of the internal aldimine shows nearly identical 
positions of the PLP-Lys303 Schiff base with base-stacked His192 in the different 
structures, being the main differences, not observed in 20, mainly related to water 
molecules number and position as well as to displacement of interface residues and 
loop3 elements.  
Molecule WatA, together with WatC, stabilizes the phosphate moiety at pH 6.5, 7.5 
and 8.5. WatA also interacts with Leu353’ and Gly354’ backbone. At pH 8 and pH 
9 only WatC is visible, being WatA absent. Wat B, as mentioned above, bridges 
His192 only at pH 7.5. Finally, WatD is present only in the published structure at 
pH 6.5 20 and concurs to phosphate binding (Figure 20B). 
In each subunit, active site residues of the same chain composing for the great part 
the active site exhibit subtle differences at the different pH values mainly visible on 
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Thr246 and Thr82 (Figure 20C). Residues contributing to this active site from the 
cognate subunit, Ile101’ and Phe103’ of loop2 and Leu353’ and Gly354’ of loop3 
exhibit larger alteration of the amino acid side chains (Figure 20D), particularly 
evident at basic pH values where the electron density of the latter two loop3 amino 
acids is missing. Notably, the larger effects are displayed by Arg355’ (immediately 
following the previous two amino acids stretch) and the interface residue Glu150. 
Interestingly, this residue immediately follows Ser147-Ala148-Ser149 triad that 
anchors the phosphate PLP moiety, as mentioned above. It can be observed that the 
glutamate side chain carboxylate is oriented towards the dimer interface at acid and 
neutral pH, while it is instead turned inside at the more basic pH values. 
In more depth, at pH 6.5 and pH 7.5, Glu150 connects the two active sites through 
sequential polar interactions that cross the inter-subunit surface (top view, Figure 
21A). In details, Glu150 side chain connects Ser147 backbone to a water molecule 
located at the center of the dimer interface (Figure 21A). This central water 
molecule is shared between the two monomers through the same weak interaction 
with the respective Glu150 residue as shown from the top view of figure 21A. At 
pH 8.5 the side chain of Glu150 rotates and contacts the backbone nitrogen of 
Ile351 on loop3 thus disrupting the bridge of interactions between the two subunits 
(Figure 21B) and the central water molecule is trapped into a small pocket. At pH 
8 and pH 9 a deep rearrangement of the dimer interface occurs. Two water 
molecules are now accommodated at the monomer-monomer interface, each one 
interacting with the Glu150 carboxylate of each monomer. As said, at pH 8.0 and 
9.0 residues Leu353’ and Gly354’ are invisible and Arg355’ moves in close 
proximity to PLP and generates a new polar contact directly with the phosphate 
moiety creating a new inter-subunit interaction (Figure 21C) between loop3 and 
PLP. The observed Arg355 plasticity is similar but not identical to that described at 
pH 7.5 in presence of carbiDopa, since in the former structure, a water molecule 
(A’) is interposed between Arg355’ and PLP. Thus, being the two active sites near 
the interface, our structures solved at different pH values suggest that an effect at 






Fig. 21. Effect of pH on the monomer-monomer interface of AADC. Human holoAADC 
structures solved under different conditions are compared with that of pk-holoAADC. AADC 
structures are represented as cartoon and residues discussed in the text and PLP are shown as 
sticks, while water molecules as spheres. Each active is shown form both a side point of view 
and from a top point of view and the dimer 2-fold axes and the dimer interface are indicated 
with a dashed red lines for clarity. Color code is indicated, A) AADCpH6.5 and AADCpH7.5 are 
colored in green and cyan respectively, B) AADCpH8.5 is colored in yellow and C) AADCpH8.0 
and AADCpH9.0 are colored magenta and pink respectively.  
 
Loop3 has been associated to catalytic functions since it includes the flexible CL 
(see above). At pH 6.5, 7.5 and 8.5 residues 328-339, 327-341 and 323-341 
respectively, are missing. Interestingly, at pH 8.0 and 9.0 a longer segment of 
residues, 323-354 is missing. A comparison of the invisible stretch of the here-
described new holo-structures with that of the apoAADC structure provides insights 
on the flexibility not only of the CL but also of the entire loop3 (the underlined 




Fig. 22. Mobility of loop3 at different pH values. A) Alignment of loop3 amino acid 
sequence of all available mammalian AADC crystal structures. CL missing residues are 
highlighted in red. Residues that differ between S. scrofa and H. sapiens are underlined. 
Loop3 sequences available for human apo AADC are shown. Apo intermediates solved in 
presence of different PLP occupancy are named apo1.5 (pdb: 3rch, one monomer showing the 
internal aldimine and the other with unbound PLP) and apo0.5 (pdb: 3rbf, unbound PLP 
present in one monomer active site). Apo0 corresponds to the loop3 sequence of pdb: 3rbl.  
B) Conformational changes visible on loop3 of holoAADC at pH 6.5, 7.5 and 8.5. Residues 
showing pH sensitivity are represented as sticks. Structures are represented as cartoon, 
colored green - pH 6.5 (pdb: 1js6), cyan - pH 7.5 and yellow - pH 8.5 respectively. Loop2 
and loop3 are represented in green and blue ribbons. 
 
There is a general trend in subtle loop3 conformational changes from pH 6.5 to pH 
9. Interestingly, residues of the part of loop3 following the CL (from Arg347 on) 
are visible at the active site and their different positions at different pH values could 
influence the mobility and thus the catalytic competence of the CL. In particular, 
Asp345 undergoes a substantial rearrangement from pH 6.5 (Figure 22B), where it 
contacts Lys327 upstream CL and His348 downstream the CL, to pH 7.5 where it 
is tilted and interacts with Arg347, to finally pH 8.5 where it is rotated on the 
opposite side bridging Phe103 of loop2. These displacements could relapse in 
altered flexibility of loop3 reflecting on CL mobility.  
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4. Effect of the pH on the active site in presence of carbiDopa 
 
In an effort to understand the role of loop3 elements, so essential for enzymatic 
activities, we solved the AADC-carbiDopa complex at different pH values. 
According to the Dunathan’s hypothesis 27, the carboxylate group of the inhibitor 
places the Cα–CO2 bond in an orthogonal orientation to the plane of the coenzyme 
ring under each pH condition (Figure 23A).  
 
Fig. 23. Effect of the pH on AADC active site in presence of carbiDopa. Proteins scaffold 
is represented as cartoon, PLP, carbiDopa and residues as sticks. Colored code: green (pk 
AADC, pH 6.5), cyan (pH 7.5), magenta (pH 8.0), yellow (pH 8.5), pink (pH 9.0). A) PLP-
carbiDopa complex together with water  molecules WatA and WatA’ solved at different pH 
are superposed showing slight differences. B) Active site of AADCpH7.5 shows Arg355 in the 
forward position, interacting with WatA’. Differently, in C) Arg355 is stacked in the 
backward conformation and Leu353 is contacting WatA. Arg347 shows a new contact with 
Phe103 on loop2 (represented as lines for clarity). Similarly, at pH 9.0 (D) loop3 shows a 
conformation where Leu353 is facing PLP and Arg347 interacts with Ser193.  
 
CarbiDopa is present as bound with the formyl group of PLP in all structures but at 
pH 8.5 since under this condition the Lys303-PLP Schiff-base is still present even 
if the carbiDopa molecule is properly positioned in a sort of Michaelis complex 
structure. Despite this difference, under all conditions, no alterations of the PLP 
anchoring residues are notable. Again, and interestingly, the relevant differences 
among the solved structures consist in the position of the structural water molecules 
and in the orientation of some loop3 residues (Figure 23A).  
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If in the ligand-free structures Arg355’ is positioned in the backward conformation 
at pH values 6.5, 7.5 and 8.5 and it is rotated inside at pH 8 and 9, in the carbidopa 
complexes it rotates forward at pH 7.5, as mentioned above, while it is located in 
the backward position at all other pH values.  
Interestingly, at pH 6.5, 8 and 8.5 loop3 seems to be more “locked” due to a new 
interaction between Arg347’ side chain and Phe103’ backbone. This is 
corroborated by the fact that Leu353’ and Gly354’ are still visible in the electron 
density map and in these structures WatA is indeed positioned in the same place as 
in the ligand-free structures. At pH 9, a further difference is present in addition to 
WatA, Leu353’ and Arg355’ stacked in the backward position, and regards 
Arg347’ interacting with Ser193 of the opposite subunit (Figure 23C).  
Altogether, the observed alterations at different pH values of the structural water 
molecules and the conformational plasticity of Leu353 and Arg355, highlight the 
role of loop3 in AADC. Interestingly, kcat of the decarboxylase reaction of AADC 
exhibits an optimum at pH 7.5 with a reduced activity at lower or higher pH that 
could be related to slightly differences in the interface and in the interconnection 
between the active sites 59.  
 
5. MD simulations show the different flexibility of the apo and holoAADC, 
the asymmetric movements of the monomer chains and domain 
communication 
 
The availability of the solved crystal structure of human apoAADC (pdb: 3rbl) 
together with the novel holoAADC structure gave us the unprecedent opportunity 
to investigate the dynamics of the apo and holo human enzymes by means of 
molecular dynamics (MD) simulations. Since both structures lack of some regions, 
we started our analysis with the kind support of Dr. Rui Ribeiro from the lab of 
Prof. Alejandro Giorgetti at the University of Verona by modeling loop2 (in the 
apo) and loop3 (in the apo and holo). For the holo system, Lys-PLP complex was 
separately parametrized as described (see materials and methods). All-atom MD 
simulations were then carried out following the protocol described in the material 




Fig. 24. Representative backbone RMSD and overviews on the structural 
rearrangement of apo and holo AADC during simulations. A) Backbone RMSD as 
function of time for representative trajectories of dimeric apoAADC (blue) and holoAADC 
(gray). After an initial structural rearrangement  during the initial 50 ns of simulation, the 
average backbone RMSDs were found to reach a plateau at 0.457 ± 0.001 nm (apo), 0.2268 
± 0.002 nm (holo). B) Comparison between the crystallographic apo (pdb: 3rbl) and holo 
(structure 1) structures and the structures equilibrated after 300 ns and representative of the 
last MD snapshot. Arrows indicates the regions where relaxation is more evident. 
 
Afterwards a 300 ns long simulation was performed. Inspection of the RMSD 
values of the backbone throughout the simulation, indicates that both systems reach 
equilibrium in 50 ns of simulations, during which time an initial structural 
rearrangement is seen (Figure 24A). Calculated values of backbone RMSD for the 
production stage show that the apo system reaches a plateau at 0.457 ± 0.001 nm, 
while the holo system at 0.2268 ± 0.002 nm. These data indicate that both systems 
reach stability during the simulations and that apoAADC is overall more dynamic 
than holoAADC. In fact, once the equilibrated apoAADC structure (structure 
relative to the last snapshot of the MD) is superimposed to the crystallographic one, 
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larger differences emerge with respect to the holo enzyme. As shown in figure 24B, 
relaxed apoAADC results in a partially closed bivalve. It has been reported that the 
two LDs of the crystal apoAADC are distant up to ~ 20 Å 24. Here, we observe that 
the equilibrated apo structure moves the two LDs closer to each other, in a reduced 
open conformation of ~ 15 Å. Moreover, the relaxation of the structure seems to 
occur symmetrically only in one monomer, and in particular in the very apical part 
of the protein in proximity of helix-6 (residues 147-171), being the top of the helix 
moved apart by ~ 10 Å in the MD structure with respect to the crystal one. This 
helix has been already seen to constitute a highly flexible region in homologous 
human HDC and GAD 25,143. As for the holo, the equilibrated structure does not 
show gross relaxation in comparison to the crystal form even if some asymmetric 
motions are visible in the proximity of helix-6 (Figure 24B).  
In order to highlight the structural/dynamical features underlying the different 
mobility between the two monomers, we compared the root mean square fluctuation 
(RMSF) of the apo chainA and chainB together with those of the holo form. The 
apo form (Figure 25A) presents overall more flexibility along the polypeptide 
chain with respect to the holo form. In general, the LD is the domain showing the 
highest flexibility in the chains of both apo and holo enzymes, being loop3, in 
particular the CL, that displays the highest mobility.  
 
Fig. 25. Flexibility profile (RMSF) provided by MD of modelled apoAADC and 
holoAADC. A) RMSF profile along chainA (magenta) and chainB (blue) sequence of 
apoAADC, B) RMSF relative to chainA (gray) and chainB (black) of holoAADC. Residue 
number are indicated in correspondence of maximum RMSF values for clarity. Domains 
division are highlighted in colors,  Loop3 fluctuation is shown in detail in the insets. C) 
regions of maximum flexibility are shown on the holo form (structure 1).  
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Concerning the differences between the two monomers of each structure, in 
addition to the CL inspection, apoAADC shows a marked different backbone 
mobility between chainA and chainB in the 189-289 region, as evidenced by higher 
RMSF values in chainA. This region constitutes the external part of the open 
bivalve indicating that the opening of the dimer leads to a relaxation of this part of 
LD and is in connection again with helix-6.  
On the contrary, the holoAADC backbone flexibility does not present relevant 
differences in terms of RMSF between the two chains, mirroring the closed and 
rigid bivalve-like structure, unless the CL (as observed above), thus reflecting a 
possible asymmetrical behavior (Figure 25B).  
Interestingly, also human HDC shows a previously unrecognized asymmetric 
mobility in the oxidized forms, which interestingly constitutes the more active 
species 143. Considering the oxidized HDC, one monomer results more flexible in 
the LD in the same regions as AADC (around residue 140, around residue 175 and 
in its CL region). In addition, in the holo and apo GAD65 dynamic structures 25, the 
CL fluctuates slightly more than the CTD, while in both HDC (reduced and 
oxidized) and AADC (apo and holo) the flexibility of the CL and loop3 is more 
relevant than small signals at the CTD and NTD. 
While in the apo AADC, loop3 swings symmetrically between chainA and chainB, 
in the holo system, chainB shows an increased rigidity at Tyr332 level. 
Interestingly, this is concomitant with an increased mobility at Leu353 suggesting 
that the overall protein conformation (even in absence of substrate) facilitates the 
positioning of the catalytic Tyr332 in proximity of the active site.  
This asymmetry in holo CL region led to a deeper inspection of the holo and apo 
structures equilibrated after 300 ns of MD simulation. Here, apoAADC maintains 
loop3 in a solvent exposed conformation in both monomers (Figure 26).   
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Fig. 26. ApoAADC structure after 300 ns of MD simulation. A) Upper view in cartoon 
representation of equilibrated apoAADC. The protein shows a partially closed conformation, 
with loop3 (represented as ribbon and colored in blue) showing the exposure of Lys334 and 
Tyr332 to the solvent. B) Side view of apoAADC. Some residues of loop3 are shown as 
sticks, Lys334, Tyr332, Leu353, Arg355, Lys303 on both monomer chainA and chainB*. 
 
Lys334, that is trypsin accessible in both apo and holo enzymes, shows a similar 
conformation in both chains, as well as Tyr332. Moreover, in the absence of PLP, 
both residues Leu353 and Arg355 at the end of loop3 are rolled out. The 
equilibrated holoAADC shows instead an asymmetric conformation (Figure 27).  
 
Fig. 27. HoloAADC structure after 300 ns of MD simulation. A) Upper view of 
holoAADC, represented as cartoon; loop3 is represented as ribbon and colored in blue, while 
CL is highlighted in cyan. PLP, and residues His192, Lys303, Try332, Lys334, Leu353, 
Arg355 are shown as sticks. CL shows two alternative conformations acting as a closed or 
open lid on the active site. B) When CL is in a closed conformation -CL in-, Tyr332 is placed 
in closed proximity of His912 and PLP and CL acts as a closed lid on the active site. C) 
Different possible conformation of loop3 showing Tyr332 and Lys334 exposed to the solvent 
-CL out-.  
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Monomer A shows indeed a conformation of loop3 in which the CL is twisted 
inward the active site (-CL in-), placing Tyr332 in proximity of His192 and PLP. 
In this conformation Lys334 is less solvent exposed. Monomer B shows instead a 
loop3 conformation in which Leu353 is still anchored to the PLP but CL is twisted 
outward the active site (-CL out-) and Lys334 is solvent exposed as indicated also 
by higher RMSF values. The found -CL in- conformation is very similar with the 
CL conformation found in HDC and GAD67 crystal structures, in which the 
catalytic tyrosine is consistently placed in proximity of the PLP (Figure 28).  
 
Fig. 28. Comparison between the AADC, HDC and GAD67 loop3 conformation. The 
AADC loop3 snapshot obtained after 300 ns of MD simulation is superposed to the 
crystallographic structures of human HDC (pdb: 4e1o) and GAD67 (pdb: 2okj). A) in the -
CL in- conformation of AADC, catalytic Tyr332 is placed in proximity of PLP similarly to 
HDC and GAD67 catalytic tyrosine, while B) shows that loop3 is similarly anchored but CL 
of AADC is positioned as an open lid. 
 
In order to detect differences in the global large-amplitude motions between the two 
proteins, we decided to apply the Principal Component Analysis (PCA) to the MD 
simulation trajectories. A comparison between apoAADC and holoAADC shows 
that the overall magnitude of the fluctuations is higher in the apoAADC while both 




Fig. 29. Principal component analysis (PCA) on the apo and holo MD trajectories. A) 
PCA analysis along chainA (magenta) and chainB (blue) sequence of apoAADC, B) PCA 
relative to chainA (gray) and chainB (black) of holoAADC. Residue number are located in 
correspondence of maximum mobility for clarity. Domains division are reported,  Loop3 
mobility is highlighted in the insets.  
 
ApoAADC displays an asymmetric profile of fluctuations along each domain, 
particularly pronounced at LD level (possibly related with the solvation properties 
of apoAADC that favors dimer opening 25). In addition, in concomitance of an 
overall mobility of LD and a slight change in NTD (in the loop connecting helix-1 
and helix-3) and CTD (on helix-16, aa416-431) on chainA, chainB exhibits high 
mobility on loop2, on surface loop 134-139 and loop3, particularly at Leu353 level 
(as shown in the inset).  
The inspection of the principal components relative to holoAADC evidences a 
global rigidity of the protein (Figure 29B). HoloAADC displays an asymmetric 
fluctuation similar to that of the apoAADC. In fact, even if both monomers are 
mobile, chainA fluctuations are visible in defined regions of the LD, while chainB 
is more mobile in the NTD (in particular at the end of helix-1), loop1, loop3 and 
the CTD (helix-16). Interestingly, loop1 is located at the NTD-CTD interface of the 
same monomer while proximal loop3, and thus CL, comes from the other monomer 




Fig. 30. Crosstalk between NTD, CTD and CL. Equilibrated structure of holoAADC 
shows two possible motions of NTD (white), CTD (gray) and CL (cyan) and the position of 
loop1 at the monomers interface. A) when Tyr332 is exposed to the solvent, CL acts as an 
open lid, while B) when Tyr332 is placed in proximity of PLP, CL acts as a closed lid. These 
two CL conformations are synchronized with the motions (“breath”) of CTD in relation to 
NTD (C). D) Similar considerations can be done on apoAADC since NTD and CTD of the 
same monomer are faced in both protein forms. 
 
CL conformations -in- and -out- could be related to CTD and NTD mobility: the -
CL in- conformation is favored by high mobility of CTD while the -CL out- 
conformation could be related to a more rigid behavior (Figure 30C). A similar but 
not identical dependency has been observed in GAD65 where the fluctuation 
amplitude of CTD complemented by the CL, influences the opening/closing the 
active site 25.  
Here, in holoAADC for the first time we add more information connecting NTD to 
both CTD and LD, mainly reflected in CL movements.  
 
6. Limited proteolysis provides additional insights on the different 
mobility of the apo and holoAADC 
 
We decided to follow the flexibility of apo and holoAADC by means of limited 
proteolysis with trypsin for identifying critical exposed regions. As previously 
described, in presence of trypsin holoAADC is nicked in the CL, in correspondence 
to Lys334. The nicked pig enzyme is digested into two species of 36 kDa and 18 
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kDa, remains folded but loses its decarboxylase activity 30. We subjected holo and 
apo human AADC to tryptic digestion and monitored the products during time on 
an SDS-page (as described in material and methods).  
 
Fig. 31. Differential N-terminal susceptibility of apo and holoAADC to trypsin. A) 
limited proteolysis of apo and holoAADC in presence of trypsin at E:S ratio of 1:100 (by 
weight) in 100 mM potassium phosphate pH 7.4 at 25 °C with the addition of 100 µM PLP 
for holoAADC. At indicated times aliquots of the reaction mixture were boiled in SDS 
sample buffer and the reactions were resolved by SDS-page. B) Same reaction mixture were 
stopped after 30 min of digestion with specific trypsin inhibitor, and analyzed by RP-HPLC 
and MS (see materials and methods). Experimental masses are listed in B) and compared 
with the expected theoretical masses of the identified peptide species. C) Proposed pattern of 
proteolysis for holo and apoAADC in accordance to the identified tryptic sites. D) 
Comparison of equilibrated holo (gray) and apoAADC (orange) showing Arg27 on helix-1 
(a-1) being involved is a salt bridge with Glu61 of helix-3 (a-3) is a similar way between the 
two forms, suggesting that the N-terminal susceptibility of apoAADC to trypsin unlikely 
depends on Arg27 conformation.  
 
Surprisingly, while the human holoAADC exhibits the formation of two bands at 
~36 kDa and ~18 kDa resulting from the cleavage of the monomer (54.7 kDa) in 
position 334-335, as the porcine enzyme, the apo protein shows a different tryptic 
pattern, characterized by the presence of novel bands. At 5 minutes, one species, 
close to that of the monomer, appears, suggesting the presence of an N- or C-
terminal novel tryptic site (Figure 31A) in addition to the 36 kDa and 18 kDa 
species of the holo. From 5 to 60 minutes, a second novel band accumulates referred 
to a species of around 30 kDa. In both apo and holo enzymes with time, further 
species are visible at molecular weight smaller that 18 kDa, possibly attributed to 
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subsequent proteolytic events. The proteolytic mixture has been analyzed by MS 
and the identified fragments are reported in figure 31B. These data confirmed the 
main tryptic site in correspondence to Lys334 in both apo and holo forms, and a 
second never observed site only in apoAADC corresponding to the N-terminal 
Arg27, in a loop connecting helix-1 and helix-3. Complementary N-terminal 
peptide 1-27 (running out of the gel) has been identified with a mass of 3208.07 
Da. Lastly, the identification of the lighter band of 17.1 kDa reveals that the C-
terminal 335-486 fragment if further cleaved at the flexible C-terminal histidine tag 
forming a 17.1 kDa as reveled from the fragment 335-479. A scheme of the 
characteristic pattern of proteolysis of holo and apoAADC is reported in figure 
31C.  
A bioinformatic inspection of the holo and apoAADC equilibrated structures shows 
that Arg27 is involved in a salt bridge with Glu61 located downstream on helix-3. 
This contact seems a structural requirement for keeping associated helix-1 and 
helix-3. As shown in figure 31D, the NTD of holoAADC superposes to the NTD 
of the apoAADC. However, MD simulations demonstrate that the overall apo 
structure is more mobile and eventually accessible to tryptic digestion. In addition, 
they reveal that the region of the first 40 amino acids is certainly more mobile in 
the apo structure than the holo one, as indicated by both PCA and RMSF analysis, 
suggesting that this stretch of residues could be relevant for conformational 
movements. A cleavage at this level could have a double consequence: on one side 
it could exert some effects on helix-16 of CTD contacted by the loop following 
helix-1, on the other, through the disassembling of the Arg27-Glu61 interaction, it 
could influence loop1 that follows helix-3. It is known that loop1 has a strong effect 
on apo to holo conformational change 24.  
Notably, also GAD65 exhibits a pattern of proteolysis 25, where apoGAD N-
terminal is susceptible to trypsin attack as apoAADC. However, here, differently 
from GAD65, holoAADC is cleaved at CL, while apoAADC is simultaneously 
cleaved at Arg27 and Lys334. Instead, apoGAD65 does not present the same 
proteolytic sites as holoGAD65 25. This should not surprise since each enzyme has 
evolved specific structural elements and performs highly specific substrate 
recognition and catalysis.  
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A superimposition of the human group II a-decarboxylases sequences shows the 
same basic N-terminal residue whose susceptibility to trypsin may constitute an 
informative probe for the global stability of the NTD (Figure 32).  
 
Fig. 32. N-terminal Arg27 is conserved among group II a-decarboxylases. A) 
Superposition of human AADC (white, structure1), HDC (green, pdb: 4e1o), GAD65 (cyan, 
pdb: 2okk), GAD67 (purple, pdb: 2kj) and CSAD (yellow, pdb: 2jis) shows the conservation 
of a basic N-terminal amino acid consisting in a lysine residue in GAD65, GAD67 and CSAD 
and in an arginine residue in AADC and HDC. B) AADC and HDC shows the formation of 
the same salt bridge between conserved arginine and glutamate.  
 
7. Removal of tryptic sites by mutagenesis provides in solution evidences 
of the asymmetric motion of the dimer. 
 
We then decided to make artificial variants R27Q and K334Q (the latter kindly 
provided by Dr. Riccardo Montioli of the University of Verona) in order to study 
the role of these residues on the holo and apo protein. Residual activity of the R27Q 
and K334Q variants resulted to be 36.2 % and 84.2 % of that of the WT 
respectively, indicating that, even if the substitutions are conservative, the effect of 
the N-terminal variant is more relevant respect to the variant of the CL region. 
When subjected to trypsin digestion, the variants provide interesting results. 
HoloR27Q shows the characteristic holo-pattern with the formation of the two 
bands deriving from the monomer cleavage in the CL. HoloK334Q remains instead 
completely resistant to proteolysis (Figure 33A). As for the apo variants, apoR27Q 
still shows the holoWT pattern and apoK334Q shows the formation of a second 
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high weighted species deriving from the N-terminal cleavage (the corresponding 
3.2 kDa migrates out of the gel).  
 
Fig. 33. Limited proteolysis of WT, R27Q and K334Q variants. Susceptibility of WT and 
R27Q and K334Q variants to digestion was determined by incubating 0.54 mg/mL of AADC 
with trypsin at the E:S ratio of 1:100 (w/w) (for WT) or 1:200 (w/w) (variants) in 100 mM 
potassium phosphate pH 7.4 at 25 °C with the addition of 100 µM PLP for the holo forms. 
Time points were taken along 1 h of incubation and compared with AADC sample in absence 
of trypsin. At each time point, the reaction was boiled in SDS sample buffer to stop trypsin 
activity. The digestion products were separated by SDS-page. B) Plot of Plot of 
disappearance and formation of digested holo and apoWT AADC during the limited 
proteolysis time course. Species are expressed as a percentage of initial undigested band. C) 
Digestion of apoK334Q with trypsin at the increased ratio of 1:50 (w/w). Time points are 
shown. D) ApoK334Q was firstly incubated 60 minutes with trypsin at the E:S ratio of 1:50 
(w/w) and then PLP was added to the final concentration of 100 µM. The enzyme was then 
reconstituted over night at 8 °C and its residual activity was evaluated.  
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The initial rate of apoWT monomer disappearance (54.7 kDa species) has been 
calculated to be ~ 3.9 fold more rapid than in the holoWT, and the increase of apo 
18.1 kDa band (resulting only from the CL cleavage) is ~ 2.1 fold more rapid than 
the holo. These observed rates reflect the higher extent of exposure of the apo CL, 
mirroring indeed the higher conformational mobility of apo loop3 highlighted with 
MD.    
Since under these experimental conditions we could not observe a complete 
conversion of the undigested species into the nicked one, we decided to increase 
the trypsin ratio up to 1:50 for apoK334Q. Surprisingly, the undigested monomer 
and its nicked derived species fast reach an equilibrium at about 50 % of undigested 
monomer suggesting the possibility that the asymmetric conformation of 
apoAADC is mirrored by an asymmetric mobility of the two monomers, as revealed 
by half of the N-terminal being attacked (Figure 33B). A second slow phase is 
visible after some hours of incubation in which the high trypsin ration lead to a 
progressive disappearance of the monomer (further derived species are visible). 
Thus, we assayed the activity of reconstituted apoK334Q obtained after 60 minutes 
of digestion (Figure 33C). While the reconstituted undigested apoK334Q shows to 
be fully reconstituted, the digested and reconstituted apo enzyme presents 50 % of 
the holo enzyme activity possibly meaning that 50 % of the protein population is 
digested and does not reactivate, while the remaining population perfectly 
reconstitutes. These results together with MD data strongly sustain evidence of an 
asymmetric mobility of AADC.  
 
Fig. 34. Analysis of the solvent accessible surface area (SASA) of Arg27. Solvent 
accessible surface area of Arg27 during MD simulations is similar in all AADC chains, both 
in the apo and holo form, suggesting that the Arg27-Glu61 salt bridge is stable along 300 ns. 
The accessibility of apoArg27 to trypsin could be due to large amplitude motions instead of 
local conformational changes. 
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A further confirmation of the trypsin accessibility of Arg27 on the apo protein is 
given by the analysis of the solvent accessible surface area (SASA) of Arg27 
(Figure 34). No differences are visible among the apo and holo chains during the 
simulation, meaning that the accessibility of the NTD for the protease is ascribable 
to the large-amplitude fluctuation of the CTD with respect to NTD. In fact, as 
evidenced by PCA analysis, residues 416-431 of helix-16 facing the NTD show the 
highest mobility only in one chain.  
 
8. Characterization of the new N-terminal tryptic site by site-directed 
mutagenesis 
 
In order to investigate the effect of the Arg27-Glu61 interaction on the protein 
features, we designed non-conservative variants R27A and E61A carrying the 
advantages of abolishing in both cases the salt bridge interaction and removing the 
tryptic site only in R27A. In addition, variant K334Q has been investigated as 
tryptic site probe of the CL. 
The biochemical analysis carried out on R27A and E61A reveals that both of them 
show a loss of their thermal stability (Tm 222 nm) and tertiary structure signals (CD 
at 280 nm) in both their holo and apo form. The coenzyme microenvironment 
generates signals (both dichroic and in absorbance) relative to an altered tautomeric 
equilibrium shifted to the ketoenamine tautomer (Figure 35A). The affinity for the 
PLP of R27A and E61A is reduce by ~ 4.3 fold and 3 fold respectively. Differently, 
K334Q exhibits unaltered spectroscopic signals, preserved thermal stability, high 




Fig. 35. Biochemical characterization of artificial R27A, E61A and K334Q variants. A) 
Near-UV visible CD spectra of holo variants compared with holoWT. Signals relative to the 
apo species are reported in the inset. CD spectra are recorded at 5 μM protein concentration, 
in 100 mM potassium-phosphate buffer, pH 7.4 in presence of 100 μM PLP for the holo 
forms. B) Internal aldimine absorbance spectra of holoWT and variants. Spectra are recorded 
at 10 μM protein concentration, in 100 mM potassium-phosphate buffer, pH 7.4. C) Limited 
proteolysis with trypsin at 1:100 (w/w) ratio were performed in 100 mM potassium phosphate 
pH 7.4 at 25 °C with the addition of 100 µM PLP. 
 
Kinetic parameters calculated for L-Dopa (Table 10) show catalytic efficiency of 
8.4 % for R27A (showing that the substitution to Ala is worse than Gln as reported 
above) and 12.1 % for E61A mainly caused by a 7 fold reduced catalytical constant 
in both variants. As expected, holoR27A is not cleaved at its N-terminal, holoE61A 
shows the typical apoWT tryptic pattern.  
  

















































































Table 10. Kinetic parameters for L-Dopa, apparent equilibrium dissociation 













WTa 7.6 ± 0.1 0.11 ± 0.01 69.1 ± 10 101 ± 10 69.42 ± 0.02 64.84 ± 0.03 
R27A 1.10 ± 0.05 0.19 ± 0.03 5.8 ± 1.1 438 ± 86 64.64 ± 0.01 61.49 ± 0.02 
E61A 1.02 ± 0.04 0.12 ± 0.03 8.4 ± 2.1 307 ± 44 65.41 ± 0.01 61.37 ± 0.02 
K334Q 6.4 ± 0.2 0.14 ± 0.02 45 ± 0.15 165 ± 30 66.04 ± 0.02 62.99 ± 0.03 
 
Altogether, mutation of residues of the new tryptic site determines heavy effects in 
terms of structure and function, evidencing that, like a domino effect, a modification 





CONCLUSIONS FROM PART 1 
 
Human AADC crystal structure has been solved in its holo and catalytically 
competent form since only porcine holo and human apoAADC were available until 
now. HoloAADC has been solved in its native and carbiDopa bound form at 
physiological pH providing new insights on the mechanism of formation of the 
external aldimine. A role in the rearrangement of the active site upon binding of the 
ligand could be attributed to loop3 conformation (in particular to residues Leu353, 
Gly354, Arg355) and to some structural water molecules. When carbiDopa-PLP 
complex is formed, Loop3 reorganization is driven by an exchange between Leu353 
and Arg355 in contacting the PLP through a water molecule, possibly favoring the 
catalytically competent CL position.  
In order to investigate the effect of pH on AADC active site we solved the crystal 
structure of the native and inhibitor bound enzyme at different pH. We identified 
the AADC monomer-monomer interface region (including loop3) to be the most 
susceptible to the pH. The position of some structural water molecules together with 
the orientation of specific residues (Glu150 and Arg355) are found to determine 
conformational changes. Glu150 has been identified as crucial in putting the two 
active sites in communication through sub sequential hydrogen bonds. The increase 
leads to an increased flexibility of loop3 as revealed by a progressive lack of the 
electron density and to slight alterations of Ile101 on loop2. Similarly, also in 
presence of carbiDopa, the effect of the pH appears to be addressed to water 
molecules, loop3 (and possibly to CL). In fact, the increase in pH leads to the 
acquisition of deficient active site conformations determined by the establishment 
of improper interactions of loop3 (via Arg347, Leu353 and Arg355). Thus, pH 
sensitivity provides us with a tool to understand Leu353 and Arg355 movements in 
coordinating the positioning of loop3 inside the active site and concurring to -CL 
in- and -CL out- conformations.  
Protein mobility has been also investigated by MD and limited proteolysis. MD 
analysis reveals that apoAADC is partially closed with respect to its 
crystallographic structure and that it shows however higher mobility than the 
corresponding holo form. Both apo and holoAADC show an asymmetric motion 
during the simulated time. In fact, chainA and chainB of each protein exhibit 
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differential fluctuations along each domain. While apoAADC shows, on one hand 
a asymmetric motion of the two monomers and on the other hand, similar loop3 
fluctuations, holoAADC reveals a different conformational plasticity involving 
loop3 of one monomer and NTD and CTD of the second monomer. In fact, a more 
rigid CL conformation, in which catalytic Tyr332 is positioned closed to PLP (-CL 
in- conformation), is stabilized in presence of more mobile CTD and NTD (that are 
facing one each other). On the contrary, a -CL out- conformation is favored when 
CTD and NTD exhibit less mobility in the respective facing regions (H1-loop-H3), 
leading to the proposal of the existence of a functional coordination between these 
regions. Limited proteolysis highlights the differential mobility between apo and 
holoAADC and reiterates the existence of asymmetric motions in AADC. Thus we 
identified Arg27 as novel tryptic site for the apo protein that could constitute a 
powerful in solution tool for assessing protein mobility.  
Our study on WT human AADC provides new elements for the comprehension of 
the structure-function relationship of AADC. Structural details might represent the 
basis for both the designing of novel specific inhibitors and for a better 










Part 2. CHARACTERIZATION OF AADC DEFICIENCY 
ASSOCIATED VARIANTS 
 
9. Localization, distribution and conservation of the residues involved in 
this study 
 
The 28 residues involved in substitutions and deletions characterized in this study 
are reported in table 11 that lists the pathogenic changes involved in AADCd and 
table 12 that displays the non-pathogenic variants. 8 out of 28 of the residues belong 
to the NTD, 16 to the LD and 2 to the CTD. Moreover, some residues belong to the 
structural elements called loop1 (His70, Trp71, Leu77), loop2 (Trp105, and 
Ala110) and loop3 (Pro330, Lys334, Arg347, Leu353) already described to be 
crucial for AADC activity (see introduction and part1).  
In order to have a preliminary idea on the role of these residues, we determined 
their conservation level by aligning the human AADC amino acid sequence with 
those of 75 homologous proteins by the ConSurf web server. Results are reported 
in table 11 as a score where 9 means highly conserved and 1 highly variable.  
About 65% of the modified residues are conserved/highly conserved (score 8 and 
9 for Tyr20, His70, Phe77, Trp105, Ala110, Leu222, Phe251, Trp267, Cys281, 
Glu283, Pro330, Arg347, Leu353). Glu25, Gly146 and Phe237 are quite conserved 
(score 6/7). Glu25 could be substituted with both positively and negatively charged 
amino acids, Gly146 with small apolar or polar residues. Phe237 could be 
substituted by polar and apolar residues. The others have a low conservation score, 
although the chemical nature of the residues (polar or apolar) is maintained for 
Val60 and Arg453. Gly96 and Pro210 show to be the residues with highest 
variability, although a negatively charged amino acid in position 96 and a 
hydrophobic one in position 210 are not contemplated in the possible substitutions.  
In this thesis, in addition to residues causing pathogenic effects, some artificial 
variants are presented. Non-pathogenic Y20A, Y20S and W71A variants will be 
discussed as controls together with their counterpart pathogenic deletions Y20del 
and H70R/W71del.  
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Table 11.  Preliminary overview on the 21 residues involved in pathogenic substitutions. For each 
residue the localization is indicated. N-Terminal Domain (residues 1-85) includes loop1 (66-84), 
Large Domain (residues 86-360) includes loop2 (100-110), Lys303 stretch (200-310), loop3 (323-
357) and the flexible Catalytic Loop (CL, 327-341). The C-Terminal Domain includes residues 361-
480. Conservation score based on the alignment of 75 AADC homologues has been calculated with 
ConSurf server (http://consurf.tau.ac.il). The conservation score of 9 indicates a highly conserved 
residues while 1 is associated to highly variable residue. According to the conservation score, 
residue variety is also indicated. The variants characterized in this study are listed.  
 
resi # localizzation 
Conservation Residue 
variety mutation score 
20 NTD 9 Y Y20del 
25 NTD 6 E, R, D E25K 
60 NTD 5 I, V V60A 
70 NTD – loop1 9 H 
H70Y 
H70R/W71del 
77 NTD – loop1 8 H, Y, F F77L 
96 LD 4 G, S, A, D G96R 
105 LD – loop2 8 W W105C 
110 LD – loop2 8 A A110E 
146 LD 6 G, A, S G146R 
210 LD 4 E, S,P, C, Q P210L 
222 LD 8 L, C L222P 
237 LD 6 C, F, I F237S 
251 LD 9 F F251S 
267 LD 9 W W267R 
281 LD 9 C C281W 
283 LD 9 E E283A 
330 LD – loop3 9 P P330L 
347 LD – loop3 8 M, R R347Q 
353 LD – loop3 9 M, L L353P 
362 CTD 5 L, M M362T 




Table 12. Overview of the 6 residues involved in artificial substitutions. The localization, the 
conservation score (calculated with ConSurf server; http://consurf.tau.ac.il), the residue variety and 
the studied variants are listed.  
 






20 NTD 9 Y Y20A 
Y20S 
27 NTD 9 R R27A 
61 NTD 8 E, D E61A 
71 NTD – loop1 8 W W71A 




334 LD – loop3 5 R, Q, K K334Q 
 
In addition, Ser193 variants comprise three artificial species characterized in a 
research project regarding post translational modifications carried out in 
collaboration with Prof. Robert S. Phillips at the University of Georgia (USA). 
Preliminary in vitro analysis identified Ser193 as putative phosphorylation site in 
AADC. Interestingly, Ser193 follows His192, that is the conserved residue 
involved in the stabilization of the cofactor.  
Finally, the already characterized R347Q has been more deeply investigated to 
examine its role in loop3 119,120. 
About 50% of the studied residues are located at the large interface between the two 
monomers. This interface comprises 144 residues of the total 480 amino acids of 
each monomer and covers the 27.3% of the total solvent-accessible area (ASA) of 
each subunit. In comparison, the dimer interface of the prototype of Fold-Type I 
PLP-enzymes, aspartate aminotransferase, covers only 19.8% of the total ASA. The 
effect of the substitutions on the binding affinity between the monomers has been 
evaluated by measuring the difference of free energy between the variants and the 
WT protein using the BindProfX online software (ΔΔG = ΔGmut-ΔGWT). Results 
obtained for each monomer are listed in table 13.  
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Table 13. Effect of the interface pathogenic variants on the monomer-monomer binding affinity. 
ΔΔG has been predicted using BindProfX server. The changes in free energy are displayed as ΔΔG. 
In the case of deletions (Y20del and double mutant (H70R/W71del) the ΔΔG was not determinable 


















n.d = not determinable 
 
Table 14. Effect of interface artificial variants on the monomer-monomer binding affinity. ΔΔG has 
been predicted using BindProfX server. The changes in free energy are displayed as ΔΔG. In the 
case of deletions (Y20del and double mutant (H70R/W71del) the ΔΔG was not determinable (n.d). 












n.d = not determinable 
 
The measured ΔΔG values show that mutations H70Y, G146R, M362T even if 
involving interface residues do not affect the monomer-monomer affinity. 
Substitutions, V60A, G96R, W105C, A110E, R347Q, L353P, R453C show a 
positive ΔΔG indicating that the interaction networks between monomers is 
affected at different extent. In particular, G96R, W71A and Y20A, Y20S seem to 
be the most destabilizing substitutions, followed by L353P, A110E and W105C. In 
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order to find a structural basis for these effects, an investigation of the position and 
interaction network of each residue in the 3D structure of AADC has been 
undertaken.  
 
10. AADC crystal structure inspection provides insights on the role of the 
residues involved in the pathogenic mutations. 
 
A preliminary analysis of the position of residues undergoing substitution due to 
the new mutations identified in the last years (from 2014 to 2019) shows that they 
are dispersed in the whole ORFs of the AADC gene, as reported also by recent 
reviews 107, resulting in a protein bearing altered amino acids throughout its 
polypeptide chain.  
Here, for the first time, we can base our observations on the human ligand-free 
AADC structure solved as described in part 1 of this thesis. 
 
Fig. 36. In silico inspection of the mutation sites located at the NTD and CTD. Dimeric 
holoAADC has been obtained from structure1 (see part1) using Pymol 2.2.3 (The The 
PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC). The two monomers 
are colored white and gray. Loop1, loop2 and loop3 are represented as ribbon and colored 
red, green and blue respectively. In each panel the mutation sites (yellow) and the interacting 
residues (cyan) are indicated and represented as sticks. Lys303 is colored white and PLP is 
colored yellow. Residues of loop2 are colored green.  
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Starting from the NTD, Tyr20 and Glu25 are located at the end of helix-1 and, 
although close to each other, interact with different structural elements. Glu25 
generates the turn of the helix by interacting with His459 of the CTD, Tyr20 makes 
a hydrogen bond with His70, located on loop1, immediately preceding Trp71. 
Trp71 is a loop1 residue described to be involved in the direct interaction with loop2 
of the neighboring subunit, in a hydrophobic network with residues such as Phe103 
proposed to facilitate the binding of the substrate aromatic ring 24 (Figure 36A). 
Phe77 is another loop1 residue that is part of a stacking sandwich with residues 
Phe448 and Phe388, thus acting as a communication element with the CTD.  
Val60 contributes to the monomer-monomer interface and its side chain engages 
the helix 85-99, that connects loop1 to loop2, of the neighboring subunit by several 
hydrophobic contacts (Figure 36B). 
Gly96 belongs to helix 85-99 at the end of loop1 and just before the beginning of 
loop2 (Figure 36B). At the beginning of the same helix, Ser84 interacts with both 
Gly96’ on the second monomer and with Arg453 of the same monomer favoring 
loop1 correct positioning. Moreover, Arg453 provides an additional junction 
between CTD and loop1, since its side chain is in proper position to interact with 
Met1’ backbone oxygen of the neighboring subunit by a H-bond contributing to the 
monomer-monomer interaction (Figure 36B). 
Trp105 and Ala110 belong to loop2, a short stretch of amino acids that protrudes 
towards the active site of the neighboring subunit placing Ile101 and Phe103 in 
strict contact with the aromatic ring of the substrate. Figure 37A, shows also 
residue Cys100 which has been object of a project in collaboration with Prof. 
Kurian Manju and Dr. Giada Rossignoli at the University College of London (UK) 
(see paper 2). Cys100 is placed in a small apolar pocket sandwiched between loop1 
and loop3. Trp105 seems to be involved in a weak interaction relay involving 
Glu113 and Leu38 (whose pathogenic substitution causes a dramatic decrease of 
activity 119. 
Ala110 is the last residue of loop2, belongs to the monomers interface and is placed 
into an apolar cavity at the beginning of the large domain and for this reasons it 
should be better considered as borderline between loop2 and LD. Its substitution 
with glutamate may lead to local steric hindrance between the two subunits and 
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could exert some effects on the position of the residues present at the active site, 
i.e. Ile101 and Phe103 (Figure 37A). This is corroborated by results obtained in the 
biochemical characterization and the molecular dynamics simulation of the 
recombinant A110Q protein 119.  
 
Fig. 37. In silico inspection of the residues located on loop2, loop3 and at the interface. 
Dimeric holoAADC has been obtained from structure1 (see part1) using Pymol 2.2.3 (The 
The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC). The two 
monomers are colored white and gray. Loop1, loop2 and loop3 are represented as ribbon and 
colored red, green and blue respectively. In each panel the mutation sites (yellow) and the 
interacting residues (cyan) are indicated and represented as sticks. Lys303 is colored white 
and PLP is colored yellow. Residues of loop2 are colored green. 
 
Pro330 and Leu353 belongs to loop3, the former at the very beginning, the latter at 
approximately the end. Pro330 belongs to the CL and is therefore invisible in the 
AADC crystal structure. Pro330 is followed by Thr331 and by the essential 
catalytic residue Tyr332, suggesting that its substitution could affect CL. Leu353 
(Figure 37A) is placed at the dimer interface, participates in the active site 
architecture, and contacts PLP through a water molecule together with Gly354 (see 
part 1).  
Gly146 is located immediately below Glu150 (see part 1) on a turn connecting 
helix-6 and a b-sheet at the center of the monomer-monomer interface. In fact, 
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Gly146 of monomerA faces Gly146 of monomerB at the distance of 9.2 Å (Figure 
37B). 
 
Fig. 38. Localization of residues located on the protein surface and/or in hydrophobic 
clusters. Dimeric holoAADC has been obtained from structure1 (see part1) using Pymol 
2.2.3 (The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC). The two 
monomers are colored white and gray. Loop1, loop2 and loop3 are represented as ribbon and 
colored red, green and blue respectively. In each panel the mutation sites (yellow) and the 
interacting residues (cyan) are indicated and represented as sticks. Lys303 is colored white 
and PLP is colored yellow. Residues of loop2 are colored green. 
 
Pro210, Leu222, Phe237 and Trp267 belong to a b-barrel system of the LD that 
surrounds the two active sites and that constitute the typical PLP-dependent enzyme 
architecture (Figure 38A). Pro210 is placed on a flexible stretch on the surface (aa 
209-218). Leu222 belongs to the helix 218-232 and lies into a hydrophobic cleft. 
Phe237 and Trp267 lie on two adjacent β-sheets and are involved in several 
hydrophobic contacts contributing to the folding of the β-barrel.  
Phe251 lies on the loop 234-252 in proximity of the protein surface and participates 
to a hydrophobic network involving residues of the LD and of the CTD (Figure 
38B). 
Cys281 and Glu283 are located on the same surface helix and together with Arg285 
contribute to its stabilization 119 (Figure 38B). In detail, Arg285 contacts, among 
others, Cys281 through its backbone. Cys281 side chain is accommodated in a 
small apolar environment, unlikely being able to hosting residues with high steric 
hindrance. Glu283 is exposed on the protein surface and contacts by a salt bridge 
 96 
Arg379 side chain. This interaction represents the only connection between the 
helix283-294 on LD and helix372-395 on the CTD (Figure 38B). On the basis of 
the local microenvironment, this interaction might prevent the exposure of 
hydrophobic residues to the solvent. Met362 belongs to helix358-369 that crosses 
the molecule from the active site to the surficial helix372-395 in contact with 
Glu283. Met362 side chain is located on a hydrophobic cleft and does not 
participate in any interaction (Figure 38B).  
 
11. Some pathogenic variants exhibit low expression level in the soluble 
fraction.  
 
The analysis of the relative expression of the pathogenic proteins in the soluble 
fraction (Table 15) reveals the presence of a group of variants (P210L, L222P, 
F237S, W267R, C281W, E283A, M362T) characterized by a poor solubility (9-
30%) with respect to the WT protein. A low expression level in the soluble fraction 
may be related to a solubility alteration at least in the E. coli system, suggesting 
possible folding defects.  
These variants, whose position in the protein has been already mapped (see above), 
can be divided in two clusters: those located on same structural regions, distant 
from the active site, and commonly characterized by lying on the surface of the 
protein (P210L, E283A) and those belonging to hydrophobic clusters (L222P, 
F237S, W267R, C281W, M362T), as already shown in figure 38.  
The effect of decreasing solubility can be not only determined by the position but 
also by the identity of the substitution. As for M362T, even if methionine to 
threonine is a conservative substitution, a threonine residue could lead to a 
destabilization of the helix also affecting Glu283. In addition, C281W and E283A 
low solubility could be probably attributable to the loss of the surficial Glu283-
Arg379 salt bridge with the consequent exposure of hydrophobic patches. L222P, 
F237S and W267R are alterations changing the chemical feature of the residues 
located on a hydrophobic region on the b-barrel system. It has been previously 
observed that some AADC variants affecting the same region can show low 
purification yields, in particular, R285W exhibited a ~20% of solubility level 
respect with the WT 119.  
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Table 15. Analysis of the relative expression level of the pathogenic variants in the soluble fraction 
of E. coli.  
 
Protein % expression 























All the other variants are expressed and present in the soluble fraction at higher 
amount, ranging from 72% to 103% of the WT, with the exception of P330L that 
exhibit a 38 % of expression. This may be related with the type of substitution, 
being Pro ® Leu localized on the CL that is exposed to the solvent thus may reduce 
protein solubility. 
Considering the protein yields after purification, some variants exhibit nearly good 
to good yields i.e 30–85% with respect to the WT (Y20del, E25K, H70R/W71del, 
F77L, G96R, W105C, A110E, G146R, F251S, L353P, R453C). Others display low 
5–10% (V60A, H70Y, P330L, M362T) and very low (less than 2% for E283A, 
P210L, W267R) yields. Unfortunately, it was not possible to purify L222P, F237S 
and C281W which were recovered in extremely low amounts (<0.3%) preventing 
us to carry out a complete biochemical characterization. The purified variants 
appear to be homogenous as indicated by a single band on SDS-page with mobility 
identical to that of the corresponding WT protein (Figure 39). Once purified, all 




Fig. 39. Quality of all AADC variants preparations. All purified variants appear to be 
homogenous as indicated by a single band on SDS-page with mobility identical to that of the 
corresponding WT protein. Lane numbers are the following: 1-WT, 2-Y20del, 3-Y20A, 4-
Y20S, 5-E25K, 6-R27A, 7-V60A, 8-E61A, 9-H70Y, 10-H70R/W71del, 11-W71A, 12-F77L, 
13-G96R, 14-W105C, 15-A110E, 16-G146R, 17-S193A, 18-S193D, 19-S193E, 20-P210L, 
21-F251S, 22-W267R, 23-E283A, 24-P330L, 25-R347Q, 26-L353P, 27-M362T, 28-R453C.  
 
 
12. Aggregation propensity of the apo forms of the low solubility variants 
 
Given the great variability in both solubility level and purification yield of the 
analysed variants (also reported in sporadic cases for other characterized AADC 
variants 119,122) DLS analyses have been carried out in order to monitor the 
aggregation propensity of the purified enzymes under physiological conditions (58 
mM potassium phosphate buffer, pH 7.4 at 37 °C). DLS measurements evaluating 
the increase in the mean count rate (kcps) of the holo and apo forms of the majority 
of AADC variants and of WT do not show aggregation under these experimental 
conditions. Instead, apoP210L, apoE283A and apoM362T, even if at different 
extent, tend to aggregate as indicated by the increase in kcps (Figure 40).  
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Fig. 40. Some pathogenic variants exhibits aggregation propensity in their apo form. 
Aggregation of apoP210L, apoE283A, apoR285W, apoM362T, apoR412W in comparison 
with apoWT recorded at 4 μM protein concentration in 58 mM potassium phosphate pH 7.4 
at 37 °C. DLS analysis as function of time reveals an increase of the mean count rate (Kcps) 
proportional to protein aggregation. 
 
Since in 2014 it was reported that R285W and R412W variants were poorly 
expressed in E. coli 119, we re-expressed and purified them to investigate their 
possible aggregation propensity. It is known that Arg285 belongs to the same helix 
of Glu283 (paragraph 3) while R412W variant has been proposed to affect global 
CTD folding 119. Interestingly, their apo forms show a similar propensity to 
aggregate. With the exception of apoP210L that shows a scattered and almost linear 
aggregation curve, all other apo variants show a complete or partial sigmoidal 
aggregation process, constituted by a first lag phase followed by a consistent 
increase in the mean count rate. 
This analysis provides the first evidence of in vitro aggregation of AADC variants. 
Taken together, these data underline the relevance of residues belonging to the LD 
and to the first part of the CTD for the global protein folding. Either if present on 
the surface (Pro210, Glu283, Glu285 and Arg412) or in hydrophobic clefts 
(Leu222, Phe237, Trp267, Cys281, Met362), they deeply affect solubility and, in 
some cases, show aggregation propensity of their apo forms.  
 
13. Secondary structure content and thermal stability of new pathogenic 
AADC variants 
 
In order to monitor overall protein stability, at first far-UV CD spectra of holo WT 
and of the new holo AADC variants have been carried out.  































Fig. 41. Overall Integrity of all WT and AADC variants. Far-UV CD spectra of holo WT 
(black dashed line) and all holo AADC variants (coloured lines) recorded at 5 μM protein 
concentration, in 100 mM potassium-phosphate buffer, pH 7.4 with the addition of 100 μM 
PLP.   
 
 
They overlap and display unaffected signals or slightly differences in the secondary 
structure content, thus indicating no gross modifications in the total percentages of 
secondary structure elements of the enzymatic species (Figure 41). The fact that 
the secondary structure content is maintained almost unchanged implies that, in 
addition to WT, the purified variants are properly folded species.  
Then, melting temperature of all purified holo and apoAADC variants and WT have 
been measured by following the loss of the a-helical dichroic signal at 222 nm.  
Table 16, lists the Tm values of the holo and apo forms in comparison to those of 
the WT. As for the holo forms, variants can be grouped in those faintly affecting 
the Tm (± 3°C), such as W105C, G146R, P210L, F251S, W267R, P330L, L353P, 
M362T and R453C, or deeply decreasing the Tm (-4 to -10 °C) as Y20del, E25K, 
V60A, H70Y, H70R/W71del, F77L, G96R, A110E, and E283A. It should be noted 
that the most affected variants seem to be those mapping on NTD-loop1 (Figure 
42A, B).  
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Table 16. Melting Temperatures of WT AADC and pathogenic variants. Melting temperature values 
obtained by following the CD signal at 222 nm and varying the temperature linearly from 25 to 90 
°C with a slope of 1.5 °C/min.  
 
                                  Tm (°C) 
Enzyme holo apo 
WT 69.42 ± 0.02 64.84 ± 0.03 
Y20del 59.01 ± 0.03 58.04 ± 0.02 
Y20A 63.20 ± 0.02 61.72 ± 0.02 
Y20S 59.97 ± 0.01 57.13 ± 0.02 
E25K 65.26 ± 0.02 63.64 ± 0.03 
V60A 62.13 ± 0.02 59.30 ± 0.03 
H70Y 65.95 ± 0.04 63.28 ± 0.05 
H70R/W71del 63.71 ± 0.02 63.46 ± 0.03 
W71A 71.85 ± 0.02 63.95 ± 0.02 
F77L 63.58 ± 0.03 61.70 ± 0.03 
G96R 65.64 ± 0.05 58.46 ± 0.04 
W105C 69.45 ± 0.01 62.00 ± 0.01 
A110E 63.20 ± 0.05 62.04 ± 0.04 
G146R 69.77 ± 0.02 62.15 ± 0.05 
P210L 66.10 ± 0.10 60.91 ± 0.05 
L222P n.p n.p 
F237S n.p n.p 
F251S 70.49 ± 0.04 63.37 ± 0.06 
W267R 70.30 ± 0.10 63.60 ± 0.03 
C281W n.p n.p 
E283A 62.89 ± 0.02 58.66 ± 0.07 
P330L 68.04 ± 0.02 62.47 ± 0.02 
R347Q 66.64 ± 0.02 63.60 ± 0.02 
L353P 68.10 ± 0.07 60.82 ± 0.03 
M362T 67.54 ± 0.02 59.89 ± 0.02 






Fig. 42. Destabilization effect of the mutations along each AADC domain. Effect of the 
mutations on A) apo and B) holo thermal stability expressed ΔTm(WT-mut) represented along 
protein sequence. C) Preferential effect of the variants on the apo or on the holo form 
expressed as ΔTm(holo-apo). 
 
In particular the following apo species are weakly affected in Tm values (± 3°C) 
E25K, H70Y, H70R/W71del, F77L, W105C, A110E, G146R, F251S, W267R, 
P330L and R453C. The other apo species result in Tm values decreased by 4 to 6 
degrees and are Y20del, G96R, P210L, E283A, L353P and M362T. In order to 
better understand the differential effect of the mutation on the two protein forms, 
we evaluated the ΔTm value (Tm(holo-apo)) for each protein (Figure 42C). The 
ΔTm(holo-apo) of the WT AADC is 4.6 °C and this value represents the different 
thermal stability of the closed and open conformations. In this view, a change of 
the ΔTm(holo-apo) may indicate a preferential effect of the mutation on just one form. 
The NTD results to be the region with a clear reduction of the ΔTm(holo-apo). This 
effect is mainly due to a destabilized holo protein that leads to a reduced difference 
in Tm respect to the corresponding apo form, arguing that these enzymatic species 
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resemble more apo than holo structures. The more prominent effect of the decreased 
ΔTm(holo-apo) is evident in the deletion variants, Y20del and H70R/W71del. The site-
directed variants Y20A and Y20S show Tm values for the holo and apo species 
slightly different from those of the pathogenic naturally occurring Y20del 
exhibiting curiously the Ala substitution a less destabilizing effect than the Ser 
modification. On the contrary, W71A site specific substitution demonstrates that 
Trp71 does not play a crucial role on protein thermal stability  (Table 16) being its 
holo and apo Tm values nearly identical to those of the WT. Thus, the results 
collected with the H70R/W71del species should be related to His70 that is highly 
affected in the holo rather than in the apo form.  
Even if the effect of the variants of the LD is more heterogeneous some 
considerations could be done. The majority of the variants showing unchanged or 
small changes in both holo and apo Tm values belong to this domain: W105C, 
G146R, F251S, and W267T. The two CTD variants M362T and R453C have the 
same behaviour in Tm even if apoM362T is less stable than apoWT, as evidenced 
by its propensity to aggregate.  
Notably, some exceptions should be mentioned: A110E has a same value in holo 
and apo Tm due especially to holo rather than apo destabilization and the two 
surface variants, P210L and E283A, exhibit a pronounced destabilization effect on 
both the holo- and apo-protein resulting in an overall ΔTm(holo-apo) similar to that of 
the WT but due to an overall less stable protein. 
 
14. Aromatic amino acids microenvironment and PLP binding in AADC 
pathogenic variants  
 
We characterized the structural features of pathogenic variants in their apo and holo 
form by near UV CD spectroscopic signals related to the asymmetric aromatic 
amino acids environment, with respect to protein moiety, providing insight into 
tertiary structure arrangement. As already mentioned in the Introduction apo and 
holo WT AADC display near UV signals presenting a major band at 280 nm, being 
that of the apo in magnitude about half that of the holo. Here, taking into 
consideration all pathogenic variants, a decrease is evident for both apo and holo 
species, however the apo enzymes signals are diminished by no more than 50%, 
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being Y20A, E25K, H70Y and R453C the variants with a 40-50% decrease of the 
apo CD signal. A much wider spectrum of alteration is visible for the dichroic 
signals relative to the holo forms, spanning from ~ 0 to 100 % of the WT signal 
(Figure 43A). Interestingly, mainly evident in the holo protein, the NTD variants 
are, above all species, those highly affected by the change in the aromatic 
microenvironment with a decrease more than 50%, being those of the LD less 
affected and the two belonging to the CTD mid affected (Figure 43). 
 
Fig. 43. Near-UV CD spectra of WT AADC and pathogenic variants in their holo and 
apo forms. The spectra are recorded at 5 μM protein concentration, in 100 mM potassium-
phosphate buffer, pH 7.4. Spectra of the holo forms are recorded in the presence of 100 μM 
PLP. Spectra of all AADC apo variants (colored lines) are shown superposed to that of the 
apoWT (dashed blue line) (A) and along protein sequence (B). Holo variants spectra are 
shown in comparison to the holoWT (dashed blue line) and along each protein domain.  
 
In order to explain the behaviour of the CTD residue Arg453 (so similar to those of 
the NTD) and of the two deletion mutants, it can be observed that, as reported by 
the bioinformatic analyses above, Arg453 is spatially close to Tyr20, Arg27 and 
His70. The artificial variant Y20S presents apo and holo signals similar to those of 
the natural occurring Y20del, while Y20A shows to affect protein structure even at 
a higher extent. This could be interpreted as the loss of Tyr20 has a deep impact 
 105 
into tertiary structure environment. W71A exhibits increased signals in both apo 
and holo enzymatic species respect to the pathogenic counterpart, and the 
combination of the effects of natural H70Y, H70R/W71del together with artificial 
W71A shows that the removal of Trp71 is not detrimental by itself in tertiary 
structure assembly (and for protein thermal stability). 
The binding of the coenzyme is associated with characteristic bands in the visible 
range as revealed by absorption and circular dichroism in the visible region.  
 
Fig. 44. Visible CD spectra and absorbance profile of WT AADC and pathogenic 
variants in their holo forms. A) CD spectra are recorded at 5 μM protein concentration, in 
100 mM potassium-phosphate buffer, pH 7.4 in presence of 10 μM PLP. B) Representation 
of impact to the mutations on the tautomeric equilibrium (ratio between q335 nm and q420 nm) 
along protein sequence. C) Absorbance profile of WT and holo variants recorder in the near-
UV visible range. Inset represents the magnification of the internal aldimine bands. D) 
Tautomeric equilibrium (ratio between Abs335 nm and Abs420 nm) along protein domains.  
 
As shown in figure 44, AADC variants exhibit great variability in their visible CD 
and absorption spectra. These differences are consistent with an alteration of the 
equilibrium between the two tautomers at 335 nm and 420 nm. The WT internal 
aldimine presents a characteristic 335 nm/420 nm ratio in the dichroic bands of 
about 1.7. AADC variants show a distribution of ratios consistent to both the 
prevalence of the ketoenamine band over the enolimine (variant A110E, R453C 
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together with variants of the NTD) and the prevalence of the second one over the 
ketoenamine (variants of the LD - with the exception of A110E). In this picture, 
M362T constitute a midpoint between the two groups of variants, showing a ratio 
of ~1 (Figure 44A). Absorbance spectra for all pathogenic variants show the same 
behaviour highlighting a wide spectrum of alteration of the tautomeric equilibrium. 
The ratio Abs 335 nm/Abs 420 nm correlates with the CD 335 nm/420 nm ratio 
with R2 = 0.8652 (Figure 45A).  
 
Fig. 45. Correlation between CD and absorbance signals. A) The correlation between the 
tautomeric equilibrium observable by dichroism or absorbance can be well described by a 
linear fit with R2 = 0.8652. B) The % of the 280 nm dichroic band is plotted versus the 
tautomeric equilibrium and fitted to a linear regression with R2 value of 0. 7776.  
 
The tautomeric equilibrium has been generally related with the PLP 
microenvironment 44,53,60,119,120, with no focus on the relation with global tertiary 
structure of the protein. Figure 45B shows as the loss of CD 280nm signal is 
concomitant with the decrease of the 335 nm band and the increase of the 420 nm 
band. This tendency correlates with a linear fit with a R2 = 0.7776. The artificial 
variants Y20A, Y20S and W71A confirm the features of their naturally occurring 
counterpart, being the combination of W71A and H70Y less affected than 
H70R/W71del. 
In order to correlate the alterations in the tautomeric PLP environment to the 
equilibrium dissociation constant of PLP, we measured this value for all variants as 
described under Materials and Methods section. As shown in table 17 the variants 
exhibit a great heterogeneity in the coenzyme affinity.   
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Table 17. KD(PLP) values for AADC wild-type and variants. a PLP affinity value for R347Q has been 
obtained from 119. 
 
Enzyme KD(PLP) (nM) 
Wild-Type 101 ± 10 
Y20del 970 ± 120 
Y20A 778 ± 50 
Y20S 648 ± 121 
E25K 594 ± 24 
V60A 252 ± 35 
H70Y 70 ± 18 
H70R/W71del 420 ± 60 
W71A 148 ± 13 
F77L 222 ± 38 
G96R 132 ± 14 
W105C 162 ± 17 
A110E 321 ± 26 
G146R 120 ± 20 
P210L 47 ± 7 
L222P n.p 
F237S n.p 
F251S 33 ± 9 
W267R 121 ± 10 
C281W n.p 
E283A 330 ± 30 
P330L 123 ± 19 
R347Qa 54 ±10 
L353P 199 ± 34 
M362T 271 ± 20 
R453C 468 ± 36 
 
Some variants exhibit PLP affinity very similar to that of the WT (H70Y, P210L, 
F251S, R347Q), others show a wide array of values ranging from only small 
changes (W71A, G96R, W105C) to a 6/10-folds decreased affinity (such as Y20del, 
Y20A, Y20S, E25K). Interestingly, most of the variants exhibiting more than 2-
fold higher KDPLP with respect to the WT are located on the NTD (with the exception 
of loop1 variants H70Y and W71A, underlining here a possible requisite of a 
hydrophobic environment for PLP binding) and on the CTD (Figure 46). Among 
the variants of the LD, A110E, E283A and L353P show the worst decrease in 
coenzyme affinity.  
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Fig. 46. Distribution of the KD(PLP) effect on AADC domains. Variants at the N-terminal 
domain are colored in cyan, at the Large domain are colored green, and those on the C-
terminal domain are colored in magenta. 
 
Overall, the KDPLP values of the pathogenic variants show an inverse correlation 
with the CD signals at 280 nm arguing that the more the aromatic microenvironment 
is similar to the WT, the higher is the affinity for the PLP, tautomerized in favor of 
the enolimine form (Figure 47).  
 
Fig. 47. Correlation between different structural signals. Thermal stability of the holo 
proteins and KD(PLP) values are plotted as function of tertiary structure integrity. The 
subdivision between NTD-CTD variants and LD variants is highlighted in cyan and yellow. 
In the plot also non-pathogenic variants are included, and will be discussed later in the text.  
 
The addition of the Tm values to this plot exhibits a trend evocative of a preserved 
thermal stability with preserved tertiary structure content (CD signal at 280 nm) 
and low KD(PLP) values (Figure 47). Notably, NTD and CTD (with the exception of 
A110E) residues are found at the left part of the plot (low CD 280 nm values, low 
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Tm values and high KD values), and the variants of the LD are found on the right 
part of the plot, suggesting that the maintenance of a correct folding ensures high 
coenzyme affinity and high thermal stability. In this sense, the substitution due to 
mutations of residues mapping on NTD and CTD seems to be detrimental to reach 
a structurally competent holo scaffold, while LD residues, in particular those of 
loop3, experience less global destabilization.  
In addition, none of the variants involving residues in close proximity to the PLP 
moiety, or taking part to the active site architecture at different extents (i.e Trp71, 
Trp105, Pro330, Arg347 and Leu353), shows a dramatic decrease in the apparent 
equilibrium dissociation constant (ranging between 54% to 162% of the WT, with 
L353P having a 2-fold decrease PLP affinity) arguing that the KD(PLP) values are 
related to a larger folding and/or stability effects rather than subtle and localized 
active site changes. Since the signals related to the cofactor microenvironment 
(335nm/420nm ratio in both absorbance and CD measurements) is related to the 
280 nm CD value (Figure 45), we can add that, at the extremes of the plot, the LD 
residues favour the enolimine tautomer of PLP, as the WT, while those of the NTD 
favour the ketoenamine one. 
Having determined the structural determinants of the coenzyme binding and the 
affinity for PLP, the functional properties in terms of catalytic activity have been 
measured. 
 
15. Steady-state kinetic parameters for L-Dopa of pathogenic variants 
 
The study of the effect of AADCd variants on the decarboxylase activity has been 
carried out by measuring the kinetic parameters for L-Dopa under steady state 
conditions (Table 18).  
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Table 18. Steady-state kinetic parameters for L-Dopa of wild-type AADC and variants. a WT 
parameters has been firstly reported in 44, and those of b in 119.  
 
Enzyme 
kcat  Km  kcat/Km  
(s-1) (mM) (sec-1mM-1) 
WTa 7.6 ± 0.1 0.11 ± 0.01 69.1 ± 10 
Y20del 0.04 ± 0.01 0.44 ± 0.04 0.088 ± 0.024 
Y20A 0.0197 ± 0.0005 0.12 ± 0.01 0.16 ± 0.01 
Y20S 0.0250 ± 0.0006 0.12 ± 0.01 0.21 ± 0.01 
E25K 1.4 ± 0.1 0.07 ± 0.01 20 ± 3.2 
V60A 1.7 ± 0.6 0.18 ± 0.02 9.44 ± 3.34 
H70Y 0.58 ± 0.09 0.26 ± 0.04 2.23 ± 0.41 
H70R/W71del 0.00067 ± 0.00004 0.22 ± 0.06 0.0023 ± 0.0009 
W71A 0.12 ± 0.05 0.16 ± 0.04 0.75 ± 0.36 
F77L 0.35 ± 0.07 0.51 ± 0.05 0.68 ± 0.15 
G96R 3.72 ± 0.7 1.81 ± 0.03 2.06 ± 0.38 
W105C 0.0067 ± 0.0004 0.18 ± 0.04 0.037 ± 0.001 
A110E 0.00031 ± 0.00001 0.09 ± 0.01 0.0037 ± 0.0007 
G146R 0.17 ± 0.01 8.34 ± 0.94 0.020 ± 0.002 
P210L 4.4 ± 0.2 0.12 ± 0.02 36.6 ± 6.3 
L222P n.p n.p n.p 
F237S n.p n.p n.p 
F251S 4.1 ± 0.1 0.09 ± 0.01 45.77 ± 5.19 
W267R 2.11 ± 0.04 0.194 ± 0.014 10.9 ± 0.81 
C281W n.p n.p n.p 
E283A 6.4 ± 0.2 0.29 ± 0.05 22.0 ± 0.04 
P330L 0.056 ± 0.001 0.12 ± 0.01 0.45 ± 0.04 
R347Qb 0.087 ± 0.005 0.49 ± 0.08 0.16 ± 0.06 
L353P 0.00062 ± 0.00006 0.26 ± 0.03 0.0023 ± 0.0003 
M362T 4.6 ± 0.2 0.18 ± 0.06 25.5 ± 8.6 
R453C 0.67 ± 0.07 0.40 ± 0.06 1.67 ± 0.31 
 
A first consideration comes from the comparison between the effect of the 
mutations on kcat and Km parameters. Variants exhibit a wider range of alterations 
in terms of kcat than of Km since the first ones span from 1-3 orders of magnitude of 
difference to about 2.5×105 decrease with respect to the WT. Substrate affinity is 
instead less variable with an average alteration of about 2-folds respect to the WT 
once excluded variants G96R and G146R that show a dramatic increase in Km of ~ 




Fig. 48. Effect of the mutations on the protein catalytic efficiency along protein 
sequence. Catalytic efficiency is indicated as percentage of that of the WT and represented 
along protein sequence. The variants exhibiting a kcat/Km lower than 1% with respect of the 
WT are highlighted with a red arrow. N-terminal domain is colored in cyan, the large domain 
in green, and the C-terminal domain is colored in magenta.  
 
In order to find a possible rationale, the catalytic efficiency, kcat/Km, has been 
compared as percentage of that of the WT. Figure 48 shows that there are variants 
exhibiting a medium-to-good catalytic efficiency (>1%). In particular, variants of 
the NTD (E25K, V60A and the loop1 H70Y, W71A, F77L) retain a catalytic 
efficiency of 1-30 % with respect to the WT, while variants of the LD present on 
the surface or related to the surface (P210L, F251S, W267R and E283A) retain 
good values of catalytic activity (from 15% to 70%) with the exception of G96R 
(about 3%, value highly influenced by its Km). The two variants of the CTD show 
marked differences, conserving M362T an efficiency of about 40%, while R453C 
of about 2.5%. Since Arg453 is predicted to be a junction between CTD and NTD 
by bioinformatic analyses, it is not strange that its kcat/Km is similar to those of NTD 
variants. 
A consistent different group includes those variants with a dramatic decrease in the 
kcat/Km below 0.6% of that of the WT. These variants, severely impaired in 
catalysis, are present on NTD and on loop2 and loop3 of LD and are: Y20del (and 
also the artificial Y20A and Y20S), double mutant H70R/W71del, W105C, A110E, 
G146R, P330L, and L353P. Although distributed in different protein regions, all 
these variants, belong to the dimer interface and the amino acid substitutions, 
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induced by the mutation, lead to DDG (monomer-monomer) values (Table 13) that 
indicate an overall destabilization of the dimer interface.  
In an attempt to correlate the structural data to the functional results we have plotted 
kcat/Km and kcat as a function of the structural parameters and obtained interesting 
insights (Figure 49). 
 
Fig. 49. Correlations between structural and functional signals. Functional parameter 
kcat/Km (as well as kcat in the insets) has been correlated with different structural parameters, 
A) dichroic signal at 280nm, B) CD 335 nm/420 nm ratio, C) KD(PLP) and D) holo thermal 
stability. Catalytic incompetent variants W105C, P330L, R347Q and L353P together with 
G146R are shown in red. In the plot also non-pathogenic variants Y20A, Y20S, R27A, E61A, 
W71A, K334Q, S193D, S193E are included. S193D and S193E and will be discussed later 
in the text. 
 
Data of both kcat/Km and kcat as a function of the CD 280 nm signal show that there 
are some variants whose catalytic signals are correlated with aromatic 
microenvironment (E25K, V60A, H70Y, F77L, G96R, P210L, F251S, E283A, 
M362T and R453C),  and a group of catalytically incompetent variants that can be 
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clustered in: those altered in dichroic signals (Y20del and the two artificial ones, 
H70R/W71del and A110E) and those retaining a high CD signal at 280 nm 
(W105C, G146R, P330L, R347Q and L353P), (Figure 49). Notably, the first group 
is mainly composed by NTD residues while the second one by loop2 and loop3 
variants. The only exception is A110E. 
This behavior of kcat/Km and kcat is also mirrored by the same correlation as function 
of the tautomeric equilibrium (insets of Figure 49A, B). These findings, on one 
side, suggest that the enolimine building up is proportional to best kcat value and, 
on the other side, place the following variants W105C, G146R, P330L and L353P 
outside of the correlation. Interestingly, also the already characterized R347Q is 
clustered with this group 119,120. 
The comparison of the kcat/Km data with the thermal stability of the holo species as 
well as with KD for PLP shows the same trend in terms of different behavior of the 
two groups of catalytically incompetent variants (Figure 49C, D). If on one side it 
is easy to understand the catalytically inert NTD variants: lower extent of structural 
signals, of thermal stability and of equilibrium binding of PLP, it is difficult to find 
a rationale for the other group of residues belonging to loop2 and loop3 of the LD. 
The fact that all of them belong to the interface is not sufficient to explain the lack 
of correlation of the well-structured incompetent variants. 
 
16. The external aldimine of AADC incompetent pathogenic variants with 
Dopa methylester (DME) and carbiDopa 
 
In order to understand if the external aldimine microenvironment of all incompetent 
variants is altered as that of internal aldimine, we carried out an extensive spectral 
characterization in the presence of two analogs that are inhibitors of AADC: DME, 
unable to perform decarboxylation given the esterified carboxylate 47,120, and 
carbiDopa (a known drug used for Parkinson’s disease to inhibit peripheral AADC) 





Fig. 50. Spectral modification of WT, Y20del, Y20A, Y20S, H70R/W71del incompetent 
variants in presence of different catechol endowed substrates. Absorbance spectra of 10 
μM enzyme in presence of saturating concentrations of DME, carbiDopa (cDopa) and L-
Dopa recorded in 100 mM potassium phosphate, pH 7.4 at 25 °C within 30 min. Dashed lines 
represent the spectra of the protein recorded in absence of substrate.  
 
The absorbance spectrum of human WT AADC in presence of DME, shows a rapid 
(within 1 minute) formation of the external aldimine displaying a band with a lmax 
at 395 nm that remains stable with time (Figure 50). The spectral modifications 
displayed by the catalytically incompetent variants permitted us to cluster them in 
two groups. The variants of the NTD (Y20del, Y20A, Y20S, H70R/W71del) and 
A110E show a major band at around 420 nm decreasing with time in concomitance 
with an increase at 329 nm. Variants belonging to the LD (W105C, G146R, P330L 
and L353P) show, in addition to a peak at 395-420 nm, the presence of a 500 nm 
species reminiscent of the ability of AADC to deprotonate DME at the a-carbon 
reaching an equilibrium between external aldimine and quinonoid species 30,47. 





Fig. 51. Spectral modification of W105C, A110E, G146R, P330L, L353P incompetent 
variants in presence of different catechol endowed substrates. Absorbance spectra of 10 
μM enzyme in presence of saturating concentrations of DME, carbiDopa and L-Dopa 
recorded in 100 mM potassium phosphate, pH 7.4 at 25 °C within 30 min. Dashed lines 
represent the spectra of the protein recorded in absence of substrate. The formation of the 
quinonoid species is highlighted with a red arrow. 
 
The addition of carbiDopa to the WT determines the formation of a stable band 
absorbing at 395 nm. In presence of carbiDopa the NTD variants (Y20del, Y20A, 
Y20S, H70R/W71del) and A110E show a main band visible at 374 nm and second 
one at 329 nm both slowly increasing during the first 30 minutes. Instead, the group 
of variants of the LD presents the same spectral signals of WT binding carbiDopa 
with a band at 395 nm that remains stable during time (Figures 50 and 51). Only 
for G146R small alterations in the spectrum can be measured in the first 30 min 
with the ~ 390 nm band decreasing and shifting after 2 minutes to 380 nm with the 
concomitant formation of a 329 nm band. 
These spectral results join to the above reported structural signals. We identify a 
difference among the incompetent variants also in terms of enzyme-ligand complex 
formation: those of the NTD show differences in external aldimine 
microenvironment with respect to the WT while those of the LD behave similarly 
to the WT. 
We then decided to check spectral changes in the presence of the natural substrate 
L-Dopa (Figures 50 and 51). In presence of L-Dopa, NTD (and A110E) variants 
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show a fast decrease of the 420 nm band and a concomitant increase of a 329 nm 
band. The second group of incompetent variants of LD (W105C, G146R, P330L 
and L353P) show a fast increase of the 420 nm band concomitant with a small 
amplitude decrease of the 335 nm band shifted to 329 nm in the first minute of 
analysis (Figures 50 and 51). After few minutes, the 420 nm band slowly decreases 
and the 329 nm slowly increases.  
In order to understand the consequences of the spectral modifications and thus the 
alteration of the requirements for productive external aldimine positioning, we 
decided to analyze in depth the spectral modifications for variants A110E and 
L353P in presence of L-Dopa since these two are the less active variants of the two 
emerging groups of incompetent variants.  
 
Fig. 52. Spectral modification of A110E and L353P variants in presence of L-Dopa. 
Panels A) and B) show the absorbance spectra of 10 μM A110E and L353P respectively in 
presence of 2 mM L-Dopa. Spectra were recorded in 100 mM potassium phosphate, pH 7.4 
at 25 °C for 2 h. Dashed lines represent the absorbance spectra of A110E and L353P variants 
in absence of substrate. The arrows indicate the increase at 329 nm and the concomitant 
decrease at 420 nm with time. Insets: increase of the 329 nm and decrease of the 420 nm 
signals as a function of time.  
 
As shown in figure 52, A110E exhibits a constant decrease of the 420 nm band and 
an increase of the band at 329 nm. These two bands generate an isosbestic point 
indicating that one single process is responsible for the direct conversion of one 
species to another. Differently, L353P shows a more complex process since the first 
phase (I) of increase of the 420 nm band, possibly related to the slow formation of 
the external aldimine (4’-N-protonated), is followed by a second phase (II) 
consisting in the decrease of the 420 nm. Concomitantly, a constant increase of a 
band peaking at 329 nm is visible (Figure 52).  
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Since under the same experimental conditions WT AADC determines the formation 
of a 390 nm absorbing species, interpreted as a 4’-N-unprotonated Schiff base 59, 
both these variants seem to be impaired in the conversion of the 4’-N-protonated 
external aldimine to the 4’-N-unprotonated one.  
 
17. Coenzyme modification during the reaction of pathogenic variants with 
L-Dopa. 
 
In order to identify possible coenzyme modifications during catalysis, we 
performed an HPLC analysis of the reaction of free PLP and AADC variants with 
substrate L-Dopa. A reaction mixture containing 20 μM free PLP or 10 μM enzyme 
with saturating concentration of L-Dopa has been treated and subjected to HPLC 
analysis, as reported in Materials and Methods section. It has been already 
demonstrated that PLP converts in the presence of the catechol ring of L-Dopa into 
a cyclic adduct due to a Pictet-Spengler condensation 30. Once the adduct is eluted, 
collected and the pH adjusted, its absorbance spectrum shows two bands centered 
at 290 nm and 326 nm (Figure 53).  
 
Fig. 53. Absorbance profile of PLP-L-Dopa adduct and PMP. Absorbance spectra of 
HPLC purified Pictet-Spengler adduct between PLP and L-Dopa. D) Absorbance spectra of 
commercially available PMP. Both spectra are recorded in in 100 mM potassium phosphate 
buffer, pH 7.4 at 25 °C 
 
This non-enzymatic reaction does not occur with the WT AADC since the reaction 
rate of L-Dopa decarboxylation is faster than Pictet-Spengler condensation 30, 
however the formation of this adduct has been demonstrated for WT in the presence 
of non-natural substrates such as D-Dopa or by some previously characterized 
AADC pathogenic variants 44. Free PLP in the presence of L-Dopa is completely 
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converted into the cyclic adduct in about 15 min (Table 19). All incompetent 
variants exhibit a gradual decrease of the initial PLP amount concomitantly with 
the irreversible transformation into an inactive coenzyme-derived species (Figure 
54A, B) attributed to a Pictet-Spengler condensation.  
 
Fig. 54. Coenzyme modification during the reaction of incompetent variants with L-
Dopa. HPLC analyses results of the reaction mixture of 10 μM incompetent variants in 
presence of saturating concentration of L-Dopa in 100 mM potassium phosphate buffer, pH 
7.4 at 25 °C. PLP (A), PLP-L-Dopa adduct (B), PMP (C) and dopamine (D) are normalized 
for the initial amount of PLP detected in absence of substrate.  
 
Notably, it can be observed that a group of them, comprising those of the NTD 
together with A110E and G146R, irreversibly convert 50% the cofactor into the 
Pictet-Spengler adduct in about 12-17 min and are almost completely inactivated in 
90 min (Table 19).  
A second group of variants, accounting for those of loop3 (P330L, R347Q and 
L353P) and W105C are much less prone to undergo Pictet-Spengler condensation. 
The overall decrease in the initial PLP content of this second group is about 5-folds 
slower respect with the first group and about 20-fold slower respect with the 
control. Furthermore, in addition to the Pictet-Spengler adduct, these variants also 
form small amounts of pyridoxamine 5′-phosphate (PMP) (whose absorbance 
spectrum is reported in Figure 53), also produced by WT AADC in the presence of 
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D-5-hydroxytryptophan 30 or as intermediate of the oxidative deamination reaction 
catalyzed by AADC on aromatic amines 47, a-methylDopa and D-tryptophan 
methyl ester 50 (Figure 54C). 
 
Table 19. Initial velocities of PLP decrease, Pictet-Spengler and PMP increase and dopamine 
formation following reaction of 10 μM AADC incompetent variants with saturating concentration 


















PLP 3.3 0.200 ± 0.024 0.163 ± 0.006 / / 
Y20del 12.4 0.056 ± 0.005 0.050 ± 0.004 / 1.65 ± 0.04 
Y20A 16.4 0.041 ± 0.003 0.052 ± 0.006 / 0.90 ± 0.02 
Y20S 14.2 0.048 ± 0.007 0.040 ± 0.004 / 1.49 ± 0.05 
H70R/W71del 17.0 0.041 ± 0.005 0.047 ± 0.003 / 0.0316 ± 0.0005 
W105C 52.9 0.013 ± 0.006 0.002 ± 0.003 10⋅10-5 ± 1.4⋅10-5 0.176 ± 0.002 
A110E 17.6 0.039 ± 0.003 0.033 ± 0.003 / 0.0133 ± 0.0002 
G146R 22.8 0.030 ± 0.004 0.025 ± 0.003 / 8.70 ± 0.64 
S193D 73.5 0.009 ± 0.005 0.013 ± 0.004 9.5⋅10-5 ± 0.8⋅10-5 1.46 ± 0.02 
S193E 124.5 0.005 ± 0.004 0.005 ± 0.001 10.2⋅10-5 ± 2.6⋅10-5 1.04 ± 0.01 
P330L 32.4 0.021 ± 0.004 0.007 ± 0.001 207⋅10-5 ± 5.8⋅10-5 1.42 ± 0.02 
R347Q 31.3 0.014 ± 0.005 0.012 ± 0.002 291⋅10-5 ± 7.5⋅10-5 0.260 ± 0.002 
L353P 119.1 0.006 ± 0.004 0.003 ± 0.002 85.4⋅10-5 ± 1.7⋅10-5 0.040 ± 0.001 
 
The identity of Pictet-Spengler adduct and PMP, whose absorbance spectra are 




Fig. 55. NMR analysis of purified products. 1H-NMR spectrum of HPLC-isolated peak 
corresponding to the Pictet-Spengler adducted formed by variants A110E (A) and L353P (B) 
in comparison with the spectrum of the chemically synthesized cyclic adduct (C). 1H-NMR 
spectra of HPLC purified PMP after the enzymatic reaction of variant L353P with L-Dopa 
(D) in comparison with the spectrum of commercially available PMP (E). Signals arising 
from impurities in the buffer are indicated with an asterisk. Proton assignment is indicated 
with grey letters. 
 
Formation of dopamine is also included (Figure 54D) and shows that all variants 
catalyze slow amine formation in long times. This rules out that any of the residues 
involved is essential for the catalytic mechanism of decarboxylation. After one hour 
of reaction time some variants have slowed down their reaction rate due to 
irreversible entrapment of the coenzyme in the cyclic adduct. 
While the behavior of NTD and loop3 variants is clear and continuously validated 
from structural to functional results (see the correlation plots), G146R behaves in a 
borderline manner. Its bioinformatics localization and spectral features with 
substrate analogs DME and carbiDopa are similar to loop3 variants but it shows a 
kinetics of PLP conversion analogous to NTD enzymes. It should be remembered 
that this particular amino acid substitution leads to a variant with an unusually high 
Km for L-Dopa (8.34 ± 0.94 mM) that could account for fast loss of coenzyme 
during catalysis. In addition, the loop2 variants W105C and A110E display 
differences among them. W105C resembles loop3 variants from a structural and 
kinetic point of view, while A110E is more similar to NTD variants. This behaviour 
can be interpreted by their specific localization on loop2, being Trp105 in close 
proximity to loop3 residues, while Ala110 can be found at the end of loop2. 
Previous studies have tried to explain the loss of the coenzyme during the catalysis 
of pathogenic variants as consequence of the mispositioning of the PLP located in 
an altered microenvironment and/or as the inability of the protein to acquire a closed 
 121 
and catalytically competent conformation 30,44. Here, we can add more information 
suggesting that incompetent variants are mainly at the interface of the dimer and 
group in those structurally impaired (NTD and loop1) and those without structural 
modifications but affecting loop3, sensitive to slight alterations (as reported in 
part1) and connected to CL correct positioning.  
 
18. Limited proteolysis affects NTD incompetent variants but not those of 
loop3. 
 
It is already known that WT AADC is susceptible to trypsin attack on Lys334-
Leu335 site of the CL and also some variants present the same accessibility 44. 
Moreover, in part1 it has been shown that apoAADC undergoes a second tryptic 
cleavage at Arg27-Gln28 on NTD.  
In order to detect possible alteration on flexible regions on the incompetents 
variants, we treated all incompetent variants with trypsin in a 1:100 ratio for 1 h 
and aliquots of the mixture were withdrawn at different incubation times and the 
digestion patterns analyzed on SDS-page (Figure 56). Surprisingly, some 
holoAADC variants exhibit the typical digestion pattern of the apoWT, showing 
the formation of the 18.1 kDa and 36.6 kDa species resulting from the CL cleavage 
and the additional 51.5 kDa and 33.4 kDa bands from the N-terminal cleavage.  
The results show that catalytically impaired NTD variants are also cleaved at Arg27 
as the apoWT, while the loop3 incompetent variants display the same tryptic pattern 
as the holoWT. This would suggest that the NTD variants present the H1-loop-H3 
exposed and flexible in their holo proteins as the already mentioned artificial 
holoE61A.  
In this sense, similarly to what emerged from the structural and functional analyses, 
limited proteolysis reveals the presence of two different groups of incompetent 
variants (Figure 56). W105C, P330L, R347Q and L353P, showing a digestion 
pattern identical to that of the WT protein, both in their apo and holo form, are 
characterized by (i) maintenance/preservation of the WT structural features (near-
UV and visible region, thermal stability, KD(PLP)), (ii) a microenvironment for 





Fig. 56. Limited proteolysis of holoAADC incompetent variants in comparison with the 
holo and apoWT. Susceptibility of WT and incompetent variants to digestion has been 
determined by incubating 0.54 mg/mL of AADC with trypsin at the E:S ratio of 1:100 (by 
weight) in 100 mM potassium phosphate pH 7.4 at 25 °C with the addition of 100 µM PLP 
for the holo forms. Time points were taken within 1 h of incubation and compared with 
AADC sample in absence of trypsin. At each time point, the reaction was boiled in SDS 
sample buffer to stop trypsin activity. The digestion products were separated by SDS/PAGE.  
 
On the contrary, variants Y20del, Y20A, Y20S, H70R/W71del and A110E show a 
proteolytic pattern similar to that of the apoWT both in their holo and apo form, are 
characterized by structural defects in terms of tertiary structure, coenzyme 
microenvironment, thermal stability, mispositioning of PLP during external 
aldimine formation, leading to a rapid coenzyme irreversible inactivation during 
catalysis. Altogether it could be suggested that the NTD holo variants impairment 
is connected to an increased mobility of the NTD, as the apoWT and holoE61A. An 
exception is represented by G146R since from one side it shows good structural 
features as the loop3 incompetent variants (in terms of stability and tertiary 
structure) and on the other side the dramatically decreased Km for L-Dopa lead the 
enzyme to the release of the coenzyme during catalysis similarly to the NTD 
incompetent variants. Notably, N-terminal cleavage is visible in G146R, even if at 




Fig. 57. Limited proteolysis of holoAADC pathogenic variants show a wide range of 
susceptibility to trypsin digestion. HoloAADC variants were incubated with trypsin at the 
E:S ratio of 1:100 (by weight) in 100 mM potassium phosphate pH 7.4 at 25 °C with the 
addition of 100 µM PLP. Digestion time course was analyzed on SDS-page and compared 
with holoWT. A) Disappearance of the monomer band and concomitant formation of the N-
terminal nicked monomer resulting from the cleavage at Arg27 level. All gels were scanned 
and analyzed using National Institute of health IMAGE J software. B) Impact of the 
mutations on AADC N-terminal conformation. The susceptibility of each variants to trypsin 
attack at Arg27 level is represented as initial rate of formation of the N-terminal nicked 
monomer (51.5 kDa species) and constitutes a bar in the figure.  
 
We have then enlarged the proteolysis analysis to all variants (not only the 
catalytical incompetent once) to understand if the rate of N-terminal cleavage could 
be correlated to former structural and functional analyses (Figure 57) (as samples, 
digestion mixture of E25K, F77L, R453C have been analyzed by MS confirming 
the sites, see table 20)). 
In their holo form, the variants exhibit heterogeneity in the proteolytic pattern, 
spanning from variants showing gross to modest accessibility of the N-terminal site 
to variants with no exposure of this site under these experimental conditions 
(Figure 57B). It can be observed that NTD variants are those mainly sensitive to 
Arg27 cleavage as expected. In addition, a slight propensity of the CTD variants is 
visible, confirming the communication between NTD and CTD, as evidenced in 
part1. Finally, also some LD variants, (P210L, E283A) show a small extent of N-
terminal cleavage. 
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Table 20. Identification of the tryptic sites on some AADC variants. Experimental masses are listed 
and compared with the expected theoretical masses of the identified peptide species. Some peptides 
















n.f 54716.19 54681 54683.11 54763.5 54664.08 1-486 
n.f 36623.17 36588 36623.17 36623.5 36624.11 1-334 
18111.5 18111.04 18112 18111.04 18059 18057.99 335-486 
3206.6 3208.68 3209.5 3209.62 3210 3209.62 1-27 
33433 33432.50 33396 33398.49 33433 33432.50 28-334 
n.f 51525.53 51499 51491.51 n.f 51472.48 28-486 
17159 17159.08 n.f 17159.08 n.f 17106.03 335-479 
 
 
19. Hydrodynamic radii of incompetent variants 
 
We aimed at determine the particle size of Y20del, Y20A, Y20S, H70R/W71del, 
W105C, A110E, G146R, P330L, R347Q and L353P  by means of dynamic light 
scattering as the effect of the mutations may be reflected on the hydrodynamic 
radius. Since the difference in particle size between holo and apoWT reflects the 
closed and partially open conformation of the dimer, and possibly also the 
difference is domain mobility and loop3 conformation, one could expect that a 
variant with a relaxed and somehow open conformation would result is a particle 
size similar or even bigger than that of the apoWT.  
As shown in figure 58, almost all variants in both their holo and apo form show a 
difference in the particle size. The statistical analysis revealed that all holo proteins 
exhibit a significantly higher dimer size (p value <0.0001 with respect to the WT) 
particularly evident in Y20S and H70R/W71del (12.43  ± 0.19 nm and 10.67  ± 0.10 
nm respectively while those of the holoWT is 9.32 ± 0.04 nm). As for the apo 
proteins, all variants show a statistically significant increase in the particle size, 
showing at the same time great differences (such as for Y20S and A110E) and 
smaller ones (P330L, L353P).   
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Fig. 58. In solution particle size obtained by DLS. Comparison between diameters 
measured at 25°C for WT and catalytically incompetent variants. A) holo, B) apo forms. Each 
circle represent the diameter size mean value obtained from one measurement. Each 
measurement was the accumulation of 12-18 runs. Mean is reported with standard deviation.  
 
In the light of previously observed data, the increased hydrodynamic radio may be 
related to both an increased solvent exposure of loop3 (Pictet-Spengler cyclization 
may indicates a somehow more ‘open’ active site) and an increased protein mobility 
(as revealed by limited proteolysis).  
 
Table 21. Comparison of the hydrodynamic diameter estimation of holo and apo WT and variants. 
DLS measurements were collected at about 4 µM protein concentration in 100 mM potassium 
phosphate, at pH 7.5 with the addition of 100 µM PLP for the holo forms, at 25 °C. 
 
Enzyme WT Y20del Y20A Y20S H70R/W71del 
form holo apo holo apo holo apo holo apo holo apo 
mean±SEM a 9.32±0.04 9.63±0.05 9.70±0.05 10.97±0.08 10.08±0.05 10.25±0.07 12.43±0.19 12.96±0.25 10.67±0.10 10.22±0.10 
P value 
summary b 
 **** **** **** **** **** **** **** **** **** 
      
Enzyme W105C A110E P330L R347Q L353P 
form holo apo holo apo holo apo holo apo holo apo 
mean±SEM a 9.78±0.08 10.15±0.10 9.82±0.03 11.50±0.08 9.83±0.08 9.99±0.05 9.79±0.08 9.90±0.6 9.60±0.06 9.99±0.05 
P value 
summary b **** **** **** **** **** **** **** ** **** **** 
 
 a Data are reported as mean ± SEM and expressed in (nm) 
b Results were compared using Student’s t-test between holoWT and holo variants and between 
apoWT and apo variants. ApoWT is compared to holoWT. *P < 0.05; **P < 0.01; ***P < 0.001; 
****P < 0.0001. 
 
Despite this, the distinction between the two previously identified groups of 
incompetent variants is here not evident. It is however notable that all the variants 
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showing a fast release of the Pictet-Spengler adduct exhibit in their apo form a mean 
dimer size bigger than the other variants (Figure 58 and table 21) meaning that 
these mutations affect the overall shape of the protein also in their open 
conformation. 
 
20. Crystal structure of L353P AADC variant 
 
We have here obtained the first structure of a pathogenic variant of AADC, in 
particular of the catalytically incompetent L353P since the Leu353 belongs to loop3 
immediately after the CL and could shed light on an important protein region. In 
addition, MD simulations (part 1) and the inspection of both the ligand-free and 
carbiDopa bound enzyme structures at different pH values have demonstrated the 
propensity of this Leu residue to undergo small alterations, revealing how its 
movements could be related to conformational changes at the active site. L353P 3D 
structure has been solved at 2.05 Å resolution at pH 8.0 (table9 in part1).  
 
 
Fig. 59. Overall topology of holoWT and holoL353P crystal structure. Domain 
organization and secondary structure elements are obtained with PDBsum server 144. 
Mutation site is indicated by the symbol ⦻.  
 
As the WT AADC, L353P is a perfect symmetric dimer. Its backbone atoms 
superpose to the WTpH8.0 structure with a RMSD of 0.089 Å and to the WTpH7.5 with 
a RMSD of 0.141 Å indicating that no gross structural alterations are induced by 
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the mutation, thus corroborating structural results obtained in solution with this 
variant (Figure 59).  
 
Fig. 60. Structural effects of L353P at loop2 and loop3 level. Cartoon representation of 
superimposed WTpH 7.5 (cyan), WTpH 8.0 (magenta) and L353PpH 8.0 (green) crystal structures. 
Protein residues of monomer a are shown as sticks, while only Lys3030-PLP of facing  
monomer b are represented as sticks. Loop2 and loop3 are indicated. A) Effect of the pH and 
L353P substitution on loop3 at Atg355 and Arg356 level. At pH 8.0 (both WT and L353P) 
stretch 327-354, including Leu353, is missing. Structural water molecule indicated with W 
and represented as a red sphere is relative to WTpH 7.5 structure. B) Effect of pH and L353P 
mutation on loop2. Main differences between the three structures are visible at Ile98, Cys100, 
Ile101, Phe103, Ser104 and Trp105 level. C) L353P structural effect on loop2 and loop3. 
Novel interactions are highlighted and measured distances are shown. D) Superimposition of 
WTpH 8.0 and L353PpH 8.0. The effect of the mutation on loop2 conformation and its steric 
hindrance is highlighted by showing the protein surface of monomer a, while monomer b is 
only represented by Ly303-PLP complex.  
 
Unfortunately, as shown in figure 60, L353P loop3 misses residues 327-354 thus 
the LeuàPro substitution is not visible. Notably, as for WTpH8.0, L353P shows that 
Arg355 is rotated in the forward position and contacts the PLP phosphate moiety 
(see part1). In addition to Arg355 rotation, Arg356 displays a novel conformation 
distinguishing the WT and the L353P proteins (Figure 60A, B). In analogy to 
loop3, also loop2 results affected by the mutation. In fact, as shown in figure 60B, 
the backbones of residues 98-103 in WTpH7.5 and WTpH8.0 are almost 
superimposable; on the contrary, L353P shows a different conformation of the loop, 
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with a particular alteration on Ile98, Cys100, Ile101 and Phe103 stretch. A deeper 
investigation reveals that the mutation causes the formation of a network of weak 
electrostatic interactions (3.2-3.8 Å) between loop3 and loop2 (Figure 60C). In 
fact, the altered loop2 conformation is stabilized by novel contacts between Ile101 
backbone and Arg355 side chain and Phe103 backbone together with novel contacts 
between Arg356 sidechain with Gly99 and Cys100 backbones. Taken together, 
these alterations cause (i) a change in the steric hindrance of loop2 (Figure 60D) 
with potential effect on substrate binding since Ile101 is involved in its stabilization 
and (ii) a dramatic change in loops conformation due to established new contacts 
between loop3 and the PLP (via Arg355) and between loop2 and loop3 (via Arg355 
and Arg356).  
These observations are mirrored by the in solution biochemical results, indicating 
that the variant as compared with the WT protein shows (i) an overall preserved 
tertiary structure, (ii) a reduced thermal stability only in its apo-form (probably due 
to an increased mobility of loop3 in the open conformation). The previously 
observed slight increase in the hydrodynamic diameter of holoL353P (9.60 ± 006 
nm vs 9.32 ± 0.04 nm of the holoWT) may indeed be related with the mobility of 
loop3. The coenzyme microenvironment does not show relevant spectroscopic 
differences with the WT even if the PLP and substrate affinity shows a 2-fold 
reduction (Table 18). Moreover, the dramatically reduced dopamine synthesis is 
not linked to a high conversion of PLP into the cyclic adduct, thus the catalytic 
defect is not due to gross structural effects, as for the NTD incompetent variants. 
The residue Leu353 is on the same time not essential for the decarboxylation 
mechanism. The “local” structural alterations visible at the active site indicate that 
it is well constructed in each monomer. However, the residues coming from the 
partner monomer that complete the active site architecture  in substrate binding 
(loop2) and functionality (loop3) are somewhat displaced and more connected by 
weak interactions, maybe rendering overall loop3 and its CL less prone for 
productive catalysis.  
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21. In solution secondary structure differences of apo and holo WT and 
L353P by microfluidic modulation spectroscopy (MMS) 
 
It is well known that, in crystals, a protein is rigidly constrained in the crystal lattice 
and its dynamic movements are prevented. As shown for the WT AADC in part 1 
of this study, during the initial 50 ns of MD simulations both holo and apoAADC 
show a structural rearrangement before reaching the equilibrium. Similarly, on one 
side L353P crystal structure provides important structural details and on the other 
side it does not represent the protein in its natural occurring dynamics. The 
combination of near-UV CD, X-ray crystallography and limited proteolysis, 
provides us a comprehensive picture of the Protein Higher Order Structure (HOS) 
of both WT protein and L353P variant in terms of secondary, tertiary structure, 
protein folding and spatial arrangements.  
We have already measured the far-UV CD spectra of apo and holo WT and of holo 
variants. These spectra do not show traits of a dissimilar organization (Figure 41).  
 
Fig. 61. Secondary structure content of WT AADC and L353P by means of CD and 
MMS. A) Far-UV CD spectra of holo and apo WT and L353P. B) Estimation of the structural 
content were obtained with the K2D3 server 145. C) Overlaid second derivative MMS spectra 
of holo and apoWT and L353P variant recorded in the IR amide I band region (1590-1710 
cm-1). B) Percentage of secondary structure composition of holo and apoL353P compared to 
holo and apoWT. 
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However, far-UV CD does not constitute a highly sensitive approach in determining 
in solution secondary structural differences between different AADC variants since 
the intense a-helical signals lead to a loss in the sensitivity to the other signals. In 
fact, the far-UV CD spectra of holo and apo WT and L353P are superimposable 
(Figure 61A).  
The predicted secondary structure content estimated with the K2D3145 server 
indicates a slight increase of the helical content in L353P (from 53.2 % of the WT 
to 54.8 %) and an unchanged b-sheet content (18.4 %) in both apo and holo 
enzymes (Figure 61B). Since FTIR spectroscopy has long been used as powerful 
approach (as powerful as far-UV CD) in the study of protein secondary structure, 
we decided to follow the absorbance of the amide I band (1710 – 1590 cm-1) for 
studying secondary structure element such as b-sheet, a-helix, turns and unordered 
142. In collaboration with RedSchift BioAnalytics we analyzed AADC samples with 
the novel automated IR spectroscopy technique called Microfluidic Modulation 
infrared Spectroscopy (MMS) 146,147.  
Figure 61C shows the MMS absorbance spectra in the IR region of WT and L353P 
in their holo and apo forms. We then determined the amount of secondary structures 
by gaussian curve fitting as described (materials and methods, 146,147). As reported 
in figure 61D, MMS detects small differences with high sensitivity. As expected, 
for the WT protein MMS data reflect the different conformation between apo and 
holoAADC mainly in terms of acquisition of order and rigidity. In fact, we can 
observe a conversion of the extended unordered content (from 27.3 % of the apo to 
21.5 % of the holo) to a higher composition of a-helix and total b-sheets (increased 
a-helix from 19.9 % to 24.2 % and almost unchanged global b-sheets). Variant 
L353P shows a similar trend between its apo and holo state in terms of acquisition 
of helical content (from 19.5 % to 21.7 %). However, differently form the transition 
observed in the WT, the variant shows an overall gain in turn content (from 29.5 % 
in the apo to 34.4 % in the holo) with a decrease of both parallel and antiparallel b-
sheets. If compared to the holoWT, holoL353P shows an increased unstructured 
content (from 53.2 % to 58 %) (Figure 61D). These results highlight the great 
sensitivity of MMS technology if compared to far-UV CD spectroscopy.  
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The reduced contribution of secondary structured elements and the increased 
unstructured content, together with the observed differences revealed by 
crystallographic analyses occurring on loop2 and loop3, corroborate more 
quantitatively the observed differences. 
 
22. An investigation on Ser193 role provides further information on loop3  
 
S193A, S193D and S193E are three non-pathogenic variants designed on the basis 
of preliminary data obtained in collaboration with Prof. Robert S. Phillips at the 
University of Georgia (USA). AADC has been extensively characterized in the 
recombinant purified form but little is known 
about its regulation, and post-translational 
modifications both in vitro and in vivo. We 
have recently found that AADC is 
phosphorylated by murine recombinant protein 
kinase A (PKA) in vitro. The modified residue 
has been identified to be Ser193 by mass 
spectrometry 148. Interestingly, the solvent 
exposed Ser193 is located at the active site of 
AADC and is highly conserved among 
homologous proteins (see Table 14).  
 
Fig. 62. Localization of Ser193 and proposed 
effect of S193D and S193E on loop3 mobility. 
A) Ser193 is located at the active site and its side 
chain is not involved in polar interactions. In 
silico mutagenesis suggests that aspartate (B) 
and glutamate (C) variants could interact with 
Arg347 already observed to be highly sensitive 
to slight alterations of the active site.  
 
In AADC Ser193 follows His192 base stacked with the PLP ring and its side chain 
does not seem to be involved in any polar interaction (Figure 62A). Functional 
analysis of phosphorylated AADC revealed an influence on the kinetic parameter 
in increasing the catalytic efficiency toward L-Dopa mainly due to a decrease in Km 
148. 
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Table 22. Kinetic parameters for L-Dopa, apparent equilibrium dissociation constant for PLP and 













WTa 7.6 ± 0.1 0.11 ± 0.01 69.1 ± 10 101 ± 10 69.42 ± 0.02 64.84 ± 0.03 
S193A 1.8 ± 0.1 0.096 ± 0.02 17.7 ± 4.9 92 ± 10 69.09 ± 0.02 65.08 ± 0.03 
S193D 0.032 ± 0.001 0.31 ± 0.04 0.103 ± 0.004 84 ± 10 70.67 ± 0.02 67.55 ± 0.03 
S193E 0.026 ± 0.001 0.25 ± 0.03 0.104 ± 0.004 98 ± 13 70.69 ± 0.02 66.85 ± 0.04 
 
Variants S193A, S193D and S193E have been designed with the aim of 
determining the role of the serine residue. The functional characterization of the 
three Ser193 variants provide unexpected informations (Table 22). S193A displays 
the 25.6 % of catalytic efficiency of the WT AADC, mainly due to a ~ 4-fold  
reduced kcat. S193D and S193E are found to be catalytically incompetent. In fact, 
their kcat/Km value is less than 0.6% of that of the WT (being both around 0.15 %). 
S193D and S193E exhibit a dramatic decrease in kcat as well as a decreased substrate 
affinity. The possibility that these two variants share common features with the 
identified LD incompetent ones (W105C, P330L, R347Q, L353P) is confirmed by 
the following structural analysis. Figure 63A and B show the spectroscopic 
features of Ser variants as revealed by near-UV visible CD and absorbance.  
The variants show a preserved tertiary structure in both their apo and holo form. As 
for the Lys303-PLP internal aldimine, the tautomeric equilibrium is similar to that 
of the WT, with a predominance enolimine band over the ketoenamine one. The 
PLP affinity measured for these variants show to be maintained, being very similar 
to that calculated for the WT (Table 17). 
Limited proteolysis revealed that catalytically incompetent S193D and S193E are 
resistant to N-terminal cleavage while S193A is only faintly cleaved (Figure 63C).  
S193D and S193E in presence of DME show spectral modifications within 30 
minutes consistent with the formation of the external aldimine, peaking at 395 nm, 
and the observable 500 nm band relative to an equilibrium between the external 




Fig. 63. Characterization of artificial S193, S193D and S193E variants. A) Near-UV 
visible CD spectra of holo variants compared with holoWT. Signals relative to the apo 
species are reported in the inset. CD spectra are recorded at 5 μM protein concentration, in 
100 mM potassium-phosphate buffer, pH 7.4 in presence of 100 μM PLP for the holo forms. 
B) Internal aldimine absorbance spectra of holoWT and variants. Spectra are recorded at 10 
μM protein concentration, in 100 mM potassium-phosphate buffer, pH 7.4. C) Limited 
proteolysis with trypsin at 1:100 (w/w) ratio were performed in 100 mM potassium phosphate 
pH 7.4 at 25 °C with the addition of 100 µM PLP. Figure shows the disappearance of the 
dimer along 1 hour of incubation. D) hydrodynamic diameters calculated by DLS. a Data are 
reported as mean ± SEM and expressed in (nm) b Results were compared using Student’s t-
test between holoWT and holo variants and between apoWT and apo variants *P < 0.05; 
***P < 0.001; ns not significantly different. apoWT is compared to holoWT. 
 
When L-Dopa is added to the mutants, a first fast phase occurs within 1 min in 
which an increase of the 420 nm band and a shift of the 335 nm band to 329 nm are 
visible. A second slower phase consists in the decrease of the 420 nm species and 
the concomitant increase of the 329 nm band, as observed for L353P. The HPLC 
analysis of the coenzyme during the reaction with L-Dopa shows the trapping of 
the PLP into the cyclized adduct with L-Dopa and the linear formation of PMP with 
initial rates consistent with those observed for W105C, P330L, R347Q and L353P 




Fig. 64.  External aldimine of S193D and S193E in presence of DME, carbiDopa and L-
Dopa and coenzyme modifications during reaction with L-Dopa. A) Absorbance spectra 
of 10 μM enzyme in presence of saturating concentrations of DME, carbiDopa (cDopa) and 
L-Dopa recorded in 100 mM potassium phosphate, pH 7.4 at 25 °C within 30 min. Dashed 
lines represent the spectra of the protein recorded in absence of substrate. The formation of 
the quinonoid species is highlighted with a red arrow. B) Coenzyme modification was 
followed by HPLC during the reaction 10 μM S193D and S193E in presence of saturating 
concentration of L-Dopa in 100 mM potassium phosphate buffer, pH 7.4 at 25 °C. PLP (blue), 
PLP-L-Dopa adduct (cyan), PMP (brown) and dopamine (green) are normalized for the initial 
amount of PLP detected in absence of substrate.  
 
These findings of Ser193 variants indicate that this conserved residue located at the 
active site does not play a crucial role in the catalysis since S193A biochemical 
features are only slightly affected. Our study on S193D and S193E provide on one 
side unsuccessfully results data on the comprehension of possible effect of the 
phospho-serine since we found a dramatic drop of the catalytic efficiency. On the 
other side, these two variants reinforce our analysis on the group of the catalytically 
incompetents. In fact, in silico mutagenesis provide suggestions for a possible novel 
inter-subunit interactions between Glu/Asp193 and Arg347 of loop3 thus 
corroborating loop3 sensitivity to slight alterations at the active site. This 
interaction may be related with the observed increased of thermal stability, 
particularly evident in the apo forms.  The particle size estimated for variants 
S913D and S193E (Figure 63D) might indicate that the glutamate and aspartate 
substitutions do not affect neither the domains mobility nor loop3 solvent exposure. 
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It is however evident from functional data that loop3 conformation is impaired, and 
as already suggested in 120, the acquisition of an incorrect loop3 conformation is 
associated with functional impairment, as confirmed by the WT crystal structures 
solved at different pH values (see part1) and in L353P crystal structure. 
Altogether, the biochemical data relative to variants S193A, S193D and S193E 
provide additional value to the above proposed correlations between structural and 
functional features of AADC pathogenic variants. In fact, the three Ser193 mutants 
display the characteristic features of the LD variants, exhibiting good structural 
features in terms of tertiary structure, thermal stability, internal and external 
aldimine spectroscopic signals. S193D and S193E, behaving similarly to the loop3 
and W105C catalytically incompetent variants, reinforce the finding that an impact 




CONCLUSION OF PART 2 and OVERALL DISCUSSION 
 
The present study provides a biochemical characterization of recently identified 
AADC variants associated to AADC deficiency. This effort was driven by the aim 
of providing the molecular basis for the pathogenicity of each enzymatic species 
leading to a better comprehension of the severity/mildness of the clinical 
phenotype.  
While previously characterized variants were mainly localized in a ‘central 
belt’ of AADC 119, the novel pathogenic amino acid substitutions are spread over 
almost every region of the protein allowing us to widen the spectrum of enzymatic 
phenotypes related to AADC deficiency. In particular, a novel cluster of variants, 
mapping in the LD (P210L, L222P, F237S, W267R, C281W, E283A, M362T) is 
characterized by a low (or null) recovery in the soluble fraction. A deep discussion 
on this novel phenotype is presented in paper 1 33. Here, we underline the 
identification of a LD region as responsible for the aggregation of these variants in 
their apo form. In fact, respect to 33, C281W and M362T have been newly 
characterized and, together with R285W and R412W, have been analyzed for their 
propensity to aggregate in the apo form. Since P210L, W267R, E283A, M362T 
variants do not exhibit gross functional impairments and structural alterations, their 
pathogenicity is attributable to a folding defect and possibly to an aggregation 
propensity.  
Structural and functional signals obtained from the characterization of the 
total AADCd variants have been combined with those of some non-pathogenic ones 
(Y20A, Y20S, R27A, E61A, W71A, S193A, S193D, S193E). The range of the 
structural modifications was found to be wide, as well as the extent of functional 
alterations. We could relate different structural signals (Figure 47) observing that 
the loosening of the aromatic microenvironment is associated by a reduced thermal 
stability and by an impact on the cofactor binding (both in terms of affinity and 
tautomeric equilibrium). Moreover, the degree of the structural effects is mirrored 
by the extent of the catalytic effects (both in terms of catalytic efficiency and 
catalytical constant) (Figure 49). A gradient of severity of the effect of the 
mutations on AADC biochemical features is observable along the three protein 
domains. In fact, we could observe that variants located at the NTD and CTD show 
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a highest detrimental effect on protein structure and activity, while gradually 
proceeding along the LD, milder effects are reported. The observed linear structure-
function relationship nicely describes the behavior of all N-terminal and C-terminal 
variants, and the majority of the LD ones. In fact, at one extreme the NTD variants 
exhibiting a dramatic loss of structural signals show to be incompetent from a 
catalytically point of view, while mutations of the LD at the opposite extreme 
(regarding both variants distant from the active site, i.e E283A and F251S, or close 
to the PLP, i.e S193A) maintain good catalytical competence.  
Tautomeric equilibrium expressed as the ratio between the intensity of the 335 nm 
and 420 nm bands has been for the first time cotrelated to other structural and 
functional signals. The disruption of the tertiary structure and the loosing of the 
NTD-CTD might be related to a structural alteration at the active site that favors 
the ketonic tautomer of the PLP, peaking at 420 nm. It is indeed still unclear if the 
alteration of the tautomeric equilibrium is related with an altered binding of the PLP 
and/or to a chemical modification. It is however deducible that dichroic visible 
bands of PLP and KD(PLP) share common structural aspects related again with 
protein mobility (Figure 49).  
In addition to the spectroscopic techniques, we have used limited proteolysis 
as a powerful structural tool for studying protein mobility/flexibility. It has been 
reported in part 1 of this thesis that N-terminal cleavage likely results from large 
amplitude motion of the NTD-CTD (particularly visible on H1-loop-H3 and helix-
16), that makes Arg27 accessible to trypsin only in the apo and not in the holo form. 
Thanks to MD simulations and artificial variants (R27A, E61A and K334Q), 
limited proteolysis has the advantages, with respect to the spectroscopic techniques, 
of localizing the structural elements responsible for the observed data, thus 
confining the affected region. 
The finding that some variants exhibit in their holo form a similar N-terminal 
cleavage to that of apoWT, may indicate that these proteins manifest an 
inadequate/altered NTD-CTD mobility. Some of them show to be somehow more 
mobile than apoWT, as revealed by higher rate of proteolysis, especially those 
variants located at the monomer-monomer interface (Y20del, Y20A, Y20S, V60A, 
E61A, H70Y, H70R/W71del, G96R, A110E, M362T, R453C) or in the interface 
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between NTD and CTD of the same monomer (E25K, F77L). Others, mainly 
located on the LD, distant from Arg27 and distant from the active site, show to be 
less prone to digestion and thus more similar to holoWT.  
Since structural results were shown to be related to each other, we aimed at 
establishing a relationship among signals. As shown in figure 65, the rates of 
cleavage at the N-terminal domain (related to N-terminal mobility) correlate to the 
previously discussed structural data: 280 nm CD band, 335nm/420 nm ratio, 
thermal stability and KD(PLP). Importantly, in addition to kcat, also catalytic efficiency 
exhibits a dependence on the protein mobility (Figure 65, insets). Altogether these 
correlations suggest that the functional effects of the mutations are related to 
common structural causes, leading to a wide spectrum of similar enzymatic 
phenotypes. 
 
Fig. 65. Correlations of N-terminal cleavage with other structural and functional 
parameters. The structural effect of the mutations at NTD level has been correlated with A) 
tertiary structure CD signal at 280 nm and the tautomeric equilibrium (inset); B) global 
thermal stability (ΔTm(holo-apo)) and holo Tm (inset); (C) kcat and (D) KD(PLP) . ApoWT is 
included and represented as green circle. Catalytic incompetent variants W105C, S193D, 
S193E, P330L, R347Q and L353P together with G146R are shown in red.  
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Our data provide novel insights on the structure-function relationship of 
AADC. In fact, the PCA analysis discussed in part1, and proposed again here 
(Figure 65A), shows high mobility of those N-terminal residues facing the CTD, 
in particular on loop1 and Tyr20. This is mirrored by high mobility of the facing C-
terminal residues (416-438, including helix-16) of the same monomer. This 
flexibility observed on one side of the protein, asymmetrically corresponds to a -
CL in- conformation (low mobility) on the same side of the protein. It follows that, 
on the other side of the protein, NTD and CTD are more rigid and CL is found in a 
-CL out- conformation (showing higher mobility). The existence of a functional 
crosstalk between these regions has been proposed on the basis of MD simulations 
and limited proteolysis. The study on the AADC variants reinforce this hypothesis 
since we observe a progressive decrease of the activity concomitantly with the 
increased accessibility of the N-terminus. Affecting protein mobility would 
ultimately lead to alter CL conformation by disrupting domains crosstalk.  
Among highly similar human enzymes involved in pathogenic states, whose 
structure have been solved (HDC and GAD), the motion of specific domains and 
the possible implication in catalytic mechanism has been proposed but not 
addressed.  
The correlation between variants CD signals and NT-cleavage suggests that 
the aromatic microenvironment responsible for the 280 nm dichroic band (generally 
attributed to the global tertiary structure) is highly susceptible to the NTD-CTD 
motion. In support of this, two considerations can be done, both addressing a 
dependency between NTD-CTD mobility and 280 nm CD signal.  
Firstly, apoWT shows ~2.2 fold decrease dichroic 280 nm band with respect of 
holoWT and shows an NT-cleavage consistent with that of those holo variants with 
a similar CD signal of about 50 % of that of the holoWT, such as H70Y (Figure 
65A).  
Secondly there is a group of previously reported variants (figure 66B) showing an 
abolished 280 nm dichroic signal in their apo and/or holo form 119. Variants causing 
gross decrease (> 70%) of the CD aromatic signal (in the holo and/or apo form) are 
L38P, P47H, H70T, H72Y, P81L, R412W, R447H, R462P from 119 and residues 
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Tyr20 from this thesis (Figure 66C). Similarly, variants causing a modest reduction 
of the 280 nm CD band are E25K, R27A, V60A, E61A, A110E, R453C from this 
thesis and F80A from 119.  
 
Fig. 66. Role of the interface between NTD and CTD in protein mobility. A) PCA 
analysis described in part1 of this study is proposed again, highlighting the different mobility 
of chainA (gray line, colored filled area in accordance to the different regions) and chain B 
(black line and white area) in specific regions: 1-120 (including the NTD, loop1 and loop2), 
315-360 including loop3 and the motion of the C-terminal region encompassing residues 
400-470. Panel B and C show AADC crystal structure (structure 1) represented as cartoon. 
All variants reported to have gross tertiary structure alterations in this study or in previous 
reports 44,119 are located at the NTD or CTD of AADC. NTD is colored in cyan, LD in green, 
CTD is colored in magenta. Loop1 is represented as ribbon and colored in red. PLP is 
represented as sticks and colored in yellow while all discussed residues are represented as 
spheres. Residues involved in substitutions with gross impact on AADC tertiary structure 
(near UV CD signal) are colored in blue (B) while those sites involved in substitutions 
leading to a ~50 % decreased CD signal are colored in yellow (C).  
 
All these residues exhibit the common feature of being located in proximity of the 
interface between the NTD and CTD of the same monomer. In addition, most of 
them show a decreased catalytical efficiency 33,119.  
These results were initially interpreted on the basis of the role attributed to loop1 
24,119. Variants belonging to loop1, or interacting with it, were proposed to be 
impaired in the apo to holo transition. Here, by means of correlations between 
structural and functional parameters, we propose novel insights on AADC 
structure-function relationship. We can advance that the impact of the mutations on 
AADC catalytic activity can be attributed to an impairment of protein mobility or 
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to a direct effect on loop3. In the first case, a wide spectrum of alterations has been 
observed, ranging from variants exhibiting slight structural and functional 
alterations (F251S, K334Q, E283A) to variants that are drastically affected in their 
structural signals and from a catalytic point of view can be considered incompetent 
(Y20del, Y20A, Y20S, H70R/W71del, A110E). All these proteins (accounting for 
the majority of the AADCd associated variants) show an altered protein mobility 
that has lastly an impact on CL conformation. In the second case, we identified a 
group of catalytic incompetent variants (W105C, S193D, S193E, P330L, R347Q 
and L353P) belonging to loop3 or interacting with it that, despite exhibiting good 
structural features, have a dramatically reduced catalytic efficiency. These variants 
escape from the described correlations (structure-function). Affecting loop3 results 
in an extremely slowed down decarboxylation reaction and to the aberrant 
formation of PMP, whose origin still has to be determined. Nonetheless, the specific 
features of this group of variants have been furtherly dissected by solving the crystal 
structure of L353P and identifying the subtle alterations caused by the substitution, 
mainly visible on loop2 and loop3 conformation.    
A specific exception to the proposed hypothesis emerged. W71A exhibits a 
decrease activity on one side and good structural features on the other side. Despite 
this, W71A cannot be considered incompetent since no cyclic PLP-L-Dopa adduct 
nor PMP have been detected during reaction. A possible explanation for its 
behavior could be related with the type of substitution, suggesting that (i) Trp71 is 
not involved in substrate affinity as previously proposed, (ii) aromatic 
microenvironment generating CD signal in the near UV region does not account on 
Trp71, (iii) the sensitivity of NTD-CTD to loop1 conformation is not affected by 
W71A mutation.  
To the best of our knowledge, this is the first deep investigation of correlation 
between structural and functional data for a consistent number of variants causing 
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A B S T R A C T
AADC deficiency is a rare genetic disease caused by mutations in the gene of aromatic amino acid decarboxylase,
the pyridoxal 5′-phosphate dependent enzyme responsible for the synthesis of dopamine and serotonin. Here,
following a biochemical approach together with an in silico bioinformatic analysis, we present a structural and
functional characterization of 13 new variants of AADC. The amino acid substitutions are spread over the entire
protein from the N-terminal (V60A), to its loop1 (H70Y and F77L), to the large domain (G96R) and its various
motifs, i.e. loop2 (A110E), or a core β-barrel either on the surface (P210L, F251S and E283A) or in a more
hydrophobic milieu (L222P, F237S and W267R) or loop3 (L353P), and to the C-terminal domain (R453C).
Results show that the β-barrel variants exhibit a low solubility and those belonging to the surface tend to
aggregate in their apo form, leading to the identification of a new enzymatic phenotype for AADC deficiency.
Moreover, five variants of residues belonging to the large interface of AADC (V60A, G96R, A110E, L353P and
R453C) are characterized by a decreased catalytic efficiency. The remaining ones (H70Y and F77L) present
features typical of apo-to-holo impaired transition. Thus, defects in catalysis or in the acquirement of the correct
holo structure are due not only to specific local domain effects but also to long-range effects at either the protein
surface or the subunit interface. Altogether, the new characterized enzymatic phenotypes represent a further
step in the elucidation of the molecular basis for the disease.
1. Introduction
Aromatic amino acid decarboxylase (AADC) deficiency is a rare
autosomic disease first reported by Hyland et al. [1,2] nearly 30 years
ago. It is caused by mutations (mainly missense but also frameshift and
splicing alterations) present in homozygosis or compound heterozygosis
in the gene encoding for AADC, the pyridoxal 5′-phosphate (PLP) en-
zyme responsible for the synthesis of dopamine and serotonin following
decarboxylation of L-Dopa and 5-hydroxytryptophan [3,4]. The disease
is mainly diagnosed in infancy and exhibits many different symptoms
reflecting the lack or low levels of catechol and indole biogenic amines.
Patients experience several altered physiological functions such as hy-
potonia, hypokinesia, oculogyric crises, development and behavioural
problems, autonomic dysfunctions such as nasal congestion, modified
circadian rhythm, pain and temperature instability [5–10]. The present
pharmacological treatment foresees a combination of pyridoxine, the
precursor of PLP to keep AADC saturated with its coenzyme, mono-
amine oxidase inhibitors, to avoid dopamine and serotonin further
depletion, and dopamine agonists, to mimic the effect of dopamine.
Unfortunately, in many cases, the response is generally poor and this
infantile form of Parkinsonism is particularly threatening and, in the
most severe forms, leads to death in the first decade of life.
Up to now, nearly 120 patients have been identified worldwide [9],
but the number is continuously growing since knowledge about this
defect is increasing among child neurologists. Moreover, the extent of
affected people might be even higher considering i) newly reported case
of a heterozygous patient that possesses one allele with a mild muta-
tion, while the other allele has no mutations [11], ii) another hetero-
zygous case with typical AADC deficiency symptoms (case II-2 in Ref.
[12]) and iii) a milder case of AADC deficiency reported by Ref. [13].
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These unsuspected patients expand the spectrum of AADC deficiency
with recent estimates [14,15] predicting that the number of affected
people is higher than reported and many patients remain not diagnosed
or misdiagnosed [15].
In order to counteract AADC deficiency, some strategies have cur-
rently been undertaken. Firstly, a gene therapy approach has been
carried out in Taiwan by Dr. Hwu and co-workers [16–19] and in Japan
[20] with some patients, leading to some benefits but still not decisive
improvements. Secondly, mouse models with different genetic defects
have been generated to simulate AADC deficiency and understand the
human disease [21–24], but much has still to be done.
A biochemical research of genotype to phenotype correlation has
been carried out in order to elucidate the molecular basis of an altered
phenotype by characterizing the related enzymatic variant. Previously,
the structural/functional correlation of the effects of mutations for 16
AADC variants were studied [25]. This approach deepened the under-
standing of the role played by individual amino acids on enzyme
structure and function, suggesting more effective therapeutic inter-
ventions.
After five years the number of identified mutations has rapidly in-
creased. The total number of the identified AADC mutations leading to
the disease, including missense mutations determining homozygosis or
compound heterozygosis, insertions, deletions, introns and non-coding
regions modifications, has been recently updated [15]. In particular, 13
new mutations have been identified in homozygosis or hemizygosis and
their protein variants are listed in Table 1. Notably, the variants of His-
70 and Ala-110 have been re-characterized since they were incorrectly
reported (see Table 1).
On the basis of the structure of AADC, solved both in the pig holo
(~90% sequence identity with the human enzyme) [26] and in the
human apo form [27], the new sites of mutation are spread overall the
entire protein and not only in the central part of each monomer as
previously claimed [25] (Fig. 1).
Here, by a combination of bioinformatic and physico-chemical
techniques, we present a structural and functional characterization of
the new homozygous and hemizygous variants of AADC. The data ob-
tained pertain to residues that belong to: i) loop1 (aa 66–84) of the N-
terminal region (H70Y and F77L), ii) the interface between monomers
(V60A, G96R, A110E, L353P and R453C) and iii) different regions of
the large domain (P210L, L222P, F237S, F251S, W267R and E283A).
The correlation between position and functional effect represents a
powerful approach for disease phenotype prediction.
2. Materials and Methods
2.1. Materials
PLP, L-Dopa, dopa methylester (DME), hydroxylamine hydro-
chloride, isopropyl-β-D-thiogalactopyranoside (IPTG), trini-
trobenzenesulfonic acid (TNB), phenylmethylsulfonyl fluoride (PMSF),
protease inhibitor cocktail (P8849), were purchased from Sigma. Anti
AADC monoclonal antibody (8E8) and mouse IgG kappa binding pro-
tein (m-IgGk BP) conjugated with HRP were purchased from Santa Cruz
Biotechnology.
2.2. Site-directed mutagenesis
AADC variants were obtained by mutating the template DNA on the
pDDChis vector as previously described [25]. Each mutagenesis
Table 1
New reported AADC homozygous or hemizygous variants from 2014 to 2019.
new variant reference Note
V60A Hwu et al., 2017 [13] in hemizygosis, the other allele produces a protein that ends prematurely at 248 amino acids,
with no formation of the active site
H70Y Manegold et al., 2009 [10];
Gucuyener et al., 2014 [45]
Montioli et al., 2014 [25]
homozygous, reported incorrectly as H70T
F77L www.bioku.org/pnd/home.asp homozygous, on line submission in database in 2012
G96R Hwu et al., 2017 [16] in hemizygosis, the other allele produces a protein that ends prematurely at 248 amino acids,
with no formation of the active site
A110E Ide et al., 2010 [44]; Wassenberg et al., 2010 [46]; Montioli
et al., 2014 [25]
homozygous, reported incorrectly as A110Q
P210L Helman et al., 2014 [42] in hemizygosis, the other allele has a mutation leading to a premature stop codon
L222P Helman et al., 2014 [42] Homozygous
F237S Leuzzi et al., 2015 [12] in hemizygosis, the other allele has a mutation leading to a premature stop codon
F251S Chien et al., 2016 [14] in hemizygosis, the other allele produces a protein that ends prematurely at 248 amino acids,
with no formation of the active site
W267R R. Pons, personal communication homozygous, R. Pons, personal communication
E283A Hwu et al., 2017 [13] in hemizygosis, the other allele produces a protein that ends prematurely at 248 amino acids,
with no formation of the active site
L353P Hwu et al., 2017 [13] in hemizygosis, the other allele produces a protein that ends prematurely at 248 amino acids,
with no formation of the active site
R453C Graziano et al., 2015 [43] homozygous, reported incorrectly as R375C
Fig. 1. New and already identified amino acid substitutions in AADC
variants. Ribbons representation of the holo AADC (pdb ID 1JS6). The two
monomers are white and light orange, respectively, and PLP molecules are
represented as green sticks. Mutation sites of previously characterized variants
and new variants are presented as orange and yellow sticks, respectively. Image
was rendered by PyMol software (Schrödinger). (For interpretation of the re-
ferences to colour in this figure legend, the reader is referred to the Web version
of this article.)
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reaction has been performed using the Quick-Change II kit (Agilent
technologies) using the appropriate oligonucleotides (summarized in
Table S1) and their complements. All mutations were confirmed by
DNA sequence analysis of the whole ORF.
2.3. Expression and purification of AADC variants
E. coli BL21 (DE3) cells were transformed by heat shock at 42 °C
with the desired construct and grown in 4.5 L of Luria–Bertani (LB)
broth in presence of ampicillin (100 mg/ml). The cultures were grown
at 37 °C to an OD600nm of 0.4–0.6, and expression was induced with
0.1 mM IPTG for 15 h at 30 °C. Cells were harvested and resuspended in
20 mM sodium phosphate buffer pH 7.4, containing 0.5 M NaCl, 20 mM
imidazole, 50 μM PLP, 0.5 mM PMSF and protease inhibitor cocktail.
Lysozyme was then added to a concentration of 0.2 mg/ml and the
culture was incubated for 20 min at room temperature. After a freeze-
thaw, leupeptin and pepstatin (both at 1 μg/ml concentration) were
added and the suspension was centrifuged at 16,000 g for 30 min. The
crude cellular lysate was loaded on a HisPrep FF 16/10 column (GE
Healthcare) equilibrated with 20 mM sodium phosphate buffer pH 7.4,
containing 0.5 M NaCl and 20 mM imidazole. AADC was eluted with a
linear gradient (0–100% in 200 ml) of the same buffer containing
500 mM imidazole. After addition of 50 μM PLP, the protein solution
was concentrated and imidazole and unbound coenzyme were removed
by extensive washing with 100 mM potassium phosphate buffer pH 7.4,
using Amicon Ultra 15 concentrators (Millipore). The enzymes con-
centration was determined using an εM of 1.42 × 105 M−1 cm−1 at
280 nm. PLP content was determined by releasing the coenzyme in
0.1 M NaOH using εM of 6600 M−1 cm−1 at 388 nm [28].
2.4. Size-exclusion liquid chromatography
Size-exclusion liquid chromatography was applied as further pur-
ification step. Samples were loaded on a Superdex 200 (10/300) (GE
Healthcare) column equilibrated with 100 mM potassium phosphate
buffer pH 7.4, on an Akta FPLC system (GE Healthcare). The run was
performed using the same buffer at a flow rate of 0.3 ml/min with
detection at 280 nm.
2.5. Determination of solubility level of the AADC variants
E. coli has been used as a model for the expression study of the
pathogenic AADC variants. Chemical competent bacteria were trans-
formed with the proper mutagenized plasmid as described in the ex-
pression and purification section. Cultures were grown even in the
absence or in the presence of 50 μM exogenous PLP and 1 ml of each
culture was processed following the same procedure described above.
After lysis, samples were treated with DNase (10 U) at room tempera-
ture for 30 min. The whole cell extract was separated by centrifugation
at 13,200 rpm, 10 min, 4 °C. Total protein content in the crude cellular
lysate was quantified and 15 μg of total protein was run on a 12% (w/
w) SDS-PAGE gel. The same amount of a sample consisting of the
membrane insoluble pellet of wild-type (WT), P210L, L222P, F237S,
W267R and E283A variants was analyzed. Proteins from the gel were
transferred on a nitrocellulose membrane by a Mini Trans-Blot cell (Bio-
Rad). Membrane was blocked with a 5% (w/w) milk solution at 37 °C
for 1 h and, after the washing steps, it was incubated with a 1:200 (v/v)
diluted anti-AADC monoclonal antibody solution over night at 4 °C.
Membrane was then washed and then incubated with a 1:4000 (v/v)
anti-mouse secondary antibody solution for 1 h at 25 °C. Blotted pro-
teins were detected and quantified with ECL (Millipore), using the
ChemiDoc XRS Imaging System (Bio-Rad, Hercules, CA). Quantification
of the band was obtained with ImageJ software (Fiji).
2.6. Apoenzyme preparation and coenzyme binding affinity measurements
Apoenzyme was obtained by incubating 5 μΜ holoenzyme with
10 mM hydroxylamine in 0.5 M potassium phosphate buffer pH 6.8 at
25 °C for 3 h. The solution was then loaded on a Desalting 26/10
column (GE Healthcare) pre-equilibrated with 0.5 M potassium phos-
phate buffer pH 6.8 and eluted at 1 mL/min. The eluted enzyme was
then concentrated on an Amicon Ultra 15 concentrators (Millipore) and
washed with 100 mM potassium phosphate buffer pH 7.4.
The equilibrium apparent dissociation constant for PLP, KD(PLP), was
determined by measuring the quenching of the intrinsic fluorescence of
0.1 μM AADC apoenzyme incubated in the presence of PLP at con-
centrations ranging from 0.005 to 20 μM for 3 h at 25 °C (in the dark) in
100 mM potassium phosphate buffer pH 7.4.
The data were fitted to the following equation:
=
+ + − + + −
Y Y
E PLP K E PLP K E PLP
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where [E]t and [PLP]t represent the total concentrations of the enzyme
and PLP, respectively, Y refers to the intrinsic quenching changes at a
PLP concentration, and Ymax refers to the fluorescence changes when all
enzyme molecules are complexed with coenzyme. Curves fitting was
performed using Origin® 9.1 Pro (OriginLab).
2.7. Enzyme activity assays
The decarboxylase activity was measured by a stopped spectro-
photometric assay [29,30]. Each variant enzyme (at appropriate con-
centration) was incubated under saturating PLP concentration (10 μM)
and different L-Dopa concentrations in a final volume of 250 μL in
100 mM potassium phosphate buffer pH 7.4 for a time within which a
linear product formation is observed. The reaction was then stopped by
heating at 100 °C for 2 min. TNB (1 ml of a 4.3 mM solution) and
toluene (1.5 ml) were added and the extraction of trinitrophenyl-deri-
vative was carried out at 42 °C for 45 min with continuous shaking. The
concentration of trinitrophenyl-derivative in the toluene layer was
quantified using prepared calibration curve of absorbance at 340 nm as
a function of trinitrophenyl-derivative concentration [31]. The kinetic
parameters were determined by fitting the data obtained with the Mi-
chaelis-Menten equation using Origin® 8 Pro (OriginLab).
2.8. Spectroscopic measurements
All spectral measurements were acquired in 100 mM potassium
phosphate, pH 7.4, at 25 °C. CD measurements were recorded with a
Jasco J-710 spectropolarimeter at a scan speed of 50 nm/min with a
bandwidth of 2 nm at a protein concentration of 1–5 μM and 10 μM of
exogenous PLP for the holoenzymes. Thermal denaturation was per-
formed by monitoring the CD signal at 222 nm of 4 μM enzyme on a
25–90 °C linear temperature gradient, with a temperature slope of 1 °C/
min. Intrinsic fluorescence emission spectra were monitored using a FP-
750 Jasco spectrofluorometer at a protein concentration of 1 μM setting
at 5 nm excitation and emission bandwidths upon excitation at 280 nm.
2.9. Dynamic light scattering (DLS)
Aggregation study was performed on a Zetasizer Nano ZS instru-
ment (Malvern) with a constant 90° scattering angle and a 633 nm
wavelength laser. Protein samples were prepared at 4 μM concentration
under physiological conditions (58 mM potassium phosphate, pH 7.4 at
37 °C). The buffer was filtered immediately before the use.
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2.10. HPLC analysis of coenzyme modification and dopamine formation
Catalytically inactive AADC variants were incubated at 10 μM
protein concentration with 2 mM L-Dopa in 100 mM potassium phos-
phate buffer, pH 7.4 at 25 °C. Concentration-time curves were followed
by withdrawing aliquots at time intervals and quenching the reaction
by adding trichloroacetic acid to a final concentration of 10% (v/v).
Proteins were then precipitated in ice and removed by centrifugation.
Supernatants were analyzed by HPLC as described [32] using a Gemini
C18 column (150 × 4.6 mm, Phenomenex, CA, USA) and performed on
a Jasco PU-2080 Plus HPLC system equipped with a UV-1570 detector
set at 295 nm. Samples were eluted in 50 mM potassium phosphate, pH
2.35, at a flow rate of 1 mL/min. Standard curves of peak area as a
function of coenzyme or cyclic adducts concentration were prepared
with commercially available PLP and coenzyme adducts obtained by
synthesis.
2.11. NMR experiments
Before NMR analysis, the HPLC-purified compounds were ex-
changed in water, lyophilized and re-dissolved in D2O. All the NMR
spectra were recorded at 298 K on a 600 MHz Bruker AVIII HD spec-
trometer equipped with a TCI cryogenic probe. For the acquisition we
used a spectral width of 20 ppm, an acquisition time of 1.36 s, 32,000
data points and 128 or 256 scans. NMR data were processed with
Topspin 3.2. PLP and PMP peak assignments were confirmed by com-
paring the chemical shifts of the 1D 1H NMR spectra with those from
reference spectra deposited in the Biological Magnetic Resonance Data
Bank (BMRB). The 1H NMR peak assignments to the Pictet-Spengler
adduct were verified by comparing the chemical shifts with previously
reported resonances [33] and supported by 2D correlation NMR ex-
periment (TOCSY).
2.12. Limited proteolysis in presence of the substrate analog DME
Protection studies against tryptic proteolysis were performed as
described [32]. WT AADC and variants were incubated with the sub-
strate analog DME at concentration of 2 mM for 30 s, 10 min and
30 min and then digested with trypsin for 10 min at the 1:50 (w/w)
ratio. Proteolysis was stopped with the addition of trypsin inhibitor at
the 1:10 (w/w) ratio and the reaction samples were then analyzed on a
10% (w/w) SDS-PAGE gel.
2.13. Bioinformatics analyses
Human AADC sequence was aligned with 75 homologues sequences
retrieved form Uniref-90 database by the homolog search algorithm
PSI-BLAST and aligned using Multiple Sequence Alignment software
CLUSTALW on ConSurf server (http://consurf.tau.ac.il). A conservation
score (9 = highly conserved, 1 = highly variable) was attributed to
each residue. Structural analysis and in silico mutagenesis of the pig
DDC (PDB: 1JS6; ~90% sequence identity with the human homo-
logous) was carried out using Pymol 2.0 (The PyMOL Molecular
Graphics System, Version 2.0 Schrödinger, LLC.). BindProfX was used
to predict changes in binding affinity upon mutations in the form of
ΔΔG (change in free energy of binding) values. The algorithm combines
the FoldX physics-based potential with the conservation scores from
pairs of protein-protein interaction surfaces sequence profiles. Interface
residues and solvent accessible area (ASA) have been determined
starting from the available crystal structure of pig DDC (PDB: 1JS6) by
means of the Protein interfaces, surfaces and assemblies' service PISA at
the European Bioinformatics Institute (http://www.ebi.ac.uk/pdbe/
prot_int/pistart.html) [34].
3. Results
3.1. Solubility and purification yields of the new AADC variants
The 13 new AADC variants were examined for their presence in the
soluble fraction. Soluble V60A, H70Y, F77L, G96R, A110E, F251S,
L353P and R453C levels are similar with respect to the WT (more than
70%), while P210L, L222P, F237S, W267R and E283A are poorly ex-
pressed in the soluble fraction (10–30%) (Fig. 2). The addition of PLP
did not significantly improve expression of either the WT or the var-
iants. A low expression level might be related to a solubility alteration
at least in E. coli system, suggesting folding defects for low expressed
variants.
The insoluble fractions of the poorly expressed variants show that
the amount of protein recovered in the pellet is slightly higher as
compared to that of the WT (Fig. S1). However, considering the high
soluble/insoluble ratio of WT AADC expressed in E. coli system, even
subtle differences in insoluble fractions might be indicative of high
differences in protein solubility.
Considering the protein yields after purification, some variants ex-
hibit nearly good to good yields (30–85% with respect to the WT), in-
cluding A110E, L353P, R453C, F251S, F77L and G96R. Others display
low (5–10% for V60A and H70Y) and very low (less than 2% for E283A,
Fig. 2. Soluble fractions of WT and variants
AADC. Western blot analysis is performed with
10 μg of total protein content from soluble lysates
of E. coli loaded on 12% acrylamide gel. Each
bacteria culture has been grown in absence (−) and
presence (+) of exogenous PLP. Determination of
the expression levels of each variant was estimated
using ImageJ software (Fiji) and is reported in the
text as percentage with respect to the WT.
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P210L and W267R) yields. Unfortunately, it was not possible to purify
L222P and F237S which were recovered in extremely low amounts
(0.3%) preventing us to carry out a complete biochemical character-
ization.
3.2. Aggregation of apoP210L and apoE283A
Given the great variability in both solubility level and purification
yield of the analyzed variants (already reported in sporadic cases for
other characterized AADC variants [25,35–37]), DLS analyses were
carried out in order to evaluate the aggregation propensity of the
purified enzymes under physiological conditions (58 mM potassium
phosphate buffer, pH 7.4 at 37 °C). DLS measurements of the holo and
apo forms of the majority of AADC variants and of WT (Fig. 3A) do not
show signs of aggregation suggesting that the enzyme is not prone to
aggregate under these experimental conditions. Instead, apoP210L and
apoE283A, even if at different extent, tend to aggregate as demon-
strated by both the increase in kcps and the disappearance of the di-
meric species (Fig. 3B and C). While dimeric apoE283A disappears in
about 300 min, apoP210L aggregation process is much slower. This led
us to conclude that some AADC variants in their apo form are prone to
undergo an aggregation process.
3.3. Secondary structure and thermal stability of the new AADC variants
The structural integrity of all variants in terms of secondary struc-
ture has been evaluated by measuring the far-UV CD spectra of all
purified variants in the 190–260 nm region. The signals are super-
imposable to that of the WT indicating that the substitutions do not
alter the secondary structure of the protein (data not shown). In order
to determine the intrinsic stability, we measured the Tm's of holo and
apo forms of all variants (Table 2) by following the loss of the dichroic
signal at 222 nm under physiological conditions (58 mM potassium
phosphate buffer, pH 7.4).
As for the holo proteins, the value of Tm for F251S, W267R, L353P
and R453C is almost identical to that of the WT. Instead, the ΔTm value
(Tm(variant)-Tm(WT)) is consistently lower for V60A, A110E and E283A
followed by F77L, G96R, H70Y and, to a lesser extent, P210L.
The apo species of V60A, G96R and E283A evidence a marked de-
crease in Tm with respect of the WT, followed by L353P, P210L, F77L
and A110E, while the others exhibit ΔTm of± 2 °C.
It is interesting to note that the ΔTm(holo-apo) for the WT is of about
5 °C. This value, indicative of the different thermal stability of the holo
and the apo form, is maintained (or even increased) for all variants but
V60A, H70Y, F77L, A110E, and R453C.
3.4. Aromatic amino acids dichroic and fluorescence signals and coenzyme
dichroic microenvironment features of the new AADC variants
We then measured signals, collected by near UV-CD and intrinsic
fluorescence, related to aromatic amino acids environment to monitor
possible folding alterations in AADC variants. The near UV-CD at
280 nm provides insight into asymmetric aromatic amino acid residues,
mainly tryptophan(s), located in an appropriate position, and is linked
to a proper protein tertiary structure arrangement. While the holo forms
of G96R, P210L, F251S, and E283A have a 280 nm CD signal very si-
milar to that of the WT, the other variants exhibit decreases in the in-
tensity of the 280 nm band, although at different extent, particularly
relevant in V60A, F77L and A110E (Fig. 4A and B). Since the apo form
has a spatial arrangement different from the holo one [27], it is useful
to compare the 280 nm CD signals of the apo variants in order to better
understand how substitutions exert their effects on the entire protein
structure or if the modifications are confined to the PLP binding region.
An analysis of the CD near UV bands of the apo forms (insets of Fig. 4A
and B) reveals that they are almost superimposable to that of the WT,
unless a subtle decrease of the 280 nm band in G96R, F251S and E283A
and a more evident one in V60A and R453C.
Interestingly, the signals in the near UV region of the holo forms of
Fig. 3. DLS analyses of apo WT, apo P210L and apo E283A as a function of
time. 4 μM apo WT (A), apo P210L (B) and apo E283A (C) are incubated in
58 mM potassium phosphate buffer pH 7.4 at 37 °C. Grey open symbols indicate
the size of the dimer, solid squares indicate the mean count rate.
Table 2
Melting Temperatures of WT AADC and variants. Melting temperature va-
lues obtained by following the CD signal at 222 nm and varying the tempera-
ture linearly from 25 to 90 °C with a slope of 1.5 °C/min.
Tm (°C)
Enzyme holo apo
WT 69.42 ± 0.02 64.84 ± 0.03
V60A 62.13 ± 0.02 59.30 ± 0.03
H70Y 65.95 ± 0.04 63.28 ± 0.05
F77L 63.58 ± 0.03 61.70 ± 0.03
G96R 65.64 ± 0.05 58.46 ± 0.04
A110E 63.20 ± 0.05 62.04 ± 0.04
P210L 66.10 ± 0.10 60.91 ± 0.05
L222P n.d n.d
F237S n.d n.d
F251S 70.49 ± 0.04 63.37 ± 0.06
W267R 70.30 ± 0.10 63.60 ± 0.03
E283A 62.89 ± 0.02 58.66 ± 0.07
L353P 68.10 ± 0.07 60.82 ± 0.03
R453C 69.36 ± 0.03 66.70 ± 0.02
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V60A, F77L, and A110E are not so much different from the corre-
sponding ones in the apo species.
The intrinsic fluorescence signal is measured to provide insight into
the correct folding features of the enzyme. Following excitation at
280 nm, the fluorescence spectrum of holo WT is characterized by an
emission spectrum with a maximum at 332 nm indicative of the buried
environment of the aromatic amino acid residues (Fig. S2). Those var-
iants displaying a decrease of the 280 nm CD band present in general an
emission band higher than that of the WT, while the 332 nm fluores-
cence emission is similar to that of the WT for the other variants whose
280 nm CD band is identical or similar to that of the WT. Considering
that consistent alterations of tertiary structure were found mainly in the
holo forms, the deleterious effects of mutations are reasonably due to an
impairment in the correct holo folding rather than to the achievement
of the spatial structure of the apo form.
It should be remembered that the apo WT emits at nearly the same
wavelength as the holo but with higher intensity values given to dif-
ferent position of aromatic amino acids in this structure or to the energy
transfer process from aromatic side chains fluorophores to the pyridine
ring of the cofactor. This suggests that some variants remain in a sort of
apo structure being somewhat prevented in the apo-to-holo transition
or in the acquirement of a correct holo folding, as evidenced above.
Altogether, these spectroscopic results witness slight alterations in
global protein folding of the new variants.
As for possible coenzyme microenvironment modifications, we
measured the visible CD spectrum of all species. WT AADC presents two
bands centered at 335 nm and 420 nm indicative of a tautomeric
equilibrium between the enolimine and the ketoenamine forms of the
internal aldimine that PLP forms with Lys-303. The spectra of the new
variants display small differences with respect to the WT. In details, the
spectra of H70Y, G96R, F251S and L353P are similar to that of the WT,
while P210L and E283A exhibit a 420 nm band lower than the corre-
sponding one of the WT. On the contrary, V60A, F77L, A110E and
R453C show a predominance of the ketoenamine over the enolimine
tautomer (Fig. 4A and B). Since this tautomeric equilibrium is unrelated
with catalytic efficiency (see below), these results only reveal subtle
PLP microenvironment modifications influencing the tautomeric equi-
librium of the internal aldimine.
3.5. Kinetic parameters and apparent PLP equilibrium dissociation
constants, KD PLP, of new AADC variants
The purified variants were functionally characterized by measuring
their kinetic parameters. It could be observed (Table 3) that the cata-
lytic efficiencies of P210L, F251S and E283A are not so much affected
being 52%, 31% and 31%, respectively, compared to that of the WT.
These values are due to a small decrease in kcat and nearly equal Km
values for P210L, while in F251S and E283A the decrease of kcat is
negligible with respect to that of the WT and Km is slightly increased.
W267R exhibits a catalytic efficiency value of 15% with respect to
WT caused by a decrease in kcat of about 70% and an increase in Km of
about 1.7-fold.
The other variants (V60A, H70Y, F77L, G96R and R453C) are
characterized by a marked decrease in catalytic efficiency. This drop is
due to a concomitant strong decrease in kcat (mainly for V60A and
H70Y) and increase in Km (mainly for G96R) or both (F77L and R453C).
Notably, A110E and L353P are catalytically incompetent under the
standard assay conditions.
As for the coenzyme binding affinity, while the KD PLP is almost
invariant for H70Y and P210L, it increases by 2 up to 5-fold in F77L,
G96R, F251S, W267R and L353P and by 6 up to 10-fold in V60A,
A110E, E283A and R453C. Thus, the cofactor in many variants is
mispositioned and its contacts with the protein moiety are somewhat
altered, as also witnessed by the visible CD signals.
3.6. Some AADC variants convert PLP into cyclic Pictet-Spengler adduct in
the presence of L-Dopa
Among the variants, A110E and L353P seem to be severely impaired
in catalysis since the kinetic parameters could not be measured under
the standard assay conditions. Noteworthy, the addition of L-Dopa to
Fig. 4. Near UV and visible CD spectra of WT AADC and variants in their holo and apo forms. The spectra are recorded at 5 μM protein concentration, in
100 mM potassium-phosphate buffer, pH 7.4. Spectra of the holo forms are recorded in the presence of 10 μM PLP. (A) The holo forms of: WT, F251S, E283A, G96R.
(B) The holo forms of: WT, P210L, L353P, R453C, H70Y, A110E, V60A and F77L. Spectra of the corresponding apo forms are reported in the insets.
Table 3
Steady-state kinetic parameters and apparent equilibrium dissociation constant,
Kd, for PLP of the new AADC variants.
Enzyme kcat (s−1) Km (mM) kcat/Km (s−1 mM−1) KD PLP (nM)
WT 7.6 ± 0.1 0.11 ± 0.01 69.1 ± 10 43 ± 12
V60A 0.93 ± 0.02 0.16 ± 0.01 5.8 ± 0.4 252 ± 35
H70Y 0.58 ± 0.09 0.26 ± 0.04 2.2 ± 0.5 70 ± 18
F77L 0.35 ± 0.07 0.51 ± 0.05 0.7 ± 0.1 222 ± 38
G96R 5.7 ± 0.4 3.5 ± 0.4 1.6 ± 0.2 132 ± 14
A110E n.d. n.d. n.d. 321 ± 26
P210L 4.4 ± 0.2 0.12 ± 0.02 37 ± 6 47 ± 7
L222P n.p. n.p. n.p. n.p.
F237S n.p. n.p. n.p. n.p.
F251S 5.7 ± 0.2 0.26 ± 0.02 22.0 ± 0.2 88 ± 16
W267R 2.11 ± 0.04 0.19 ± 0.01 11.1 ± 0.6 120 ± 10
E283A 6.4 ± 0.2 0.29 ± 0.05 22.0 ± 0.2 330 ± 30
L353P n.d. n.d. n.d. 199 ± 34
R453C 0.67 ± 0.07 0.40 ± 0.06 1.7 ± 0.3 468 ± 36
n.d., not detectable under standard assay conditions; n.p., not purified.
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both A110E and L353P leads to a decrease of the 420 nm absorbance
band and an increase of the 335 nm band that slightly shifts to 329 nm
with time. These absorbance bands are associated with the coenzyme
bound at the active site. The spectral modifications are indicative of a
reaction determining the conversion of the external aldimine between
PLP and L-Dopa into an intermediate absorbing at ~330 nm, already
observed for other AADC variants [35,38] located in proximity of the
active site and attributed to the Pictet-Spengler adduct [33]. The pro-
cess is faster in A110E and slower in L353P (Fig. 5A and B). A reaction
mixture containing 10 μM A110E or 10 μM L353P with 2 mM L-dopa
has been treated and subjected to HPLC analysis, as reported in Mate-
rials and Methods section. As shown in Fig. 5C and D, in both cases the
PLP content decreases with an initial rate similar to that of the increase
of the Pictet-Spengler cyclic adduct [32,33]. Table 4 shows the initial
velocities, measured as slopes in the linear part of each curve (PLP
decrease and Pictet-Spengler increase) for the two variants in compar-
ison with free PLP under the same experimental conditions. It should be
noted that a small amount of dopamine is also produced by both var-
iants (Table 4). Given the fact that WT forms dopamine in the presence
of saturating L-Dopa (2 mM) with an initial velocity of 7.6 nmol/s/
nanomol of enzyme (Table 3), it follows that the initial velocity of
A110E is approximately 7.6 × 104 times and that of L353P of
6.8 × 103 times slower than that of the WT value under the same ex-
perimental conditions. It should be noted that, in the case of L353P, a
small aliquot of pyridoxamine 5′-phosphate (PMP) is formed, due to the
ability of AADC to catalyze multiple side reactions in addition to the
main decarboxylation one [33].
While free PLP incubated with L-Dopa forms the cyclic adduct with
an initial rate faster than in the two variants (Table 4), WT AADC does
not form it since the protein moiety prevents unwanted reactions of its
highly reactive coenzyme. This suggests that in both A110E and L353P
the altered enzyme active site structure renders PLP rather free. The
identification of the Pictet-Spengler adduct between L-Dopa and PLP
was confirmed by NMR analyses [33] (Fig. S3). In order to check if the
active site of the two catalytic variants is somewhat open or not capable
of attaining the correct closed and catalytically competent conforma-
tion, we added to WT, A110E and L353P the substrate analog DME that
binds to PLP but is unable to undergo decarboxylation. At the indicated
times (Fig. 6), we subjected the enzyme-analog complex to limited
proteolysis to monitor the extent of protection. It has been already
demonstrated that [33] a protection from proteolysis is indicative of
active site correct closure and productive catalysis. While WT does
Fig. 5. Absorbance spectra of A110E and L353P in the presence of L-Dopa. To a solution of 10 μM A110E (A) and L353P (B), L-Dopa has been added and spectra
are recorded with time in 100 mM potassium phosphate buffer, pH 7.4 at 25 °C. Dotted line: variant without L-Dopa. The arrows indicate the increase at 329 nm and
the concomitant decrease at 420 nm with time following addition of 2 mM L-Dopa. Insets: increase of the 329 nm and decrease of the 420 nm signals as a function of
time. HPLC analyses results of the reaction mixture of 10 μM A110E (C) and L353P (D) in the presence of 2 mM L-Dopa in 100 mM potassium phosphate buffer, pH
7.4 at 25 °C. PLP (●), Pictet-Spengler PLP-L-Dopa (◯), dopamine (▲) and PMP (▽).
Table 4
Initial velocities of dopamine formation, PLP decrease, Pictet-Spengler and PMP




A110E L353P free PLP
v0 dopamine 0.006 ± 0.001 0.067 ± 0.001 –
v0 PLP decrease 0.040 ± 0.004 0.006 ± 0.002 0.12 ± 0.01
v0 Pictet-Spengler 0.042 ± 0.006 0.005 ± 0.003 0.10 ± 0.04
v0 PMP – 0.002 ± 0.00005 –
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protect from proteolysis, both A110E and L353P do not protect, sug-
gesting that some structural elements of the active site are altered and
the closed catalytically competent conformation could not be attained.
3.7. Bioinformatic analyses
In order to verify the conservation level of the newly identified
residues of AADC undergoing pathogenic substitution, the AADC amino
acid sequence was aligned with those of 75 homologous proteins by the
ConSurf web server. About 60% of the modified residues are highly
conserved (His-70, Phe-77, Ala-110, Leu-222, Phe-251, Trp-267, Glu-
283 and Leu-353). Phe-237 is quite conserved and substituted only by
apolar residues or amino acids endowed by a π-system. The others have
a low conservation score, although the chemical nature of the residues
(polar or apolar) is maintained for Val-60, Gly-96 and Pro-210, while
Arg-453 resulted more prone to be substituted by several amino acids in
homologous enzymes (Table S2).
A bioinformatic analysis examining the arrangement of each residue
undergoing substitution was then carried out to understand the in-silico
impact of each substitution on protein structure and/or binding net-
works (Fig. 7A).
Each monomer of AADC is composed of three domains: the N-
terminal domain (residues 1–85) which comprises the structural ele-
ment loop1 (residues 66–84), the large domain (residues 86–360),
which in turn includes loop2 (residues 100–110), the PLP-Lys-303 loop
(residues 300–310) and loop3 (residues 323–357, containing the flex-
ible catalytic loop 328–339), and, finally, the C-terminal domain (re-
sidues 361–480) [26,27]. In the holo dimer the two monomers are
strictly intertwined leading to a large interlocked interface and, as for
the active site, the flexible catalytic loop together with loop1 of each
subunit directly interacts with elements of the loops 2 and 3 of the
neighbouring one [27]. As for the role played by these key loops: loop1
is located in proximity to the active site and is involved in the apo-to-
holo conformational change of AADC [27], loop2 hosts residues near
the active site, possibly interacting with the substrate moiety [25,26],
and loop3 is functionally essential for catalysis [26,27,31,39].
Starting from the N-terminal stretch, Val-60 contributes to the
monomer-monomer interface and its side chain engages the helix
85–99, that connects loop1 to loop2, of the neighbouring subunit by
several hydrophobic contacts (Fig. 7B). V60A modification reduces the
inter-chain hydrophobic contacts within the two N-terminal regions of
the AADC dimer. Moreover, the mispositioning of the helix 52–67, due
to the substitution of Val-60 with Ala, affects the conformation of loop1.
His-70 and Phe-77 belong to loop1. In particular, His-70 side chain
interacts with Tyr-20 by an H-bond linkage, while Phe-77 is involved
mainly in a base-stacking interaction with the Phe-448 side chain
(Fig. 7C). Together His-70 and Phe-77 represent two anchoring points
of loop1 and, of course, of the N-terminal and to the C-terminal domain
influencing loop1 correct positioning.
Gly-96 belongs to helix 85–99 at the end of loop1 and just before the
beginning of loop2 (Fig. 7B). Its backbone oxygen interacts with the
Asn-308 side chain of the adjacent monomer in proximity of the active
site. The G96R substitution could generate a consistent steric hindrance
between the two antiparallel helices 85–99 probably perturbing the
dimer assembly and the active site.
Ala-110 is the last residue of loop2, belongs to the monomers in-
terface and is placed into an apolar cavity (Fig. 7D) at the beginning of
the large domain. Its substitution with glutamate generates local steric
hindrance between the two subunits and seems to exert some effects on
the position of residues present at the active site (i. e. Phe-103 and Ile-
101, that face PLP, and are part of loop2). This is corroborated by re-
sults obtained in the biochemical characterization and the molecular
dynamics simulation of the recombinant A110Q protein [25].
Pro-210, Leu-222, Phe-237 and Trp-267 belong to a β-barrel-helices
system of the large domain that surrounds the active site. Such complex
architecture is highly conserved in the large domain of PLP-dependent
enzymes. In details, Pro-210 is placed on a flexible surface stretch (aa
209–218) joining a β-strand to a surface α-helix (Fig. 7E). The P210L
substitution exposes a hydrophobic residue on the protein surface
probably inducing local structural rearrangement. Leu-222 belongs to
the α-helix 218–232 and lies into a hydrophobic cleft (Fig. 7E). The
exchange to Pro could alter, or even interrupt, the α-helix folding
causing a dramatic structural effect. Phe-237 and Trp-267 lie on two
adjacent β-sheet elements and are involved in several hydrophobic
contacts contributing to the folding features of the β-barrel (Fig. 7F). It
can be expected that the drastic changes of polarity and dimension of
the residues introduced by the F237S or W267R substitutions could
affect the proper folding of the β-strand/helices packaging.
Phe-251 lies on the loop 243–252 in proximity of the protein surface
and takes place to a hydrophobic network involving residues of the
large and C-terminal domains (Fig. 7G). The substitution F251S does
not generate significant steric hindrance but it is expected to abolish
most of the hydrophobic contacts.
Glu 283 is exposed on the protein surface and contacts by a salt
bridge the Arg 379 side chain (Fig. 7H). This interaction represents the
only connection between the helix 283–294 and the helix 372–395 and,
on the basis of the local microenvironment, might prevent the exposure
of hydrophobic residues to the solvent. The E283A substitution abol-
ishes such interaction and therefore generates a local conformational
change by altering the relative position of surface secondary structure
elements.
Leu-353 belongs to loop3 of the large domain, and, in particular, is
placed at the dimer interface, near the active site, at a proper distance
to interact by hydrophobic contact with two residues: Phe-103, a re-
sidue essential for the active site conformation [26] and Arg-347, a key
catalytic residue [25,31] (Fig. 7D). This network is established in a
region critical for catalysis and the substitution of Leu with Pro might
determine deep effects on the active site architecture.
Lastly, Arg-453, even if it belongs to the C-terminal domain, pro-
vides an additional junction between the C-terminal domain and the
Fig. 6. Limited tryptic proteolysis of WT (A), A110E (B) and L353P (C) in the presence of DME. WT, A110E and L353P are incubated at a concentration of 10 μM
protein with 2 mM DME for various times and then digested with trypsin for 10 min at the trypsin/enzyme ratio 1:50 (w:w). t0 is the control in the absence of trypsin.
R. Montioli, et al. Archives of Biochemistry and Biophysics 682 (2020) 108263
8
loop1, in fact the arginine side chain interacts with the Ser-84 backbone
oxygen through an H-bond (Fig. 7C) and would favour loop1 correct
conformation. Moreover, Arg-453 side chain is in proper position to
interact with Met-1 backbone oxygen of the neighbouring subunit by a
H-bond contributing to the monomer-monomer interaction.
Considering that a significant number of the new mutations are
localized at the dimer interface (V60A, G96R, A110E, L353P and
R453C), we predicted the values of ΔΔG of the monomer-monomer
interaction of WT AADC and of all interface variants using BindProfX
(Table S3). Results indicate that, even if at different extent, all the in-
terface mutations significantly destabilize the AADC dimer interface.
4. Discussion
In an effort to understand the molecular bases of AADC deficiency,
our biochemical approach is aimed to unravel the structure-function
relationships of the so-far identified variants in order to elucidate the
enzymatic phenotypes. The present study is focused on 13 new patho-
genic variants of AADC reported in literature from 2014 to 2019 in
homozygosis and hemizygosis. At a first glance, it can be observed that
these new amino acid substitutions are spread on the entire protein and
not only in the central belt as the previously characterized mutations
[25]. Until now, the previously studied enzymatic phenotypes resulted
in impaired apo-to-holo transition and catalysis [25,31,35,40].
Following the investigations previously published [25], the loop1
variants H70Y and F77L resemble, in terms of catalytic efficiency and of
structural conformation, the already studied ones affecting loop1 [25].
They are characterized by a drop in kcat and in catalytic efficiency. Less
evident are the effects regarding KD(PLP). This behaviour is reasonably
due to a stabilizing function of this region [25], whose alteration causes
perturbation of both protein conformation and active site architecture.
Moreover, the ΔTm's values with respect to the WT of both holo and apo
proteins are notable and the holo-to-apo Tm's difference is diminished
with respect to the WT, evidencing that substitutions in loop1 are
characterized by a lesser variation in terms of degrees, arguing that
these enzymatic species resemble apo rather than holo structures, as
also shown by their spectroscopic signals. Interestingly, the clinical
phenotypes of patients carrying these mutations are severe [10,13].
Overall, these new data support the fact that loop1 is crucial for apo-
holo transition as suggested by Ref. [25].
In addition to this, the remaining newly characterized variants al-
lowed us to widen the spectrum of enzymatic phenotypes related to
AADC deficiency. In particular, an interesting cluster of variants is re-
presented by those belonging to the large domain (P210L, L222P,
F237S, F251S, W267R and E283A). The bioinformatic analysis reveals
that these residues are located either on the surface (P210L, F251S and
Fig. 7. In silico inspection of the mutation sites. Ribbons representation of the holo AADC (pdb ID 1JS6). The two monomers are white and light orange,
respectively, loop1 (aa 66–84) is magenta and PLP molecules are represented as green sticks. In each panel: (i) the mutation sites are indicated and represented as
yellow sticks; (ii) specific interacting residues are in cyan; (iii) clusters of hydrophobic residues are represented as orange sticks. *residues belonging to the
neighbouring subunit. Image was rendered by PyMol software (Schrödinger). (For interpretation of the references to colour in this figure legend, the reader is referred
to the Web version of this article.)
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E283A) or in hydrophobic environments (L222P, F237S and W267R).
Except for F251S (see below), all of them are characterized by a low (or
null) recovery in the soluble fraction.
Since their apo near UV CD signals are similar to that of the apo WT
and their holo near UV CD as well as intrinsic fluorescence spectra are
not so much affected, it follows that these purified proteins do not
present deep changes in their global structure. This can be correlated to
the good catalytic efficiency as well as the quite high PLP affinity,
unless for E283A, displayed by these variants. Thus, another me-
chanism for the pathogenicity for this class of variants should be con-
sidered in addition to the already proposed ones [25]. Indeed, the DLS
analysis shows that apoE283A and apoP210L have a tendency to ag-
gregate, while neither WT nor any of the other characterized variants
has. Even if the time course of disappearance of the dimeric apoE283A
and apoP210L is slow under our experimental conditions, it might re-
present a signal of a trend for these proteins to undergo an aggregation
process in their apo form that in part explains the reason why the ex-
pression of these variants is so low. Only a small fraction is thus able to
reach a competent state binding the coenzyme and performing cata-
lysis, while the great part undergoes aggregation in the apo form. No-
tably, in the highly crowded cellular microenvironment the aggregation
process might be reinforced and facilitated, even if we have no in-
formation regarding relative rates of aggregation with respect to apo-to-
holo transition. Interestingly, these two variants present a large effect of
ΔTm of the holo and apo form with respect to holo and apo WT, sug-
gesting that their structure is more labile. Consistently, the very low Tm
value of apoE283A may be correlated with the aggregation propensity
of this variant. The bioinformatic analyses support the possible protein
misfolding effect caused by these variants. The affected soluble ex-
pression level of the other large domain variants suggests possible
folding defects, whose process should be studied in a more appropriate
cell model, as performed previously [40]. The low expression is also in
line with what we have observed for R160W variant [37]. The reported
clinical phenotypes of patients carrying these mutations are from mild
to severe. Patients with F237S substitution have rather mild manifes-
tations compared to others [12], reaching adulthood and for one of
them a successful pregnancy has been reported [41]. The other clinical
phenotypes are from intermediate to severe [13,42], suggesting that
alterations in the large domain could give rise to a wide spectrum of
disease outputs.
Phe-251 is an exception for this cluster of residues in the large do-
main since its substitution to Ser gives rise to a protein variant which
behaves in a similar way to the already characterized S250F variant
[40]. The bioinformatic analysis of F251S shows the modest effect ex-
erted that is in line with the results obtained and with the mildness of
the clinical phenotype of the patient [14]. This variant is only slightly
affected by the substitution in catalytic parameters, in PLP affinity and
in the spectroscopic signals.
Considering the remaining new variants (V60A, G96R, A110E,
L353P and R453C), their common feature is the belonging to the large
interface of AADC. This interface comprises 144 residues of the total
480 amino acids of each monomer and covers the 27.3% of the total
solvent-accessible area (ASA) of each subunit. In comparison, the dimer
interface of the prototype of Fold-Type I PLP-enzymes, aspartate ami-
notransferase, covers only 19.8% of the total ASA. The AADC interface
goes through the contact surface of the two subunits crossing different
regions from the N-terminal to the large domain and to, finally, the C-
terminal. Taken together, interface variants could be distinguished in
those showing modest effects on catalysis (V60A, G96R and R453C) or
large catalytic drops (A110E and L353P). This is expected since they
affect different protein regions and may exert long-range effects acting
at the strictly tight monomer-monomer interface of AADC. Since the
active sites are at the interface, a defect in this wide part of the protein
might affect catalysis and/or coenzyme binding.
The interface variants V60A, G96R and R453C are characterized by
a low catalytic efficiency due to low kcat for V60A and R453C and high
Km for G96R. This could be also mirrored by the fact that the affinity for
the coenzyme is compromised in V60A and R453C, as well as the en-
vironment of aromatic amino acids, and decreased in G96R. Their ΔTm
variations are similar to those recorded for loop1 variants, however the
measured ΔΔG values show that the interaction networks between
monomers is here affected. The bioinformatic analyses show that Val-
60 and Gly-96 maintain the protein interface and are thus involved in
dimer assembly, while the effect of Arg-453 on interface affects N-
terminal and loop1 proper positioning. Notably, V60A and G96R dis-
play the lowest values of Tm for their apo structures, supporting the
stabilizing role for this interface region. The effects for R453C are less
pronounced and this might in part be related to the observation that
patients with R453C substitution have a milder clinical phenotype than
the others of this group [43].
A110E and L353P are interface variants with strong catalytic im-
pairments. Both A110E and L353P exhibit a change in the aromatic
amino acid environment even if at a different extent. Moreover, the lack
of catalytic activity, the irreversible trapping of the coenzyme into a
cyclic inactive form and the incapability of these variants to protect
from proteolysis in the presence of the substrate analog DME, witness a
direct effect of the substituted residues in the active site. This effect is
expected since both residues are located in proximity to critical amino
acids at the active site such as Ile-101, Phe-103 and Arg-347. The cri-
tical role of Arg-347 has already been discussed [31]. Other AADC
variants near the active site have been previously described and were
able to perform Pictet-Spengler condensation reaction [35] even if at a
slower rate. The ΔΔG value for A110E and L353P is positive and sug-
gests that a proper active site closure depends on a productive dimeric
assembly. This alteration is also witnessed by changes in Tm values with
respect to the WT of both holo and apo A110E (whose ΔTm(holo-to-apo) in
terms of degrees is of only 1 °C) and apo L353P. It derives that AADC
residues affecting catalysis are positioned not only at the active site but
also at the dimer interface affecting elements of the active site directly
(such as Leu-353) or by long-range interactions (such as Ala-110). It is
not strange that patients bearing these mutations are severely affected
[13,44].
Altogether, the combination of bioinformatic analyses with bio-
chemical data has been useful in defining the behaviour of enzymatic
variants and deepens the knowledge on enzymatic phenotypes. We
have here characterized a new enzymatic phenotype leading to ag-
gregation of AADC variants that open the way on investigations re-
garding the variants with the hallmark of being low expressed.
Furthermore, we have encountered new types of variants located at the
protein interface able to play short-range (L353P) and long-range
(V60A, G96R, A110E and R453C) effects at the active site, highlighting
the importance of the large interface of AADC in protein proper func-
tioning.
The ultimate aim of our approach is to correlate the position of each
mutation occurring in a defined protein region to the severity of the
enzymatic phenotype in order to contribute in the understanding of the
clinical phenotype.
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Abstract
Aromatic L-amino acid decarboxylase (AADC) deficiency is a complex inherited neurological 
disorder of monoamine synthesis which results in dopamine and serotonin deficiency. The 
majority of affected individuals have variable, though often severe cognitive and motor delay, 
with a complex movement disorder and high risk of premature mortality. For most, standard 
pharmacological treatment provides only limited clinical benefit. Promising gene therapy 
approaches are emerging, though may not be either suitable or easily accessible for all patients. 
In order to better characterize the underlying disease pathophysiology and guide precision 
therapies, we generated a patient-derived midbrain dopaminergic (mDA) neuronal model of 
AADC deficiency from induced pluripotent stem cells (iPSCs). The neuronal model 
recapitulates key disease features, including absent AADC enzyme activity and dysregulated 
dopamine metabolism. We observed developmental defects affecting synaptic maturation and 
neuronal electrical properties, which were improved by lentiviral gene therapy. Bioinformatic 
and biochemical analyses on recombinant AADC predicted that the activity of one variant 
could be improved by L-3,4-dihydroxyphenylalanine (L-DOPA) administration; this 
hypothesis was corroborated in the patient-derived neuronal model, where L-DOPA treatment 
leads to amelioration of dopamine metabolites. Our study has shown that patient-derived 
disease modelling provides further insight into the neurodevelopmental sequelae of AADC 
deficiency, as well as a robust platform to investigate and develop personalised therapeutic 
approaches.
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Introduction
Neurodevelopmental processes are commonly disrupted in the vast majority of inborn errors 
of metabolism, resulting in a wide repertoire of clinical manifestations from severe cognitive, 
neuropsychiatric, and motor problems to more subtle learning difficulties.1 Aromatic L-amino 
acid decarboxylase (AADC) deficiency is a rare inborn error of neurotransmitter metabolism 
due to bi-allelic mutations in DDC, which encodes the enzyme that catalyzes the final step of 
serotonin and dopamine synthesis.2 The resultant enzyme deficiency leads to combined 
serotonin and catecholamine (dopamine, norepinephrine, epinephrine) deficiency.3 Although 
there is a wide phenotypic spectrum,4,5 the majority of affected patients show many of the 
typical features seen in recessively inherited, early-onset neurotransmitter disorders6, including 
severe global neurodevelopmental delay, oculogyric crises, a complex movement disorder 
(characterised by central and peripheral hypotonia with commonly features of dystonia/chorea) 
and symptoms of dysautonomia, as well as secondary gastrointestinal, respiratory and 
orthopedic complications.7,8 As a result, the majority of patients have significant disability and 
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high risk of premature mortality. AADC deficiency is associated with a characteristic CSF 
monoamines profile, with reduced 5-hydroxyindoleacetic acid, homovanillic acid (HVA), and 
3,4-dihydroxyphenylacetic acid (DOPAC), and a concomitant increase in 5-
hydroxytryptophan, L-3,4-dihydroxyphenylalanine (L-DOPA), and 3-O-methyldopa (3-
OMD). Definitive diagnosis is ideally achieved by confirming a decrease or absence of plasma 
AADC enzymatic activity, and DDC gene sequencing. To date, there are no clear correlations 
between patient genotype, CSF monoamine profile, AADC enzyme activity and phenotype.
A recently published consensus guideline outlines recommendations for the diagnosis and 
management of AADC deficiency.8 Pharmacological therapy provides some, though often 
limited, clinical benefit and patients often show variable drug response. It has been postulated 
that the variability in disease severity and medication response may be partly attributed to 
genotype9,10 and as a result, a number of studies have focused on characterising the underlying 
molecular defects caused by different pathogenic variants.11–15 More recently, promising gene 
therapy approaches are emerging for AADC deficiency, with a number of clinical trials 
evaluating the safety and efficacy of targeted intraparenchymal delivery of AAV2-based 
vectors.16–18 It is hoped that with time, these studies may clarify the effect of patient genotype, 
age at surgery, pre-treatment motor function and target delivery site on overall therapeutic 
efficacy. Although early clinical studies on AADC gene therapy are encouraging, it is likely 
that this therapeutic strategy may not be either viable, suitable or easily accessible for a 
proportion of patients. Moreover, with advances in diagnostic testing, the global incidence and 
prevalence of AADC deficiency continues to increase,19 and the need for alternative precision 
therapies is increasingly apparent.
Recently, patient-derived cellular models of neurodevelopmental disorders have proven to be 
a valuable experimental system to unravel disease mechanisms and test novel therapeutic 
strategies with translational potential.20 As such, we have developed a humanized neuronal 
model of AADC deficiency, by reprogramming patient fibroblasts into induced pluripotent 
stem cells (iPSCs) for differentiation into midbrain dopaminergic (mDA) neurons. This model 
system has allowed us to gain further insight into the neurodevelopmental consequences of 
AADC deficiency, with effects on synaptic maturation and neuronal function. Moreover, it has 
also provided a suitable platform to evaluate the effects of precision medicine approaches at a 
cellular level, demonstrating the potential for rational development of patient-specific 
strategies in such rare monogenic disorders.
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Materials and methods
iPSCs generation and maintenance
Generation of iPSCs from patient dermal fibroblasts was approved by the Local Research 
Ethics Committee (Reference 13/LO/0171). Written informed consent was obtained from all 
patients. Age-matched healthy control fibroblasts were collected from the MRC Centre for 
Neuromuscular Disorders Biobank. Patient fibroblasts were isolated from skin biopsies and 
maintained in DMEM (Gibco), 10% fetal bovine serum (Gibco), 2 mM L-glutamine (Gibco), 
1% MEM non-essential amino acids (Gibco), and 1% penicillin/streptomycin (P/S, Gibco), and 
tested for mycoplasma contamination. Reprogramming was performed using the commercially 
available CytoTune®-iPS 2.0 Sendai Reprogramming kit (Invitrogen), following manufacturer 
instructions. Fibroblast were transduced at 80% confluence (1-1.5x105 cells/well). After 6 days, 
infected cells were harvested with TrypLETM (Invitrogen) and 8,000 cells/well were seeded 
onto gamma-irradiated mouse embryonic fibroblasts. After 24 hours, cells were cultured into 
KO-DMEM (Gibco), 20% serum replacement (Gibco), 2 Mm L-glutamine, 50 µM 2-
mercaptoethanol, 1% MEM non-essential amino acids, 1% P/S, and 10 ng/ml basic fibroblast 
growth factor (Gibco). 13 days post-transfection, cells were cultured in gamma-irradiated 
mouse embryonic fibroblasts-conditioned medium. Around day 30 post-transduction, 8-10 
independent colonies with iPSCs-like morphology were collected and expanded using ReLeSR 
(Stemcelltm technologies). Between passage 15 and 20, 3 colonies were converted to mTeSR1 
medium (Stemcelltm technologies) on Matrigel® (Corning®) coated plates. Derived iPSC lines 
were maintained in mTeSR1/matrigel system, regularly passaged with 
ethylenediaminetetraacetic acid, 0.02% solution (Sigma-Aldrich) and again tested for 
mycoplasma infection, as previously. Two iPSC lines for each patient (Patient 1-04, Patient 1-
10; Patient 2-01, Patient 2-06) and the age-matched healthy control (Control-05, Control-03) 
were characterized at the iPSCs stage and further differentiated into mDA neurons to exclude 
clonal variability. Given the relative homogeneity reported in clonal lines with respect to 
transcriptome, growth, and capability of germ layer formation,21,22 one clone per patient 
(Patient 1-04; Patient 2-01) and age-matched healthy control (Control-05) were then used for 
downstream experiments.
Differentiation of iPSCs into mDA neurons
iPSCs were differentiated into mDA dopaminergic neurons as previously described.23 Briefly, 
iPSCs were harvested using TrypLETM (Invitrogen), and plated onto non-adherent bacterial 
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dishes in a concentration of 1.5x105 per cm2 in DMEM/F12:Neurobasal (1:1), N2 (1:100) and 
B27 minus vitamin A (1:50) supplements (Invitrogen), 2 mM L-glutamine and ROCK-inhibitor 
for the first two days. EBs were plated at day 4 onto polyornithine (PO; 15 μg/ml; Sigma), 
fibronectin (FN; 5 μg/ml Gibco) and laminin (LN; 5 μg/ml; Sigma) coated dishes in 
DMEM/F12:Neurobasal (1:1), N2 (1:200), B27 minus vitamin A (1:100), 2 mM L-glutamine. 
From day 0 to day 9, medium was supplemented with: 10 μM SB431542 (Tocris Bioscience), 
100 nM LDN193189 (Stemgent Inc.), 0.8 µM CHIR99021 (Tocris Biosceince) and 100 ng/ml 
hSHH-C24-II (R&D Systems). On day 2, 0.5 μM purmorphamine (Cambridge Bioscience) was 
added. SB431542 was withdrawn on day 6. On day 11, cells were either processed for mDA 
precursors analysis or harvested with Accumax and re-plated on PO/FN/LN coated dishes in 
droplets of 1-1.5 x104 cells/µl in Neurobasal/B27 minus vitamin A (1:50), 2 mM L-glutamine, 
0.2 mM ascorbic acid (AA) and 20ng/ml BDNF (Miltenyi Biotech). On day 14 of 
differentiation, 0.5 mM dibutyryl c-AMP (Sigma-Aldrich) and 20ng/ml GDNF (Miltenyi 
Biotech) were added. On day 30 of differentiation, cells were re-plated as describe above onto 
PO/FN/LN coated dishes or Labteck slides (NuncTM), and γ-secretase inhibitor DAPT (10 μM, 
Tocris) was added until final differentiation at day 65. Cells were then harvested or processed 
for further analysis.
AADC activity assay
AADC enzyme assay was performed using the refined method developed in 24, from 25. 
Neuronal cultures at day 65 in phenol red free medium were harvested and lysed by snap 
freezing twice in liquid nitrogen in 100 µl of 10 mM Tris pH 7.4 (Sigma-Aldrich), 1 mM 
ethylenediaminetetraacetic acid, 320 mM sucrose (Sigma-Aldrich) and protease inhibitor 
cocktail (Roche). 50 μl of cell lysate was incubated with 70 μM pyridoxal 5’-phosphate (PLP, 
Sigma-Aldrich) in assay buffer composed by 500 mM sodium phosphate pH 7.0, 0.167 mM 
ethylenediaminetetraacetic acid, and 39 mM dithiothreitol (Sigma-Aldrich) for 120 min at 
37°C, and subsequently 2 mM final concentration of L-DOPA (Sigma-Aldrich) was added and 
incubated for 20 min at 37°C. The reaction was stopped with 250 μl of 0.8 M perchloric acid 
(final concentration 0.4 M) for 10 min at room temperature and centrifuged at 12.000×g for 5 
min at 4°C. A substrate blank with no L-DOPA and a sample blank without cell lysate were 
performed for each sample. Dopamine in the supernatant was then quantified by High 
Performance Liquid Chromatography (HPLC, see below).
HPLC for quantification of activity assay and metabolic profile
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Dopamine produced in the activity assay was separated by reverse-phase HPLC using a HiQSil 
C18 column 250x4.6mm (Kya technologies) and detected by coulometric electrochemical 
detection using a Coulochem III detector (ESA) with 5010 analytical cell (ESA) setting the 
detector electrode at 350 mV and the screening electrode at 20 mV. The mobile phase consisted 
of 50 mM sodium phosphate pH 3.6, 5 mM octaensulfonic acid, 67 μM 
ethylenediaminetetraacetic acid, 43 mM orthophosphoric acid and 230 ml/l methanol diluted 
in 18.2 Ω HPLC grade water, at a flow rate of 1.2 ml/min at 25 °C. Dopamine was quantified 
with Azur software package using a 1000 nM external standard and enzymatic activity was 
expressed as pmol/min/mg protein.
HPLC analysis of metabolic profile in derived mature cultures was performed on the phenol 
red-free medium incubated for 48h on day 65 mDA neurons. 1:1 medium was mixed with 
perchloric acid to a final concentration of 0.4 M, incubated 10 min at 4°C in the dark, 
centrifuged at 12000×g for 5 min at 4°C, and supernatant was collected for analysis by HPLC 
26. Metabolites were separated by reverse-phase HPLC using a C:18HS column 250 mm×4.5 
mm (Kromatek) and detected by coulometric electrochemical detection using a Coulochem II 
detector (ESA) with 5010A analytical cell (Thermo Fisher Scientific) setting the detector 
electrode at 450 mV and the screening electrode at 20 mV. Mobile phase consisted of 20 mM 
sodium acetate trihydrate pH 3.45, 12.5 mM citric acid monohydrate, 100 μM 
ethylenediaminetetraacetic acid, 3.35 mM octaensulfonic acid and 16% methanol diluted in 
18.2 Ω HPLC grade water, at a flow rate of 1.5 ml/min at 27 °C. Metabolites were quantified 
with EZChrom EliteTM chromatography software (JASCO) using a 500 nM external standard 
mixture, and expressed as pmol/mg protein.
Bulk RNA-Seq analysis
Total RNA was isolated using the RNeasy mini kit (Qiagen) following manufacturer’s 
instructions. RNA libraries were prepared from 100 ng of total RNA using KAPA mRNA 
HyperPrep kit (Roche) according to manufacturer’s protocol and sequenced with Illumina 
NextSeq 500 Mid Output 75bp paired-end (~22M reads/sample). FASTQ obtained files were 
uploaded to Galaxy web platform, and the public server at usegalaxy.org was used for 
downstream analyses.27 FASTQ-files were filtered with Trimmomatic (v.0.38), with 
SLIDINGWINDOW trimming and low quality (phread score <20) reads filter.28 Obtained 
reads were mapped to human reference genome (GRCh38) with HISAT2 (v.2.1.0).29 
Fragments counts for genes were extracted with featureCounts (v.1.6.4) excluding duplicates, 
multimapping reads and chimeric fragments.30 Differential gene expression was analysed using 
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edgeR (v.3.24.1), filtering low counts with 0.35 minimum CPM in at least 3 samples,31 and 
comparing disease status (patients vs control) and disease-specific genotype (patient 2 vs 
patient 1). DEGs with a p-value<0.05 and absolute fold change>2 were considered as 
statistically significant. Heatmaps were generated from the row-scaled z-score of DEGs 
normalised counts obtained by EdgeR with complete-linkage Euclidean hierarchical clustering. 
GO enrichment analyses were performed using ShinyGO v0.6132 for biological process, and 
ClueGO v.2.5.733 for cellular component and molecular function enrichments and groupings, 
with Benjamini-Hochberg p-value correction of FDR<0.05 for statistical significance. Results 
from the expression analysis along with the raw sequence data were deposited in GEO (Gene 
Expression Omnibus), under accession GSE153990.
Electrophysiology
Current-clamp recordings were performed on neurons at day 65 of differentiation. The internal 
solution contained 135 mM K-gluconate, 4 mM KCl, 10 mM Hepes, 4 mM Mg-ATP, 0.3 mM 
Na-GTP, and 10 mM of Na2-phosphocreatine, at pH 7.3 and mOsm 291-295. The recording 
extracellular solution contained 125 mM NaCl, 2.5 mM KCl, 2 mM MgCl2, 1.25 mM KH2PO4, 
2 mM CaCl2, 30 mM glucose, and 25 mM of HEPES at pH 7.4. Experiments were performed 
at room temperature (22-24°C). Neurons with unstable resting potential (or >-50mV), bridge-
balance >20MΩ and/or holding current >200pA were discarded. Bridge balance compensation 
was applied in current clamp and the resting membrane potential was held at -70mV. Current 
steps protocol was used to evoke APs injecting 250ms long depolarizing current steps of 
increasing amplitude (Δ10pA). APs were triggered holding the neurons around -60mV/-55mV. 
Neurons with repetitive spontaneous APs and repetitive evoked APs were considered to be 
functional mature mDA neurons. Recordings were acquired using a Multiclamp 700A 
amplifier (Axon Instruments, Molecular Devices) at 10kHz and filtered at 2kHz (Bessel) using 
WinEDR (John Dempster, University of Strathclyde). Recording were not corrected for liquid 
junction potentials. The approximate cell capacitance was computed as capacitance=tau/Ri, 
whereby the time constant tau was found by fitting a single exponential function to the time 
points where the membrane voltage was between 10% and 95% of the initial charging decay 
slope of a negative hyperpolarizing current step. Input resistance was calculated fitting ΔV/ΔI 
at two hyperpolarising steps (-20 and -10pA) and a positive one (+10pA). APs were identified 
when the voltage signal crossed 0V. sEPSCs were recorded in voltage clamp and automatically 
detected with a template-based algorithm using Clampfit (Molecular Device).
Treatment with L-DOPA and cytotoxicity assay
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Neuronal cultures at day 65 of differentiation were treated with 80 µM L-DOPA in phenol red-
free medium for 24 h. The medium was subsequently removed and analysed by HPLC, as 
described above. Dead-cell proteases release measurement was quantified using CytoTox-
Glo™ Cytotoxicity Assay (Promega) according to manufacturer instructions.
Statistical Analysis
Two-tailed Student’s t-test for single comparisons and statistical one-way ANOVA followed 
by Tukey’s multiple comparisons test were performed using GraphPad Prism. Results are 
reported as mean SEM from at least three independent biological replicates, the exact number 
of which is stated for each experiment in each figure legend. Significance levels were 
determined by p-value, and shown on graphs with asterisks. One asterisk (*) represents p-
values between 0.05 and 0.01, two asterisks (**) represent p-values between 0.01 and 0.001, 
and three asterisks (***) represent p-values of less than 0.001.
Data availability
Data supporting the findings of this study are available from the corresponding authors, upon 
reasonable request.
Results
Patient-derived mDA neurons show disease-specific loss of AADC enzymatic activity and 
dysregulated dopamine synthesis.
Dermal fibroblasts were obtained from two patients with AADC deficiency (Table 1). Patient 
1 (homozygous missense variant c.1039C>G, p.R347G) presented with classical infantile onset 
disease, with early hypotonia, oculogyric crises and neurodevelopmental delay.15 He is 
currently 6½ years of age, and although he continues to make neurodevelopmental progress, 
remains non-ambulant and non-verbal. Patient 2 (compound heterozygous variants c.19C>T, 
p.Arg7*; c.299G>C, p.C100S) had a classical infantile-onset presentation of disease with 
severe global developmental delay, oculogyric crises and hypoglycaemia, but over time 
showed a positive response to therapy and had an overall milder disease course. Once AADC 
deficiency was diagnosed at 3½ years of age, the instigation of dopaminergic medication and 
other specific AADC deficiency treatments was associated with neurodevelopmental progress; 
independent ambulation was achieved by 4½ years and spoken language by 5½ years. From 
10-18 years, adjunct therapies were needed to combat side effects from long-term use of the 
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original treatments to maintain basic motor and verbal function. Now aged 22 years, he has 
ongoing learning difficulties, mild motor impairments, behavioral issues, autistic traits and 
neuropsychiatric symptoms of anxiety and intermittent low mood. iPSC lines were generated 
from dermal fibroblasts of both patients and from an age-matched healthy individual (Control). 
Sequencing of genomic DNA confirmed that patient iPSC lines retained their specific DDC 
mutation (Supplementary Fig. 1A). All iPSCs lines showed clearance of viral transgenes, 
genomic integrity (Supplementary Fig. 1B-C), and true pluripotency (Supplementary Fig. 2A-
D).
iPSCs were then differentiated into mDA neurons, and both patient and control iPSC lines 
showed similar differentiation efficiency. After 11 days of differentiation, all lines showed high 
levels of mDA progenitors and typical midbrain precursors gene expression profile 
(Supplementary Fig. 3A-C). By 65 days of differentiation, both control and patient lines 
comparably matured into neurons, in particular with dopaminergic identity (Supplementary 
Fig. 4A-B). Both control and patient-derived neuronal cultures showed upregulation of 
midbrain-related genes (Supplementary Fig. 4C). Whole-cell patch clamp electrophysiology 
confirmed that iPSC-derived mDA neurons were functional and exhibited continuous and 
rhythmic pacemaker-like activity (Supplementary Fig. 4D). Derived neuronal cultures were 
almost devoid of serotonergic neurons, restricting all further analyses specifically to the mDA 
neuronal subtype (Supplementary Fig. 5A).
We first investigated the effect of patient mutations on AADC enzyme activity and protein 
expression. Measurement of AADC activity showed significantly lower enzymatic function in 
patients when compared to control-derived neurons (Fig. 1A). HPLC analysis of extracellular 
metabolites showed a disease-specific absence of dopamine and HVA with significantly 
reduced levels of DOPAC. In contrast, 3-OMD, a downstream metabolite of the AADC 
substrate L-DOPA, was significantly increased in patient-derived neurons (Fig. 1B). Analysis 
of AADC protein levels showed an increase in Patient 1 neuronal cultures when compared to 
the Control; in contrast, a significant reduction of AADC protein was detected in Patient 2 
neuronal cultures (Fig. 1C-D and Supplementary Fig. 5B), in line with the second heterozygous 
early stop codon variant predicted to result in nonsense mediated mRNA decay.
We then explored whether the aberrant AADC protein levels in patients could be linked to a 
difference in intrinsic protein stability. Recombinant AADC proteins were produced for the 
homozygous R347G variant (Patient 1) and C100S variant (Patient 2). Circular dichroism and 
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dynamic light scattering analyses showed comparable values for both mutant and wild-type 
AADC protein, inferring similar intrinsic protein stability (Supplementary Table 1).
To investigate whether aberrant AADC protein levels related to DDC gene expression, qRT-
PCR studies were undertaken. In line with protein expression data, we observed a statistically 
significant increase in DDC expression in Patient 1 when compared to the Control 
(Supplementary Figure 5C). For Patient 2, we observed comparable levels of DDC expression 
to the Control (Supplementary Figure 5C), despite the predicted nonsense-mediated decay of a 
proportion of transcripts. We also observed an increase in tyrosine hydroxylase (TH) gene and 
protein expression in both patient lines when compared to the control (Supplementary Figure 
5D-E).
AADC deficiency has mutation-specific effects on neuronal synaptic maturation and 
connectivity.
We then sought to investigate the neurodevelopmental consequences of AADC deficiency in 
our in vitro model. Immunofluorescence analysis of the mature neuronal marker NeuN showed 
comparable levels in Patient 1 and Control mDA neurons, while Patient 2 cultures showed a 
significant decrease in NeuN positivity when compared to both Control and Patient 1 lines (Fig. 
2A-B). Moreover, analysis of the vesicular protein synaptophysin revealed a significant 
decrease in protein levels for both Patient 1 and 2 when compared to control-derived neuronal 
cultures (Fig. 2C-D).
In order to further investigate the neurodevelopmental effects of AADC deficiency, we 
undertook bulk RNA sequencing for analysis of differentially expressed genes (DEGs) between 
patient and control-derived neurons, with a particular focus on protein-coding genes. In a 
combined analysis of Patient 1 and Patient 2-derived neuronal cultures, we identified 750 
DEGs (75% underexpressed and 25% overexpressed) when compared to the Control (Fig. 3A). 
Gene Ontology (GO) analysis of underexpressed DEGs revealed a strong enrichment in 
synaptic transmission-related biological processes and nervous system development, whilst 
overexpressed DEGs mainly enriched protein transcription and general organ developmental 
processes (Fig. 3B). Furthermore, underexpressed DEGs were associated with membranous 
cellular compartments (in particular the cell periphery and synaptic region), and enriched in 
gated channels and regulators of membrane transport (Fig. 3C). In contrast, overexpressed 
DEGs were associated with non-membrane-bounded cell compartments (nucleus), with 
enrichment in transcriptional regulator proteins (Fig. 3D).
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Considering the previously detected differences between the two patient lines (Fig. 2), single-
comparison RNA sequencing analysis was also performed. We identified 842 protein-coding 
DEGs for Patient 1 compared to the Control (Supplementary Fig. 6A) and 871 protein-coding 
DEGs for Patient 2 compared to the Control (Supplementary Fig. 7A). For both analyses, 
underexpressed genes showed common enrichment for synaptic transmission (Supplementary 
Fig. 6B and 7B) - reflected in the significant P-values observed in the combined analysis (Fig. 
3B) - representing genes encoding proteins mainly localized at the cell periphery or synapses, 
and associated with ion channel function (Patient 1 and Patient 2) and gated channel function 
(for Patient 2 in particular) (Supplementary Fig. 6C and 7C). Differences in separate single 
Patient 1 and Patient 2 comparisons with the Control were mainly detected for upregulated 
genes with regard to biological processes and significance (Supplementary Fig. 6B and 7B): 
for Patient 1, overexpressed DEGs were enriched for developmental and cell projection 
assembly genes (Supplementary Fig. 6B and 6D), whilst for Patient 2 overexpressed DEGs 
were enriched for genes encoding endoplasmic reticulum and membrane-targeting processes 
and function (Supplementary Fig. 7B and 7D). Despite these inter-patient differences, the 
combined analysis reflects a common, disease-specific overexpression of developmental and 
transcriptional/translational processes from both single comparisons (Fig. 3B).
We then explored DEGs between the two different patient-derived neuronal cultures. We 
identified a total of 763 protein-coding DEGs for Patient 2 when compared to Patient 1 (Fig. 
4A). The underexpressed DEGs showed enrichment in cell adhesion and membrane transport-
related processes, while overexpressed DEGs enriched endoplasmic reticulum and membrane-
targeting processes categories (Fig. 4B). Underexpressed DEGs corresponded to proteins 
localized both in cell periphery/membrane regions and nuclear compartment, with enrichment 
for genes regulating transcription and transmembrane transport (Fig. 4C). Overexpressed 
DEGs showed enrichment in both cytosolic transcriptional and extracellular compartments, 
with molecular functions mainly linked to structural/binding molecules, and 
transcriptional/activity regulators (Fig. 4D), resembling the result from the single comparison 
between Patient 2 and Control (Supplementary Fig. 7B and 7D).
Whole-cell patch clamp electrophysiology studies were undertaken to determine whether the 
observed differences in gene expression were associated with functional differences in 
neuronal activity. The parameters analysed are similar to other studies using iPSC-derived 
dopaminergic neurons, with comparable findings for firing pattern, pacemaker and synaptic 
activity in controls.34–37 Recordings with increasing current amplitude (Fig. 5A) showed that 
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the current threshold to elicit an action potential (AP) for Patient 2 was significantly lower than 
for the Control (Fig. 5B-C) and failed to follow current injection up to 100pA (Fig. 5D). On 
investigation of passive neuronal properties, both patients displayed lower capacitance 
compared to control neurons without affecting input resistance (Fig. 5C), in accordance with a 
decreased average number of primary neurite branches (Fig. 5E). For both control and patient-
derived neurons showing spontaneous excitatory postsynaptic currents (sEPSC), we observed 
no differences in either the percentage of functionally connected neurons or current amplitude, 
although the inter-event interval was significantly higher in Patient 2-derived neurons (Fig. 
5F).
DDC lentiviral gene-transfer significantly improves neurodevelopmental defects in 
patient-derived neurons.
Given that gene therapy is an emerging new treatment for AADC deficiency,16–18 we sought to 
investigate the cellular effects of human DDC (hDDC) transgene delivery in our model; in 
particular we wished to evaluate whether this therapeutic approach could improve the 
neurodevelopment sequelae of AADC deficiency, independent of genetic background. We 
generated a lentiviral construct for the delivery of hDDC under the control of the neuronal-
specific promoter human synapsin (hSyn1) (Supplementary Fig. 8). Patient-derived mDA 
precursors were transduced at day 24 of differentiation and analysed at day 65. For both patient 
lines, lentiviral gene transfer resulted in an increase in AADC protein levels (Supplementary 
Fig. 9A-B), and rescued enzymatic activity to levels comparable to those observed in Control 
neurons (Supplementary Fig. 9C). Furthermore, Patient 2 transduced neurons showed a 
significant increase in the NeuN-positive neuronal population, and in particular mDA neurons, 
to levels comparable to Patient 1 (Fig. 6A-B and Supplementary Fig. 10A). hDDC lentiviral 
delivery also resulted in a significant increase in synaptophysin protein levels in both patients-
derived neuronal cultures (Fig. 6C) and more specifically in the mDA neuronal subpopulation 
(Fig. 6D and Supplementary Fig. 10B), with a significant increase in primary branching (Fig. 
6E).
In silico and recombinant biochemical analyses predict mutation-specific L-DOPA 
response for Patient 2.
The different mutations harbored by Patient 1 and 2 were further investigated to determine 
whether they had differential effects on enzymatic function. For Patient 1, despite 
supraphysiological levels of protein expression (Fig. 1C), the homozygous missense 
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substitution R347G significantly impairs catalytic function of AADC leading to undetectable 
enzyme activity (Fig. 1A) without impacting the protein structure by a molecular mechanism 
extensively investigated in 15. In contrast, despite significantly low levels of AADC protein in 
Patient 2-derived neuronal cultures (Fig. 1C), residual enzymatic activity was still detected, 
albeit at a fraction of that evident in Control line (Fig. 1A). It is likely that this residual AADC 
enzyme activity can be attributed to the p.C100S variant, since the second heterozygous 
mutation leads to an early stop codon at Arg7, predicted to result in nonsense mediated mRNA 
decay and absent protein production. The missense mutation C100S results in an amino acid 
substitution at the beginning of an essential loop (loop 2, residues 100 to 110) that contains key 
hydrophobic active site residues involved in substrate binding, in particular Ile101 and 
Phe103.38 The cysteine-to-serine amino acid substitution has the potential to alter the 
conformation of loop 2 and consequently the substrate-binding cleft, thereby affecting substrate 
affinity (Fig. 7A). AADCC100S was produced in vitro in recombinant form to further 
characterize the effects of this mutation through spectroscopic, circular dichroism and 
fluorescence analyses, and calculation of kinetic parameters. A minor perturbation of PLP 
cofactor microenvironment (in particular for the enolimine tautomer) was observed 
(Supplementary Fig. 11A-B). However, PLP binding affinity (Supplementary Table 1) was not 
particularly affected, with a KD(PLP) consistently lower than previously reported values for 
AADC variants with cofactor binding impairment.13 Calculation of kinetic parameters 
(Supplementary Table 1) revealed that AADCC100S retains more residual enzyme activity 
than that reported for other AADC variants.12,13 The catalytic activity (kcat) of AADCC100S 
was indeed similar to that observed for wild-type, with the actual decrease in overall 
AADCC100S catalytic efficiency (kcat/KM) attributed to a slight decrease in L-DOPA affinity 
(KM) (Supplementary Table 1). As such, we postulated that dopamine production by 
AADCC100S could be enhanced with L-DOPA administration, as demonstrated for other 
AADC variants.39
Patient 2-derived mDA neurons specifically respond to L-DOPA administration.
To determine whether the C100S mutation resulted in L-DOPA responsivity, we sought to 
investigate the effect of L-DOPA treatment in Patient 2-derived mDA neurons. After 65 days 
of differentiation, both patients and control-derived neuronal cultures were incubated with 80 
µM L-DOPA for 24 hours, a dose just below that considered to be toxic in neuronal and other 
cellular systems.40,41 Subsequent HPLC analysis of extracellular metabolites was then 
undertaken. As expected in a system with catalytically competent AADC, HVA levels were 
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significantly higher in treated Control compared to untreated Control neurons (Fig. 7B). 
Furthermore, as predicted, there was no detectable HVA in Patient 1-derived neuronal cultures 
both pre- and post- L-DOPA treatment. However, for Patient 2, we observed a significant 
increase of HVA levels in L-DOPA treated cultures when compared to untreated cultures (Fig. 
7B). In order to evaluate any potential toxicity related to L-DOPA administration40 or 
dopamine production,42 we measured dead-cell protease release and found no increase in 
membrane permeability for both Patient and Control-derived neuronal cultures treated with 80 
µM L-DOPA for 24 hours (Fig. 7C). Moreover, analysis of JNK protein phosphorylation, 
which increases in response to toxic levels of dopamine,43 showed a significant increase in the 
phosphorylated form of this kinase in treated Control neurons only, while no significant 
increase was detected in both treated Patient 1 and  2 cultures (Supplementary Fig. 11C).
Discussion
AADC deficiency is a complex and often pharmacoresistant neurological disorder, with a broad 
phenotypic spectrum, variable drug response, substantial burden of disease and significant risk 
of premature mortality.7 Improved understanding of the underlying pathogenic mechanisms 
and the development of better targeted treatments, such as gene therapy and other personalised 
medicine approaches, will be key in modifying disease and long-term outcome. In this study, 
we have developed a new humanized model of AADC deficiency. Our in vitro patient-derived 
mDA neuronal model of AADC deficiency has provided further insight into mechanisms 
governing disease, as well as an ideal system to evaluate the impact of approaches such as gene 
therapy at cellular level and a unique research platform to evaluate mutation-specific precision 
medicine approaches.
Importantly, our patient-derived mDA model recapitulates key features of the human 
phenotype with near-absent AADC enzyme activity and impaired dopamine metabolism. In 
our dopaminergic model, we observed a greater degree of residual AADC enzyme activity in 
Patient 2, which may relate to the more advanced motor gains observed in this patient. We also 
observed patient-specific altered levels of AADC protein. The reasons for this are not entirely 
clear, given that little is known about factors that govern AADC enzyme regulation. Our 
biochemical investigations did not show a differential intrinsic protein stability between mutant 
and wild-type protein. We did however observe a clear patient-specific increase in DDC gene 
expression for Patient 1 and higher than expected levels of DDC expression for Patient 2, given 
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the predicted nonsense-mediated decay of a proportion of Patient 2 transcripts. Furthermore 
for both patients there was an increase in TH gene and protein expression; interestingly, TH 
gene and protein expression has previously been shown to increase in Parkinson’s disease, as 
a likely compensatory response to a state of dopamine deficiency in the context of striatonigral 
degeneration.44,45 As such, it is plausible that the similar state of dopamine deficiency in 
AADC-deficient patient lines drives a positive feedback mechanism to modulate neuronal 
levels of key enzymes driving dopamine synthesis.
Moreover, our study suggests that AADC dysfunction may have widespread effects on gene 
expression that may impact neuronal development and functional maturation. As well as its 
pivotal role in monoamine neurotransmission, dopamine is postulated to have important 
functions in modulating neuronal structure and connectivity.46 The early production of 
dopamine in midbrain development suggests that it may have neurodevelopmental influence,47 
a notion that is further corroborated by DDC knock-in mice and knockout zebrafish which 
show abnormal development.48,49 Interestingly, our patient-derived cell model also shows that 
defective AADC enzymatic activity and dysregulated dopamine metabolism affects neuronal 
maturity, with altered expression of genes involved in neurodevelopment and synaptic 
formation, as well as disruption of electrophysiological properties and functional activity. 
Considering that iPSC-derived neurons resemble fetal neurons,50 it is possible that the neuronal 
maturation defects observed in our in vitro model correlate with prenatal disease onset in 
humans. This is not surprising, given that many affected patients present with their first 
clinically discernible symptoms in early infancy. Our results are particularly relevant in the 
current climate of emerging gene therapy approaches,18 where neuronal plasticity is considered 
to be an important requisite for clinical benefit.51 It is likely that gene therapy within this 
‘therapeutic window’ of brain plasticity may predict a more favorable long-term 
neurodevelopmental outcome.
In our system, we identified around the same number of differentially expressed genes between 
patients (when combined) and control and between the two patients; the latter observation 
likely reflects both the biological and clinical differences between patients affected by a disease 
with a broad phenotypic continuum. Patient 2-derived cultures showed indeed a greater degree 
of neuronal immaturity. Notably, Patient 2 had a number of behavioural issues, significant 
autistic traits and prominent neuropsychiatric symptoms, features that were less evident in 
Patient 1. Our data may indicate that the greater degree of neuronal immaturity evident in 
Patient 2 lines as seen on maturation marker analysis, transcriptome profiling and 
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electrophysiology may contribute to the aforementioned neurodevelopmental symptoms. 
Importantly, lentiviral treatment of patient-derived neurons restored AADC protein levels and 
enzymatic activity with significant improvement in neuronal maturity. Whether AADC protein 
has additional functions in governing neurodevelopment processes, that are independent of its 
catalytic activity in dopamine production, remains yet to be determined. Further studies with a 
greater number of patient lines and age-matched/isogenic controls, or analysis of multiple 
clones from each line, will help confirm and further delineate the complex neurodevelopmental 
biological phenotypes identified in this study. Additional genetic, epigenetic and 
environmental factors may also play a role in such phenotypic variability seen in the cell model 
and human phenotype; over time, advances in next generation sequencing technologies may 
also help further elucidate some of the underlying contributory genetic factors.
Our patient-derived model of AADC deficiency has proven to be a useful tool for evaluating 
therapeutic approaches. We have shown recovery of AADC enzyme activity and specific 
neuronal maturation defects using a gene therapy approach in patient-derived neurons. In 
tandem with other models, such therapeutic testing in iPSC-based systems may in the future 
guide and influence clinical trial design. Our model has also demonstrated the potential utility 
of L-DOPA treatment for some patients with AADC deficiency. Although L-DOPA is not 
traditionally used in the majority of patients,8 it has been previously empirically used in patients 
suspected to have L-DOPA responsive AADC deficiency.39 Our study confirms that it may 
indeed have a role for patients with specific DDC mutations associated with residual enzymatic 
activity due to altered substrate affinity. A planned therapeutic trial will further inform whether 
the positive effects of L-DOPA observed in vitro are recapitulated in vivo. More generally, our 
study shows that better definition of the physiochemical properties of specific mutations with 
subsequent validation in patient-relevant models has great potential in guiding personalised 
pharmacological strategies for rare disorders. 
In conclusion, as new therapeutic avenues emerge for patients with AADC deficiency, our 
study shows the clear utility of an iPSC-based modelling system to elucidate disease 
mechanisms and evaluate therapeutic strategies.
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Figures:
Fig. 1: Patient-derived neurons show loss of AADC enzymatic activity and dysregulated 
dopamine synthesis.
(A) AADC activity assay relative to total protein (n=19, 9, and 6 for Control, Patient 1 and 
Patient 2, respectively). (B) HPLC detection of extracellular dopamine, HVA, DOPAC and 3-
OMD in Control, Patient 1 and Patient 2-derived neuronal cultures. Values are relative to total 
protein (n=6, 3, 3; n=3, 3, 3; n=5, 3, 3; n=4, 3, 3 respectively). (C) Immunoblot analysis for 
AADC protein in Control, Patient 1 and Patient 2 derived neurons at day 65 of differentiation. 
Quantification relative to loading control (GAPDH) (n=6, 5, 7 respectively). (D) 
Representative images for AADC and TH immunofluorescence in derived neurons. Scale bar 
100µm. Data are represented as mean ±SEM. *P <0.05; **P <0.01; ***P <0.001, one-way 
ANOVA followed by Tukey’s multiple comparisons test.
Fig. 2: Patient-derived neurons show defects in developmental maturation.
(A) Representative immunofluorescence images for NeuN and TH in Control and Patient-
derived neurons. Arrows indicate double positive cells. Scale bar 100µm. Inserts show higher 
magnification of NeuN-positive dopaminergic neurons. (B) Quantification of NeuN positive, 
TH positive and NeuN negative, and TH/NeuN double positive cells in derived neuronal 
cultures (n=3 for all). (C) Representative immunoblot for synaptophysin and loading control 
(β-ACT) and quantification of relative synaptophysin abundance in total neuronal cell lysates 
(n=5 for all). (D) Representative immunofluorescence for synaptophysin and TH in derived 
neurons. Scale bar 100µm. Inserts show higher magnification of synaptophysin-positive 
dopaminergic neurons. Data are represented as mean ±SEM. *P <0.05; **P <0.01; ***P 
<0.001, one-way ANOVA followed by Tukey’s multiple comparisons test.
Fig. 3: Bulk RNA-Seq analysis shows an abnormal gene expression profile in AADC 
deficiency patients.
(A) Heat map showing hierarchical clustering of protein-coding DEGs in AADC deficiency 
patients compared to Control (n=3). (B) GO terms enrichment for biological process of 
underexpressed (blue) protein-coding and overexpressed (red) protein-coding DEGs. Top 5 
categories are shown. (C-D) ClueGO analysis of GO terms enrichment of under- (C) and over- 
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(D) expressed protein-coding DEGs, showing network graph and pie chart for cellular 
component (CC), and pie chart for molecular function (MF). Network graph nodes represent 
GO terms (the most significant are named) and edges indicate shared genes between GO terms. 
Functional groups of GO terms are indicated by the same color. Pie charts show the percentages 
of each functional group representation, named with the most significant term. GO functional 
groups exhibiting higher statistically significant differences using Benjamini-Hochberg p-
value correction (FDR<0.05) are shown.
Fig. 4: Bulk RNA-Seq analysis reveals differences in gene expression profiles between 
Patient 1 and 2 derived-neurons.
(A) Heat map showing hierarchical clustering of protein-coding DEGs in Patient 2, compared 
to Patient 1 (n=3). (B) GO terms enrichment for biological process of underexpressed (blue) 
protein-codifying and overexpressed (red) protein-codifying DEGs. Top 5 categories are 
shown. (C-D) ClueGO analysis of GO terms enrichment of under- (C) and over- (D) expressed 
protein-codifying DEGs, showing network graph and pie chart for cellular component (CC), 
and pie chart for molecular function (MF). Network graph nodes represent GO terms (the most 
significant are named) and edges indicate shared genes between GO terms. Functional groups 
of GO terms are indicated by the same color. Pie charts show the percentages of each functional 
group representation, named with the most significant term. GO functional groups exhibiting 
higher statistically significant differences using Benjamini-Hochberg p-value correction 
(FDR<0.05) are shown.
Fig. 5: Patient-derived neurons show altered neuronal electrophysiological properties 
and defects in primary neurite branching.
(A) Representative traces of action potentials (APs) elicited by injecting 40pA current in 
patients and control lines. (B) Input/output plot showing number of APs triggered by 
incremental current steps. (C) Active (current threshold and max current sustained) and passive 
(capacitance) properties of neurons in Control, Patient 1 and Patient 2 neurons (n=39, 34, 26, 
n=35, 34, 25, and n=41, 38, 32, respectively, from 4 biological replicates). (D) Percentage of 
neurons which sustain >100pA current injection. (E) Representative images for dopaminergic 
neurons branching (scale bar 10µm) and quantification of average primary neurite branching 
in Control, Patient 1 and Patient 2 mDA neurons (n=11, 7, 11 respectively). (F) Representative 
traces showing sEPSCs at -70mV and quantification of neurons with sEPSC, sEPSC amplitude 
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and inter-time intervals in Control, Patient 1 and Patient 2 neurons (n=5 for all, n=27, 28, 28, 
and n=24, 28, 18, respectively, from 4 biological replicates).
Data are represented as mean ±SEM. *P <0.05; **P <0.01; ***P <0.001, one-way ANOVA 
followed by Tukey’s multiple comparisons test and chi-square test in (D).
Fig. 6: Gene therapy significantly improves maturation defects in patient-derived 
neurons.
(A) Representative immunofluorescence for NeuN and TH of patient-derived neurons 
transduced with LV GFP or LV DDC-GFP. Scale bar 100µm. Inserts show higher 
magnification of NeuN-positive dopaminergic neurons. (B) Quantification of NeuN positive, 
TH positive and NeuN negative, and TH/NeuN double positive cells in patient-derived 
neuronal cultures transduced with LV GFP and LV DDC-GFP (n=3 each). (C) Representative 
immunoblot for synaptophysin and loading control (GAPDH), and quantification of relative 
synaptophysin abundance from total cell lysates extracted from LV GFP and LV DDC-GFP 
transduced neurons. Results are normalized to the corresponding LV GFP for each patient (n=4, 
4, 5, 5 respectively). (D) Representative immunofluorescence for synaptophysin and TH in 
patient-derived neurons transduced with LV GFP or LV DDC-GFP. Scale bar 100µm. Inserts 
show higher magnification of synaptophysin-positive dopaminergic neurons. (E) 
Representative images for dopaminergic neurons branching (scale bar 10µm) and 
quantification of average primary neurite branches in patient-derived neurons transduced with 
LV GFP or LV DDC-GFP (n=15, 18, 13, 18 respectively). Data are represented as mean ±SEM. 
*P <0.05; **P <0.01; ***P <0.001, two-tailed Student’s t-test.
Fig. 7: L-DOPA treatment increases dopamine metabolite production in Patient 2 derived 
neuronal cultures, with no evidence of cellular toxicity.
(A) Localisation of Cys100 in AADC protein structure. The structure corresponds to sus scrofa 
holoenzyme (PDB code: 1JS3), solved in complex with PLP and carbidopa, and rendered using 
PyMol™ software. AADC is shown as a schematic, with the two monomers composing the 
native rearrangement of the enzyme (wheat and marine blue, respectively). PLP and carbidopa 
are represented as green and yellow sticks, respectively. The side chain of Cys100 is 
represented as a pink stick. Side chains of Ile101 and Phe103 are represented as orange sticks. 
(B) HPLC detection of extracellular HVA after 80 µM L-DOPA treatment of neuronal cultures 
for 24 h. Values are relative to total protein (n=3, 3, 5, 5, 4, 4 respectively). (C) Dead-cell 
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proteases release assay after treatment. Results are normalized to the corresponding non-treated 
condition (n=3 for all).
Data are represented as mean ±SEM. *P <0.05; **P <0.01; ***P <0.001, one-way ANOVA 
followed by Tukey’s multiple comparisons test.
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Fig. 1: Patient-derived neurons show loss of AADC enzymatic activity and dysregulated dopamine synthesis. 
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Fig. 2: Patient-derived neurons show defects in developmental maturation. 
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Fig. 3: Bulk RNA-Seq analysis shows an abnormal gene expression profile in AADC deficiency patients. 
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Fig. 4: Bulk RNA-Seq analysis reveals differences in gene expression profiles between Patient 1 and 2 
derived-neurons. 
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Fig. 5: Patient-derived neurons show altered neuronal electrophysiological properties and defects in primary 
neurite branching. 
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Fig. 6: Gene therapy significantly improves maturation defects in patient-derived neurons. 
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Fig. 7: L-DOPA treatment increases dopamine metabolite production in Patient 2 derived neuronal cultures, 
with no evidence of cellular toxicity. 
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Table 1 Phenotype and genotype features of AADC deficiency patients
Patient 
number
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Rossignoli et al. develop the first humanized neuronal model of AADC deficiency. 
They use this patient-derived neuronal system to elucidate disease mechanisms, 
and in particular to better define neurodevelopmental features, as well as to test 
precision therapy approaches. 
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Abstract
The versatility of reactions catalyzed by pyridoxal 5′-phosphate (PLP) enzymes is largely due to the chemistry of their 
extraordinary catalyst. PLP is necessary for many reactions involving amino acids. Reaction specificity is controlled by the 
orientation of the external aldimine intermediate that is formed upon addition of the amino acidic substrate to the coenzyme. 
The breakage of a specific bond of the external aldimine gives rise to a carbanionic intermediate. From this point, the dif-
ferent reaction pathways diverge leading to multiple activities: transamination, decarboxylation, racemization, elimination, 
and synthesis. A significant novelty appeared approximately 30 years ago when it was reported that some PLP-dependent 
decarboxylases are able to consume molecular oxygen transforming an amino acid into a carbonyl compound. These side 
paracatalytic reactions could be particularly relevant for human health, also considering that some of these enzymes are 
responsible for the synthesis of important neurotransmitters such as γ-aminobutyric acid, dopamine, and serotonin, whose 
dysregulation under oxidative conditions could have important implications in neurodegenerative states. However, the 
reactivity of PLP enzymes with dioxygen is not confined to mammals/animals. In fact, some plant PLP decarboxylases have 
been reported to catalyze oxidative reactions producing carbonyl compounds. Moreover, other recent reports revealed the 
existence of new oxidase activities catalyzed by new PLP enzymes, MppP, RohP, Ind4, CcbF, PvdN, Cap15, and CuaB. 
These PLP enzymes belong to the bacterial and fungal kingdoms and are present in organisms synthesizing bioactive 
compounds. These new PLP activities are not paracatalytic and could only scratch the surface on a wider and unexpected 
catalytic capability of PLP enzymes.
Keywords Pyridoxal 5′-phosphate-dependent enzymes · Decarboxylase · Oxidase activity · Oxidative stress · Aromatic 
aldehyde
Abbreviations
PLP  Pyridoxal 5′-phosphate
AADC or DDC  Aromatic amino acid or dopa 
decarboxylase
GAD  Glutamate decarboxylase
DHPAA or DOPAL  3,4-Dihydroxyphenylacetaldehyde
DHPAAS  3,4-Dihydroxyphenylacetaldehyde 
synthase
PAAS  Phenylacetaldehyde synthase
GABA  γ-Aminobutyric acid
ODC  Ornithine decarboxylase
LDC  l-Lysine decarboxylase
ROS  Reactive oxygen species
TH  Tyrosine hydroxylase
Pyridoxal 5′‑phosphate (PLP)‑dependent 
enzymes are able to react with oxygen
Approximately 30 years ago, it was reported (Abell and 
Schloss 1991) that some enzymes that do not bind metals/
cofactors typical of redox reactions are able to consume oxy-
gen. These enzymes belong to diverse families and catalyze 
different chemical reactions.
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The paper of Abell and Schloss represented a milestone, 
since it was the first time, after the identification of the oxy-
genase reaction catalyzed by ribulose 1,5-bisphosphate car-
boxylase/oxygenase (RuBisCO) (Bowes et al. 1971), that 
other enzymes were reported to catalyze an oxygenase side 
reaction and raised the issue of how such activity could 
occur.
Actually, the question of the reactivity with oxygen for 
enzymes lacking a proper metal or redox cofactor is still 
puzzling. It is known that molecular oxygen could be present 
as an excited singlet and a ground triplet state, the former 
being highly reactive, the latter more stable, since its reac-
tion with organic substrates is a spin-forbidden process. This 
latter biradical species must be activated by a series of one-
electron stepwise transfer reactions leading sequentially to 
superoxide anion, hydrogen peroxide, hydroxyl radical, and, 
finally, water (Klinman 2007). A metal or a redox cofactor 
like flavin can readily accomplish these subsequent steps. 
Flavoproteins are often considered a prototype, since the 
flavin cofactor is able to catalyze single-electron transfers in 
the absence of a metal. The spin-forbidden paradox is over-
come in this class of enzymes by a single-electron transfer 
of a reduced flavin to the triplet state of oxygen to generate 
superoxide and flavin semiquinone cage radical pair, leading 
to different reaction pathways spanning from the dissociation 
to produce oxygen radicals, to a second electron transfer to 
form hydrogen peroxide and oxidized flavin, to the forma-
tion of a covalent hydroperoxy-flavin leading to further dis-
sociation to hydrogen peroxide or insertion of an oxygen 
atom into the substrate (Mattevi 2006; Chaiyen et al. 2012; 
Daithankar et al. 2012).
Schloss and others studied many enzymes that have unu-
sual and non-canonical reactivity with  O2 (Abell and Schloss 
1991; Hixon et al. 1996) and, based on the knowledge col-
lected on RuBisCo that forms a oxygen-reactive enolate 
intermediate (Bowes et al. 1971), they suggested that any 
enzyme capable of forming carbanionic intermediates could 
have the propensity to react with molecular oxygen (Abell 
and Schloss 1991). The difference between the carbanion-
forming enzymes consuming molecular oxygen and those 
exhibiting no susceptibility to it was proposed to lie in the 
accessibility of the carbanion intermediate and in the sta-
bilization of a subsequent intermediate, a peroxide anion, 
occurring through protonation and/or metal coordination 
(Abell and Schloss 1991).
The oxygenase off-pathway activities of enzymes gen-
erating carbanionic intermediates have been designated 
as the so-called paracatalytic reactions with  O2 (Christen 
et al. 1976; Cogoli-Greuter et al. 1979; Christen and Gas-
ser 1980). They have been proposed to play a role in the 
generation of reactive species important in signaling and 
also in contributing to the progression of neurodegenerative 
diseases (Bunik et al. 2007).
One of the enzymes able to catalyze an oxygenase side 
reaction (identified by Abell and Schloss) was the PLP-
dependent E. coli glutamate decarboxylase (GAD). The 
authors reported that GAD was able to consume  O2 in the 
presence of l-glutamic acid, generating succinic semialde-
hyde at a rate of about 0.1% that of the main decarboxylation 
reaction generating γ-aminobutyric acid (GABA) (Abell and 
Schloss 1991). The peculiarity of this reaction is that dioxy-
gen is not at all a substrate for PLP enzymes, whose usual 
substrates are amino acids, amines, and some few sugars.
It is known that the versatility of reactions catalyzed by 
PLP-dependent enzymes is largely due to the chemistry 
of their extraordinary catalyst. PLP is necessary for most 
reactions of amino acids, and it is invariably bound to the 
protein moiety of all PLP enzymes through a Schiff base 
linkage with a lysine residue forming an internal aldimine 
structure. In the presence of an incoming amino acid, the 
ε-amino group of the internal aldimine is exchanged with 
the α-amino group of the substrate generating the exter-
nal aldimine intermediate. From this point, the different 
reaction pathways diverge leading to multiple non-electron 
transfer reactions: transamination, decarboxylation, race-
mization, elimination, and substitution (Fig. 1). This is 
accomplished by the breakage of a specific bond of the 
external aldimine. In 1966, Dunathan proposed (Dunathan 
1966) that the scissile bond is oriented perpendicular to 
the plane of the imine–pyridine ring, since, in this confor-
mation, the highest orbital overlap is achieved and, thus, 
the best transition state stabilization could be reached. 
Indeed, it is the protein scaffold that directs the position-
ing of the bond to be broken. This explains how reac-
tion specificity of PLP-dependent enzymes is controlled. 
It follows that once the external aldimine is formed, the 
possibilities are that a carboxylate or a proton or a side 
chain will be removed. Thus, three possible different car-
banionic intermediates, the quinonoid species Q1 or Q2 or 
Q3, are formed and, depending on the reaction that each 
of these quinonoids undergoes, several different pathways 
will be followed giving rise to the various PLP-dependent 
enzymatic activities (Fig. 1). This also explains the versa-
tility of the PLP enzymes, which comprise up to 1.5% of 
enzymes in microbial genomes (Percudani and Peracchi 
2003) and about 4% of all enzyme activities (Hoegl et al. 
2018). However, the protein moiety is not able to com-
pletely abolish the intrinsic high reactivity of the cofactor, 
and this is the reason why PLP enzymes are promiscu-
ous and able to catalyze, in addition to the main reaction, 
also side reactions with amino acids, albeit less efficiently 
(John 1995). Following this view, as an example, the pro-
totype of all PLP enzymes, aspartate aminotransferase, can 
also perform a β-elimination and/or a racemization reac-
tion (John and Fasella 1969; Kochhar and Christen 1988, 
1992) in addition to the transaminase main reaction. This 
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ability to catalyze one or more side reactions holds true 
for the majority of PLP enzymes; however, the substrates 
of these side reactions are always amino acids or amines. 
Nevertheless, given the common feature of generating car-
banionic intermediates, PLP-dependent enzymes represent 
likely candidates also for oxygenase reactions (Fig. 1).
Since the identification of the reaction of GAD (Abell 
and Schloss 1991), reactivity towards  O2 has been deter-
mined for many other PLP enzymes, as reported in the recent 
reviews (Hoffarth et al. 2020; Bunik et al. 2011), highlight-
ing that this propensity is more widespread than heretofore 
imagined and not only confined to paracatalytic reactions.
Fig. 1  Reaction pathways of 
PLP enzymes. The internal 
aldimine is converted into 
the external aldimine which, 
subsequently, undergoes a bond 
breakage. The fate of the gener-
ated carbanionic intermediate, 
the quinonoid Q1 or Q2 or Q3, 
depends on reprotonation to 
α-carbon or to C4′ leading to 
the different products and PLP-
dependent enzyme activities
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A recent detailed overview of all reactions catalyzed by 
PLP enzymes involving  O2 (Hoffarth et al. 2020) stimulates 
to provide more insight into the intricacy of these reaction 
mechanisms and to the physiological significance of this 
reactivity.
Looking into the literature, it is evident that reactions 
of PLP enzymes in aerobiosis and in anaerobiosis have 
been annotated in different ways: decarboxylation, oxida-
tive deamination, decarboxylation-dependent transamina-
tion, decarboxylation-dependent oxidative deamination, 
oxidative decarboxylation, and decarboxylating oxygena-
tion. While the first four reactions can be typical of PLP 
enzymes, oxidative decarboxylation is best used for ketoacid 
dehydrogenases, since the products of such reactions are not 
aldehydes/ketones nor ammonia. For the decarboxylating 
oxygenation, it is used as decarboxylation-dependent oxida-
tive deamination; however, some attention should be payed 
(see below). To dispel some doubts, some terminology and 
activity to which it refers is given to contribute and improve 
clarity (Fig. 2).
The paradigmatic case of dopa 
decarboxylase (DDC)
DDC, also known as aromatic amino acid decarboxylase 
(AADC), has a broad substrate specificity being able to 
convert both L-dopa and L-5-hydroxytryptophan to dopa-
mine and serotonin (Fig. 3a), respectively, in addition to 
other aromatic amino acids, producing the so-called trace 
amines (Bertoldi 2014). A scheme of all reactive substrates 
or products of DDC is reported in Fig. 4. A decarboxylation-
dependent transamination was identified as a side reaction 
for DDC (O’Leary and Baughn 1977). This reaction con-
sists of an off-pathway step following decarboxylation at 
Cα (Fig. 1) where protonation of Q1 occurs at C4′ instead 





Fig. 2  Terminology of PLP reactions. a Decarboxylation of an 
amino acid to an amine catalyzed by a PLP decarboxylase; b oxida-
tive deamination of an amine into the corresponding carbonyl com-
pound and ammonia together with  O2 consumption; c decarboxyla-
tion-dependent transamination of an amino acid converted into the 
corresponding carbonyl compound and ammonia. Enz-PLP refers to 
the catalytic competent decarboxylase, Enz refers to a decarboxylase 
whose catalytically active coenzyme PLP has been transformed into 
PMP which is not a coenzyme for decarboxylation. Thus, once the 
PLP of the enzyme has been all transformed into PMP, the enzyme 
is inactivated. For this reason, the products are equimolar to PLP; d 
decarboxylation-dependent oxidative deamination of an amino acid 
first decarboxylated and then converted into the corresponding car-
bonyl compound and ammonia concomitantly with  O2 consumption
Oxygen reactivity with pyridoxal 5′-phosphate enzymes: biochemical implications and…
1 3
and pyridoxamine 5′-phosphate (PMP), a coenzyme inca-
pable of performing further decarboxylation and thus lead-
ing to enzyme inactivation. However, experimental data in 
the presence of α-methyldopa did not support this reaction 
mechanism, since the produced carbonyl compound far 
exceeded, on a molar basis, coenzyme content (Barboni 
et al. 1981). This behavior remained obscure until the end 
of last century, when our group has demonstrated that mam-
malian DDC catalyzes an oxidative deamination reaction 
with serotonin, dopamine, and α-methylDopa, following 
α-methyldopamine formation, concomitantly with oxygen 
consumption (Bertoldi et al. 1996, 1998, 1999b; Bertoldi 
and Borri Voltattorni 2003). These reactions are accompa-
nied by enzyme inactivation through different pathways, 
mechanism-based (Bertoldi et al. 1996) or affinity labeling 
(Bertoldi et al. 1998) due to the covalent binding of the car-
bonyl product to the PLP coenzyme. This inactivation was 
interpreted as a possible regulation of DDC concurring in 
exacerbating oxidative stress conditions (see below). The 
proposed mechanism for oxidative deamination starts with 
PLP forming an external aldimine with the aromatic amine 
that is subsequently deprotonated, giving a quinonoid spe-
cies accessible to oxygen, then forming the carbonyl com-
pound, ammonia, and consuming oxygen. A small amount 
of PMP was produced, so the occurrence of the decarbox-
ylation-dependent transamination (also called abortive 
transamination in some papers) was not excluded (Fig. 3a). 
It was also assessed that, in the absence of oxygen, aromatic 
amines undergo a half-transamination reaction (Bertoldi and 
Borri Voltattorni 2003), whereas α-methyldopa underwent 
the decarboxylation-dependent transamination (Bertoldi and 
Borri Voltattorni 2000), leading, in both cases, to the conver-
sion of PLP into catalytically inactive PMP and a stoichio-
metric amount of the aldehyde/ketone. Thus, DDC has the 
ability to protonate the quinonoid intermediate at C4′ and 
not only at Cα (Fig. 3a). 
It has also been demonstrated that the main decarboxyla-
tion reaction of DDC is somewhat sensitive to oxygen, since 
in its absence, both kcat and Km for l-Dopa and L-5HTP are 
decreased and PMP is formed, due to a decarboxylation-
dependent transamination (Bertoldi and Borri Voltattorni 
2000), reinforcing a possible regulation mechanism exerted 
by  O2. Until these findings, DDC was supposed to catalyze 
only paracatalytic reactions with oxygen.
In this complex picture, it was unexpected that muta-
tion of Tyr-332, a conserved residue, to phenylalanine 
transforms DDC into a decarboxylation-dependent oxi-
dative deaminase, that is an enzyme not able to catalyze 
amine formation, rather Y332F reacts with oxygen and 
forms 3,4-dihydroxyphenylacetaldehyde (DHPAA or 
DOPAL) and ammonia (Fig. 3b) pointing out a catalytic 
role for Tyr-332 in the main decarboxylation mechanism 
as the residue responsible for the Cα protonation (Ber-
toldi and Voltattorni 2001; Bertoldi et al. 2002). This resi-
due belongs to a mobile loop of DDC presumed to play 
important roles in the activity of the enzyme, since it is 
Fig. 3  Main and paracatalytic 
reactions of Dopa decarboxy-
lase. a The reactions catalyzed 
by wild-type (WT) DDC under 
aerobic and anaerobic condi-
tions; b the reactions catalyzed 
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predicted to cover the active site as a lid positioning essen-
tial residues in a proper orientation and microenvironment 
useful for catalysis (Paiardini et al. 2017). Under anaero-
bic conditions, the reaction of the Y332F DDC with its 
substrates immediately converts PLP into PMP (Bertoldi 
et al. 2002). These observations pushed the investigation 
towards the identification of intermediates of the oxygen-
consuming reaction catalyzed by DDC. A substrate analog, 
d-tryptophan methyl-ester, that mimics the position of the 
α-proton of the aromatic amines with its stereospecificity, 
allowed the identification and validation of a quinonoid 
species as an intermediate of the oxidative deamination 
reaction (Bertoldi et al. 2005), thus confirming what was 
hypothesized by Abell and Schloss about the reactivity of 
the carbanionic intermediate with oxygen. The step for-
ward has been to elucidate what happens in the steps fol-
lowing oxygen binding to the quinonoid. An insight came 
from further investigations leading to the identification 
and characterization of other intermediates of the oxidase 
activity, so that a chemical mechanism could be advanced 
(Bertoldi et al. 2008), where it emerged how oxygen is 
able to control the equilibrium among reaction intermedi-
ates of DDC.
Overall, a reaction mechanism of DDC with  O2 has 
been finally accepted (Fig.  5) (Bertoldi et  al. 2008). 
Once the external aldimine is formed, decarboxylation or 
deprotonation takes place leading to a quinonoid species 
in equilibrium with a ketimine species that forms upon 
reprotonation to C4′. The presence of oxygen controls 
this equilibrium in favor of the quinonoid species that is 
attacked by  O2 giving rise to a radical one-electron transfer 
and forming superoxide anion and semiquinone. Superox-
ide couples with semiquinone generating a hydroperoxide 
species. From this intermediate, the products of the reac-
tion are then generated.
Fig. 4  Structures of substrates and products of DDC. Aromatic amino 
acid substrates of the decarboxylation reaction of DDC are on the 
left, aromatic amines products of decarboxylation and substrates of 
oxidative deamination are in the center, and aromatic aldehydes or 
ketones products of oxidative deamination are on the right. 5-HIA, 
5-hydroxyindoleacetaldehyde
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Other aromatic amino acid decarboxylases 
reactive towards oxygen: AADCs 
and aromatic aldehyde synthases (AAS)s
AADCs from other different sources (plants, mushrooms, 
and insects) are known, since these enzymes have evolved in 
many organisms yielding a number of paralogous enzymes 
with different substrate specificity and catalytic mechanisms 
(Facchini et al. 2000; Torrens-Spence et al. 2020).
The plant kingdom is particularly specialized, since plant 
AADCs, differently from those of mammals and insects, are 
characterized by a narrow substrate specificity, exhibiting 
a substrate preference for either phenol or indole amino 
acid, giving rise to l-tyrosine/l-dopa decarboxylases or to 
l-tryptophan decarboxylases (Noé et al. 1984; Facchini and 
De Luca 1994; Facchini et al. 2000). These enzymes, iso-
lated from a variety of plant species (Facchini et al. 2000), 
produce aromatic monoamines acting as precursors for many 
important natural products useful to plant metabolism. No 
activity towards oxygen has been reported for these enzymes 
(Fig. 6).
In 2006, a paper reported the identification of a tomato 
PLP-l-phenylalanine decarboxylase able to remove  CO2 
and produce phenethylamine, subsequently converted into 
Fig. 5  Reaction mechanism of 
oxidative deamination catalyzed 
by DDC. The substrates of the 
reaction with oxygen (both aro-
matic amino acids or amines) at 
first form an external aldimine 
that is subsequently decar-
boxylated (from amino acids) 
or deprotonated (from amines) 
to give the quinonoid that parti-
tions between C4′ protonation 
to give a ketimine that is in 
equilibrium with the quinonoid 
that could be attacked by oxy-
gen generating a radical pair, 
semiquinone, and superoxide 
anion, that form a hydroperoxy-
PLP intermediate responsible 
for the synthesis of the oxidative 
deamination products. R refers 
to the aromatic (cathecol or 
indole) moiety. (Adapted from 
(Bertoldi et al. 2008))
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phenylacetaldehyde by an identified enzymatic activity 
in the pathway of 2-phenylethanol, a compound essential 
to contribute to tomato flavor (Tieman et al. 2006). In the 
same year, the identification of rose and petunia phenylac-
etaldehyde synthase (PAAS) has been reported. These PLP-
dependent enzymes show high amino acid identity (about 
65%) with plant l-tyrosine/l-dopa decarboxylases and 
l-tryptophan decarboxylases, and directly convert l-phe-
nylalanine into phenylacetaldehyde by a decarboxylation 
followed by an oxidative deamination, consuming oxygen 
without accumulation of the amine (Kaminaga et al. 2006). 
Other aromatic aldehyde synthases (AAS) have been iden-
tified and characterized in the following years, even if it 
should be mentioned that, originally, these enzymes have 
been annotated as aromatic amino acid decarboxylases and 
not accurately investigated (Fig. 6). Then, it was assessed 
that PAAS enzymes represent a subgroup of l-tyrosine/l-
dopa decarboxylases (Torrens-Spence et al. 2012), exhibit-
ing high activity not only with l-phenylalanine but also with 
l-dopa and l-tyrosine: Arabidopsis PAAS seems to play a 
role in wounding/herbivory response and flower scent pro-
duction (Gutensohn et al. 2011), while parsley PAAS syn-
thesizes 4-hydroxyphenylacetaldehyde to enhance its stress/
defense response (Torrens-Spence et al. 2012) (Fig. 6).
In an elegant paper, Torrens-Spence and coauthors have 
demonstrated by site-directed mutagenesis that a true AADC 
could be converted into AAS and vice versa by changing the 
chemical identity of a conserved residue (Torrens-Spence 
et al. 2013). A role as a signature residue has been proposed 
for a tyrosine of the mobile loop near the active site (which 
aligns with tyrosine-332 of mammalian DDC) that can be 
substituted by a phenylalanine in AADC in different plants. 
Interestingly, the presence of tyrosine gives rise to decarbox-
ylases that produce aromatic amines, while that of phenylala-
nine gives decarboxylation-dependent oxidative deaminating 
enzymes (Torrens-Spence et al. 2013), reminiscent of the 
switch in activity displayed by the Y332F mammalian DDC 
(Bertoldi et al. 2002). The tyrosine residue has been sug-
gested not to directly protonate the α-carbon to generate the 
amine product as it does for the mammalian DDC (Bertoldi 
et al. 2002); rather, it has been proposed that an active site 
histidine forms an hydrogen bond with the loop tyrosine that 
plays an indirect role in stabilizing the histidine side chain to 
the protonation of the α-carbon (Torrens-Spence et al. 2013). 
This is not the case for mammalian DDC, since mutation of 
the same histidine (His-192) to asparagine leads to a vari-
ant able to perform both decarboxylation with production of 
amine and decarboxylation-dependent oxidative deamination 
of aromatic amines (Bertoldi et al. 2001).
Insects use dopamine, in addition to its role as a neu-
rotransmitter, in metabolic processes leading to cuticle 
sclerotization. In this context, AADC enzymes (Fig. 6) are 
known to play an important role. However, AADC from 
Aedes aegypti, with 70% sequence homology with the mam-
malian enzyme, has been demonstrated to catalyze the direct 
oxidation of l-dopa to 3,4-dihydroxyphenylacetaldehyde 
(DHPAA or DOPAL) bypassing dopamine formation, and 
is thus classified as DHPAA synthase (DHPAAS) (Vavricka 
et al. 2011). The role of aromatic aldehyde formation could 
be related to cross-linking complexes involved in cuticle 
hardening.
The mechanism of Drosophila DHPAAS has been exten-
sively investigated and a catalytic role to the active site resi-
due Asn-192 has been proposed, since its change to histidine 
leads to the partial conversion of DHPAAS to a classical 
decarboxylase (amine formation) rather to aldehyde syn-
thase. On this basis, His-192 in AADCs of insects has been 
appointed as the residue responsible for quinonoid α-carbon 
protonation. However, since the mutational analysis did not 
give rise to enzymatic species completely devoid of one of 
Fig. 6  Plant AADCs and AASs. 
Plant AADCs are special-
ized enzymes clustered in two 
groups: l-tryptophan decarbox-
ylases producing tryptamine and 
l-tyrosine/l-dopa decarboxylase 
producing tyramine/dopamine. 
A different group probably orig-
inating from l-tyrosine/l-dopa 
decarboxylases identifies AASs 
such as PAAS and DHPAAS 
converting aromatic amino 
acids into the corresponding 
aromatic aldehydes, ammonia 
and hydrogen peroxide, and 
consuming oxygen
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the two activities, the real effect of this residue (histidine or 
asparagine) appears difficult to be precisely defined (Liang 
et al. 2017).
In fungi, a few papers refer to AADC activity (Fig. 6), 
mainly related to the decarboxylation of l-tryptophan (Kalb 
et al. 2016). An in-depth investigation has been carried out 
in Psilocybe cubensis, a mushroom responsible for psycho-
active alkaloid psilocybin synthesis, revealing the presence 
of both a DHPAAS with a phenylalanine instead of a tyros-
ine in the catalytic loop and an AADC-like protein (similar 
to plant l-tryptophan decarboxylases) (Torrens-Spence et al. 
2018). Interestingly, in this AADC enzyme, a regulation by 
calcium ion was reported. (Torrens-Spence et al. 2018).
The reactivity of other fold‑type I PLP 
decarboxylases with oxygen
In the same years, it was demonstrated that among PLP 
enzymes, the PLP-dependent decarboxylases are particu-
larly able to perform oxidative reactions with  O2, in addi-
tion to their main reaction, maybe for their intrinsic pos-
sibility of exchanging  CO2 with  O2. It is not unprecedented 
that, just like RuBisCO, an enzyme able to exchange a gas 
like  CO2 could be prone to accept  O2, even this does not 
justify its reactivity.
By the way, fold-type I (or a-aspartate aminotransferase 
family) (Grishin et al. 1995) amino acid decarboxylases 
[that from an evolutionary point of view are clustered in 
Group II α-decarboxylases (Sandmeier et al. 1994)] are 
responsible for the synthesis of essential biomolecules, 
such as polyamines and hypotaurine, or neurotransmit-
ters, such as dopamine, serotonin, and γ-aminobutyric acid 
(GABA) (Paiardini et al. 2017). They comprise aromatic 
amino acid, glutamate, and histidine decarboxylases from 
all sources together with the prokaryotic ornithine and 
lysine decarboxylases.
The main activities played by these enzymes together 
with the new oxidase reactions are reported in Fig. 7. E. 
coli glutamate decarboxylase (GAD), in addition to the 
decarboxylation of l-glutamic acid into GABA, trans-
forms glutamate to succinic semialdehyde (Abell and 
Schloss 1991) and α-methylglutamate to levulinic acid 
(Bertoldi et al. 1999a) (Fig. 7a). There are some signs 
that corroborate the possibility for both human GAD65 




Fig. 7  Reactions of PLP α-decarboxylases. a GAD with l-glutamic acid and a-methylglutamate, b ODC with l-ornithine and α-methylornithine, 
and c LDC with l-lysine
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produces succinic semialdehyde from glutamate, even if 
it was not demonstrated that oxygen is required (Choi and 
Churchich 1986; Bunik et al. 2011).
Ornithine decarboxylase (ODC) from different prokar-
yotic sources, such as Lactobacillus 30a or Hafnia alvei, 
has been demonstrated to catalyze, in addition to putres-
cine formation, a decarboxylation-dependent oxidative 
deamination (Bertoldi et al. 1999a; Sakai et al. 1997) 
of both ornithine and α-methylornithine, in a reaction 
directly converting the amino acid into the corresponding 
carbonyl compound and ammonia, without accumulation 
of the amine (Fig. 7b).
An l-lysine decarboxylase (LDC) from Burkholde-
ria sp. AIU 395 has also been found to catalyze both 
α-decarboxylation, giving cadaverine, and an oxidative 
ε-deamination, giving L-2-aminoadipic 5-semialdehyde 
(Sugawara et al. 2014) (Fig. 7c).
Biological roles of oxidative side reactions 
of human PLP‑dependent decarboxylases
The interpretation given for the  O2 interaction of PLP-
dependent decarboxylases can be at least partially linked 
to pathological states or to a physiological regulation of 
the activities of some important brain enzymes (Fig. 8). It 
may be discussed if this catalytic activity could represent a 
mechanism of regulation of neurotransmitter synthesis or 
catabolism, and this fact could be of particular interest for 
diseases characterized by a dysregulation in neurotransmit-
ters, such as Parkinson’s Disease, AADC deficiency, pyri-
doxine oxidase-related epilepsy, and oxygen-induced sei-
zures. The interplay of PLP decarboxylases with dioxygen 
may be involved in and regulate oxidative/metabolic stress 
in human brain diseases (Bunik et al. 2007). In addition, 
a survey regarding oxidative paracatalytic reactions cata-
lyzed by enzymes able to form carbanionic intermediates, 
Fig. 8  Oxidative reactions played by mammalian PLP decarboxy-
lases and their possible interplay. The metabolic pathways of aro-
matic amino acids and amine metabolism start with hydroxylation 
performed by tryptophan and tyrosine hydroxylase on the corre-
sponding amino acids, and then, AADC decarboxylates L-5HTP and 
L-dopa to the corresponding amines serotonin and dopamine that in 
the presence of oxygen are oxidatively deaminated to the correspond-
ing aromatic aldehydes, 5-HIA and DOPAL. Oxygen also influences 
mammalian GAD and CSAD activity by inhibiting these enzymes. 
Altogether, oxidative products (carbonyl compounds and ROS) could 
concur in exacerbating oxidative stress conditions and contributing to 
worsen neurodegeneration and cell damages. Monoamine oxidase is 
the known enzyme deputed to oxidase amine to aldehyde in an FAD-
dependent manner. In black, amino acids amines and metabolic path-
ways, in red oxygen-related reactions, and in blue the name of the 
enzymes
Oxygen reactivity with pyridoxal 5′-phosphate enzymes: biochemical implications and…
1 3
including also some PLP-dependent enzymes, appeared in 
2011 (Bunik et al. 2011). In this review, the authors pointed 
out the effects exerted by these side reactions involving oxy-
gen especially in neurodegeneration and cancer. Regarding 
PLP enzymes, Bunik et al. highlighted that human AADC’s 
ability to produce DHPAA/DOPAL, even possibly increased 
in altered forms of the enzyme, can result in pathology due 
to the known neurotoxicity of this compound, linked to Par-
kinson’s disease neurodegeneration of the substantia nigra 
neurons (Burke et al. 2003). DOPAL neurotoxicity mecha-
nisms, indeed, included DOPAL-α-synuclein cross-linked 
oligomerization (Follmer et al. 2015) as well as extensive 
DOPAL-induced protein-quinone adduct formation (“qui-
nonization”) and protein oligomerization, ubiquitination, 
and aggregation (Jinsmaa et al. 2018). Also 5-hydroxyin-
dolacetaldehyde (5-HIA), produced by mammal AADC 
from serotonin ((Bertoldi et al. 1996), was demonstrated to 
promote α-synuclein oligomerization both in vitro and in a 
synuclein-overexpressing cell model, in a manner similar to 
DOPAL (Jinsmaa et al. 2015), possibly explaining the early 
degeneration of dorsal raphe nuclei serotonergic neurons in 
Parkinson’s disease. Interestingly, among DOPAL-modified/
inhibited targets, tyrosine hydroxylase (TH) shows a semi-
reversible mechanism with consequent decrease in overall 
L-Dopa production, but a time- and concentration-depend-
ent TH activity recovering was observed upon removal 
of DOPAL (Mexas et al. 2011). This DOPAL-dependent 
reversible inhibition of TH could provide a new perspective 
in AADC ability to perform oxidative deamination, link-
ing this side reaction to a possible physiological feed-back 
mechanism by which a minor AADC product can regulate 
l-dopa production targeting the rate-limiting enzyme in the 
dopamine synthetic pathway.
Both human recombinant GAD65 and GAD67 were 
shown to be potently and reversibly inhibited by molecular 
oxygen. In particular, GAD65-O2 dependent inhibition has 
been linked to the genesis of oxygen-induced seizures (Davis 
et al. 2001) by limiting GABA production and loading in 
vesicles (Hsu et al. 1999) and in the pathogenesis of type I 
diabetes mellitus (Trigwell et al. 2001). On the other side, 
the isoform GAD67 was shown to be related with convul-
sions induced by hyperbaric oxygen exposure both in vivo 
and in vitro (Li et al. 2008).
Like GAD65, also cysteine-sulfinic acid decarboxylase 
(CSAD) has been reported to be responsive to reversible 
inhibition by  O2 (Davis et al. 2001) (Fig. 8). Cysteine sulfinic 
acid decarboxylation product hypotaurine is then oxidized 
to taurine by an oxygenase, with the latter compound shown 
to be especially important in central nervous system, where 
it plays a wide range of different roles (Menzie et al. 2014) 
and is linked to early retinal degeneration (Preising et al. 
2019). As such, inhibition of CSAD by  O2 could contribute 
to retinal damage pointed out in premature infants exposed 
to high  O2 levels at birth (Jewell et al. 2001). Noteworthy, 
these two decarboxylases are also inhibited by nitric oxide 
(Davis et al. 2001), another radical-containing compound 
as dioxygen, suggesting a possible radical mechanism in the 
inhibition. Reactions with species such as  O2 or NO could, in 
fact, proceed through a one-electron stepwise transfer even-
tually leading to radical intermediates, as mentioned before.
The interaction of PLP-dependent decarboxylases with 
molecular oxygen opens the way to the possibility that these 
enzymes could be strongly involved in oxidative damage, 
since the oxidase activity is linked to the concomitant pro-
duction of hydrogen peroxide (Bunik et al. 2007). In this sce-
nario, an enzyme producing ROS and carbonyl compounds 
could exacerbate oxidative stress conditions (Bunik et al. 
2007). Moreover, it cannot be excluded that the proven sen-
sitivity to or interaction with oxygen of these PLP-depend-
ent decarboxylases could be extended to ROS compounds, 
underlying the possibility that these enzymes can be inacti-
vated and/or form ROS-driven adducts with other proteins, 
and the consequent necessity of monitoring them as targets 
of ROS themselves. A broader effect of the oxidative reac-
tions of PLP-dependent decarboxylases, responsible for 
neurotransmitters synthesis, could be the interplay between 
ROS and the important modulator nitric oxide which, in 
turn, leads to the production of nitrogen reactive species 
contributing to nitro-oxidative stress. Its synthesis and regu-
lation involves a network of pathways that should be taken 
into consideration (Persichini et al. 2016).
The emerging question is how the propensity to react 
with oxygen is linked to inhibition exerted by the products 
of the oxidative paracatalytic reactions and their regulation 
in PLP decarboxylases. Although it is not easy to address 
such issue, an important review (Schloss 2002) interprets the 
oxygenase reaction of GAD as a consequence of a possible 
radical character also of the main decarboxylation reaction 
of the enzyme gaining assistance also in the main activity 
played by the enzyme.
New PLP enzymes of fold‑type I are able 
to catalyze reactions involving  O2
In the last 5 years, a growth in papers reporting new oxygen-
consuming PLP enzymes has occurred. Most of them belong 
to the bacterial or fungal kingdoms and can be grouped by 
the fact that dioxygen is a substrate of their main reaction.
An excellent recent review gives extensive details about 
the oxidative reaction catalyzed by each one of these new 
enzymes (Hoffarth et al. 2020). In the present review, we 
will briefly review the activity catalyzed and the functional 
role.
Three of these new PLP enzymes have the common fea-
ture of acting on l-arginine as substrate and could catalyze 
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the four-electron oxidation of l-arginine, with a mechanism 
involving either an oxidation or a hydroxylation, that are 
similar oxidative pathways undergoing through different 
fates of the carbonyl products.
Streptomyces wadayamensis MppP is a PLP enzyme that 
catalyzes the hydroxylation and deamination of l-arginine 
consuming molecular oxygen and producing the carbonyl 
compounds 2-ketoarginine and 2-keto-3,4-dehydroarginine 
in a 1:1.7 ratio (Fig. 9) (Han et al. 2015). The latter is an 
essential guanidino acid for the synthesis of bioactive pep-
tides such as l-enduracididine (Han et al. 2015), which is a 
cyclic analog of arginine found in several antimicrobial pep-
tides useful for treatment of drug-resistant pathogens. The 
structure of MppP reveals that it is a homodimer, belonging 
to the fold-type I of PLP enzymes, as the a-decarboxylases 
reported above, with the active sites present at the inter-
face between the two subunits; however, unlike other ami-
notransferase family enzymes, in MppP, the contribution of 
the opposite chain to each active site is minimal (Han et al. 
2015). An in-depth analysis of the catalytic activity of this 
enzyme was published subsequently (Han et al. 2018) and 
reported the exact stoichiometry of all products formed. A 
refined chemical mechanism of this PLP-driven oxidase 
activity together with a structural analysis was proposed, 
highlighting the role of the N-terminus switching from an 
ordered to a disordered state during binding/catalysis.
Another PLP enzyme, RohP, contributes to the biosyn-
thesis pathway of azomycin (Hedges and Ryan 2019) and 
acts on l-arginine catalyzing an oxygen-consuming reac-
tion leading to both hydroxylation and deamination (Fig. 9) 
(Hedges et al. 2018). RohP is from Streptomyces cattleya 
and presents a high sequence identity with both MppP and 
Ind4 (see below) (Hedges et al. 2018). From a functional 
point of view, RohP acts similarly to MppP, forming an iden-
tical product, i.e., a hydroxylated ketoacid.
Finally, Streptomyces griseus Ind4, a PLP enzyme of 
the indolmycin biosynthetic pathway catalyzing a reaction 
similar to those of MppP and RohP, thus converts l-arginine 
into an oxidized product (Du et al. 2016). The peculiarity 
of this reaction is that Ind4 forms a C = C bond rather than 
a carbonyl hydroxylated compound as do MppP and RohP 
(Fig. 8) even if 2-ketoarginine is produced.
Another PLP enzyme capable of consuming molecular 
oxygen is E. coli CcbF. It belongs to the metabolic path-
way of lincosamide antibiotics, compounds that act on the 
large subunit of bacterial ribosomes blocking protein syn-
thesis (Wilson 2014). In this process, CcbF catalyzes the 
transformation of a cysteine S-conjugate into an aldehyde 
with co-production of carbon dioxide, hydrogen peroxide, 
and ammonia in the presence of molecular oxygen which is 
concomitantly consumed (Fig. 10) (Wang et al. 2016). In 
this sense, the enzyme is more similar to a decarboxylation-
dependent oxidative deaminase rather than to an enzyme 
that oxidizes an inactivated carbon–carbon bond (Wang et al. 
2016).
The following three enzymes have been classified as 
catalyzing a decarboxylating oxygenation (Hoffarth et al. 
2020); however, some differences should be pointed out. 
PvdN is a PLP enzyme of Pseudomonas involved in pyo-
verdine biosynthesis. From a structural point of view, it 
Fig. 9  Main reactions catalyzed by other PLP-dependent enzymes, MppP, RohP, and Ind4, in the presence of l-arginine
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belongs to the fold-type I of PLP enzymes (Drake and 
Gulick 2016). A recent investigation on its functional 
role suggests that it catalyzes the decarboxylation of its 
substrate generating a quinonoid intermediate that sub-
sequently undergoes an oxygenase reaction leading to the 
products through a hydroperoxide species (Fig. 10) (Rin-
gel, Dräger and Brüser 2016). The spatial structure shows 
two tunnels from each active site to the protein surface: 
a larger one accommodating the substrate and a narrower 
one for the possible exchange of  CO2 and  O2 (Drake and 
Gulick 2016). In no other structure of decarboxylases, 
catalyzing a decarboxylation and a successive oxygena-
tion has such a channel been identified.
Cap15 is a Streptomyces PLP-dependent a-amino acid 
monooxygenase–decarboxylase acting in the biosynthetic 
pathway of capuramycins, a class of antimycobacterial anti-
biotics (Huang et al. 2018). The reaction catalyzed is the 
conversion of the unusual b-hydroxy-a-amino acid 5′-C-gly-
cyluridine (GlyU) into the related carboxamide product 
CarU (Fig. 10). The novelty of such activity is that the cata-
lytic mechanism proceeds by at first the deprotonation of 
the external aldimine intermediate, followed by oxygena-
tion of the quinonoid species, generating a radical pair of 
hydroperoxy-PLP superoxide anion finally generating water 
and carbon dioxide (Huang et al. 2018), thus exclusively 
for this enzyme, decarboxylation occurs after oxygenation.
Recently, a new PLP enzyme, CuaB, has been identified 
in the gene cluster for the synthesis of an indolizidine alka-
loid, curvulamine, in fungi (Dai et al. 2020), underlining 
the fact that the reactivity of PLP enzyme with oxygen is a 
widespread feature. CuaB is a bifunctional enzyme: it cata-
lyzes the formation of C–C bonds through Claisen condensa-
tion, as other PLP enzymes are able to do, such as 8-amino-
7-oxononanoate synthase and, unexpectedly, a hydroxylation 
using dioxygen (Fig. 10). A detailed enzyme mechanism 
has been proposed on the basis of the collected products 
(Dai et al. 2020). The external aldimine with the substrate 
is deprotonated to generate a quinonoid that follows the 
pathway of synthases (Fig. 1). Once the external aldimine 
with the product is formed, it is decarboxylated generat-
ing a second quinonoid reactive towards oxygen forming a 
hydroperoxide that is converted into a hydroxylated product 
and water. Interestingly, this sequential reaction with the 
product is reminiscent of the activities of DDC with seroto-
nin, dopamine, and α-methyldopamine (Bertoldi et al. 1996, 
1998, Bertoldi and Borri Voltattorni 2003).
The identification of these enzymes mainly in Pseu-
domonas and Streptomyces is perhaps related to investiga-
tions on bioactive compounds and it can be hypothesized 
that many other PLP enzymes are dispersed in the living 
kingdoms whose activities are still unrecognized. The 
ability to couple PLP and oxygen chemistry not only for 
Fig. 10  Main reactions cata-
lyzed by other PLP-dependent 
enzymes on bioactive com-
pounds. a CcdF on a cysteine-
S-conjugate, b Cap15 on GlyU, 
c PvdN, and d CuaB on more 
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paracatalytic reactions but also in main enzymatic reactions 
broadens PLP-enzyme functional ability and paves the way 
for further studies.
A structural basis for oxygen reactivity 
of decarboxylases
This review points out that the reactivity with dioxygen, at 
first considered as a mere artifact of the carbanionic chem-
istry of some PLP decarboxylases, is more common than 
expected. From a structural point of view, it seems to be 
related not only to decarboxylases, but also to other fold-type 
I enzymes: however, it should be noticed that the majority 
of PLP enzymes consuming oxygen catalyze a decarboxyla-
tion reaction. While an oxidase activity could be related to 
a regulation role or alteration of the physiological state in 
mammalian or plant decarboxylases, it is not easy to envis-
age a role in other organisms such as bacteria or fungi. Lit-
erature on this topic is still lacking, maybe due to recent 
identification of such oxygen-consuming activities in PLP 
enzymes of these organisms.
The fact that this oxidase activity remains confined to 
enzymes of the aminotransferase family could be due, on 
one hand, to the fact that this family is the most abundant 
among PLP enzymes, on the other, to the fact that fold-type 
I enzymes could possess some structural element or active 
site conformation more prone to oxygen entrance.
There is as yet no evidence for oxygen-dependent reac-
tions in the fold-type III decarboxylases, a large group con-
taining eukaryotic lysine, eukaryotic ornithine, prokaryotic 
and eukaryotic arginine, and prokaryotic diaminopime-
late decarboxylases (Grishin et al. 1995). Oxygen is not 
reported to react with PLP enzymes even belonging to other 
fold-types.
It could be interesting to compare the structural differ-
ences of the solved spatial arrangements of prokaryotic 
(Momany et al. 1995) and eukaryotic ODC (Kern et al. 
1999) as prototypes of fold-type I and III decarboxylases, 
respectively. One of the main differences is the orientation 
of the reactive group on the external aldimine with respect 
to the buried or exposed face of the cofactor. In fold-type I 
enzymes, the lysine residue forming the internal aldimine 
is on the si face buried in the interior of the protein, while 
the opposite re face is exposed. When this intermediate is 
converted into the external aldimine, the carboxylate moi-
ety protrudes on the buried si face and reaction then pro-
ceeds. Instead, in fold-type III enzymes, the coenzyme has 
a mirrored position and the lysine of the internal aldimine 
is buried on the re face of the cofactor, while the si face is 
exposed. The external aldimine thus presents the  CO2 on the 
exposed si face (Kern et al. 1999). This fact has been linked 
to stereospecificity of catalysis (Kern et al. 1999); however, 
it can be argued that dioxygen could bind and react better in 
a buried active site. A second structural feature is the dimer 
stability much higher in fold-type I ODC than in fold-type 
III ODC (Kern et al. 1999).
An elegant example of enzymes catalyzing the same reac-
tion but belonging to different fold-types is also found in 
transaminases. The L-amino acid transaminases belong to 
fold-type I, while d-amino acid transaminase belong to fold-
type IV (Grishin et al. 1995) and the differences are the PLP 
location in the active site and the dimer assembly (Humble 
et al. 2012).
From a functional point of view, there is evidence that 
diaminopimelate decarboxylase and d-ornithine/d-lysine 
decarboxylase have a concerted decarboxylation/protonation 
step, ruling out the quinonoid intermediate formation (Fogle 
and Toney 2011; Phillips et al. 2019). This could explain 
the lack of  O2 reactivity. However, the structural determi-
nants responsible of this concerted step are presently still 
unknown. Whatever the structural difference could be, the 
identification in PvdN of the putative  O2 tunnel could foster 
re-evaluation of already deposited structures of decarboxy-
lases for the presence of any potential channels.
Conclusions
The oxygen reactivity of PLP enzymes could be of great 
physiological interest, given the fact that it seems typical of 
enzymes producing important neurotransmitters or neuro-
modulators, whose effect could be greatly affected by redox 
conditions. Following this view, it would be interesting to 
further investigate the influence of oxygen on activity and 
inhibition of these enzymes.
The new biosynthetic pathways described in the last few 
years, mainly in bacteria and fungi, increase the evidence 
of the high catalytic versatility of PLP enzymes in nature. 
These activities have been generally identified by the fol-
lowing genome sequence-based survey. The approach of 
characterizing the potentially diverse activities arising from 
the ductile nature of PLP chemistry would allow access to 
unpredictable new biological processes.
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ABSTRACT: Histidine decarboxylase is a pyridoxal 5′-phosphate enzyme
catalyzing the conversion of histidine to histamine, a bioactive molecule exerting
its role in many modulatory processes. The human enzyme is involved in many
physiological functions, such as neurotransmission, gastrointestinal track function,
cell growth, and differentiation. Here, we studied the functional properties of the
human enzyme and, in particular, the effects exerted at the protein level by two
cysteine residues: Cys-180 and Cys-418. Surprisingly, the enzyme exists in an
equilibrium between a reduced and an oxidized form whose extent depends on the
redox state of Cys-180. Moreover, we determined that (i) the two enzymatic redox
species exhibit modest structural changes in the coenzyme microenvironment and
(ii) the oxidized form is slightly more active and stable than the reduced one. These
data are consistent with the model proposed by bioinformatics analyses and
molecular dynamics simulations in which the Cys-180 redox state could be
responsible for a structural transition affecting the C-terminal domain reorientation leading to active site alterations.
Furthermore, the biochemical properties of the purified C180S and C418S variants reveal that C180S behaves like the reduced
form of the wild-type enzyme, while C418S is sensitive to reductants like the wild-type enzyme, thus allowing the identification
of Cys-180 as the redox sensitive switch. On the other hand, Cys-418 appears to be a residue involved in aggregation propensity.
A possible role for Cys-180 as a regulatory switch in response to different cellular redox conditions could be suggested.
Histidine decarboxylase (HDC, EC 4.1.1.22) is a pyridoxal5′-phosphate (PLP) enzyme that is responsible for the
conversion of histidine to histamine. Histamine plays
important roles in gastric acid secretion and immune responses
and is also involved in cell growth, memory, appetite, and
circadian rhythm regulation.1 Impairment of histamine
metabolism leads to multiple pathological states such as
inflammatory responses, peptic ulcer, and several central
nervous system disorders.2,3
From an evolutionary and structural point of view, HDC
belongs to group II PLP-decarboxylases of fold type I. A recent
review summarizes the spatial and functional correlations
among the enzymes that belong to this group.4 Although the
prokaryotic HDC enzymes are mainly pyruvoyl-dependent
(with the exception of a few Gram-negative bacteria such as
Morganella morganii together with some Enterobacter and
Klebsiella species), the eukaryotic, and thus the mammalian
and human, enzymes are PLP-dependent. E. E. Snell and co-
workers cloned, purified, and characterized the prokaryotic
PLP HDCs.5−11Today, apart from a few mechanistic papers,12
these prokaryotic decarboxylases are mainly studied for their
role in contamination of food, especially fish, to find possible
inhibitors that could prevent histamine accumulation.13−15
Mammalian HDC, which is different from the other
homologous enzymes such as aromatic amino acid decarbox-
ylase or glutamate decarboxylase,4 has been poorly charac-
terized until now, given its small quantities in the cell types
where it is expressed: mast cells, a group of hypothalamic
neurons, and enterochromaphin-like cells.16,17 Indeed, its level
is generally scarce also when it is cloned and expressed as a
recombinant protein in bacterial systems. Moreover, the rat
and mouse proteins, translated as 74 kDa inactive precursors,
are very unstable and subjected to post-translational processing
at the N- and C-termini.18,19The cleaved forms are active and
range from 53 to 64 kDa, as seen in different cell
types.20−27The minimum required for activity is 53 kDa,28
which corresponds to the homologous domain of other PLP-
decarboxylases. The mechanism of processing has been
attributed to various systems such as calpains, proteasome,
and caspase-9,22,23,29−31 but it is far from being exhaustively
elucidated.
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Besides its role in histamine production, HDC is now
attracting attention because of its involvement in the cell
proliferation of many tumors and in Tourette syndrome.
Among tumors, cholangiocarcinoma is difficult to diagnose and
has limited treatments being chemoresistant.32,33 Surgical
resection, the treatment of choice in such a case, is not always
feasible given frequent late diagnosis.34 Recently, it has been
demonstrated that HDC expression is enhanced in cholangio-
carcinoma, and the increased level of histamine secretion is
related to tumor growth.35 Treatment with an inhibitor of
HDC, namely α-methyl-D,L-histidine, decreases HDC activity
and slows cancer progression.35,36 A few inhibitors of HDC
have been further explored,4 such as α-fluoromethylhistidine,37
histidine methylester,37 epigallocatechin gallate,38 and 4(5)-
aminooxymethylimidazole,39 however with no direct clinical
results.
Tourette syndrome, a developmental neuropsychiatric
disorder, has been linked to a mutation, present in
heterozygosis, in the Hdc gene. This gives rise to a deleted
protein (W317X) with no decarboxylase activity.40 However,
despite contradictory reports, it has been recently confirmed
both in humans and in Hdc knockout (KO) mouse models that
HDC deficiency represents a rare cause of Tourette syndrome
and that histamine−dopamine interconnections in the basal
ganglia are an important knot of pathology.41 This monoamine
interplay has recently been reviewed by Pittenger.42
KO mice, generated in 2001,43 gave insights into previously
unknown pathophysiological functions of histamine, expanding
its roles from taking part in allergic and neurological responses
to being involved in different fields such as cardiology,
immunology, and infectious diseases.2
The three-dimensional structure of active human HDC
(residues 2−477) in complex with the inhibitory substrate
analogue histidine methylester was determined in 2012 using
an enzymatic form bearing a double-amino acid substitution
(C180S and C418S) to increase protein stability and prevent
nonspecific aggregation.44,45 In the functionally active dimeric
arrangement, Cys-180 belongs to the large domain of each
monomer that is responsible for dimeric interface formation
and faces near to the corresponding Cys-180 of the other
monomer, while Cys-418 is located at the surface of the C-
terminal small domain far from the other subunit. It has been
demonstrated that the catalytic efficiency of the doubly
substituted enzyme is not altered compared to that of the
wild-type (WT) enzyme45 with measured kcat values 10-fold
higher than the kcat values reported for most mammalian
HDCs (<0.1 s−1).46 A possible role for a regulation played by
the redox state and/or by calcium levels was advanced.46
Here, we show, for the first time, that human WT HDC
exists as an equilibrium between a cysteine-reduced (redHDC)
and cysteine-oxidized (oxHDC) form. These two species
exhibit slight structural and functional differences. In addition,
we show that Cys-180 is responsible for the intermolecular
disulfide-bound dimer (oxHDC) and provide insight into its
properties, while Cys-418, in agreement with ref 44, could be
involved in the propensity of HDC to aggregate.
■ MATERIALS AND METHODS
Materials. Pyridoxal 5′-phosphate (PLP), L-histidine (L-
His), 2,4,6-trinitrobenzene-1-sulfonic acid (TNB), isopropyl β-
D-thiogalactopyranoside (IPTG), protease inhibitor cocktail
EDTA-free tablets, phenylmethanesulfonyl fluoride (PMSF),
2,4,6-trinitrobenzenesulfonic acid (TNB), 1,8-anilinonaphtha-
lenesulfonic acid (ANS), dithiothreitol (DTT), β-mercaptoe-
thanol (β-MeSH), glutathione (GSH), and all the other
chemicals and reagents were purchased from Sigma-Aldrich
and were of the highest purity available. The gene encoding
human HDC was purchased from ORIGENE.
Multiple-Sequence Alignment of HDCs. Amino acid
sequences from various sources were taken from the NCBI
Web site (https://www.ncbi.nlm.nih.gov/) and aligned using
the Clustal Omega tool (http://www.ebi.ac.uk/Tools/msa/
clustalo/) keeping all parameters at their default values.
Plasmid Constructs. The gene encoding human HDC,
carried by mammalian expression vector pCMV6, was
amplified to obtain the gene sequence corresponding to the
amino acid sequence Met-2−Cys-479, followed by the
thrombin protease cleavage site. In addition, the restriction
sites for the enzymes NdeI and XhoI were inserted upstream
and downstream, respectively, for subcloning the modified
HDC gene sequence upstream of the six-His tag into bacterial
expression plasmid pET28a. The designed and synthesized
(Eurofins Genomics) primers were 5′-AGGGACCATGGGC-
ATGGAGCCTGAGGAGTACAGA-3′ for the forward primer
and 5′-ATTTACTCGAGGGATCCACGCGGAACCAGAC-
AGTGCTGACTCAGGAT-3′ for the reverse primer (the
NdeI and XhoI restriction sites are underlined in the forward
and reverse primers, respectively, while the thrombin cleavage
site is shown in bold).
The C180S and C418S variants were constructed starting
from the cloned gene in the pET28a expression vector.
Mutations were introduced by the QuickChange site-directed
mutagenesis kit (Agilent Technologies) using the oligonucleo-
tides 5′-GCTGATGAGTCCAGCCTAAATGCCCGA-3′ and
its complement and 5′-GGGTCCTAATAGTCTCACAGAA-
AATGTG-3′ and its complement for C180S and C418S,
respectively (the mutated codons are underlined) (Eurofins
Genomics). The correct nucleotide sequences of the constructs
were confirmed by DNA sequencing (BMR Genomics).
Expression and Purification. Escherichia coli BL21 (DE3)
chemically competent cells were transformed by heat shock at
42 °C with the appropriate construct and grown in 6 L of
Luria-Bertani (LB) broth supplemented with 35 mg/mL
kanamycin. The cultures were grown at 37 °C to an OD600
of 0.4−0.6, and expression was induced with 0.5 mM IPTG for
15 h at 30 °C. Cells were harvested and resuspended in 20 mM
sodium phosphate buffer (pH 7.4) containing 0.5 M NaCl, 20
mM imidazole, 50 μM PLP, 0.5 mM PMSF, and protease
inhibitor cocktail, with the addition of 10 mM β-MeSH.
Lysozyme was then added to a concentration of 0.2 mg/mL,
and the culture was incubated for 20 min at room temperature.
After a freeze−thaw cycle, leupeptin (1 μg/mL) and pepstatin
(1 μg/mL) were added, and the suspension was centrifuged at
30000g for 30 min. The cleared lysate was diluted to ∼30 mg/
mL and loaded onto a HisPrep FF 16/10 column (GE
Healthcare) equilibrated with 20 mM sodium phosphate buffer
(pH 7.4) containing 0.5 M NaCl and 20 mM imidazole in the
presence of 10 mM β-MeSH. A linear gradient was then
inserted (0 to 100% in 200 mL) with the same buffer
containing 350 mM imidazole. Soluble HDC elutes as a
symmetrical peak and was incubated with 100 μM PLP.
Imidazole and unbound coenzyme were removed by extensive
washing with 0.1 M potassium phosphate buffer (pH 7.4) and
10 mM β-MeSH, and the protein solution (redHDC) was
concentrated in the same buffer using Amicon Ultra 10
concentrators (Millipore). The enzyme concentration was
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determined by using an εM of 1.57 × 10
5 M−1 cm−1 at 280
nm,47 and the PLP content was determined by releasing the
coenzyme in 0.1 M NaOH using an εM of 6600 M
−1 cm−1 at
388 nm.48 The purity of the protein was detected by a single
band corresponding to a molecular weight of ∼56 kDa in a
12% reducing sodium dodecyl sulfate−polyacrylamide gel
electrophoresis (SDS−PAGE) gel.
Semidenaturing and Native PAGE. Semidenaturing 10%
SDS−PAGE used to evaluate the presence of the intermo-
lecular disulfide bond of 5 μg of HDC incubated with
increasing concentrations of β-MeSH, DTT, or GSH (the
concentrations are listed in the Results and Discussion) for 1 h
and loaded with the addition of 4× nonreducing sample buffer.
Native PAGE analysis was performed under the same
conditions as semidenaturing SDS−PAGE, but samples were
loaded with the addition of 2× native sample buffer.
Size-Exclusion Liquid Chromatography Analyses.
Size-exclusion liquid chromatography was used to prepare
the fully oxidized HDC (oxHDC) starting from the reduced
form. RedHDC was loaded onto a Sephacryl H-200 (16/60)
(GE Healtcare) column equilibrated with 0.1 M potassium
phosphate buffer (pH 7.4) and 0.15 M NaCl on an Akta FPLC
system (GE Healthcare). The run, using the same buffer, was
performed at a flow rate of 0.5 mL/min with detection at 280
nm. The protein eluted as a single symmetrical peak and was
incubated with 100 μM PLP. Unbound coenzyme was
removed by extensive washing with 0.1 M potassium
phosphate buffer (pH 7.4), and the protein solution was
concentrated in the same buffer using Amicon Ultra 10
concentrators (Millipore). The redox state of the eluted
protein was determined by loading it onto a nonreducing
denaturing (semidenaturing, see above) SDS−PAGE gel.
Size-exclusion liquid chromatography was used to determine
the molecular dimensions of the holoenzyme (300 μg) in both
oxidized and reduced forms. The samples were loaded on a
Sephacryl H-200 (16/60) (GE Healtcare) column equilibrated
with 0.1 mM potassium phosphate buffer (pH 7.4) and 0.15 M
NaCl with the addition of 10 mM β-MeSH for redHDC, on an
Akta FPLC system (GE Healthcare). The injection volume
was 500 μL at a flow rate of 0.5 mL/min with detection at 280
nm. Three chromatographic experiments were run per sample,
and Unicorn version 5.01 (GE Healthcare) was used to
calculate the elution volume of each peak. The apparent
molecular dimension of the eluting species was calculated by
comparing their elution volume to that of a set of molecular
weight standards under the same experimental conditions.
Spectroscopic Measurements. Absorption measure-
ments were performed using a Jasco V-550 spectrophotometer
at a protein concentration of 1 mg/mL under conditions
specified in the Results and Discussion for each case.
Circular dichroism measurements were taken with a Jasco J-
710 spectropolarimeter at a protein concentration of 1 mg/mL
for near-ultraviolet (near-UV) and visible spectra or 0.1 mg/
mL for far-UV spectra. The thermostability was determined by
monitoring the circular dichroic signal at 222 nm at a
concentration of 0.1 mg/mL and a temperature increase from
25 to 90 °C at a rate of 1.5 °C/min.
Fluorescence spectra were recorded using a FP-750 Jasco
spectrofluorimeter setting at 5 nm excitation and emission
bandwidths, following excitation at different wavelengths,
specified in the Results and Discussion for each case.
All the spectroscopic measurements were taken in 0.1 M
potassium phosphate buffer (pH 7.4) at 25 °C, with the
addition of 10 mM β-MeSH or 10 mM GSH for redHDC.
Coenzyme Binding Affinity Measurements. The
apoenzyme was prepared by incubating 10 μM redHDC or
oxHDC with 50 mM phenylhydrazine at 25 °C for 2 h in 0.5
M potassium phosphate buffer (pH 6.8), with the addition of
10 mM β-MeSH for redHDC. The solution was then loaded
on a desalting 26/10 column (GE Healthcare) preequilibrated
with the same buffer without phenylhydrazine. The eluted
enzyme was then concentrated using Amicon Ultra 10
concentrators (Millipore) and washed with 0.1 M potassium
phosphate buffer (pH 7.4), with the addition of 10 mM β-
MeSH for apo-redHDC.
The equilibrium apparent dissociation constant for PLP,
KD(PLP), was determined by measuring the quenching of the
intrinsic fluorescence of the 0.03 μM HDC apoenzyme in the
presence of PLP at concentrations ranging from 0.005 to 20
μM in 0.1 mM potassium phosphate buffer (pH 7.4), with the
addition of 10 mM β-MeSH for redHDC.
The data were fitted to the following equation:
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where [E]t and [PLP]t represent the total concentrations of the
enzyme and PLP, respectively, Y refers to the intrinsic
quenching changes at a PLP concentration, and Ymax refers
to the fluorescence changes when all enzyme molecules are
complexed with coenzyme.
Curve fitting was performed using Origin 8 Pro (OriginLab).
Dynamic Light Scattering Analysis. The dynamic light
scattering (DLS) analyses were performed using the Zetasizer
Nano S (ZEN1600) instrument (Malvern Instruments) with a
constant 90° scattering angle and a 633 nm wavelength laser at
25 °C. The sample volume used for analysis was 0.8 mL at an
enzyme concentration of 2 μM in 0.1 M potassium phosphate
buffer (pH 7.4), with the addition of 10 mM β-MeSH for
redHDC. A total of 100 scans were obtained for each sample,
after an equilibration time of 10 min, and all samples were
analyzed in triplicate.
Enzyme Activity Assay. The decarboxylase activity was
measured by a stopped spectrophotometric assay already used
for DOPA decarboxylase and useful for quantifying aromatic
amines.49 HDC (WT or variants, 0.3 μM) was incubated for an
appropriate incubation time (a time within which linear
product formation is observed) with 1 mM L-His and 10 μM
PLP in a final volume of 250 μL in 0.1 M potassium phosphate
buffer (pH 7.4), with the addition 1 mM GSH for redHDC.
The reaction was then stopped by heating the mixture at 100
°C for 2 min. TNB (1 mL of a 4.3 mM solution) and toluene
(1.5 mL) were added, and the extraction of trinitrophenylhist-
amine was performed at 42 °C for 45 min with continuous
shaking. The concentration of the trinitrophenyl derivative in
the toluene layer was measured by using a prepared calibration
curve of absorbance at 340 nm as a function of trinitrophenyl
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at 340 nm. The kinetic parameters were determined by
incubating the enzyme in the presence of different L-His
concentrations (0.025−2 mM) at a saturating PLP concen-
tration, and the obtained data were fitted to the Michaelis−
Menten equation using Origin 8 Pro (OriginLab).
Atomic Coordinates and Modeling. Atomic coordinates
of human HDC (entry 4E1O45) were taken from the Protein
Data Bank (PDB)50 and used as a starting point to model the
disulfide bond between the Cys-180 residues of the
polypeptide chain. Modeling was done using MODELER,
version 9.17,51 and PyMod.52 Subsequently, local steepest
descent energy minimization in vacuum was performed to
relieve local structural strain using GROMACS version 4.0.753
in conjunction with the GROMOS53a6 force field. The
structural stability of the obtained model was assessed by a
number of structure analysis tools. Ramachandran plot
calculations, computed with PROCHECK,54 exhibited optimal
stereochemical quality, with 95.3% of the residues in the most
favored region and only 0.5% of the residues in the disallowed
regions. The energy profile calculated by the Dope score of the
model suggests that the obtained disulfide bond is energetically
consistent and reliable. Normal mode (NM) analysis of the
structure of HDC with reduced Cys-180 residues was
performed using the elastic network model (ENM), a fast
and simple way to compute the low-frequency normal modes
of a macromolecule,55 as implemented in the PyANM tool.56
The lowest-frequency normal mode was kept and used for
visual analysis.
Molecular Dynamics (MD). All simulations have been
performed using Gromacs version 2018.2. The structures were
centered in cubic boxes with minimum distance of 0.9 nm
between each atom of the protein and the box to reduce. The
SPC water model57 was used to solvate the system. The ionic
strength was adjusted to make sure all simulations were
electrically neutral. MD simulations were performed with
periodic boundary conditions in the isothermal−isochoric
ensemble (NVT), using an integration step of 2 fs at a constant
temperature (300 K) using the velocity rescaling algorithm.58
The particle mesh Ewald method59 was used to calculate the
long-range contribution (reciprocal space) of the electrostatic
interactions using a cutoff radius of 1.0 nm. The Gromos53a6
force field60 was used. Before production runs, all systems were
subject to a minimization cycle and thermalization procedure
to bring the temperature gradually to 300 K. All runs consisted
of at least 100 ns MD simulations in an NVT ensemble. MD
analysis was performed using Gromacs and was based on the
equilibrated part of all simulations, that is, beyond 20 ns. Root-
mean-square fluctuations were calculated using the Cα atom
deviation with respect to their average position. Trajectories
were projected onto selected eigenvectors to show main
dominant protein motions. PLP was included in all
simulations, and the topology parameter of the Gromos53a6
force field was obtained using the PRODRG server.61 Figures
were generated using the Pymol 2.0 software (The PyMOL
Molecular Graphics System, version 2.0, Schrödinger, LLC).
■ RESULTS AND DISCUSSION
HDC Cys-180 Is the Only Cysteine Residue Not
Conserved among HDCs. A multiple-sequence alignment
of HDCs from mammals and other sources such as Gallus,
Drosophila, Danio, and prokaryotic organisms shows that only
one cysteine residue is not conserved among the 11 cysteine
residues present in each subunit of the functionally active
dimeric human HDC, namely Cys-180 (Figure 1). A further
comparison of the sequences of HDCs with those of
decarboxylases of group II, in particular with that of human
aromatic amino acid decarboxylase, points out that six of the
11 cysteine residues of human HDC are shared, while the
remaining four are typical of HDCs. Cys-418, the other
cysteine residue replaced with serine in the crystallization
papers by Komori and co-workers,44,45 belongs to the latter
group. Interestingly, HDCs from primates (Gorilla gorilla,
Pongo abelii, Pan paniscus, Pan troglodytes, and many species of
the genera Macaco) are predicted to have Cys-180, thus dating
at least to primates the substitution responsible for the
presence of this cysteine residue in the human protein. The
fact that Cys-180 is not conserved and, at the same time
together with Cys-418, contributes to protein stability45 raises
questions about the role it could play.
Human Wild-Type HDC Exists in an Equilibrium
between a Reduced (redHDC) and an Oxidized
(oxHDC) Form Controlled by Cys-180. Human HDC has
been cloned in pET28a, transformed in BL21 E. coli, expressed,
and purified with an affinity column as reported in Materials
and Methods. The yield is 2−5 mg/L, and the enzyme is pure
as evidenced by a single band in an SDS−PAGE gel (Figure
S1) and contains 2 mol of PLP per dimer. It has been
immediately noted that, depending on the reducing agent
concentration, HDC presents one or two bands on a
semidenaturing SDS−PAGE gel. The molecular weight of
the slow mobility band suggests that it is a dimer, while the
fastest band, at ∼56 kDa, corresponds to the monomer (Figure
2A and Figure S2A,B). β-MeSH, DTT, or GSH has been used
as a reducing agent, showing in every case the same results. To
obtain a fully reduced species, the reductant:protein dimer
ratio should be an at least 2000-fold molar excess. A native
PAGE performed at increasing GSH concentrations confirms
that HDC is present as a dimer (Figure S2C). The dimeric
arrangement is also exhibited by size-exclusion chromatog-
raphy analysis showing that the two species elute at nearly the
same volume (62.6 ± 0.1 and 61.8 ± 0.2 mL for redHDC and
oxHDC, respectively) (Figure S2D).
The C180S and C418S variant HDCs have been cloned,
expressed, and purified to homogeneity as revealed by a single
band on an SDS−PAGE gel (data not shown), and both of
them bind 2 mol of PLP/dimer. A semidenaturing SDS−
PAGE performed under the same conditions as the wild-type
method shows that C180S appears as a monomer at any GSH
concentration, while C418S exists as oxidized/reduced species
in equilibrium depending on the absence or presence of a
reducing agent, a behavior strongly ressembling that of the WT
(Figure 2B,C).
From these data, it can be inferred that HDC exists in a
reduced and oxidized state depending on the presence of a
reductant and that Cys-180 appears as a good candidate for an
intersubunit disulfide bond of one subunit with the same
residue of the neighboring subunit. No other cysteine residue
is in fact present within 10 Å of Cys-180. In this regard, it is of
interest that a possible role for regulation by the redox state
was advanced.46
We have then undertaken a spectroscopic characterization to
highlight possible differences in physicochemical signals
between redHDC and oxHDC.
The Spectroscopic Analyses Reveal That redHDC and
oxHDC Display Slight Structural Changes. The absorb-
ance spectra of redHDC (in the presence of 10 mM GSH) and
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Figure 1. Multiple-sequence alignment of HDCs. Amino acid
sequences from various sources were taken from the NCBI Web
site (https://www.ncbi.nlm.nih.gov/) and are, in order, Homo sapiens,
Mus musculus, Rattus norvegicus, Bos taurus, Gallus gallus, Danio rerio,
Drosophila melanogaster, Morganella morganii, Klebsiella aerogenes, and
Figure 1. continued
Raoultella planticola. The one-letter amino acid code is used.
Dashes represent insertions and deletions. Invariant positions
are boxed in red. Similar residues are written in red characters.
Homologous regions are boxed in light blue. The secondary
structures of human HDC (PDB entry 4E1O) are reported in
the first line of each block. α-Helices and β-strands are
rendered as squiggles and arrows, respectively. ESPript
(http://espript.ibcp.fr) was used to render this figure starting
from a Clustal Omega alignment (http://www.ebi.ac.uk/
Tools/msa/clustalo/).
Figure 2. Semidenaturing 10% SDS−PAGE analysis of (A) WT, (B)
C180S, and (C) C418S HDC with increasing β-MeSH concen-
trations. Five micrograms of (A) WT, (B) C180S, or (C) C418S
HDC was incubated for 1 h at room temperature with the
corresponding β-MeSH concentration in 0.1 M potassium phosphate
buffer (pH 7.4). M, molecular weight marker.
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oxHDC measured in 0.1 M potassium phosphate buffer (pH
7.4) show, in addition to the 280 nm band that can be
attributed to the aromatic amino acids, the presence of two
bands in the visible region with maxima at 339 and 415 nm for
redHDC and at 333 and 414 nm for oxHDC. Besides the slight
differences in wavelength maxima, the equilibrium between
these two species is altered with 339 nm/415 nm and 333 nm/
414 nm ratios of 4.22 and 2.22, respectively (Figure 3A).
These species can be reasonably attributed to the enolimine
and ketoenamine tautomers of the internal aldimine between
PLP and Lys-304, and it can be thus suggested that the PLP
microenvironment is altered in the two redox states of the
enzyme.
The dichroic signals in the visible region reflect a similar
coenzyme behavior displayed in absorbance, and in addition,
the near-UV bands show a slight difference between redHDC
and oxHDC (Figure 3B). The optical activities (millidegrees
per absorbance unit at a fixed wavelength at the same protein
concentration) for the enolimine and ketoenamine are 30.25
and 48.18 for redHDC and 24.53 and 20.12 for oxHDC,
respectively, supporting the presence of an altered PLP
microenvironment. Finally, the far-UV CD spectra are
superimposable, indicative of a similar secondary structure
content (inset Figure 3B).
Fluorescence data essentially provide the same information
about the spectrophotometric and spectropolarimetric experi-
Figure 3. Spectroscopic characterization of WT HDC. (A) Absorbance and (B) near-UV and visible dichroic spectra of redHDC (dotted line) and
oxHDC (straight line) were recorded at 1 mg/mL in 0.1 M potassium phosphate buffer (pH 7.4) without or with 20 mM GSH. The absorbance
maximum wavelengths are reported in inset A. Inset B shows the far-UV spectra measured at 0.1 mg/mL in 0.1 M potassium phosphate buffer (pH
7.4) without or with 20 mM GSH.
Figure 4. Emission fluorescence spectra of WT HDC. (A) Intrinsic fluorescence emission spectra of redHDC (dotted line) and oxHDC (straight
line) after excitation at 280 nm. Spectra were recorded at 0.1 mg/mL in 0.1 M potassium phosphate buffer (pH 7.4) without or with 20 mM GSH.
Inset A is a close-up of the fluorescence emission maximum in the 490 nm region. (B) Cofactor fluorescence emission spectra after excitation at
339 and 333 nm of redHDC (dotted line) and oxHDC (straight line), respectively, at 1 mg/mL in 0.1 M potassium phosphate buffer (pH 7.4)
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ments. Intrinsic fluorescence spectra recorded upon excitation
at 280 nm show an emission band centered at 335 nm for
redHDC and 333 nm for oxHDC with different relative
intensities (207 vs 185). A red-shifted broad shoulder is
present in oxHDC, emitting at 494 nm with a relative intensity
of ∼5 for oxHDC suggesting an energy transfer and thus a
different positioning of PLP with respect to aromatic amino
acids. (Figure 4A). Cofactor emission fluorescence upon
excitation of the enolimine tautomer at 339 and 333 nm for
redHDC and oxHDC, respectively, shows emissions at 386
and 485 nm for redHDC and 381 and 491 nm for oxHDC.
When the ketoenamine tautomer of the two species was
excited at 415 nm (redHDC) and 414 nm (oxHDC), a band
centered at 485 nm and at 496 nm was recorded (Figure 4B
and inset). Altogether, these fluorescence results witnessed a
modest change in the cofactor environment and in the
interconnections among PLP and the surrounding residues in
the two HDC forms.
These spectroscopic data suggest that redHDC and oxHDC
present slight differences in all measured signals indicative of
subtle structural changes. The optical activity values are also an
expression of modest coenzyme-to-aromatic amino acid side
chain microenvironment alterations. We thus investigated if
these changes are related to the catalytic activity and to the
stability of the enzyme.
OxHDC Is More Stable and More Active Than
redHDC. The thermostability of the two enzymatic forms
has been assessed by monitoring the dichroic signal at 222 nm
with an increase in temperature from 25 to 90 °C at a rate of
1.5 °C/min. While the Tm of redHDC is 62.78 ± 0.06 °C, that
of oxHDC is 65.97 ± 0.02 °C (Table 1), thus suggesting that
the oxidized form of HDC is slightly more stable than the
reduced form. DLS analyses show that the hydrodynamic
diameter of redHDC is 9.90 ± 0.08 nm while that of oxHDC is
11.60 ± 0.04 nm. In addition, it should be pointed out that the
theoretical diameter62 is predicted to be 8 nm calculated on
the basis of the determined structure of the double-mutant
form (C180S/C418S)45 that ressembles redHDC (see below).
Kinetic parameters of redHDC and oxHDC (Table 1) show
that the catalytic efficiency of the oxidized form is 3-fold higher
than that of the reduced form, and this is driven by the
combination of both the 1.6-fold increase in kcat and the 2-fold
decrease in Km. The apparent equilibrium dissociation constant
for the coenzyme is quite similar, i.e., 33 nM for redHDC
versus 44 nM for oxHDC.
Interestingly, the oxidized species is more active and more
stable than the reduced form. Thus, we looked for a possible
molecular cause as the basis for this different behavior.
The Cys-180 Redox State Is Responsible for a
Structural Transition Affecting the C-Terminal Domain
Reorientation and Could Be Responsible for Active Site
Alterations. The availability of the recently determined
crystal structure of human HDC (PDB entry 4E1O)45 gave
us the unprecedented opportunity to gain insights into the role
of the intersubunit disulfide bridge of Cys-180 in controlling
the structural rearrangement of human HDC and its catalysis.
However, because Cys-180 was replaced with serine to prevent
unwanted oligomerization,45 we started our analysis by
modeling the position of Cys-180 and the disulfide bridge in
their reduced and oxidized forms, respectively (Figure 5). In
their oxidized state, the two Cys-180 residues of each
monomer are in a distance range (≈2.5 Å) that is compatible
with the formation of an intersubunit disulfide bond. The
latter, in turn, could be responsible for a “locking” of the two
α-helices spanning residues 178−184 and comprising Cys-180,
which face each other at the dimer interface. On the contrary,
in the absence of the covalent bond between the two Cys
residues, the two α-helices of redHDC are expected to freely
move, because no other close contact is present. Indeed, an
inspection of the physicochemical properties of the dimer
interfaces of HDC and its close homologue aromatic amino
acid decarboxylase (PDB entry 1JS3; root-mean-square
deviation of ≈0.8 Å) in this region revealed that both enzymes
(and other group II decarboxylases, e.g., glutamate decarbox-
Table 1. Kinetic Parameters, Apparent Equilibrium Dissociation Constants for PLP, and Melting Temperatures of WT HDC
and Its Variantsa
enzyme kcat (s
−1) Km (mM) kcat/Km (s
−1 mM−1) KD(PLP) (nM) Tm (°C)
redHDC WT 0.70 ± 0.02 0.064 ± 0.008 10.9 ± 1.4 32.8 ± 0.4 62.78 ± 0.06
oxHDC WT 1.10 ± 0.05 0.033 ± 0.006 33.3 ± 6.2 44.0 ± 0.3 65.97 ± 0.02
redHDC C180S 0.60 ± 0.02 0.057 ± 0.008 10.5 ± 1.5 − −
oxHDC C180S 0.72 ± 0.02 0.062 ± 0.007 11.6 ± 1.3 30.5 ± 0.2 62.68 ± 0.04
redHDC C418S 0.74 ± 0.04 0.06 ± 0.01 12.3 ± 2.2 − −
oxHDC C418S 1.05 ± 0.03 0.042 ± 0.007 25.0 ± 4.2 43.1 ± 0.2 65.49 ± 0.04
aFrom 0.05 to 2 mM L-His reacted with 0.075 nmol of each HDC species for 10 min in 250 μL of 0.1 M potassium phosphate buffer (pH 7.4)
without or with 1 mM GSH. Dissociation constants for PLP were calculated from the measured enzyme intrinsic fluorescence quencing with an
increasing concentration of the coenzyme as reported in Materials and Methods. Melting temperatures were calculated by dichroic changes at 222
nm as reported in Materials and Methods.
Figure 5. Modeling of WT HDC in its (A) reduced and (B) oxidized
states. The two HDC subunits are represented as green and cyan
cartoons and sticks, respectively. The dashed black circle indicates the
position of the two Cys-180 residues.
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ylase 65) share solvation properties that favor a partial
opening.4 Therefore, we reasoned that the presence or absence
of a disulfide bridge between the Cys-180 residues of the HDC
subunits63 could lead to a subtle structural change, which in
turn could be transmitted to the adjacent long α-helix of
residues 150−173. The latter directly connects the α-helix of
residues 178−184 to the active site of HDC. To test this
hypothesis, we thus performed an all-Cα atom normal mode
(NM) analysis of redHDC to investigate the conformational
transitions of HDC. Indeed, it is well-known that NM analysis
can probe large-amplitude motions that are often inaccessible
to other atomistic simulations.64 Moreover, NM analysis is
insensitive to the presence of small molecules, such as PLP, in
the context of large protein systems.
The NM symmetric rigid-body motions of the PLP binding
and C-terminal domains of HDC, described by the lowest-
frequency NM, are shown in Figure 6. According to NM
analysis of human HDC, the magnitude of the structural
fluctuations was highest at the C-terminal domains (CTDs)
and at the flexible α-helix of residues 150−173 connecting the
position of the α-helix residues of 178−184 and PLP (Figure
6A). Notably, HDC displayed a symmetric profile of
fluctuations at the CTDs, as already observed in the close
homologue glutamate decarboxylase.65
The obtained results of the NM simulations of HDC
therefore suggested a tight coupling between the helix−loop−
helix motif comprising residues 150−184 and the C-terminal
domain of HDC, which in turn could drive a structural
rearrangement of the two domains and of the catalytic loop
lying at the interface between the N- and C-terminal domains
of HDC. Interestingly, the conformation of the 150−184
helix−loop−helix motif comprises both Cys-180 and residues
of the PLP binding cleft, directly linking therefore the redox
state of Cys-180 to the position and stabilization of PLP. Most
notably, the NM data corroborate the findings from the
analysis of the structural flexibility of human HDC inferred
from crystallographic B-factors45 (Figure 6B), which can be
used to assess the local dynamics of protein structures.66
To further corroborate the results obtained with coarse-
grained NM analysis, MD simulations were performed to
investigate the atomistic fluctuations of the PLP binding site as
a function of the redox state of Cys-180. All simulations were
100 ns long, and all the analyses have been performed on the
equilibrated part of all trajectories, i.e., after simulation for 20
ns. Insertion of a disulfide bridge between the Cys-180 residues
of the two HDC subunits causes a general decrease in protein
flexibility as measured by the root-mean-square fluctuation
(RMSF) (see Materials and Methods). Figure 7 shows a
comparison between the RMSF of the oxidized and reduced
HDC for each monomer. As the plot shows, the introduction
of a constraint in the S−S interchain disulfide bridge of Cys-
180 confers upon oxHDC a generally higher rigidity compared
to that of redHDC. From a structural viewpoint, the main
RMSF differences between the oxidized and reduced HDC
were localized on the helix encompassing residues 150−170.
We have checked the effect of conformational dynamics of
helix 150−170 and all residues facing the active site on PLP
mobility. In particular, we compared the flexibility (RMSF) of
PLP atoms in the two HDC simulations and found that the
RMSF in oxHDC was systematically lower than the
Figure 6. (A) NM analysis and (B) B-factors of WT HDC. (A) The two HDC subunits are represented as green and cyan cartoons. The gray
arrows are trajectory vectors of the NM analysis. Each arrow’s direction points in the direction where the residue will move, and each arrow’s length
indicates the moving scale for each residue. (B) Experimentally derived B-factor values, indicating local structural fluctuations, are in good
agreement with NM analysis data.
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corresponding values for the PLP in the redHDC simulation
(Figure 8), and this suggests that the disulfide bridge in Cys-
180 affects the conformational mobility of the PLP moiety in
its pocket by decreasing its conformational mobility
Further confirmation of this finding came from the essential
dynamics analysis on the active site subset residues. This
analysis showed that the overall fluctuation of the Cα atoms of
active site residues (as calculated from the trace of the
covariance matrix of positional atomic fluctuations of Cα
atoms) was lower in oxHDC (0.32821 nm2) than in redHDC
(0.6821 nm2). This confirms that the covalent bond in the
Cys-Cys pair at position 180 confers a higher rigidity in the
active site area.
In more detail, a ribbon representation of the HDC structure
with a thickness and color scheme proportional to the
difference between the RMSF of oxHDC and that of redHDC
is reported in Figure 9 and a close-up inset. As shown, the N-
terminal end of the redHDC is more flexible than its oxidized
counterpart. This region is within the range of contact of either
the active site lid of HDC (corresponding to residues 321−
332) or the loop spanning residues 350−353 (comprising
residues interacting with the phosphate moiety of PLP), which
also show a higher flexibility in redHDC than in oxHDC. We
suggest that this higher flexibility affects the pocket size hosting
the PL, which in turn is more likely to have greater
conformational freedom in redHDC than in oxHDC.
These bioinformatics data are in agreement with the slight
differences evidenced by the spectroscopic analyses as well as
by the kinetic features and by the protein thermal stability data
between redHDC and oxHDC and suggest that oxidation
could lead to a movement triggering subtle alterations at the
active site. The stability could be due to the additional sulfur−
sulfur covalent bond that causes a rearrangement of the overall
protein structure determining an increase in the hydrodynamic
diameter, as witnessed by DLS measurements. We then
evaluated the functional properties of single variants C180S
and C418S to gain insight into their specific contribution.
C180S Presents Features Similar to Those of redHDC,
while C418S Is Sensitive to Reductants. The analyses of
the absorbance, dichroic, and fluorescence properties of C180S
Figure 7.MD analysis of WT HDC in its reduced and oxidized states.
Root-mean-square fluctuation of oxHDC (black) and redHDC (red)
as a function of residue number for chain 1 (top) and chain 2
(bottom).
Figure 8. RMSF of PLP in oxNHD and redHDC. Root-mean-square
fluctuation of PLP atoms with respect to their average position along
the MD trajectories for the oxHDC simulation (black) and the
redHDC simulation (red).
Figure 9. Difference between the RMSF of redHDC and that of
oxHDC. Ribbon representation of the HDC structure with the
difference between RMSF of redHDC and that of oxHDC mapped
onto monomer A (rainbow scale going from 0.33 to −0.29 nm).
Monomer B is colored gray. As shown in the inset, the N-terminal end
of the redHDC is more flexible than its oxidized counterpart. This
higher flexibility affects in turn the active site lid of HDC (residues
321−332) as well as the loop spanning residues 350−353.
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and C418S variants show that these species exhibit slight
structural changes and no gross alterations in cofactor binding
microenvironment (data not shown). We then focused our
attention on the oxidized species of both variants because
oxC180S should not form a disulfide-bound species and
oxC418S should be less prone to aggregate. Interestingly,
measurements of both the hydrodynamic diameter and of the
thermostability show that oxC180S behaves like redHDC with
a diameter of 10.56 ± 0.04 nm and a Tm value of 62.68 ± 0.04
°C, while oxC418S has a diameter of 11.6 ± 0.6 nm and a Tm
of 65.49 ± 0.04 °C behaving like oxHDC. In addition, the
functional features show that the catalytic efficiencies of both
redC180S and oxC180S are almost identical to that of the
redHDC while those of both redC418S and oxC418S are
similar to those of redHDC and oxHDC, respectively (Table
1). No differences in PLP equilibrium binding constant are
measured (Table 1).
Because it has been claimed that oxHDC tends to aggregate
and for this reason the structure of the enzyme has been
determined in the C180S/C418S double-mutant species,45 we
addressed this by concentrating 500 μL of 10 μM oxHDC,
oxC180S, and oxC418S to 25 μL in an Amicon ultra device.
The supernatants and the pellets (if present) were then run on
an SDS gel under reducing and nonreducing conditions. We
determined that a pellet was present in oxHDC and oxC180S
solutions while no precipitation occurs with the oxC418S
variant. Here, it follows that Cys-418 concurs in structural
stability, although the molecular reason for the aggregation of
oxHDC needs to be further investigated.
■ CONCLUSIONS
Even if human HDC belongs to the well-known group of the
PLP-dependent α-decarboxylases, it is a poorly characterized
protein, mainly because of its intrinsic instability. The only
determined structure is that of the human protein engineered
with two cysteine-for-serine substitutions (C180S and C418S)
to increase its stability.45 Here, for the first time, we provide
evidence for the existence of an equilibrium between a reduced
and an oxidized form of human HDC, the latter being slightly
more active and stable than the former. We also identify Cys-
180 as the residue that is responsible for this redox equilibrium.
Bioinformatics analyses suggest a higher stability and active site
alteration determined by the disulfide bridge in the oxHDC
form. On this basis, human HDC may join the short list of PLP
enzymes that present redox sensitive cysteine residues.67−76
Interestingly, among PLP enzymes, the cysteine switch appears
to be a peculiar and unique feature of human HDC. It has been
documented that cysteine residues in proteins could play a role
in the response to altered redox conditions in cancer.77,78 At
present, it is not easy to envisage a physiological role of this
redox sensor in HDC. However, when the fact that the
environment of a cell is highly reduced is taken into account, it
is reasonable to suggest that HDC is mainly reduced under
physiological conditions. However, in cancer cells, where redox
conditions are altered, the highly oxidizing conditions could
favor the more active and stable oxHDC. With this view in
mind, it is worth mentioning that high histamine levels have
been reported in cholangiocarcinoma, and the involvement of
HDC in tumor progression was thus suggested.35 Our results
suggest that, under redox-altered conditions, the prevalence of
oxHDC, which is more active and more stable because of the
presence of an additional disulfide bridge involving Cys-180,
could therefore lead to an increased level of production of
histamine, which makes the pathological state worse. In this
regard, the development of specific inhibitors directed toward
oxHDC is highly desirable.
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Oleuropein aglycone stabilizes 
the monomeric α-synuclein and 
favours the growth of non-toxic 
aggregates
Luana Palazzi1, Elena Bruzzone2, Giovanni Bisello1, Manuela Leri2,3, Massimo Stefani2, 
Monica Bucciantini2 & Patrizia Polverino de Laureto1
α-synuclein plays a key role in the pathogenesis of Parkinson’s disease (PD); its deposits are found 
as amyloid fibrils in Lewy bodies and Lewy neurites, the histopathological hallmarks of PD. Amyloid 
fibrillation is a progressive polymerization path starting from peptide/protein misfolding and 
proceeding through the transient growth of oligomeric intermediates widely considered as the most 
toxic species. Consequently, a promising approach of intervention against PD might be preventing 
α-synuclein build-up, misfolding and aggregation. A possible strategy involves the use of small 
molecules able to slow down the aggregation process or to alter oligomer conformation favouring the 
growth of non-pathogenic species. Here, we show that oleuropein aglycone (OleA), the main olive oil 
polyphenol, exhibits anti-amyloidogenic power in vitro by interacting with, and stabilizing, α-synuclein 
monomers thus hampering the growth of on-pathway oligomers and favouring the growth of stable 
and harmless aggregates with no tendency to evolve into other cytotoxic amyloids. We investigated the 
molecular basis of such interference by both biophysical techniques and limited proteolysis; aggregate 
morphology was monitored by electron microscopy. We also found that OleA reduces the cytotoxicity 
of α-synuclein aggregates by hindering their binding to cell membrane components and preventing the 
resulting oxidative damage to cells.
Parkinson’s disease (PD) is one of the most widely occurring neurodegenerative disorders whose symptoms 
are attributed to the progressive loss of dopaminergic neurons in the substantia nigra1. The cause of PD is still 
unknown; however, considerable evidence suggests a multifactorial aetiology involving genetic susceptibility and 
environmental factors. The main histopathological hallmark of PD is the presence, in the affected neurons, of 
intracellular inclusions known as Lewy bodies (LB) and Lewy neurites (LN), containing fibrillar aggregates of 
α-synuclein (Syn)2. Syn is implicated at different levels in the pathogenesis of PD and other neurodegenerative 
conditions, and its aging-related aggregation into amyloid fibrils is a key step in disease aetiology3–5. Autosomal 
dominant forms of PD, resulting from mutations in SNCA, the gene encoding Syn, as well as from its duplications 
and triplications are also known, whereas mutations in a number of different genes are considered risk factors for 
sporadic PD6–10.
Syn is a predominantly presynaptic 140 residues natively unfolded protein11,12 whose structure comprises 
three domains: an N-terminal domain (residues 1–60), a non-amyloid-β component of plaques (NAC) domain 
(residues 61–95), and a C-terminal domain (residues 96–140) (Fig. 1a, left). Approximately, the first 100 residues, 
containing 7 imperfect 11-residue repeats, constitute a lipid binding domain13. The hydrophobic region spanning 
residues 61–95 is responsible for the aggregation properties of the protein14, that appear to be modulated by the 
acidic C-terminal tail, containing 15 Glu/Asp residues and many prolines15.
Syn is intrinsically disordered in solution11,12, but the protein can adopt different types of secondary structure 
in different environments, as in the presence of lipid micelles, vesicles and membranes, where it acquires α-helical 
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secondary structure16–19. Syn interaction with membranes and lipids is considered functionally important20; in 
fact, although its physiological function is not yet fully understood, it has been suggested that Syn may modulate 
the presynaptic vesicular pool size, promote SNARE-complex assembly21, and regulate dopaminergic neurotrans-
mission22. The different biological functions of Syn could be a consequence of its conformational flexibility lead-
ing to suggest that in vivo the protein exists in dynamic equilibrium between different conformational states23.
In the LB and LN, Syn is present as highly ordered insoluble polymeric fibrillar aggregates enriched in 
cross-β-sheet structure24. However, several studies have shown that soluble Syn oligomers are the toxic species 
responsible for disruption of cellular homeostasis and neuronal death through effects on various intracellular 
targets, including synaptic function25–27. Moreover, it is hypothesized a prion-like mechanism by which Syn 
oligomers can diffuse from one cell to the other, thus spreading the disease through the nervous system5,26,28. 
Increasing evidence indicates that, under pathological conditions, various types of oligomers with different mor-
phologies and physicochemical features are present in tissue26,27. Accordingly, Syn oligomers have been generated 
in vitro at different conditions, but it is still unknown whether their structural features and size are similar to 
those displayed by the species grown in vivo or isolated from pathological tissue28. Defining the structure of the 
pathological oligomeric species would be of the utmost importance to understand, at the molecular level, their 
role in neurodegeneration and in Syn toxicity.
Since the loss of dopaminergic neurons is the primary neuropathological sign of PD, dopaminergic drugs 
(e.g. levodopa, dopamine agonists and monoamine oxidase, MAO-B, inhibitors) are the main therapeutic 
options to alleviate the motor symptoms of PD29. Levodopa is effective mainly in the early stage of the disease, 
less as disease progresses. Therefore, other therapeutic strategies, directly targeting Syn, have been proposed22,30. 
Promising approaches are based on the idea to prevent the intracellular and extracellular accumulation of Syn, 
thus disfavouring its aggregation in vivo by inhibiting Syn synthesis using SiRNA31 or by increasing its autophagic 
Figure 1. (a, left) Amino acid sequence of Syn and scheme of its three major domains: the N-terminal region 
involved in lipid and membrane binding, containing the mutations associated with familial forms of PD; the NAC 
domain (61–95) responsible for Syn aggregation properties; the acidic C-terminal region. (a, right) Chemical 
structure of OleA. Interaction between monomeric Syn and OleA. (b, inset) Far-UV CD spectra of Syn in the 
absence (red line) and in the presence of OleA (Syn/OleA 1:10) (black line). Spectra were taken at 25 °C in PBS 
(pH 7.4). (b) Gel filtration and (c) RP-HPLC chromatograms of Syn in the absence (red dashed line) and in the 
presence of 1:10 OleA (black line). In (c) the peak relative to RT 51.2 is highlighted with two stars.
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degradation22. It has also been proposed to interfere directly with the aggregation process of Syn by reducing 
fibrils formation or by stabilizing toxic oligomers confining them in an off-pathway non-toxic or inert form22,30.
The use of natural or synthetic small molecules seems to be an attracting way to counteract amyloidogenesis. 
In particular, plant compounds, such as polyphenols and curcuminoids, have been reported to interfere with the 
amyloid aggregation of several proteins/peptides of neuropathological interest, including Syn, Aβ and tau32. For 
example, baicalein, curcumin and epigallocatechin 3-gallate (EGCG) have been reported to inhibit Syn fibrilla-
tion by stabilizing off-pathway oligomers or by increasing protein solubility and by disrupting long-range inter-
actions that allow a faster reconfiguration rate reducing Syn tendency to aggregate32–39. Moreover, NMR studies 
have led to hypothesize that the production of these non-toxic oligomers is driven by EGCG binding to the Syn 
region responsible for long-range intramolecular interactions36,37.
Oleuropein, the main polyphenol in olive leaves and drupes40 is a glycosylated seco-iridoid, which appears 
mainly in the de-glycosylated (aglycone) form in olive oil (Fig. 1a, right). Oleuropein aglycone (OleA) displays 
several pharmacological activities including antioxidant, anti-inflammatory, anti-atherogenic, anti-diabetic, 
anti-cancer, antimicrobial, and antiviral properties41 and is commercially available as food supplement or 
nutraceutical41. Recently, it has been reported that OleA interferes with the aggregation in vitro of several pep-
tides/proteins associated with amyloid diseases including amylin42, Aβ peptides43, tau44, transthyretin45 and 
beta2-microglobulin (M. Leri et al., data not published). It has been proposed that OleA can be beneficial against 
several amyloid diseases, either systemic (type-2 diabetes)46 or neurodegenerative47. However, no data are pres-
ently available on the interference of OleA with Syn aggregation and its possible protection against the toxicity of 
Syn aggregates.
In this study, we report that OleA interferes with the path of Syn aggregation and modifies the biophysical 
properties of preformed Syn assemblies. We also investigated the influence of OleA on the cytotoxicity of vari-
ously Syn aggregates and analysed the structural and biological features of the so-generated oligomeric species. 
Finally, we isolated and characterized an oligomeric species of Syn grown in the presence of OleA.
Experimental Procedures
Materials. Oleuropein glycoside was purchased from Extrasynthase and deglycosilated by treatment with 
almond β-glycosidase (EC 3.2.1.21, Fluka, Sigma-Aldrich) as previously described42. Briefly, a 10 mM solution of 
oleuropein glycoside in 310 μl of 0.1 M sodium phosphate buffer, pH 7.0, was incubated with 8.9 I.U. of β-gluco-
sidase overnight at room temperature. The aglycone (OleA) was precipitated by centrifuging the reaction mixture 
at 13200 × g for 10 min. The precipitate was suspended in dimethylsulfoxide (DMSO) at 50 mM concentration 
and batched in aliquots kept frozen and protected from light. Oleuropein deglycosylation was confirmed by mass 
spectrometry analysis and by assaying the glucose released in the supernatant with the Glucose (HK) Assay kit 
(Sigma-Aldrich, Saint Louis, MO, USA). Each batch of OleA was used within 1 week once opened. All chemicals 
were of analytical reagent grade and were obtained from Sigma or Fluka (St. Louis, MO).
Expression and purification of recombinant human α-synuclein. Syn was expressed in Escherichia 
coli BL21(DE3) cell line transfected with the pET28b/α-syn plasmid. The recombinant protein was expressed 
and purified according to a previously described procedure19 and further purified by RP-HPLC. The identity and 
purity of the eluted material were assessed by mass spectrometry.
Aggregation and disaggregation experiments. To induce Syn aggregation, 70 µM protein sam-
ples were filtered with a 0.22 µm pore-size filter (Millipore, Bedford, MA, USA) and incubated at 37 °C in 
PBS (8.0 mM Na2HPO4, 137 mM NaCl, 2.0 mM KH2PO4, 2.7 mM KCl, pH 7.4) for up to 7 days under shak-
ing at 500 rpm with a thermo-mixer (Compact, Eppendorf, Hamburg, DE) in the absence or in the presence 
of OleA (210–700 µM, corresponding to a Syn:OleA molar ratio of 1:3 or 1:10, respectively). Protein aggrega-
tion in sample aliquots collected at the indicated incubation times was checked by Thioflavin T (ThT) binding 
assay, 1-anilinonaphtalene-8-sulfonate (ANS) fluorescence, transmission electron microscopy (TEM), limited 
proteolysis, gel filtration (GF) chromatography and reverse phase (RP)-HPLC. The interference of OleA in 
ThT and ANS analysis was assayed by performing controls experiments where the polyphenol was added in 
pre-made Syn aggregates (48 h and 168 h) either immediately before or after the addition of ThT or ANS solution. 
Oligomer-enriched or fibril-enriched sample were prepared by incubating Syn for 48 h or up to 168 h, respec-
tively. For disaggregation experiments, 48 h-aged oligomers were incubated with OleA (1:10) at 37 °C under shak-
ing at 500 rpm, for 24 h (Syn 48 h + OleA 24 h) or 5d (Syn 48 h + OleA 5d); 168 h-aged fibrils were incubated with 
OleA for 8 h (Syn 168 h + OleA 8 h) or for 5d (Syn 168 h + OleA 5d). All aggregate concentrations were expressed 
as monomer protein concentration.
Structural characterization. Protein concentrations were determined by absorption measurements at 
280 nm using a double-beam Perkin Elmer (Norwalk, CT) Lambda-20 spectrophotometer. The molar absorptiv-
ity at 280 nm for Syn was 5960 cm−1 M−1, as evaluated from its amino acid composition by the method of Gill and 
von Hippel48. Circular dichroism (CD) spectra were recorded by a Jasco (Tokyo, Japan) J-710 spectropolarimeter, 
using a 1.0-mm path-length quartz cell and a protein concentration of 7.0 µM. The mean residue ellipticity [θ] 
(degcm2 dmol−1) was calculated according to the formula [θ] = (θobs/10)(MRW/lc), where θobs is the observed 
ellipticity in deg, MRW is the mean residue molecular weight of the protein, l is the optical path-length (as cm) 
and c is protein concentration (as mg/ml). The spectra were recorded in PBS, pH 7.4. Fluorescence measurements 
were performed using a Jasco (Tokyo, Japan) FP-6500 spectrofluorimeter and a 0.1-cm path length cuvette. The 
ThT binding assay was performed accordingly to LeVine49 using a 25 µM ThT solution in 25 mM sodium phos-
phate buffer, pH 6.0. Aliquots (30 µl) of protein samples were collected at the indicated times and diluted into the 
ThT buffer. Fluorescence emission measurements were performed at 25 °C at an excitation wavelength of 440 nm 
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by recording the ThT fluorescence emission in the 455–600 nm interval. For ANS binding experiments, a 350 nm 
excitation wavelength was used and the emission spectra were scanned in the 380–600 nm interval50. All spectra 
were recorded at 25 °C using a 50 µM ANS solution and a 2.5 µM protein solution. ANS-binding experiments 
were carried out in 50 mM Tris-HCl buffer, pH 7.4. ANS concentration was determined using a molar absorption 
coefficient of 4950 M−1 cm−1 at 350 nm. To evaluate the possible interference of OleA with the ThT and ANS flu-
orescence assay, two different controls were performed by monitoring the emission fluorescence spectra intensity 
of Syn aggregates before and after OleA addition: i) OleA was added together to the probe or ii) OleA was added 
after the probe and the fluorescence spectra were re-acquired immediately.
TEM and DLS analysis. Size and morphology of Syn aggregates were investigated by transmission electron 
microscopy (TEM) and dynamic light scattering (DLS). Negative staining was obtained by placing a drop of the 
sample solution on a Butvar-coated copper grid (400-square mesh) (TAAB-Laboratories Equipment Ltd, Berks, 
UK). Then, the sample was dried and negatively stained with a drop of uranyl acetate solution (1.0%, w/v). TEM 
pictures were taken on a Tecnai G2 12 Twin instrument (FEI Company, Hillsboro, OR) at an excitation voltage 
of 100 kV. Size distribution of protein samples was calculated on the basis of 382 particles manually extracted 
from the micrographs using ImageJ software. Only clearly defined spherical and isolated particles were selected. 
Measurements were obtained with a standard deviation of 5.04. Size distributions were also evaluated by DLS 
experiments carried out in duplicate, at 25 °C in PBS, pH 7.4, using a Zetasizer Nano-ZS instrument (Malvern 
Instrument, UK). 12 runs were collected during each measurement.
Chemical characterization. Gel filtration (GF) chromatography was performed by a Superdex 75 
10/300GL column (Amersham Biosciences, Uppsala, Sweden), using an ÄKTA FPLC system (Amersham 
Biosciences, Uppsala, Sweden). Sample aliquots (200 µL) were taken from the aggregation mixture, filtered 
(0.22 µm filters), loaded onto the column and eluted at 0.5 ml/min in 20 mM Tris-HCl, 0.15 M NaCl, pH 7.4. The 
effluent was monitored by recording the absorbance at 214 nm. Column calibration was performed using the fol-
lowing standards: blue dextran (void volume); albumin, 67 kDa; ovalbumin, 45 kDa; α-lactalbumin, 14.4 kDa and 
aprotinin, 6.5 kDa. The RP-HPLC analyses were carried out on an Agilent 1200 chromatographer (Santa Clara, 
CA) using a Jupiter C18 column (4.6 × 250 mm; Phenomenex, CA, USA), eluted with the following acetoni-
trile/0.085% TFA- water/0.1% TFA gradient: 5–25%, 5 min, 25–28%, 13 min, 28–39%, 3 min, 39–43%, 21 min. The 
effluent was monitored by recording the absorbance at 226 nm. The identity of the eluted material was assessed by 
mass spectrometry, carried out with an electrospray ionization (ESI) mass spectrometer equipped with a Q-Tof 
analyzer (Micro) (Waters, Manchester, UK) or a QTof Xevo G2S (Waters, Manchster, UK). Measurements were 
carried out at 1.5–1.8 kV capillary voltage and 30–40 V cone voltage.
Limited proteolysis. Limited proteolysis experiments of Syn and Syn/OleA (1:3, 1:10) samples were carried 
out in PBS, pH 7.4, at room temperature using proteinase K at E/S ratio of 1:1000 (by weight) at 70 µM Syn con-
centration. The reactions were quenched after 5 min by acidification with TFA in water (4.0%, v/v) and analysed 
by RP-HPLC, as described above.
Fingerprinting analysis of off-pathway oligomers. The Syn aggregated species were purified by har-
vesting the material eluted from RP-HPLC at RT 51.2 min at the conditions described above. The protein samples 
were dried in Savant and solubilised in 6.0 M guanidine(Gnd)-HCl/20 mM Tris-HCl, pH 8.5. Then, the samples 
were diluted 1:10 and trypsin was added to an 1:25 enzyme to substrate (E/S) ratio. After 15 h of incubation at 
37 °C, the proteolysis mixture was analysed with RP-HPLC by the same column and gradient used for purification 
and the peptide species were identified by ESI-MS. For proteinase K proteolysis, the sample was further diluted 
reaching a final concentration of 1.0 M Gnd-HCl before adding the enzyme (E/S 1:1000). The reactions were 
carried out for 5- or 70-min at 37 °C.
Cell culture and cell viability assay. SH-SY5Y cells were cultured at 37 °C in complete medium (50% 
HAM, 50% DMEM, 10% foetal bovine serum, 3.0 mM glutamine, 100 units/ml penicillin and 100 μg/ml strep-
tomycin), in a humidified, 5.0% CO2 incubator. All materials used for cell culture were from Sigma. The samples 
containing aggregating Syn were administered to the cells at a 5.0 μM final concentration. The cytotoxicity of 
the variously aggregated Syn samples was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT, Sigma-Aldrich) reduction inhibition assay based on the protocol described for the first time by 
Mosmann51. In all MTT-experiments, the cells were plated and incubated for 24 h at a density of 10000 cells/
well on 96-well plates in 100 μl culture medium. Then, the cells were treated for 48 h with 5.0 µM Syn aggregates 
grown in the absence or in the presence of OleA (1:10). After exposure to the aggregates, the cells were incubated 
for 2 h with 100 μl DMEM without phenol red, containing 0.5 mg/ml MTT. Then, 100 μl of cell lysis buffer (20% 
SDS, 50% N,N-dimethylformamide, pH 4,7) was added to each well and the samples were incubated at 37 °C to 
allow complete cell lysis. The blue formazan absorbance was recorded at 595 nm with an automatic plate reader 
(Bio-Rad, Hercules, Cal). Final absorption values were calculated by averaging three independent measurements 
of each sample after subtraction of the average of the blank solution (100 μl of MTT solution and 100 μl of lysis 
buffer). All data were expressed as mean ± standard deviation.
Reactive oxygen species. The intracellular reactive oxygen species (ROS) were determined by monitoring 
the increase in fluorescence at 538 nm of the fluorescent probe 20,70–dichlorofluorescein diacetate, acetyl ester 
(CM-H2 DCFDA; Sigma-Aldrich), a cell-permeant ROS indicator that becomes fluorescent on removal of the 
acetate groups by cellular esterases and subsequent oxidation. The SH-SY5Y cells were plated at a density of 
10000 cells/well on 96-well plates. The cells were exposed for 48 h to 5.0 μM aggregates, then 10 mM DCFDA in 
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DMEM without phenol red was added. After 30 min, the fluorescence values were detected by Fluoroscan Ascent 
FL (Thermo-Fisher, Illkinch, France).
Confocal immunofluorescence. Subconfluent SH-SY5Y cells grown on glass coverslips were treated for 
48 h with Syn aggregates at a 5.0 μM final concentration and then washed with PBS. Labelling at the cell surface 
monosialotetrahexosylganglioside (GM1) was obtained by incubating the cells with 10 ng/ml CTX-B Alexa488 
in complete medium for 30 min at room temperature. Then, the cells were fixed in 2.0% buffered paraformalde-
hyde for 10 min, permeabilized by a cold 1:1 acetone/ethanol solution for 4 min at room temperature and blocked 
with PBS containing 0.5% BSA and 0.2% gelatine for 30 min. After blockage, the cells were incubated for 1 h at 
room temperature with a rabbit polyclonal anti-Syn antibody (Abcam, Cambridge UK) diluted 1:500 in block-
ing solution and then washed with PBS for 30 min under stirring. The immunoreaction was revealed by Alexa 
568-conjugated anti-rabbit Abs (Molecular Probes, Eugene, Oregon, USA) diluted 1:100 in PBS. Finally, the cells 
were washed twice in PBS and once in water to remove non-specifically bound Abs. Cell fluorescence was imaged 
using a confocal TCS SP5 scanning microscope (Leica) equipped with a HeNe/Ar laser source for fluorescence 
measurements. Sample observations were performed by a Leica Plan Apo X63 oil immersion objective suited 
with optics for differential interference contrast acquisition. FRET analysis was carried out by the FRET sensitized 
emission method as previously reported52.
Data analysis and statistics. Statistical analysis was performed using Student’s t-test. The results were 
compared using Student’s t-test between two groups, *P < 0.05; **P < 0.01; ***P < 0.001 versus untreated cells 
and °P < 0.05; °°P < 0.01; °°°P < 0.001 versus cells treated with aggregates grown in the absence of OleA.
Results
Interaction between OleA and monomeric Syn. The effect of OleA on the secondary structure of Syn 
was evaluated by far-UV CD spectroscopy (Fig. 1b, inset). We found that at neutral pH the protein displays 
a far-UV CD spectrum typical of a substantially unfolded polypeptide chain, with an intense minimum near 
198 nm and the absence of characteristic bands in the 208–230 nm region (Fig. 1b, red dashed line). In the pres-
ence of OleA at two different Syn/OleA molar ratios (1:3 or 1:10), no changes in the shape or intensity of the 
spectra recorded just after sample preparation were detected, supporting the lack of any direct conformational 
modification. For simplicity, Fig. 1b, inset, reports only the spectrum relative to the 1:10 Syn/OleA ratio (black 
continuous line). To confirm this, we also analysed Syn in the absence and in the presence of OleA (1:10) by gel 
filtration (GF) (Fig. 1b) and RP-HPLC (Fig. 1c). To avoid technical problems, the samples for GF analysis were 
filtered (0.22 µm filters) before loading; to simplify the figure, the profiles obtained in the presence of 1:3 Syn/
OleA ratio are not shown. The GF profiles of Syn in the absence or in the presence of OleA are similar and show 
a major species eluting at ~9.4 ml, corresponding to monomeric Syn. In the presence of OleA a minor high MW 
species (~1%) at shorter elution volume was also seen (Fig. 1b). No variation in the retention time (RT 35.5 min) 
of Syn when eluted in the presence of OleA was seen in RP-HPLC; however, we noticed the presence of a new 
peak at RT 51.2 min (Fig. 1c, highlighted with two stars), indicating increased hydrophobicity, likely due to some 
chemical modifications or change in the aggregation state of this species. These two main fractions were collected 
and analyzed in more detail. Mass spectrometry analysis indicated the presence of Syn species in both fractions 
(Table 1). Syn appeared chemically modified in very low percentage (~5.0%) by the presence of some covalent 
adducts resulting in mass increases of 205 and 223 Da. These adducts could result from the reaction of Syn with 
demethylated and dehydrated forms of the elenolic acid arising from OleA degradation53. The presence of these 
modifications in both monomeric and late-eluting Syn allows to exclude they are the cause of the RP-HPLC shift.
OleA interferes with Syn aggregation into amyloid fibrils. When incubated in vitro at 37 °C and 
pH 7.4 for 168 h, Syn aggregates into fibrils12. The kinetics of amyloid fibril formation were monitored by follow-
ing the increase of ThT fluorescence emission at 485 nm during the aggregation process. According to previous 
data54,55, we found an initial lag phase followed by an exponential growth phase and a final plateau, consistent 
with a nucleation-dependent mechanism (Fig. 2a). TEM imaging showed that the 48 h sample was populated with 
oligomers and pre-fibrillar aggregates (Fig. 2c), while fibrils with typical amyloid morphology became the major 
aggregated species after 168 h of incubation (Fig. 2f). Then, we investigated the effect of OleA on the kinetics of 
fibril formation by using a Syn/OleA ratio of 1:3. We found that the curve maintained a sigmoid trend, yet in the 
presence of OleA (Fig. 2a), and some amyloid fibrils were still detectable in the sample (Fig. 2d,g). When we used 
























Table 1. Chemical characterization of the main protein species in the mixture formed by Syn and OleA in the 
1:10 ratio eluted from the RP-HPLC column (Fig. 1c). The term ox indicates an oxidized derivative (+16 Da). 
aProteins are listed in order of retention time (RT). bExperimental molecular masses determined by ESI-
QTOF-MS. cMolecular masses calculated from Syn amino acid sequence.
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a 1:10 Syn/OleA ratio, the ThT fluorescence intensity was scarcely increased (Fig. 2a) but other types of aggregates 
populated the sample, as seen by TEM imaging (Fig. 2e,h), suggesting some interference of the polyphenol with 
the aggregation process.
Syn aggregation was further characterized in terms of hydrophobic exposure, monitored as ANS binding, by 
recording the increase of fluorescence emission at 475 nm by ANS added to sample aliquots withdrawn from the 
aggregation mixture at different incubation times (Fig. 2b). The experimental data points fit an irregular sigmoi-
dal curve recalling, in part, the trend observed in the ThT experiment. When the aggregation was carried out at 
Syn/OleA 1:10, we found a moderate increase of fluorescence intensity during the process. Overall, these data 
confirm that OleA interferes with the aggregation process of Syn.
Mapping α-synuclein conformation during aggregation in the presence of OleA by limited pro-
teolysis. The propensity of Syn to be hydrolysed by proteinase K at different stages of amyloid aggregation was 
investigated by highlighting the sites of proteolysis in the absence or in the presence of OleA. Proteinase K was 
chosen because of its broad specificity56; accordingly, its cleavage sites are not expected to be dictated by the amino 
acid sequence, rather, they depend on the conformational and dynamical features of the polypeptide chain57,58. 
An E/S ratio of 1:1000 was used in the experiment and the proteolysis mixtures were analysed by RP-HPLC after 
5 min incubation of Syn with the protease (Fig. 3). The sites of proteolysis were determined by mass spectrometry 
analysis of the isolated HPLC fractions (Table S1). As expected from its natively unfolded character, monomeric 
Syn was highly susceptible to the proteolytic attack and many fragments were seen in the chromatogram after 5 
min-incubation (Fig. 3a). When Syn was kept for 48 h in aggregation buffer, a slightly reduced susceptibility to 
Figure 2. Effect of OleA on Syn aggregation probed by ThT (a), ANS (b) fluorescence spectroscopy and TEM 
(c–h). Syn aggregation kinetics (triangle), Syn aggregation in the presence of 1:3 (diamond) or 1:10 (square) 
OleA. For the ThT assay, aliquots (30 μl) of the protein solution, incubated for the indicated times, were 
added to a 25 µM solution (470 μl) of ThT in 25 mM phosphate buffer, pH 6.0. Excitation wavelength: 440 nm, 
fluorescence emission: 485 nm. For the ANS assay, excitation wavelength: 350 nm, fluorescence emission: 
475 nm at 25 °C. TEM pictures taken from Syn aggregation mixture after 48 h and 168 h of incubation in the 
absence (c,f) or in the presence of a 1:3 (d,g) or 1:10 (e,h) Syn/OleA ratio. Scale bar in every picture corresponds 
to 500 nm.
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proteolysis was evident (Fig. 3b); moreover, at longer incubation times, Syn became progressively more resistant 
to proteolysis, in parallel with the increase of fibril content in the aggregation mixture, as previously observed for 
other proteins58 (Fig. 3c). Then, the proteolysis experiment was carried out on the Syn/OleA 1:3 or 1:10 samples. 
We found that at time 0 all proteolytic mixtures showed a similar pattern (Fig. 3a,d,g). As the aggregation time 
increased, Syn appeared apparently less resistant to proteolysis (Fig. 3e,f,h,i); in fact, the peak relative to the intact 
protein (RT 35.5 min) was slightly less intense than that obtained in the absence of OleA (highlighted with a star 
in the figure). It is worth noting the presence of the peak at RT 51.2 min (highlighted with two stars in Fig. 3). This 
species increased as far as the aggregation time was prolonged (from T 0 to T 168 h,) and OleA concentration in 
the sample was increased (Fig. 3d–f,g–i).
Overall, the proteolysis data indicate that the presence of OleA in the aggregation mixture of Syn increases the 
monomeric Syn sensitivity to proteolysis. Moreover, OleA favours the growth of other types of aggregated species, 
that elute late in RP-HPLC and exhibit increased resistance to proteolysis. To better evaluate the relative amount 
of each population, the area of the peaks relative to the material obtained by PK digestion at different times of 
aggregation was calculated (Fig. S3) and commented in the Discussion.
Characterization of the off-pathway species arising during Syn aggregation in the presence of 
OleA. Next, we look at the fraction eluted at RT 51.2 min by RP-HPLC under aggregation conditions in the 
presence of OleA. This species was collected and concentrated for further characterization. Figure 4a reports the 
GF chromatogram relative to the Syn/OleA (1:10) mixture after 168 h of aggregation. Two main fractions (7.4 ml; 
9.4 ml) were detected. The species eluting at 7.4 ml and increasing over time (cfr. Fig. 1b) was related to that elut-
ing at 51.2 min in RP-HPLC, when an aliquot of the corresponding GF fraction was reloaded onto the RP-HPLC 
column (not shown). Its UV-vis spectrum (Fig. 4a, inset, continuous line) showed a profile characterized by 
two main signals at 340 nm and 280 nm, indicative of the presence of both OleA and Syn. The UV-Vis spectrum 
of OleA alone obtained just after sample preparation and after 168 h of incubation was shown in Fig. S1b, as a 
reference. The fraction at 9.4 ml, eluted as monomeric Syn, also contained OleA, whose absorbance bands were 
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Figure 3. Syn aggregation in the absence or in the presence of OleA 1:3 and 1:10 ratio investigated by limited 
proteolysis. During aggregation, proteinase K was added at an E/S ratio of 1:1000 (by weight) to aliquots (40 µl) 
taken from the mixture at different time intervals (0, 48, 168 h). Proteolysis was allowed to take place at 22 °C for 
5 min and then quenched by addition of 4.0% TFA in water. The proteolysis samples were analysed by RP-HPLC 
using a Jupiter C18 column (4.6 × 250 mm) and eluted with a gradient of acetonitrile/0.085% TFA vs water/0.1% 
TFA from 5.0% to 25% in 5 min, from 25% to 28% in 13 min, from 28% to 39% in 3 min, from 39% to 43% in 
21 min. The peaks relative to intact Syn and to the oligomeric species are highlighted.
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The same mixture (Syn/OleA, 1:10 ratio; 168 h) was also analysed by RP-HPLC by recording the effluent at 
340 nm (Fig. 4b) to monitor OleA absorbance. The chromatogram relative to the analysis of the freshly prepared 
Syn/OleA mixture is also reported as a reference (dashed line). The chromatograms were characterized by two 
main peaks at RT 20.5 min and RT 51.2 min, respectively. These fractions were analysed by MS, confirming the 
presence of OleA in both and the absence of protein material in the peak at 20.5 min (not shown). The intensity of 
the peaks at 20.5 min and 51.2 min reciprocally changed during incubation. At the beginning, the signal relative 
to OleA was higher and decreased with time, probably due to the formation of the OleA-Syn complex eluting at 
51.2 min. When imaged by negative stain TEM, the latter sample showed a morphology consistent with an oli-
gomeric structure (Fig. 4c, inset). These oligomers appeared as not fully homogenous spheroidal particles with 
an average diameter of 22.5 nm (12.5 nm the smaller species, 42.3 nm the larger ones). The largest aggregates 
were not included in these measurements. By DLS analysis, the average hydrodynamic diameter was of ~43 nm 
(Fig. 4c).
The far-UV CD spectrum of the RT 51.2 sample is reported in Fig. 4d. The shape of the spectrum and the 
presence of two minima at ~203 and ~220 nm indicate that oligomer structure is not disordered, when compared 
to that resulting from the CD spectrum of monomeric Syn (Fig. 1c, inset). The spectra also showed that different 
conformers, partially folded and unfolded, did exist at equilibrium. Further characterization is required to better 
define the secondary structure content of these species.
Then, we mapped the overall structure of the oligomeric species at RT 51.2 min by finger printing analysis 
using trypsin after partial destabilization of the complex by Gnd-HCl (Fig. 5). Indeed, these oligomers were 
quite resistant to proteolysis, probably because of some protection by OleA or by OleA-induced conformational 
Wavelength





















































































Figure 4. Characterization of Syn off-pathway oligomers (RT 51.2) grown in the presence of OleA. (a) Gel 
filtration chromatography of the Syn/OleA (1:10) mixture after 168 h of incubation Inset: UV-vis spectra of the 
fractions at 7.4 (−) and 9.4 (−) mL of elution volume in GF. (b) RP-HPLC chromatogram at 340 nm of the Syn/
OleA (ratio 1:10) mixture at time 0 (dashed line) and 168 h (continuous line) of incubation. (c) DLS and TEM 
(inset) analysis of the purified oligomers. (d) Far-UV CD of the purified oligomers. The oligomers were purified 
by RP-HPLC and concentrated until organic solvent and TFA removal, but never dried to avoid morphological 
changes. Other experimental details are reported in the methods section. The scale bar in the TEM image 
correspond to 200 nm.
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modifications (cfr. Fig. 3). By performing exhaustive fragmentation by trypsin (15 h), only a few peptide species 
were found in the proteolysis mixture of the RT 51.2 species (Fig. 5a), when compared with same analysis carried 
out with monomeric Syn (Fig. 5b); at variance, fragments encompassing the entire sequence were detected in the 
latter (Table S2). In particular, the large fragments corresponding to the sequences 59–140 and 46–102 remained 
undigested even after 15 h (Fig. 5a) of incubation in the proteolysis mixture, suggesting that these species are 
rigid, structured or protected. To explain the presence of these peptide species, a pattern of fragmentation can be 
Figure 5. Mapping of (a) Syn off-pathway oligomers (RT 51.2) and (b) Syn monomers by trypsin proteolysis. 
The chromatograms refer to incubation with PK of the RT 51.2 sample for 5-min (c,d) or 70 min (e,f). In (d) 
and (f), the proteolysis was carried out on samples partially destabilized in Gnd-HCl. The numbers close to the 
peaks indicate the identified fragments. The term ox refers to the presence of oxidation in the peptides.
www.nature.com/scientificreports/
1 0SCIENtIFIC REPORtS |  (2018) 8:8337  | DOI:10.1038/s41598-018-26645-5
hypothesized and it is conceivable that RT 51.2 was cleaved, initially, at the level of the 45–46 peptide bond, thus 
generating the 1–45 and 46–140 fragments. The N-terminal species 1–45 was not visible, since it was further frag-
mented into smaller fragments. The C-terminal 46–140 was further cleaved at the level of the 102–103 peptide 
bond, producing the quite resistant 46–102 fragment and the 103–140 fragment, that was further degraded in 
smaller species. On the other hand, the 59–140 fragment was also seen in the chromatogram. This species could 
arise from the cleavage of the 58–59 peptide bond in the 46–140 fragment. Then, the 59–140 species underwent 
further fragmentation generating the 59–102 species. In conclusion, the 46–102, and in minor extent the 59–140, 
are the most resistant, upon prolonged trypsin treatment and after oligomer destabilization by Gnd-HCl.
A better structural characterization of the off-pathway oligomers (RT 51.2) was obtained by carrying out the 
mapping by PK with (Fig. 5d,f) or without (Fig. 5c,e) destabilization by Gnd-HCl. Indeed, the rationale of this 
approach was based on the general observation that, in the absence of the denaturant, the substrate of the protease 
is the most flexible species in equilibrium with a more structured one, not accessible by PK. Gnd-HCl addition 
destabilized the PK-resistant species, making it more susceptible to proteolysis. Moreover, in this case, the pro-
teolysis reactions were carried out for 5- and 70-min, to identify the first proteolytic events (Fig. 5c,d) and those 
occurring subsequently on a perturbed substrate, in order to recognise the proteolysis resistant species accumu-
lating in the mixture (Fig. 5e,f). In the absence of Gnd-HCl, the RT 51.2 species was only partially fragmented 
by the protease, as indicated by the fact that its peak was still visible even after 70 min of reaction (Fig. 5e) and 
that any peculiar fragment did not accumulate in the mixture. However, following partial destabilization of the 
complex, this species was almost exhaustively digested upon incubation up to 70 min (Fig. 5f). Moreover, in the 
presence of Gnd-HCl, after 5 min some species seemed to accumulate and two main cleavages did occur (Fig. 5d). 
The first, involving the 56–57peptide bond, generated the 1–56 and 57–140 fragments, whereas the other, involv-
ing the 72–73 peptide bond, produced the 1–72 and 73–140 fragments (Table S3). The two N-terminal fragments 
(1–56 and 1–72) were scarcely represented in comparison to the C-terminal ones (57–140 and 73–140) since 
the former were probably cleaved into smaller hydrophilic fragments. After longer incubation with the enzyme 
(Fig. 5f, 70 min), further cleavages took place on the C-terminal species, which generated mainly the 57–89, 
73–89 and 90–140 fragments, that remained undigested even after 70 min of incubation with PK (Fig. 5f). These 
data confirm those obtained by trypsin and suggest the coexistence of two different population of off-pathway oli-
gomers: one more susceptible to proteolysis, undergoing fragmentation in the absence of denaturant, and another, 
more resistant, that is cleaved only after denaturation. Moreover, from a comparison between the two proteo-
lytic patterns, those encompassing residues 46–102, 57–89, 59–140 and 90–140 appear to be the more protected 
regions, belonging to the NAC and C-terminal regions of the Syn sequence.
Syn aggregates grown in the presence of OleA show reduced cytotoxicity. Once described at the 
molecular level the interference of OleA with Syn aggregation, we investigated whether OleA also affected aggregate 
cytotoxicity. A first experiment was designed to determine the cytotoxicity of Syn aggregates at different fibrillation 
times. To this purpose, we used human neuroblastoma, SH-SY5Y, cells exposed for 24 or 48 h to Syn solutions 
enriched of protein in different conformations: monomer, oligomers or fibrils, obtained by incubating the protein for 
0, 48 or 168 h in aggregation conditions, respectively. Oligomers and fibrils were dose-dependently cytotoxic to cells 
exposed for 48 h, as shown by the MTT assay (Fig. 2S). Under these conditions, the solution enriched in Syn fibrils 
(Syn 168 h) was the most cytotoxic sample, followed by the solution enriched in oligomers (Syn 48 h); some cytotox-
icity, not dose-dependent, was also seen in the case of the monomeric protein before aggregation started (Syn) (Fig. 
2S). Based on these data, we decided to expose the cells for 48 h to the three different Syn solutions (5.0 μM) enriched 
in monomers, oligomers or fibrils, in the absence or in the presence of 1:10 Syn/OleA. The MTT assay showed a 
significant decrease of toxicity when the cells were treated with samples aggregated for 48 or 168 h in the presence 
of OleA (Syn 48 h/OleA, Syn 168 h/OleA) (Fig. 6a). Cell survival after exposure to the Syn 48 h/OleA was around 
100% ± 10.6 while cell survival was around 80% ± 3.1 in the presence of the Syn 168 h/OleA indicating that OleA 
was only partially effective in protecting cells against fibril cytotoxicity. Furthermore, the evaluation, by MTT assay, 
of the toxic power of the species eluted in RP-HPLC at RT 51.2 min showed that this sample was completely harmless 
even when tested purified at the final concentration of 5.0 μM (Fig. 6a).
In consideration of the key role performed by oxidative stress in the pathogenesis of PD, we also sought to 
assess the redox status of the variously treated cells by using the ROS-sensitive fluorescent probe CM-H2 DCFDA. 
We found that the different Syn aggregates stimulated some ROS production in SH-SY5Y cells that was particu-
larly evident when the cells were exposed for 48 h to Syn fibrils (Syn 168 h) (Fig. 6b). However, cell exposure to the 
different aggregates of Syn grown in the presence of 1:10 Syn/OleA did not result in any statistically significant 
increase of ROS levels (Fig. 6b). These data led us to conclude that the presence of OleA during Syn aggregation 
decreases the ability of the resulting aggregates to raise ROS production thus making non-toxic the oligomers 
whereas the toxicity of the fibrillar sample was not completely abolished.
OleA effect on pre-formed Syn oligomers and fibrils. Once established that OleA interferes with Syn 
aggregation yielding substantially non-toxic aggregates, we analysed the effect of OleA on preformed Syn oli-
gomers and fibrils to assess whether it favoured fibrils disassembly with leakage of toxic oligomers. OleA (1:10 
ratio) was added to preformed solutions enriched in oligomeric species (48 h) or fibrils (168 h). The disaggre-
gation activity by OleA was followed by fluorescence spectroscopy, limited proteolysis and MTT assay. The 
ThT spectra (Fig. 7a) were obtained from Syn oligomers (48 h) after further 24 h of incubation in the presence 
(48 h + OleA 24 h) or in the absence (72 h) of OleA in comparison with Syn oligomers (the starting point) (48 h). 
As expected, in the absence of OleA, the aggregation process proceeded towards fibrils formation with substantial 
increase of ThT intensity (as indicated by the arrow). The 48 h + OleA 24 h sample showed a decrease of ThT flu-
orescence, indicative of a stop or a slowdown of the formation of Syn aggregates. The same experimental scheme 
was followed with Syn fibrils samples (168 h). In this case, ThT fluorescence spectra were recorded after further 8 h 
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of incubation with (168 h + OleA 8 h) or without OleA (176 h). We did not find any remarkable reduction of ThT 
fluorescence in the (168 h + OleA 8 h) sample, which indicated a negligible effect of OleA on preformed fibrils.
The same samples were also subjected to limited proteolysis (Fig. 7c–h). As expected, the sample aged for 72 h 
in the absence of OleA (Fig. 7d) showed a slightly increased resistance to proteolysis in comparison to the sample 
aged for 48 h (Fig. 7c) and small fragments eluting at short RT appeared in the chromatogram. In the proteolytic 
pattern obtained from samples treated with OleA for 24 h (48 h + OleA 24 h), the low intensity of the peak relative 
to intact Syn (RT 35.5 min) suggested that the monomeric Syn still present in the mixture was fragmented and 
resulted, under these conditions, more susceptible to proteolysis (Fig. 7e). In the meantime, the species at RT 
51.2 min, previously found to increase as far as the aggregation time was prolonged, appeared in the chromato-
gram. In synthesis, monomeric Syn underwent formation of a species more susceptible to proteolysis (the peak of 
intact Syn was decreased) and a protease-resistant one (RT 51.2).
The proteolytic patterns relative to the aggregation mixture at 168 h and 176 h, in the absence of OleA, are 
quite similar since no critical events occurred in this time (Fig. 7f,g). However, upon addition of OleA (Fig. 7h), 
the proteolytic pattern was completely different and the RT 51.2 species arose in higher percentage (Fig. S4). Also 
Figure 6. Cell viability and ROS levels. (a,b) SH-SY5Y cells treated for 48 h with a 5.0 μM Syn solution obtained 
at different times of aggregation (0, 48 and 168 h) enriched in monomeric (Syn), oligomeric (Syn 48 h) or 
fibrillar (Syn 168 h) species, respectively. Each sample was obtained in the absence or in the presence of OleA 
(Syn:OleA, 1:10). (a) Cell viability assessed by the MTT reduction assay and (b) by ROS production. For the 
MTT assay, the RT 51.2 species purified by RP-HPLC was also tested. (c,d) OleA modulates the toxicity of 
preformed Syn assemblies. (c) MTT assay and (d) ROS endogenous levels in SH-SY5Y cells exposed for 48 h to 
5.0 μM Syn enriched in oligomers (Syn 48 h) or fibrils (Syn 168 h). The oligomeric samples were also analysed 
following addition of OleA after further incubation of 24 h or 5 d (Syn 48 h + OleA 24 h) and (Syn 48 h + OleA 
5d). The fibrillar species were analysed after 8 h or 5 d of incubation in the presence of OleA (Syn 168 h + OleA 
8 h) and (Syn 168 h + OleA 5d). The RT 51.2 samples purified by RP-HPLC from the mixture corresponding 
to (Syn 48 h + OleA 24 h) sample (RT 51.2a) and from that corresponding to (Syn 168 h + OleA 8 h) sample 
(RT 51.2b) were also tested by the MTT assay. Error bars indicate the standard deviation of independent 
experiments carried out in triplicate. Statistical analysis was performed using Student’s t-test. The results were 
compared using Student’s t-test between two groups, *P < 0.05; **P < 0.01; ***P < 0.001 versus untreated cells 
and °P < 0.05; °°P < 0.01; °°°P < 0.001 versus treated cells with Syn aggregates grown without OleA.
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in this case, the proteolysis data can be explained with the co-existence, in the mixture, of species characterized by 
different susceptibility to proteolysis. The species eluting at RT 51.2 min, an aggregated and highly hydrophobic 
one induced by the presence of OleA either during aggregation or at the end of the latter, was accumulating in the 
mixture and represented a PK- resistant fraction.
Figure 7. OleA-induced Syn disaggregation probed by (a,b) ThT fluorescence and (c–h) limited proteolysis. 
During aggregation, aliquots were collected from the mixture at 48 h and 168 h, then OleA was added to a 1:10 
final Syn:OleA ratio. ThT spectra in (a) refer to Syn samples corresponding to 48 h of aggregation (48 h) and to 
further 24 h of incubation in the absence (72 h) or in the presence (48 h + OleA 24 h) of OleA. The ThT spectra 
in (b) were recorded at 168 h and after additional 8 h of incubation without (176 h) or with (168 h + OleA 8 h) 
OleA. (c-h) RP-HPLC analysis of the proteolysis mixture of Syn samples during aggregation (c) at 48 h, (d) after 
further 24 h of incubation in buffer without polyphenol (72 h), (e) in the presence of OleA. The same scheme 
was followed for Syn samples collected from the aggregation mixture at 168 h of incubation (f), after further 8 h 
of incubation in the absence (g) or in the presence (h) of OleA. (e,h, inset), TEM images taken from samples 
corresponding to the peaks eluting at RT 51.2 min; scale bar: 200 nm.
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We also investigated whether OleA modified the toxicity of Syn preformed oligomers and fibrils. To this aim, 
we compared the (Syn 48 h + OleA 24 h) and (Syn 168 h + OleA 8 h) cytotoxicity to SH-SY5Y cells with that dis-
played by the same samples without the polyphenol by using the MTT and ROS assay. In addition, Syn oligomers 
and fibrils were incubated in the presence of OleA for an extra time (5 days), to assess whether OleA had some 
effects under extreme experimental conditions. Figure 6c,d show that the (Syn 48 h + OleA 24 h) sample main-
tained its potential toxicity; however, a prolonged OleA treatment (Syn 48 h + OleA 5d) made it harmless to cells 
(Fig. 6c) that also displayed reduced endogenous ROS levels (Fig. 6d). As far as the effect of OleA on preformed 
fibrils is concerned, we observed a very slight decrease of fibril cytotoxicity in both samples (Syn 168 h + OleA 
8 h) and (Syn 168 h + OleA 5d) (Fig. 6c). In spite of an evident cell sufferance, the fibrils treated with OleA for 
short and long incubation times, induced a significant decrease in ROS intracellular levels (Fig. 6d). We also 
evaluated the toxicity of the RT 51.2 samples after its purification by RP-HPLC from the mixture corresponding 
to the Syn 48 h + OleA 24 h sample (RT 51.2a) and from that corresponding to the Syn 168 h + OleA 8 h sample 
(RT 51.2b). The MTT assay confirmed that this sample was completely innocuous to SH-SY5Y cells (Fig. 6c).
OleA interferes with the interaction of Syn aggregates with the cell membrane. Finally, we 
investigated whether OleA interfered with the ability of Syn aggregates to interact with the cell membrane. In fact, 
recent data have widely reported that amyloid aggregates are able to bind to lipid bilayers and that aggregate inter-
action with the cell membranes is a crucial step of amyloid cytotoxicity59,60. In particular, it has been reported that 
exogenous oligomers and fibrils bind to the cell membrane and accumulate in lipid rafts, liquid-ordered mem-
brane microdomains rich in functional proteins (receptors, carriers, signalling molecules), sphingosine, choles-
terol and ganglioside GM161,62. In this context, Syn oligomers have been reported to display membrane-disrupting 
power on anionic lipid bilayers and to alter the permeability and the integrity of the cell membrane63.
To assess whether Syn amyloid species grown in the presence of OleA modified their propensity to interact 
with the cell membrane, we performed a sensitized FRET analysis between Alexa-488 GM1 fluorescence and 
Alexa-546 immunofluorescence on Syn aggregates. We found that both Syn oligomers and fibrils interacted with 
the cell membrane at the lipid raft level, as shown by the aggregate-GM1 co-localization (Fig. 8a,c) and by FRET 
efficiency (Fig. 8b,d). Such interaction was drastically reduced when the cells were treated with Syn aggregates 
grown in the presence of OleA (Fig. 8e,f,g,h). Then, SH-SY5Y cells were treated for 48 h with preformed Syn 
assemblies exposed for short (Syn 48 h + OleA 24 h, Syn 168 h + OleA 8 h) or long (Syn 48 h + OleA 5d, Syn 
168 h + OleA 5d) time to OleA before supplementation to the cell medium. Confocal images and FRET analysis 
revealed that short treatment of the aggregates with the polyphenol did not alter significantly the ability of the 
Syn 48 h and Syn 168 h samples to interact with the membrane at the level of the GM1 component of lipid raft 
domains (Fig. 8i,l,m,n), whereas a prolonged exposure reduced significantly oligomers, but not fibrils, interaction 
with the cells (Fig. 8o,p,q,r), in agreement with the results of the toxicity experiments reported in the preceding 
section.
Discussion
In this study, we show that OleA interferes with Syn fibrillation in a dose-dependent manner, with the optimal 
1:10 Syn/OleA ratio; the inhibition is due, apparently, to OleA interaction with Syn monomeric and oligomeric 
species, an effect similar to that reported for other polyphenols64,65. We also report that OleA reduces the toxicity 
of Syn amyloid aggregates, favouring the growth of harmless off-pathway oligomers. In fact, Syn aggregates grown 
in the absence or in the presence of OleA, displayed a very different ability to interact with the plasma mem-
brane and to induce sufferance and oxidative stress in exposed cells. Recently, the ability of Syn to self-propagate 
and spread progressively between interconnected brain regions via a cell-to-cell transmission in PD model and 
patients has been repeatedly reported and is increasingly accepted as a central mechanism in the development 
of the disease66,67. In view of this notion, several new therapeutic strategies to combat PD are aimed at inhibiting 
not only Syn misfolding and aggregation, but also the prion-like interneuronal transport of aggregation seeds22. 
In this context, our findings showing a decreased interaction of the OleA/Syn complex with GM1-enriched sites 
at the cell membrane and the OleA interaction with preformed Syn aggregates (notably oligomers and prefibril-
lar assemblies), converting them into stable and inert species are of interest. Overall, these data suggest that the 
polyphenol, besides interfering with the aggregation path, also hinders the association of Syn and/or its aggre-
gates with the cell membrane, presumably, by generating new species with different surface properties. Our find-
ings are of importance in the evaluation of the potential use of OleA in PD treatment, suggesting that OleA could 
be beneficial not only by interfering with toxic aggregation of Syn and by favouring aggregate disassembly in 
non-toxic species, but also by hampering their self-propagation.
To better elucidate the mechanism of OleA effects at the molecular level, we investigated the modifications 
of the structure and cytotoxicity of Syn in different aggregated states arising in the presence of OleA. Syn-OleA 
interaction was probed by several biophysical and biochemical techniques. We found that OleA does not modify 
the secondary structure of monomeric Syn and its chromatographic behaviour (retention time in RP and elution 
volume in GF). On the other hand, the immediate appearance, in the protein/OleA mixture, of a late eluting 
species in RP (51.2 min), yet earlier than monomeric Syn in GF, clearly indicates that the polyphenol exerts an 
instantaneous effect on Syn, inducing the formation of a new species (see Figs 4 and 5, for its characterization). 
The abundance of this species appeared to be dependent on incubation time and OleA concentration, however 
it did not evolve into fibrils; overall, the structural features of this species allow to classify it as a population of 
off-pathway oligomers28,68. Interestingly, when OleA was added to the aggregation mixture during the elonga-
tion phase, the growing aggregates (oligomers and protofibrils) were apparently solubilised into species recalling 
the off-pathway oligomers formed when OleA was present since the beginning of aggregation. The harmless 
off-pathway oligomers appeared characterized by a heterogeneous morphology, even though mainly spheroidal. 
Their secondary structure was substantially random, yet in the presence of a minor content of beta-sheet. Of note, 
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the proteolysis mapping experiments on off-pathway oligomers showed that the NAC and C-terminal regions 
of Syn are most persistent in solution and suggested a high affinity of OleA for specific regions of Syn. In fact, 
OleA stabilized the NAC and C-terminal region and hindered the long-range interactions favouring amyloid 
aggregation.
The limited proteolysis data provided important information on Syn dynamics and structural rearrangement 
during the aggregation process in the presence or in the absence of OleA. Actually, Syn displayed increased 
resistance to proteolysis as far as the aggregation process proceeded; this is not surprising, when one con-
siders that, as reported for other amyloid forming proteins, during aggregation the Syn polypeptide chain is 
progressively embedded into the highly ordered, compact fibrillar structure58,69. In the presence of OleA, Syn 
exhibited a reduced tendency to aggregate and a concomitant increased sensitivity to proteolysis, whereas, the 
off-pathway oligomeric species eluting at RT 51.2 min were proteolysis-resistant. To better describe this finding, 
the Syn species were classified as PK-sensitive, PK-resistant and PK-resistant off-pathway oligomers (Fig. S3). 
The first fraction contained the soluble components of the aggregation mixture; the PK-resistant Syn contained 
the pre-fibrillar and fibrillar species in equilibrium with the soluble ones; the PK-resistant off-pathway oligomers 
fraction contained the protease-resistant molecular species eluting at RT 51.2 min. At the beginning of the aggre-
gation (Fig. S3a), the most populated fraction was the PK-sensitive one. As expected, as far as aggregation pro-
ceeds, the PK-resistant population increased, at the expense of the PK-sensitive fraction that decreased inversely 
(Fig. S3b,c). However, when Syn aggregation was carried out in the presence of OleA, the PK-sensitive frac-
tion was stabilized, preventing the formation of the PK-resistant Syn species, while the PK-resistant off-pathway 
oligomers were increasingly produced over time. The same approach was used to understand (i) whether the 
same partitioning event between PK-sensitive and PK-resistant species resulted from aggregate disassembly by 
OleA added at the elongation and plateau phases and (ii) to define Syn conformers preference of OleA. For these 
Figure 8. The complex OleA-Syn does not bind to the plasma membrane. (a,e and c,g) Z-projection of Syn 
samples grown in the presence (Syn 48/OleA, Syn 168/OleA) or in the absence of OleA (Syn 48 h, Syn 168 h) 
by immunostaining (red) and GM1 staining (green) on SHSY5Y cell membrane. (b,f and d,h) FRET analysis 
between GM1 staining and aggregate immunostaining. OleA affects preformed Syn assemblies and their 
membrane interaction. (i,o, and m,q) Z-projection of preformed Syn assemblies (oligomers and fibrils) treated 
with OleA for two different times (Syn 48 h + OleA 24 h and Syn 48 h + OleA 5d) and (Syn 168 h + OleA 8 h and 
Syn 168 h + OleA 5d) by immunostaining (red) and GM1 staining (green) on SH-SY5Y cell membrane. (l,p, and 
n,r) FRET analysis between GM1 staining and aggregate immunostaining.
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reasons, we carried out limited proteolysis on samples enriched either in on-pathway oligomers aged 48 h or 
on fibrils aged 168 h. ThT measurements clearly showed that OleA decreases fibril formation, when added to a 
solution enriched in oligomers. In this case, the PK-resistant fraction strongly decreased, while the PK-sensitive 
Syn increased and the PK-resistant off-pathway oligomers were grown (Fig. S4a). These data confirm that the 
oligomeric species in the mixture do interact with OleA, giving rise to off-pathway oligomers (PK-resistant RT 
51.2) and to a stabilized form of monomeric Syn (PK-sensitive). Moreover, the species populating this sample 
showed a membrane activity and cytotoxicity that decreased as far as the incubation with the polyphenol was 
prolonged. In parallel, we observed a concomitant decrease in ROS levels, one of the events associated to amy-
loid toxicity, which, in this case, was assigned to OleA re-modelling of the growing assemblies, that, eventually, 
showed different surface properties. In the case of pre-formed fibrils, the ThT data showed a modest effect of 
OleA. However, the limited proteolysis experiments suggest that the polyphenol induces the formation of the 
PK-resistant species eluted at RT 51.2 with reduction of PK-resistant Syn, whereas monomeric PK-sensitive Syn 
was scarcely affected (Fig. S4b). Furthermore, the toxicity of pre-formed fibrils treated with the polyphenol was 
not significantly affected even after a prolonged treatment (5 days), yet in the presence of a significant reduction 
of oxidative stress. The reduced cellular levels of ROS could result from the radical scavenging properties of OleA 
in accordance with previous studies describing the role of the antioxidant properties of this polyphenol in the 
prevention of amyloid assembly cytotoxicity70,71. However, in this case, aggregate toxicity persisted because OleA 
failed to reduce the membrane activity of the pre-formed fibrils treated with the polyphenol.
In conclusion, our data support the existence of parallel mechanisms of action of OleA. We hypothesized 
that OleA interacts differently with the previously reported interconverting conformers of monomeric Syn in 
solution72, stabilizing the best-fitting conformation. Moreover, OleA might select the most prone-to-aggregation 
conformation, confining it into a non-toxic off-pathway oligomer. This view can be supported by the faster con-
version of the aggregation-prone monomeric Syn into off-pathway oligomers in the presence of OleA, during 
the early elongation phase; the latter normally is populated by aggregation-prone monomeric Syn and early 
on-pathway oligomers, that become solubilised and stabilized in the presence of OleA. At the plateau phase, the 
effect of OleA on pre-formed fibrils is different, since OleA did not solubilize the fibrils but converted them into 
smaller assemblies that eluted in RP-HPLC as the off-pathway oligomers grown from aggregation prone Syn. In 
addition, at molecular level, OleA stabilized the NAC and C-terminal regions of Syn, preventing the long-range 
and hydrophobic interactions that favour amyloid aggregation72,73.
Taken together, our data support the potentiality of polyphenols and similar compounds as neuroprotective 
agents extending the beneficial properties of olive polyphenols or their molecular scaffolds as promising can-
didates for long-term nutraceutical treatment of PD. The latter could reduce and delay aging-associated neu-
rodegeneration in sporadic PD limiting the need of the symptomatic pharmacological treatment, the only one 
presently available, in the expectation that new therapies, such as cell therapy, will improve their efficacy in large 
number of patients. Moreover, our analysis of the structural and biological features of the Syn oligomeric species 
grown at different aggregation conditions provides an useful contribution to better understand, at the molecular 
level, their neurotoxicity in neurodegeneration, as issue of particular relevance in PD pathogenesis.
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Abstract
The biological function of α-Synuclein has been related to binding to lipids and membranes
but these interactions can also mediate α-Synuclein aggregation, which is associated to
Parkinson’s disease and other neuropathologies. In brain tissue α-Synuclein is constitutively
N-acetylated, a modification that plays an important role in its conformational propensity,
lipid and membrane binding, and aggregation propensity. We studied the interactions of the
lipid-mimetic SDS with N-acetylated and non-acetylated α-Synuclein, as well as their early-
onset Parkinson’s disease variants A30P, E46K and A53T. At low SDS/protein ratios α-
Synuclein forms oligomeric complexes with SDS micelles with relatively low α-helical struc-
ture. These micellar oligomers can efficiently nucleate aggregation of monomeric α-Synu-
clein, with successive formation of oligomers, protofibrils, curly fibrils and mature amyloid
fibrils. N-acetylation reduces considerably the rate of aggregation of WT α-Synuclein. How-
ever, in presence of any of the early-onset Parkinson’s disease mutations the protective
effect of N-acetylation against micelle-induced aggregation becomes impaired. At higher
SDS/protein ratios, N-acetylation favors another conformational transition, in which a sec-
ond type of α-helix-rich, non-aggregating oligomers become stabilized. Once again, the Par-
kinson’s disease mutations disconnect the influence of N-acetylation in promoting this
transition. These results suggest a cooperative link between the N-terminus and the region
of the mutations that may be important for α-Synuclein function.
Introduction
Parkinson’s disease (PD) is the most common neuronal motor system disorder affecting more
than 1% of the population aged over 65 [1]. PD is characterized by the loss of dopaminergic
neurons in the “substantia nigra” and the appearance of intraneuronal inclusions known as
Lewy bodies, which are composed principally by fibrillar amyloid aggregates of proteins. α-
Synuclein (aS) is the major component in these aggregates [2]. A genetic link between PD and
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aS was also established with the discovery of several missense mutations, corresponding to
A30P, E46K and A53T substitutions, in the gene SNCA encoding for aS in kindreds with auto-
somal-dominantly inherited, early-onset PD [3–5]. Other pathogenic mutations have also
been reported more recently [6,7]. A variety of environmental and physiological factors can
induce aS self-assembly into oligomers and aggregates, some of which are highly neurotoxic,
leading to PD and other neurodegenerative disorders [8,9].
aS is a 140-residue protein widely expressed in brain cells and particularly abundant at the
presynaptic terminals of neurons [10]. Its sequence comprises a N-terminal domain, which
contains seven imperfect 11-residue lipid-binding repeats, and a C-terminal highly acidic tail.
Accumulating evidence relates aS function to a variety of interactions with lipids and mem-
branes. This protein seems to modulate presynaptic vesicle pool size and vesicle recycling and
participates in the regulation of synaptic plasticity and dopamine neurotransmission [11]. It
also participates in the transport and regulation of polyunsaturated fatty acids (PUFAs) in
dopaminergic neurons [12,13], sequestration of arachidonic acid in exocytosis regulation [14],
and induction of curvature and remodeling of membranes [15–17].
Although native soluble aS has been considered for many years to be an intrinsically disor-
dered protein [18,19], it acquires α-helical structure upon binding to membranes [20], micelles
[21,22] or PUFAs [23,24]. This suggests an important role for this helical structure in aS func-
tion. Diverse studies with model micelles and membranes have described that, depending on
the surface curvature, aS can adopt different α-helical conformations in its membrane bound
state, including an extended helix [20,25], a curved helix [26], or a helix-turn-helix hairpin con-
formation [21,27]. On the other hand, the influence of lipid interaction on aS aggregation is
complex and whether lipids and membranes favor or inhibit formation of toxic oligomers and
amyloid fibrils depends on the aS/lipid proportion and the environmental context [28–30].
The anionic surfactant sodium dodecyl sulfate (SDS) has been widely used in biophysical
studies to mimic lipid interactions with proteins and to study its effects on protein aggregation
[31–33]. Previous studies have shown that SDS can strongly enhance aS fibrillation at relatively
low SDS/aS ratios, whereas formation of α-helical structure and interaction with bulk SDS
micelles protects from fibrillation [34–36].
The N-terminal region of aS has been described to play a crucial role in the interaction of
aS with lipid membranes [37,38]. N-terminal acetylation increases helical propensity of the N-
terminal region of aS in its free monomeric state [39]. It also enhances helical structure of aS
in the bound state to SDS micelles or negatively charged lipid micelles, as well as affinity for
physiological membranes [40,41]. In addition, it has been observed that N-acetylation reduces
the aS fibrillation rate by in vitro incubation in buffer under shaking conditions [39,42], as well
as in the presence of lipid vesicles containing GM1 ganglioside [40]. Despite the evidence that
N-acetylated aS (Ac-aS) is universally present in vivo, in both the soluble and insoluble frac-
tions of brain tissues of PD patients [43], most in vitro biophysical studies of aS aggregation
and micelle and membrane interaction have been made with recombinant non-acetylated aS.
It is therefore important to increase our understanding of how aS modifications such as N-
acetylation and early-onset PD mutations affect the interplay between aS conformational
changes, lipid interactions oligomerization and aggregation propensity.
Here we used a variety of biophysical methods to analyze the effects of the interactions with
SDS on the structure, oligomerization and amyloid aggregation of aS and Ac-aS. We show that
both aS and Ac-aS variants bind and stabilize diverse micellar SDS-aS complexes. In this pro-
cess, the proteins acquire several interconverting conformational/oligomerization states at dif-
ferent SDS/protein ratios. N-acetylation and early-onset PD mutations alter significantly the
equilibrium between these states in different ways, changing the propensity of aS to
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oligomerize and aggregate. The results suggest the existence of a cooperative link between the
N-terminus and the regions of PD mutations than may play an important role for aS function.
Materials and methods
Protein production and purification
The different aS variants were produced by overexpression in E.Coli modified with the plasmid
containing the respective sequences. To obtain the respective N-acetylated form, the N-terminal
acetyl-transferase B (NatB) plasmid was added to the cells together with 5 μg/mL chloramphen-
icol to the culture media [44]. The cells were cultured in LB media in the presence of 100 μg/mL
of ampicillin at 37˚C with shaking until an optical density at 600 nm of 0.6–0.8. Protein expres-
sion was induced by adding isopropyl 1-thio-β-D-galactopyranoside to a final concentration of
50 μg/mL (0.2 mM) for 4 h. The cells were harvested by centrifugation at 2200 g for 10 min at
4˚C. The pellets were resuspended in buffer (25 mM Tris, 1 mM EDTA, 0.1 mM DTT, pH 7.4,
1 x protease inhibitor mixture (Roche, Penzberg, Germany) and lysed by ultrasonication. The
lysate was ultracentrifuged at 105000 g for 45 min at 4˚C. The supernatant was filtered
(0.45 μm) and applied onto a HiTrap QFF anion-exchange column (GE Healthcare, Chicago,
Illinois) previously equilibrated in buffer (50 mM Tris, 0.1 mM DTT, pH 7.4). The protein was
eluted using a NaCl gradient of (0–500 mM). After analysis by SDS-PAGE, the pooled protein
fractions were precipitated with ammonium sulfate at 47.5% of saturation and the suspension
was ultracentrifuged at 105000 g for 30 min at 4˚C. The precipitate was resuspended (50 mM
Tris, 50 mM NaCl, 0.1 mM DTT, pH 8.3, containing 8M urea) and injected onto a HiLoad 26/
60 Superdex 200 column (GE Healthcare, Chicago, Illinois). Subsequently, the protein fractions
were pooled and dialyzed extensively against the same buffer in the absence of urea. Then, the
protein was concentrated (Amicon ultracentrifugal filter units MWCO 3.000, Millipore, Biller-
ica, Massachusetts) and injected onto a HiLoad 26/60 Superdex 75 column (GE Healthcare,
Chicago, Illinois). Pure pooled fractions were dialyzed against 20 mM HEPES, 0.05% NaN3, pH
7.2, lyophilized and kept frozen at −20˚C. The purified proteins were>95% pure according to
SDS-PAGE. The identity of each protein was assessed by electrospray mass spectrometry.
Circular dichroism
Far-UV CD measurements were performed at 25˚C with a Jasco J-715 spectropolarimeter
(Tokyo, Japan) equipped with a thermostatic cell holder in a 0.2 mm path length cuvette. The
protein concentration was 100 μM and SDS was added from a stock solution of 100 mM to a
final concentration ranging between zero and 10 mM. The CD spectra were the average of 5
scans using a bandwidth of 1 nm and a scan speed of 100 nm/min. Baseline spectra were mea-
sured with buffer containing each SDS concentration and subtracted from the sample spectra.
Data were normalized as mean residue ellipticity and the α-helix content was obtained using
its value at 222 nm as described previously [45].
Dynamic light scattering
DLS measurements were performed at 25˚C using a DynaPro MS-X instrument (Wyatt Tech-
nology Corporation, Santa Barbara, CA, USA) in a thermostated 30 μL quartz cuvette. The
protein solutions and the buffer were filtered through 0.02 μm Anotop 10 filters (Whatman
plc, Brentford, Middlesex, UK) before the measurements. Sets of DLS data were acquired
every 5 s until at least 20 sets of data were obtained. The measurements were performed in trip-
licate. Dynamics V6 software (Wyatt Technology Corporation, Santa Barbara, CA, USA) was
used in data collection and processing. The experimental autocorrelation curves were analyzed
to obtain the particle size distributions using the implemented regularization fit.
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Size-exclusion chromatography
SEC experiments were carried out at room temperature on a Superdex 200 10/300 GL column
(GE Healthcare, Chicago, Illinois) at a flow rate of 0.5 mL/min, equilibrated in 20 mM HEPES,
0.05% NaN3, pH 7.2, including the appropriate SDS concentration. The column was first cali-
brated with protein standards of different molecular weight. The aS and Ac-aS samples were
freshly prepared in the same buffer, containing the desired SDS concentration at a protein
concentration of 100 μM and filtered through 0.02 μm Anotop 10 filters (Whatman plc, Brent-
ford, Middlesex, UK).
Measurement of aggregation rates by thioflavin T fluorescence
Amyloid aggregation was monitored at 37˚C by thioflavin T (ThT) fluorescence using a Varian
Cary Eclipse spectrofluorimeter (Agilent Technologies, Santa Clara, CA, USA) equipped with
a Peltier-controlled thermostatic cell holder. Protein samples at a final concentration of
100 μM were freshly prepared in 20 mM HEPES, 0.05% NaN3, pH 7.2, containing 10 μM ThT
and the appropriate SDS concentration. To avoid evaporation during the experiments, the
cuvette was sealed using a specific stopper.
NMR spectroscopy
NMR experiments were performed on a Varian Direct Drive 600 MHz spectrometer (Califor-
nia, USA) at 25˚C. For each experiment samples were freshly prepared in deuterium oxide at a
protein concentration of 100 μM in 5 mM sodium phosphate buffer, 0.05% sodium azide, pH
7.2, containing the desired SDS concentration. Diffusion-ordered spectroscopy (DOSY) spectra
were obtained using a gradient length of 3 ms and a diffusion delay of 250 ms. Gradient strength
was previously calibrated using the HDO signal in a doped D2O standard. The DOSY data sets
were composed by 30 gradient strengths with 128 scans every increment. The DOSY data were
processed using MestreNova 10.0 (Mestrelab Research S.L, Spain). Diffusion coefficients were
obtained by fitting the intensity decays versus the gradient strength as described elsewhere [46].
The hydrodynamic radii were calculated with the Stokes-Einstein equation, Rh = kBT/6πηD,
where kB is the Boltzmann constant, T is the absolute temperature, D is the diffusion coefficient
and η is the viscosity of D2O at 298 K.
Transmission electron microscopy
The morphology of aS aggregates was studied using a Carl Zeiss LEO 906E transmission elec-
tron microscope (Zeiss, Oberkochen, Germany). Freshly prepared protein samples were previ-
ously incubated at 37˚C for different time periods in the presence of several SDS
concentrations. 10 μL of the incubated protein solution were left to adsorb on a Formvar
300-mesh copper grid (ANAME, Madrid, Spain) for 1 minute. Then, the sample was nega-
tively stained with 10 μL of 1% (w/v) uranyl acetate solution for 1 minute without previous
washing steps. Excess stain was removed with a tissue paper and the grids were air dried before
visualization. The samples were observed at a magnification between 60000× and 100000×.
Results
Conformational transitions of aS induced by SDS
The structural changes of 100 μM wild-type (WT) aS and Ac-aS induced by SDS were observed
by CD spectroscopy at 25˚C varying the SDS concentration from zero to 10 mM. Under the
conditions of this study (20 mM HEPES, pH 7.2, 25˚C), the critical micellar concentration
(CMC) of SDS was determined by scattering measurements to be 6.4 ± 0.6 mM (S1 Fig),
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analogous to the value of 7.5 mM reported elsewhere under similar conditions but pH 7.0 [34].
We chose this low ionic strength buffer in order to attain a relatively wide sub-CMC SDS con-
centration range, since previous studies have shown that binding of helical aS to bulk SDS
micelles protects it from aggregation [36]. Below 0.3 mM SDS the two aS variants are mostly
unstructured as previously observed, with an estimated 8% α-helix, indicating some α-helical
propensity (Fig 1). Above 0.4–0.5 mM SDS there is a gradual formation of α-helical structure
produced by SDS. The data suggest three structural transitions. First, between 0.4 mM and
Fig 1. Effect of SDS on the secondary structure of aS and Ac-aS. (A and B) Far-UV CD spectra were
recorded at 25˚C in 20 mM HEPES buffer pH 7.2, in presence of increasing SDS concentrations for aS (A)
and Ac-aS (B). The protein concentration was 100 μM in all measurements. The spectra were normalized to
mean residue molar ellipticity. (C) Percentage of α-helix structure of 100 μM aS (filled symbols) and Ac-aS
(open symbols) at different SDS concentrations. The values have been calculated from the mean residue
ellipticity at 222 nm measured in the far-UV CD spectra [45]. The error bars correspond to at least two
independent measurements.
https://doi.org/10.1371/journal.pone.0178576.g001
Effect of N-acetylation on SDS-induced structure and aggregation α-Synuclein
PLOS ONE | https://doi.org/10.1371/journal.pone.0178576 May 31, 2017 5 / 24
about 3 mM SDS the α-helix percent increases gradually to about 40%. In this SDS concentra-
tion range the changes are very similar for aS and Ac-aS. Second, between 3 and 5 mM SDS
the α-helicity increases slightly more steeply and reaches a maximum. This maximum appears
slightly more pronounced for N-acetylated aS although the difference is not statistically signifi-
cant. Third, between 7 mM and 10 mM SDS the α-helical structure decreases again to about
45%. Similar conformational transitions were observed in a previous study for aS [36].
Formation of SDS-aS oligomeric complexes
To investigate the changes in molecular size of aS and Ac-aS as a result of their interaction
with SDS, we analyzed the mixtures by dynamic light scattering (DLS) (Fig 2). In the absence
of SDS, both aS and Ac-aS show identical hydrodynamic radius (Rh) of 2.6 ± 0.1 nm, in agree-
ment with compact disordered aS [47]. Between zero and 0.3 mM SDS the apparent Rh does
not change significantly for most of the protein mass and only trace amounts of oligomers and
large aggregates could be detected. Between 0.4 mM and 0.8 mM SDS, a significant and
increasing fraction of the proteins form particles with apparent Rh ranging between 5 and 9
nm, which may be attributed to SDS-associated aS oligomers. These oligomers could be dis-
cerned from the aS monomers only in some of the DLS measurements, whereas in others the
two different sizes could not be resolved, resulting in an averaged Rh. This may be due to a lim-
ited resolving power of DLS for these size differences but is also possible that the time scale of
DLS (μs to ms) may be close to that of this oligomerization equilibrium. The fraction of protein
mass that forms oligomers increases rapidly for both variants with a rise in SDS concentration,
with concomitant reduction in the monomer fraction. From 1 mM to 3 mM SDS, a single
average Rh value could only be measured for both proteins, reaching about 4.5 nm between 0.8
mM and 1.5 mM SDS and then decreasing gradually to about 3 nm at *3 mM SDS for Ac-aS
and at *4 mM for aS. This suggests a reduction in the number of aS molecules in each SDS-aS
complex but it could also indicate a more compact conformation of aS in the bound state, as a
result of a higher α-helical content, as observed by CD. In fact, the average α-helix content of
both Ac-aS and aS increases up to about 40% at these SDS concentrations.
More prominent differences between the two protein variants were found in the 4–10 mM
SDS concentration interval. A second increase in the apparent Rh takes place between 3 and 6
mM SDS for Ac-aS. This is again a result of exchange between two types of particles of differ-
ent sizes that could be resolved in some DLS measurements. A maximum average Rh of 4 nm
is observed for Ac-aS between 5 and 6 mM SDS, coincidently with the maximum α-helical per-
centage, and is followed by a further Rh decrease to about 2.5 nm at the highest SDS concentra-
tion investigated (10 mM). These results indicate that self-association of protein-SDS
complexes to form larger particles involves an additional α-helical conformational change in
Ac-aS. This second oligomerization process is considerably less pronounced for non-acety-
lated aS.
Free SDS and aS are in rapid exchange with SDS-aS oligomeric
complexes
The protein-SDS mixtures were also analyzed by size-exclusion chromatography (SEC) at dif-
ferent SDS concentrations (Fig 3). Unfortunately, the SDS concentration could be increased
only up to 3 mM because SDS interacted with the column matrix at higher concentrations. In
the absence of SDS, both monomeric aS and Ac-aS elute at volumes corresponding to a 36
kDa globular protein, in good agreement with the apparent hydrodynamic radii measured by
DLS corresponding to a compact disordered protein. At 0.4 mM SDS a considerable peak
broadening could be observed, suggesting exchange between the free monomer and SDS-
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bound protein oligomers. At higher SDS concentrations the proteins eluted at lower elution
volumes and always as single peaks indicating fast exchange between aS monomers and
aS-SDS oligomers. When aS was preincubated with SDS and then analyzed in pure buffer the
protein eluted as monomer (not shown), which confirms that the SDS-protein interaction is
rapidly reversible. No evidence of large aggregates eluting in the exclusion volume was
Fig 2. Changes in molecular size of aS (A) and Ac-aS (B) as a result of interactions with SDS. The
apparent hydrodynamic radius (Rh) of 100 μM protein in presence of different SDS concentrations was
measured by DLS at 25˚C. The black symbols represent the Rh of particles (left scale) corresponding to more
than 2% of the protein mass and more than 10% of the scattered intensity. Measurements reporting two
different particle sizes (circles and triangles) are represented with filled symbols. The black solid line
corresponds to the intensity-averaged Rh at each SDS concentration. The red symbols represent the mass
percent of each type of particle (right scale).
https://doi.org/10.1371/journal.pone.0178576.g002
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observed under these conditions. The elution volumes changed in parallel for both proteins
with the SDS concentration. The lowest elution volume was observed at 1.5 mM SDS corre-
sponding to that of a globular protein of about 220 kDa.
1D 1H-NMR spectra of the two aS variants were recorded at 25˚C at different SDS concen-
trations. To avoid interference from the intense resonances from the HEPES buffer, we used 5
Fig 3. Hydrodynamic properties of aS and Ac-aS. Size-exclusion chromatography analysis aS (A) and Ac-
aS (B) in presence of different SDS concentrations, as indicated in different colors. (C) Elution volumes of
each peak maximum at each SDS concentration.
https://doi.org/10.1371/journal.pone.0178576.g003
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mM sodium phosphate buffer pH 7.2 in 100% D2O for these experiments. The ionic strength
of this buffer (about 0.014 M) is similar to that of the HEPES buffer used in the rest of the
experiments. Many protein resonances become broadened at SDS concentrations between
0.25 mM and 3.5 mM and sharpened again above 5 mM SDS (Fig 4). Particularly evident is the
behavior of the well-resolved Hε1 resonance of the His50 side chain, which is considerably
broadened and gradually downfield shifted between 7.7 and 8.5 ppm, as a result of the interac-
tions with SDS. This is consistent with a moderately rapid exchange in the NMR time scale
between the free protein and SDS-aS oligomeric complexes. The conformational change
sensed by His50 is complete above 5 mM SDS. Another interesting observation is that below 2
mM there are no visible sharp resonances attributable to free monomeric SDS, as a result of
strong line broadening. Above 3.5 mM the free SDS resonances start to emerge in the spectra,
although still broadened, and their intensities increase linearly with the total SDS concentra-
tion. Signal integration around the position of the free SDS signals shows two separate trends
with a sharp break around 4.5 mM (Fig 4C). These results indicate a maximum binding stoi-
chiometry of about 40–50 SDS molecules per aS molecule, similar to that reported elsewhere
[36]. At higher concentrations, SDS is in rapid exchange between SDS monomers, free SDS
micelles and SDS-aS micellar complexes.
Diffusion-ordered spectroscopy (DOSY) 1H-NMR measurements were carried out for each
aS variant at 100 μM protein concentration in the presence of SDS from zero to 10 mM. The
CMC of free SDS under these conditions was determined as 3.7 ± 0.3 mM by scattering mea-
surements (S1 Fig) and 3.8 mM from DOSY measurements (Fig 5A). The diffusion coefficient
of monomeric SDS is (4.6 ± 0.2) × 10−10 m2 s−1, in good consistency with values ranging from
4.7 to 4.9 × 10−10 m2 s−1, as published elsewhere [48]. Above the CMC, monomeric SDS is in
rapid exchange with micelles and its diffusion coefficient decreased progressively with an
increase in concentration.
Translational diffusion coefficients were measured for aS and Ac-aS by fitting the decay of
the intensity of the protein resonances with the gradient strength, using the integrals of spec-
tral regions devoid of the influence of SDS signals, i.e., the region between 6.5 and 7.5 ppm,
corresponding to the aromatic protons, and the region between 1.7 and 3.2, in the aliphatic
region. The diffusion coefficients of both proteins are represented in Fig 5A. The apparent
hydrodynamic radii derived from these data are plotted in Fig 5B. In the absence of SDS the
apparent Rh of the two proteins is consistent with their monomeric state. Above 0.5 mM SDS
the Rh of the two proteins increases to about 5.5 nm at 1.25–1.5 mM SDS and then decreases
to about 3 nm at 3.5 mM SDS, consistently with the observations by DLS. However, in contrast
to DLS, monomeric and oligomeric particles could not be resolved in the DOSY experiments.
The size increase starts at slightly lower SDS concentration for Ac-aS than for aS. At higher
SDS concentrations there is another size increase for Ac-aS that is much less pronounced for
aS, as it was observed by DLS. This confirms that Ac-aS shows a higher propensity than aS to
form oligomeric complexes with SDS in the high SDS concentration range.
To estimate the diffusion coefficient of SDS in the mixtures we used the decays of the inte-
grals of two spectral regions around the SDS signals, i.e., the region between 4.5 and 3.2 ppm
and the region between 1.6 and 0.4 ppm. Since these regions include both SDS and protein res-
onances, the signal decays were fitted using a double exponential function, fixing the diffusion
coefficient of the protein to the values previously obtained from the spectral regions devoid of
SDS resonances (S2 Fig). The diffusion coefficient of SDS (Fig 5A) decreases sharply between
zero and 1 mM SDS and then fluctuates around 1.5–2.0×10−10 m2 s−1 for the rest of the SDS
concentration range. These diffusion coefficients tend to converge with those measured for
free SDS above its CMC. These data suggest that above 1 mM a major fraction of SDS becomes
incorporated in aS-SDS micellar complexes.
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Fig 4. Effect of SDS on the NMR spectra of aS and Ac-aS. Aromatic and aliphatic regions of the 1D 1H
NMR spectra of aS (A) and Ac-aS (B) in 100% D2O, 5 mM sodium phosphate buffer pH 7.2, in the presence of
different SDS concentrations. Spectra were acquired at 25˚C at 100 μM protein concentration. The intensities
of each spectral region have been adapted for proper visualization. The Hε1 resonance of the His50 is
identified with arrows at 0 and 10 mM SDS. The signal marked with a cross corresponds to an impurity. The
positions of the free SDS resonances have been marked with asterisks. (C) Signal intensity at the position of
the resonance of α-methylene protons of free SDS at different SDS concentrations in presence of 100 μM aS
and Ac-aS. The intensity values correspond to the integral of the spectra between 3.80 and 3.95 ppm.
https://doi.org/10.1371/journal.pone.0178576.g004
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Rapid formation of amyloid oligomers and fibrils induced by SDS
To investigate how the N-terminal acetylation influences the aggregation of aS induced by
SDS, we monitored the aggregation of both acetylated and non-acetylated aS variants in the
presence of different SDS concentrations by thioflavin T (ThT) fluorescence. Aggregation
kinetics were measured at 37˚C in 20 mM HEPES buffer pH 7.2 at a protein concentration of
0.1 mM under quiescent conditions (Fig 6). In the absence of SDS, neither of aS nor Ac-aS
aggregated significantly for several weeks under our experimental conditions. However, low
SDS concentrations ranging between 0.2 mM and 1.5 mM induced rapid aS aggregation (Fig
6A–6B). The initial slopes in the kinetics are representative of a rapid nucleation of amyloid
structure [49]. The measured initial rates (Fig 6D) show however considerable variability in
different sample preparations with identical SDS concentrations, resulting in large uncertain-
ties. Nevertheless, aggregation of non-acetylated aS is significant above 0.3 mM SDS.
Fig 5. Hydrodynamic properties of SDS, aS and Ac-aS measured by DOSY NMR. (A) Diffusion
coefficients of SDS, aS and Ac-aS in free SDS solutions and protein-SDS mixtures at different SDS
concentrations. DOSY experiments were carried out at 25˚C in 100% D2O, 5 mM sodium phosphate buffer pH
7.2. Protein concentration in the mixtures was 100 μM. Errors correspond to 95% confidence intervals of the
fittings of the DOSY intensity decays. The CMC of SDS (3.8 mM) was estimated from the intercept of the two
observed linear tendencies. (B) Apparent hydrodynamic radius of aS and Ac-aS in presence of different SDS
concentrations calculated from the diffusion coefficients shown in (A).
https://doi.org/10.1371/journal.pone.0178576.g005
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Maximum aggregation rates occur between 0.5–0.8 mM SDS and then decrease. At 1.25 mM
SDS, an incipient lag phase becomes noticeable in the kinetics (Fig 6C). Above 2.5 mM SDS
the aggregation rate is negligible. A similar tendency was observed for Ac-aS but the aggrega-
tion rates are considerably reduced compared to aS and some lag is perceptible at lower SDS
concentrations (Fig 6C). For both protein variants, the maximum aggregation rates occur at
SDS concentrations where monomeric aS coexists with large SDS-aS oligomeric complexes,
suggesting that both states may contribute to productive formation of amyloid nuclei.
The morphology of the aS aggregates induced by SDS was analyzed by transmission elec-
tron microscopy (TEM) (Fig 6E–6H and S3–S5 Figs). At early time points during the aggrega-
tion kinetics, only small globular aggregates or clusters of them and few small protofibrils were
observed for both proteins. Formation of these aggregates produced a rapid growth of ThT
fluorescence, which indicates that they have amyloid structure. After 16 hours of incubation,
more protofibrils and curly fibrils appear to develop by association of the globular aggregates.
Longer and straighter fibrils grow after several weeks of incubation for both protein variants
(S5 Fig). No clear differences in the morphology of the aggregates could be observed between
aS and Ac-aS, although the progress of the fibril assembly under each condition seemed to be
slower for the acetylated protein, in agreement with the ThT fluorescence experiments.
Fig 6. Amyloid aggregation induced by SDS. (A and B) Representative aggregation kinetics of aS (left panel) and Ac-aS (right panel) at
37˚C followed by ThT fluorescence in presence of different SDS concentrations. (C) Scale expansion of some of the kinetics showing
incipient lag phases. Numbers alongside each trace indicate the SDS concentration for aS (blue) and Ac-aS (red). (D) Initial aggregation
rates at 37˚C of WT aS and Ac-aS in presence of different SDS concentrations. The rates have been determined from the initial slopes of the
ThT fluorescence kinetics. Error bars correspond to standard deviations from several independent measurements. (E-H) Transmission
electron microscopy images of SDS-induced aggregates of aS (E and F) and Ac-aS (G and H). Samples at 100 μM concentration were
incubated at 37˚C in presence of SDS during the times lengths and at the SDS concentrations indicated on top of each image.
https://doi.org/10.1371/journal.pone.0178576.g006
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Effects of N-acetylation in early-onset PD variants
We also explored the influence of the early-onset PD mutations A30P, E46K and A53T, on the
conformational changes and interactions of aS and Ac-aS induced by SDS by CD and DLS
measurements. In the absence of SDS, all variants have a similar disordered structure and prac-
tically identical hydrodynamic radii. None of the mutations affects noticeably the growth of α-
helical structure in the low SDS concentration range. The structural differences in the high
SDS concentration range are however more remarkable. Both the acetylated and non-acety-
lated A53T variants acquire higher α-helix content between 4 mM and 10 mM SDS than the
two WT variants (Fig 7). In contrast, the A30P variants show a more steady growth in α-helix
structure than the WT forms and do not display a clear maximum in α-helix between 4 and 10
mM SDS. The E46K variants show a conformational behavior more analogous to the WT
proteins.
According to our DLS analysis, all the PD variants form SDS-aS oligomers similar to the
WT proteins between 0.4 mM and 4 mM SDS (Fig 8). The overall evolution of the averaged Rh
with the SDS concentration is roughly similar for all the aS variants in this SDS concentration
range, with only subtle differences. Similarly to the WT variants, at low SDS/aS concentration
ratios two different particle sizes could be resolved in some DLS measurements, indicating
coexistence of monomeric protein with large oligomeric SDS-protein complexes. This is par-
ticularly evident for the non-acetylated A53T aS variant. In contrast, the formation of α-helix-
rich oligomers at high SDS concentrations is affected considerably by the mutations. The
A53T mutation clearly promotes the formation of this type of oligomeric complexes to a simi-
lar extent as the WT Ac-aS, as evidenced by the transient increase in Rh, coincidently with the
high content in α-helix observed for this variant in this concentration range. In contrast, none
of the A30P variants showed a size increase in the 4–10 mM SDS concentration range, in
agreement with the absence of transient α-helical increase. This indicates that the A30P muta-
tion inhibits this transition irrespective of the presence or absence of N-acetylation. The E46K
aS variant shows an intermediate behavior similar to the WT non-acetylated aS but in contrast
to the WT protein the N-acetylation of this variant appears to reduce the oligomerization
Fig 7. Changes in secondary structure in early-onset PD variants. Percentage of α-helix structure of
early-onset PD variants of aS (filled symbols) and Ac-aS (open symbols) at different SDS concentrations. The
values have been calculated from the mean residue ellipticity at 222 nm measured in the far-UV CD spectra
[45].
https://doi.org/10.1371/journal.pone.0178576.g007
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process. This suggests an antagonistic effect between the E46K mutation and the N-acetylation
with regards to this oligomerization transition.
The aggregation rates of the early-onset PD variants in the presence of SDS were also mea-
sured by ThT fluorescence (Fig 9 and S6 Fig). Similar to the WT variants, most the aggregation
kinetics show no lag phases but the initial aggregation rates varied considerably in measure-
ments with carefully prepared identical experiments. Nevertheless, overall effects of the muta-
tions could be observed. The maximum aggregation rates measured did not change
Fig 8. Changes in molecular size of early-onset PD variants. The apparent hydrodynamic radius (Rh) of
100 μM aS variants (left panels) or Ac-aS variants (right panels) in presence of different SDS concentrations
was measured by DLS at 25˚C. The open symbols represent the Rh of particles (left scale) corresponding to
more than 2% of the protein mass and more than 10% the scattered intensity. Measurements reporting two
different particle sizes (circles and triangles) are represented in red. The black solid line corresponds to the
intensity-averaged Rh at each SDS concentration. Closed symbols represent the mass percent of each type
of particle (right scale).
https://doi.org/10.1371/journal.pone.0178576.g008
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Fig 9. Amyloid aggregation rates of early-onset PD variants. Initial aggregation rates at 37˚C of aS and
Ac-aS PD variants in presence of different SDS concentrations were measured by ThT fluorescence. The
rates were determined from the initial slopes of the ThT fluorescence kinetics. Error bars correspond to
standard deviations from several independent measurements.
https://doi.org/10.1371/journal.pone.0178576.g009
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dramatically between the different variants but the SDS concentration range where significant
aggregation occurs was markedly different. The fastest aggregation of the A53T aS variant
occurred around 0.3–0.5 mM SDS, a concentration where a majority of the protein is mono-
meric. However, this variant aggregates over a broad range of SDS concentrations and signifi-
cant aggregation remains even up to 3 mM SDS. This may be related to the coexistence of
large oligomers and aS monomers over a relatively broad SDS concentration range as detected
by DLS for the non-acetylated A53T variant (Fig 8). N-acetylation of the A53T variant appears
to reduce only moderately the aggregation rates in the high SDS concentration range. The
A30P variants aggregate in an intermediate range of SDS concentrations, whereas the two
E46K variants only aggregate around 0.5 mM in a much narrower SDS concentration range
than the other variants. No significant changes in aggregation propensity due to N-acetylation
could be measured for these two variants. These results suggest that the protective effect of N-
acetylation against micelle-induced aggregation observed for the WT proteins is considerably
impaired for the PD variants.
Discussion
In this study we examined in detail the interactions between SDS and aS, both in its N-acety-
lated and non-acetylated forms. Many observations made in previous studies for WT non-
acetylated aS [34,36,50,51] were confirmed here but we provided new evidence highlighting an
essential role of oligomerization in a variety of interactions between aS and SDS, as well as in
the SDS-mediated aS aggregation. Fig 10 shows a schematic cartoon illustrating the proposed
conformational-oligomerization equilibria of aS and SDS at different SDS concentrations and
explaining how the interactions with SDS micelles may induce or inhibit aS aggregation
depending on the SDS/aS ratio.
Fig 10. Schematic illustration of the proposed conformational-oligomerization equilibria of aS in the
presence of different concentrations of SDS. The N-terminal lipid-binding region of aS is colored in blue,
the NAC region in green and the acidic C-terminal tail in red. Spherical SDS micelles have been depicted for
simplicity. The effect of N-acetylation and PD mutations on the amyloid aggregation rate and on the stability of
α-helix-rich oligomers is indicated with + or − symbols.
https://doi.org/10.1371/journal.pone.0178576.g010
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Under an SDS concentration threshold α-Synuclein remains as a
compact disordered monomer irrespective of N-acetylation
In a low SDS concentration range (0–0.3 mM) all the aS variants studied are mainly unstruc-
tured and monomeric. Our DLS and DOSY data did not detect any size change in either aS
or Ac-aS in this SDS concentration range. Moreover, the apparent diffusion coefficient of
SDS was not significantly reduced in presence of the proteins at 0.25 mM SDS. Therefore,
although monomeric aS may interact with SDS in this concentration range, this interaction
is likely weak and unspecific and does not induce a detectable conformational change. In
the absence of SDS, N-acetylation has been shown previously to increase the α-helical pro-
pensity at the first nine residues in WT aS and produce long-range perturbations at regions
28–31, 43–46 and 50–66 of the sequence [39]. These effects did not produce however any
detectable changes in the size or overall conformation when comparing N-acetylated and
non-acetylated aS variants. Nevertheless, these long-range links between conformational
propensities of the N-terminus and the regions of the early-onset PD mutations have been
proposed to be important in the fibrillation propensity of aS in the absence of SDS [52].
This is of interest because we observed high SDS-induced aggregation rates under condi-
tions where a large fraction of aS is still monomeric, suggesting a key role of the monomer
as substrate for aggregate growth. The importance of the ratio of monomeric to aggregated
forms for productive amyloid fibril growth and neuronal toxicity has also been highlighted
for β-amyloid peptide [53].
Mixed SDS-aS oligomeric amyloidogenic complexes form at low SDS/aS
ratios
Above 0.4–0.5 mM and up to 0.8–1 mM SDS, depending on the aS variant, there was a rapid
increase in the fraction of aS that becomes associated to SDS. This process resulted in an
increase in the average molecular size and in the overall α-helix structure. Our results show
that the maximum rate of formation of amyloid aggregates occurs when monomeric disor-
dered aS is in exchange with a significant population of large oligomeric SDS-aS complexes
where aS acquires partial α-helical structure. This supports the notion that aS clustering within
these complexes may favor the conformational conversion necessary to nucleate the amyloid
structure, which further grows by monomer incorporation. Supporting this view there is a
recent study showing that rapid aS fibrillation is nucleated on the surface of negatively charged
lipid vesicles [54]. This nucleation mechanism becomes enhanced by several orders of magni-
tude relative to other nucleation mechanisms likely due to a local concentration effect. How-
ever, productive aggregation appears to depend also on the availability of aS monomers, as
inferred by the decrease in the rates of aggregation at SDS concentrations where monomeric
aS is depleted favoring the SDS-aS complexes.
Given the key role of the SDS-aS oligomeric complexes in aggregation it is important to
discuss about their nature. Even assuming that a large fraction of SDS is bound to aS under
these conditions, a relatively low SDS/aS stoichiometry is conceivable in the oligomers
formed between 0.5 and 1 mM SDS. Also, aS still has a low level of α-helix structure (<20%)
in this SDS concentration range, which implies a relatively disordered protein in these micel-
lar complexes. Ahmad et al. [34] also reported the formation of fibrillogenic SDS-aS ensem-
bles below 2 mM SDS under conditions very similar to this study. In these complexes aS was
described as partially structured and exposing significant hydrophobic surface according to
the observed binding of bis-ANS. Giehm et al. [36] also described maximum aS fibrillation
around 0.4–0.6 mM SDS. These authors proposed a model in which fibrillogenic complexes
are formed by an average of 4 aS molecules associated to a micelle of 40–50 SDS molecules.
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On the surface of such small micelles, 4 aS molecules are likely too crowded to acquire con-
siderable α-helix structure and therefore remain relatively unstructured. The size of such a
micellar complex would be however relatively small compared to the oligomers detected
here by DLS. This suggests a self-association of SDS/aS micelles, likely mediated by hydro-
phobic collapse between unstructured aS regions and possibly involving the non-amyloid
component (NAC) region. These clusters would provide a template facilitating intermolecu-
lar interactions leading to nucleation of amyloid structure by incorporation of existing aS
monomers (Fig 10).
N-acetylation reduces the rate of amyloid nucleation but PD mutations
impair this protective effect against aggregation
In our study N-acetylation did not appear to alter dramatically the conformational- oligomeri-
zation transitions in WT aS at low SDS concentrations. We could not detect significant
changes in the onset of the formation SDS/aS complexes or in the growth of α-helical struc-
ture. However, we observed a clear reduction in the rate of amyloid aggregation induced by
SDS as a result of N-acetylation. It is likely that subtle changes produced by N-acetylation on
the conformational propensity and dynamics of the aS monomer could make it a poorer sub-
strate for amyloid nucleation, as discussed above. Another possibility is that an increase in
alpha-helical propensity at the N-terminal region produced by acetylation may become propa-
gated through the aS chain to the NAC region, enhanced by the interaction with the micelle
surface, as observed for small vesicles [55]. A higher affinity for SDS and an enhanced α-helical
structure in the SDS-bound state induced by N-acetylation, as reported elsewhere [41], may
increase the kinetic barrier of the conformational changes necessary to nucleate amyloid struc-
ture within the micellar complexes.
Similarly to the WT variants, the PD variants aggregate mostly under conditions where
monomeric aS coexists with a population of the large SDS-aS oligomer complexes. Each PD
mutation appears however to favor or disfavor this situation differently, altering the range of
SDS concentrations where aggregation occurs. The A53T variants and to a lesser extent the
A30P variants aggregate in a broader SDS concentration range than the WT forms. In contrast,
the E46K variants aggregate only in a narrow SDS concentration range. The effects of PD
mutations in the non-acetylated aS are similar to those observed for aS aggregation catalyzed
by surface of small unilamelar vesicles [56]. These effects do not correlate, however, with the
overall affinity of each variant for membrane surfaces. The A30P mutation has been reported
to decrease aS affinity for anionic phospholipids, whereas the E46K mutation enhances it and
the A53T variant shows a similar affinity to the WT form [57]. It is possible that the mutations
alter differently the structure and dynamics of the micelle-bound state, as it has been observed
for aS interactions with phospholipid vesicles [58], allowing diverse propensities to intermolec-
ular interactions. Nevertheless, N-acetylation does not appear to protect the variants against
SDS-induced aggregation as it does for WT aS. This suggests that a long-range cooperative
connection between the N-terminal region and the region mediating aggregation may be
impaired by the early-onset PD mutations.
Charge removal by N-acetylation in the context of the different PD mutations may also play
a role in changing the aggregation propensity but these effects are difficult to envisage in the
absence of more precise information about the amyloidogenic aS-SDS micelle clusters. Also,
the interactions with the negatively charged SDS head groups may play a determinant role.
Different charge-charge interactions might contribute to modify the oligomeric arrangement
of aS molecules within these complexes favoring or disfavoring the correct intermolecular con-
tacts for the nucleation process.
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An increase in SDS/aS ratio enhances SDS-aS interactions and reduces
aS aggregation
A subsequent rise in SDS concentration above 1.2–1.5 mM produced a gradual decrease in
molecular size of the SDS-aS complexes and involves additional growth in the α-helix struc-
ture. A higher availability of SDS would probably allow a reduction in the number of aS mole-
cules per micelle [36] allowing and a higher degree of α-helical folding of aS on a larger micelle
surface. In the absence of any additional transition, the progressive size decrease would con-
tinue up to 10 mM SDS and higher to reach the expected size of a SDS micelle decorated with
a single aS molecule, which should be slightly higher than the Rh of a SDS micelle (about 2.1
nm). Such behavior is actually observed for the A30P aS variants. In these compact and struc-
tured micellar complexes aS becomes protected against aggregation, as observed in all aS
variants.
N-acetylation stabilizes aS-SDS oligomeric complexes with extended α-
helical structure
In another transition between approximately 4 and 7 mM SDS, a transient maximum in α-
helix structure could also be associated to different oligomerization process, as observed by
DLS and DOSY experiments. Contrary to the first one, this transition is considerably
enhanced by N-acetylation in the WT protein. Giehm et al. [36] also observed a transient max-
imum in α-helix, which was attributed to non-fibrillogenic clusters of highly α-helical aS-deco-
rated SDS micelles. Another comprehensive study by CD of the aS-SDS interactions under a
variety of pH values and temperatures described a multistate conformational behavior of aS
under the effect of SDS binding [50]. In addition to the disordered structure, two partially
folded conformations with different α-helical content were proposed, i.e., a broken-helix
horseshoe bent structure, similar to that observed in micelle-bound aS [21], and an elongated
helical conformation, such as that observed for aS bound to small unilamellar vesicles [26].
This extended conformation was also described using pulsed dipolar ESR measurements with
doubly spin-labeled aS variants [59]. Single-molecule FRET studies using dye-labeled aS con-
firmed the existence of the micelle-bound bent and extended helical structures occurring at
different SDS concentrations [51,60].
Collectively, all this previous evidence in combination with our results indicate that aS can
transiently acquire an extended α-helical conformation at SDS concentrations near the CMC
of SDS, resulting in micelle crosslinking or micelle remodeling, giving rise to α-helix-rich olig-
omeric SDS-aS particles (Fig 10). We show here that this transition is enhanced by N-acetyla-
tion in WT aS. Assuming that the bent-to-extended conformational transition must involve α-
helical folding of the 37–45 segment in the N-terminal domain, there must be some type of
long-range connection between this region and the aS N-terminus. This sort of cooperativity
appears to be encoded in the aS sequence [39] and would also operate in the initiation and
enhancement of membrane binding [37,55].
Many studies have suggested that the actual native functional form of aS is an aggrega-
tion-resistant helical multimer [61–63], favored by N-acetylation [40,64] and a yet-to-know
additional component, likely of lipid nature [65]. In addition, the equilibrium between aS
monomers and aggregation-resistant helical multimers in vivo has been associated to a vesi-
cle clustering function of aS [63,66]. These observations may have fundamental conse-
quences to define the role of aS in PD because they suggest that dissociation and unfolding of
the helical tetramer could be an obligatory step in the formation of the pathological aggre-
gates [63].
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PD mutations strongly affect the propensity of aS to undergo a bent-to-
extended conformational-oligomerization transition
While N-acetylation of WT aS enhances the formation of extended helical oligomers, this
effect appears to be disconnected in the PD variants. The two A53T variants could form
highly alpha-helical oligomers at high SDS concentrations, independently of N-acetylation.
In contrast, none of the A30P variants could undergo this oligomerization transition. The
behavior of both E46K aS variants was similar to that of the non-acetylated WT protein but
no enhancement of the transition was observed as a result of N-acetylation. These observa-
tions are fully consistent with those observed by Ferreon et al. for the non-acetylated PD
variants [67]. Our results support the view that the PD mutations may impair the coopera-
tive connection between the N-terminal acetylation and the ability to undergo this confor-
mational-oligomerization transition.
It has been proposed that the switch between the bent and the extended conformation of aS
may have a key role for aS function in vivo by allowing the protein to bridge between different
membranes, thereby regulating synaptic vesicle fusion [59]. aS can induce membrane curva-
ture, budding and tubulation [68] and has been shown to remodel phospholipid vesicles into
cylindrical micelles, in which bound aS acquires an extended helical conformation [69]. aS has
been also shown to form membrane-bound multimers that promote SNARE complex assem-
bly during vesicle fusion [70] and aS multimerization have been proposed to be implied in the
clustering synaptic vesicles, regulating neurotransmitter release [66]. On the other hand, oligo-
mers of aS in a broken helix structure form around small lipid nanoparticles, when incubated
at low lipid/protein ratios [71]. This lipoprotein-like function has been related to intracellular
transport and metabolism of lipids. All this variety of lipid and membrane interactions are
likely to be very finely regulated in vivo and involve the concerted action of other proteins.
Therefore, besides its importance in initiating and enhancing aS membrane interactions, N-
acetylation may have an important role in finely tuning the conformational switch that allows
aS to adapt to diverse lipid and membrane contexts related to its function. In this regard,
early-onset PD variants may act by deteriorating this connection resulting in diverse deleteri-
ous effects under a variety of physiological contexts.
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Abstract: Peroxiredoxin-2 (Prx2) is the third most abundant cytoplasmic protein in red blood cells.
Prx2 belongs to a well-known family of antioxidants, the peroxiredoxins (Prxs), that are widely
expressed in mammalian cells. Prx2 is a typical, homodimeric, 2-Cys Prx that uses two cysteine
residues to accomplish the task of detoxifying a vast range of organic peroxides, H2O2, and per-
oxynitrite. Although progress has been made on functional characterization of Prx2, much still
remains to be investigated on Prx2 post-translational changes. Here, we first show that Prx2 is
Tyrosine (Tyr) phosphorylated by Syk in red cells exposed to oxidation induced by diamide. We
identified Tyr-193 in both recombinant Prx2 and native Prx2 from red cells as a specific target of Syk.
Bioinformatic analysis suggests that phosphorylation of Tyr-193 allows Prx2 conformational change
that is more favorable for its peroxidase activity. Indeed, Syk-induced Tyr phosphorylation of Prx2
enhances in vitro Prx2 activity, but also contributes to Prx2 translocation to the membrane of red cells
exposed to diamide. The biologic importance of Tyr-193 phospho-Prx2 is further supported by data
on red cells from a mouse model of humanized sickle cell disease (SCD). SCD is globally distributed,
hereditary red cell disorder, characterized by severe red cell oxidation due to the pathologic sickle
hemoglobin. SCD red cells show Tyr-phosphorylated Prx2 bound to the membrane and increased
Prx2 activity when compared to healthy erythrocytes. Collectively, our data highlight the novel link
between redox related signaling and Prx2 function in normal and diseased red cells.
Keywords: peroxiredoxin-2; tyrosine phosphorylation; Syk; sickle cell disease; oxidation
1. Introduction
Peroxiredoxin-2 (Prx2) is the third most abundant cytoplasmic protein in red blood
cells. Prx2 belongs to a well-known family of antioxidant proteins, the peroxiredoxins
(Prxs), widely expressed in mammalian cells [1–7]. Prx2 is a member of the typical,
homodimeric, 2-Cys Prxs, a wider group that uses two cysteine residues to accomplish
Antioxidants 2021, 10, 206. https://doi.org/10.3390/antiox10020206 https://www.mdpi.com/journal/antioxidants
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the task of detoxifying a vast range of organic peroxides, H2O2, and peroxynitrite. The
catalytic mechanism is characterized by a sequence of events, starting from one cysteine
sulfhydryl of the first subunit that is oxidized by the substrate, to sulfenic acid (the so-called
peroxidatic cysteine, Cys-SPH). This is then resolved by the action of a second cysteine
sulfhydryl of the cognate subunit (the so-called resolving cysteine, Cys-SRH) through the
formation of a disulfide subsequently re-reduced by the action of thioredoxin or glutathione
and glutathione reductase [2,8].
In addition to the enzymatic function, Prxs have been shown to acquire a chaper-
one function under oxidative stress conditions, and are able to interact with multiple
proteins [2,9]. Accordingly, a crucial role is played by the possibility of switching the
oligomeric structure from a homodimer to a homodecamer in the reduced state, while
sulfur oxidation of the two essential cysteine residues leads to decamer dissociation into
disulfide-linked dimers. Hyperoxidation of the peroxidatic cysteine (Cys-SPO2H) leads to
the formation of catalytically inactive, high-molecular-weight oligomers with chaperone
function [2]. Since redox conditions are so crucial for cell viability, it is not strange that
Prxs could be highly regulated by several modifications, such as phosphorylation, acetyla-
tion, glutathionylation, and nitrosylation. Prx1 and Prx2 exhibit particular sensitivity to
post-translational changes [8,10,11].
Focusing on phosphorylation, Prx1 has been reported to be phosphorylated both
on tyrosine (Tyr) and on threonine/serine residues. Although several phosphorylation
sites of Prx1 have been identified, limited data are available on their impact on Prx1
function [10,12]. Concerning Prx2, several threonine/serine residues and only one Tyr
residue (Tyr-193) have been identified as being phosphorylated [12]. We carried out a
revision of the literature and found Tyr-193 to be the most frequently tyrosine residue
identified as phosphorylated in Prx2, suggesting a possible biologic importance of this
post-translation modification for Prx2 function (Figure 1).
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Previous studies have shown that changes in the phosphorylation of Prxs might affect
not only their activity, but also their molecular size, by shifting the dimer–decamer protein
equilibrium to an inactive, high-molecular-weight decamer species with a chaperone
function [12]. This suggests a possible link between oligomerization, peroxidase activity,
chaperone activity, and post-translational modifications.
Red cells are an exceptional model to study Prx2 function and post-translational
modifications, due to their highly oxidative physiologic environment. Recently, we have
shown that Prx2 is important in both red cells and erythropoiesis to ensure cell survival,
growth, and differentiation against physiologic and pathologic oxidation [13–16]. In addi-
tion, we found that Prx2 might act as a chaperone-like protein targeting key membrane
proteins, such as band 3, against oxidation [17–19]. Indeed, mice genetically lacking Prx2
display accelerated red cell senescence. This is associated with an overactivated Syk
kinase-dependent intracellular signaling pathway, ending with the release of erythroid
microparticles to clear damaged proteins [17–20]. In red cells, the biologic importance of
redox-related signaling pathways is supported by studies in red cells from both animal
models and human subjects with hemoglobinopathies or glucose 6-phosphate dehydro-
genase G6PD deficiency [13–15,17,21,22]. In response to oxidation, Syk translocates to the
membrane and favors band 3 clusterization, resulting in erythroid vesiculation followed by
red cell membrane rearrangement [17–19]. This mechanism is important in pathologic red
cells, such as in β-thalassemia, or in sickle cell disease (SCD) [14,17,20]. Both conditions are
characterized by severe membrane oxidation and activation of the intracellular Syk signal-
ing pathway [14,17,20]. In red cells from a mouse model of SCD, we previously reported a
membrane translocation of Prx2 in response to oxidation related to hypoxia/reoxygenation
stress, mimicking sickle cell-related vaso-occlusive crisis [22,23]. This suggests a possible
connection between the redox-related signaling pathway and Prx2 in both normal red cells
exposed to exogenous oxidation and pathologic erythrocytes, such as in SCD.
Here, we first found that Prx2 is Tyr-phosphorylated in response to oxidation and
translocates to the membrane. We identified Tyr-193 on Prx2 as specific target of Syk kinase,
resulting in increased Prx2 activity. The bioinformatic analysis revealed that Tyr-193 is
involved in the conformational changes that Prx2 undergoes during catalysis. The biologic
importance of phosphorylated, active Prx2 is further supported by the observation of
phospho-Prx2 bound to the membrane that is associated with increased Prx2 activity in
sickle red cells. Taken together, our data show that Tyr-phosphorylation of Prx2 contributes
to activating Prx2, and to partitioning Prx2 between the cytoplasm and membrane, thus
participating in redox-related signaling machinery linking the Syk pathway to Prx2 post-
translational changes in normal and diseased red cells.
2. Materials and Methods
2.1. Mouse Strains and Design of the Study
The Institutional Animal Experimental Committee of University of Verona (CIRSAL) and
the Italian Ministry of Health approved the experimental protocols (prot. 56DC9.21). Three-
month old C57B6/2J wild-type (WT) mice and SCD (Hbatm1(HBA)Tow Hbbtm2(HBG1,HBB*)Tow) mice
were studied [24–26]. Whenever indicated, red cells underwent to in vitro treatments with oxida-
tive agents or specific inhibitors [17,27,28]; details are reported in the Supplementary Materials.
2.2. Two-Dimensional Electrophoresis, Phosphoprotein Enrichement, Western-Blot Analysis, and
Immunoprecipitation Assay
Red cell membrane (ghost) and cytosol fractions were obtained as previously re-
ported [13,15,26,29,30] (Figure S1).
2.2.1. Two-Dimensional Electrophoresis (2D) Analysis
Red cell membrane proteins underwent two-dimensional electrophoresis (2D) analysis
and separated, in the first dimension, onto a 3.0–5.6 immobilized pH gradient IPG strip, and
in the second dimension, by SDS-PAGE [31]. Details are in the Supplementary Materials.
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2.2.2. Phosphoprotein-Enriched Samples
Phosphoprotein-enriched samples were generated from red cell membrane protein
extracts using a TALON PMAC Phosphoprotein Enrichment Kit (ClonTech, CA, USA)
according to the manufacturer’s instructions [32,33].
2.2.3. Western-Blot Analysis and Immunoprecipitation Assay
Red cell membrane (ghost) and cytosol fractions were analyzed by SDS-
PAGE [13,15,26,29,30]. Gels were transferred to nitrocellulose membranes for immunoblot
analysis with specific antibodies. Details are in the Supplementary Materials. Immuno-
precipitations of anti-phospho-Tyr proteins from red cells were carried out using Protein
A Agarose (Thermo Fisher Scientific, Waltham, Massachusetts, United States), as well
as a mix of the anti phospho-Tyrosine monoclonal antibodies PY99 (Santa Cruz Biotech-
nology, Dallas, TX, USA) and 4G10 (Merck Group, Darmstadt, Germany) as previously
reported [17].
2.3. Generation of Recombinant Prx2 and In Vitro Prx2 Activity
Human WT Prx2 and mutated Prx2-Y193F and Prx2-Y115F were cloned in a pET15b
vector to produce the recombinant enzymes. Details are reported in the Supplementary
Materials. Prx2 activity of recombinant enzyme (both of the control and the phosphory-
lated enzyme) was performed according to the basic protocol IV reported in Nelson and
Parsonage [34], with minor modifications (see Figure S2 and Supplementary Materials).
2.4. Mass Spectrometry
Proteins were either analyzed by a Tofspec SE (Micromass, Manchester, United King-
dom) and a LTQ Orbitrap XL Hybrid Ion Trap-Orbitrap Mass Spectrometer (Thermo Fisher
Scientific, Bremen, Germany). Details are reported in the Supplementary Materials.
2.5. Bioinformatic Analysis
Structural analysis of the Prx2 active site in its hyperoxidized (PDB = 1qmv) and
oxidized disulfide form (PDB = 5ijt) was carried out using Pymol 2.0 (PyMOL Molecular
Graphics System, Version 2.0 Schrödinger Inc, New York, NY, United States). In order to
simplify the representation, only a dimer for each decamer is shown.
2.6. Prx2 Activity on Mouse Red Cells
Enzymatic activity of Prx2 on red cells from wild-type and humanized sickle cell [24,25]
mice was assayed, as previously reported [15] in the presence of the coupled assay thiore-
doxin, thioredoxin reductase, and NADPH. The relative activity was determined by mea-
suring the ∆A/min at 340 nm of 10 µL of samples for both WT and SCD, considering as a
reference the activity of WT as 100% of peroxidase activity.
2.7. Statistical Analysis
Data were analyzed using either a t-test or one-way ANOVA for longitudinal stud-
ies, or one-way ANOVA for multiple comparisons. A difference with p < 0.05 was
considered significant.
3. Results
3.1. Prx2 Is Tyrosine-Phosphorylated in Response to Oxidation and Associates to the Membrane
To address the question of whether post-translational modification might affect Prx2
in response to oxidation, we exposed wild-type mouse erythrocytes to diamide, an oxi-
dant known to promote red cell membrane damage, requiring Prx2 membrane transloca-
tion [13,17]. We performed 2DE analysis of the membrane fraction (ghost) from mouse
red cells treated with either vehicle or diamide (2 mM) [13,14]. Prx2 was identified by
mass-spectrometric analysis in both vehicle- and diamide-treated red cells (AC #Q61171,
Prdx2_mouse; the vehicle matched 5 peptides, with coverage of 24%, while the Prx2 di-
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amide matched 4 peptides, with coverage of 22%) (Figure 2a). The immunoblot analysis
carried out in twin-gels revealed the presence of trains of Prx2, which were left shifted in
red cells treated with diamide when compared to vehicle-treated erythrocytes, suggesting a
possible post-translational Prx2 modification, such as phosphorylation (Figure 2a). This in-
trigued us, since previous studies on Tyr-phospho-maps of red cells from both healthy mice
and human subjects did not find phospho-Tyr–Prx2 associated with the membrane [14,31].
We then carried out phospho-peptide enrichment using a phospho-specific metal ion affin-
ity resin (TALON PMAC Phosphoprotein Enrichment Kit) of mouse red cells exposed to
diamide [32,33]. Prx2 was identified by MALDI-TOF analysis and further confirmed by
LC-MS/MS analysis (Figure 2b).
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following peptides: RGLFIIDAKG; KNDEGIAYRG; KSLSQNYGVLKN; RQITVNDLPVGRS; K.SAPDFTATAVVDGAFKE.
Since Syk is the key kinase i red cell signaling networks in onse to oxida-
tion, we have explored the Syk pathway in diamide-treate erythrocyte with respect to
Prx2 [17–19,31,35]. As shown in Figure 3a, Syk was activated in diamide-treated red cells,
compared to vehicle-treated erythrocytes. The amount of active phospho-Syk was further
increased in the presence of NaVO4, blocking families of phosphatases (Figure 3a). No ma-
jor change was observed in Syk activity in H2O2-treated erythrocytes (Figure 3a) [13,17,28].
Thus, we focused on diamide-treated red cells. As shown in Figure 3b, we found increased
membrane association of both Tyr-phosphorylated Prx2, corresponding to almost 47% of
total membrane-bound Prx2, and Syk in response to oxidation when compared to vehicle-
treated erythrocytes. This was paralleled with increased Tyr phosphorylation of Prx2, also
in the cytoplasmatic compartment of diamide-treated red cells (corresponding to 3% of
total cytoplasmic Prx2; Figure 3b, see also Figure S3a).
Antioxidants 2021, 10, 206 6 of 16
Antioxidants 2021, 10, x 6 of 16 
 
found increased membrane association of both Tyr-phosphorylated Prx2, corresponding 
to almost 47% of total membrane-bound Prx2, and Syk in response to oxidation when 
compared to vehicle-treated erythrocytes. This was paralleled with increased Tyr 
phosphorylation of Prx2, also in the cytoplasmatic compartment of diamide-treated red 
cells (corresponding to 3% of total cytoplasmic Prx2; Figure 3b, see also Figure S3a).  
 
 
Figure 3. Prx2 is Tyr-phosphorylated in diamide-treated red cells, characterized by activation of the Syk canonical pathway. (a) 
Upper panel: Western blot (Wb) analysis with specific antibodies against P-Syk and Syk of the cytosolic fraction from red cells 
of WT mice treated with vehicle or diamide, NAVO4, and/or H2O2. Band 3 is used as loading control. One representative gel 
from other four with similar results is presented. Lower panel: densitometric analysis is presented as means ± standard error of 
the mean (SEM) (n = 4); * p < 0.05 compared to vehicle-treated red cells. (b) Upper panel: ghost and cytosol fractions from red 
cells of wild-type (WT) mice treated with either vehicle or diamide underwent immunoprecipitation with specific anti-phospho-
tyrosine antibodies (IP: pY), and were then revealed with specific anti-Prx2 or anti-P-Syk antibodies. Band 3 and catalase, as 
well as colloidal Coomassie-stained gels (see Figure S3a) in whole-cell lysate (WCL), were used as loading controls. One 
representative gel from the other four with similar results is presented (see also Figure S3a). Lower panel: densitometric analysis 
is presented as means ± SEM (n = 4); * p < 0.05 compared to vehicle treated red cells. 
To explore whether the membrane translocation of phospho-Prx2 was dependent on 
Syk activation, we used specific inhibitors for either Syk or Src family kinases, such as PP1 
and PP2. As shown in Figure 4a, Syk inhibitors I–II fully blocked Prx2 phosphorylation 
and Prx2 membrane translocation. However, PP1 and PP2 did not modify the amount of 
Tyr-phosphorylated Prx2 associated with the membrane of diamide-treated red cells 
(Figure 4a). The oxidative dependent compartmentalization of Prx2 was further 
supported by the observation that dithiotretol (DTT), a known thiol group donor, 
prevented the membrane association of Tyr-phosphorylated Prx2 (Figure 4b) [15,21]. 
Noteworthily, Prx2 was associated with the membrane as both a monomer and dimer in 
diamide-treated red cells, and DTT again prevented Prx2 dimer formation, as previously 
reported by us [13,36] (Figure S3b). Taken together, our data suggest that Prx2 is Tyr-
phosphorylated by Syk in response to oxidation, binding to the membrane of diamide-
treated red cells.  
Figure 3. Prx2 is Tyr-phosphorylated in diamid -tr ated red cells, characterized by activation of the Syk ca onical pathway.
(a) Upper panel: Western blot (Wb) analysis with specific antibodie against P-Syk and Syk of the cytosolic fraction from
red cells of WT mice treated with vehicle or diamide, NAV 4, and/or H2O2. Band 3 is used as loading control. One
representative gel from other four with similar results is presented. Lower panel: densitometric analysis is presented
as means ± standard error of the mean (SEM) (n = 4); * p < 0.05 compared to vehicle-treated red cells. (b) Upper panel:
ghost and cytosol fractions from red cells of wild-type (WT) mice treated with either vehicle or diamide underwent
immunoprecipitation with specific anti-phospho-tyrosine antibodies (IP: pY), and were then revealed with specific anti-Prx2
or anti-P-Syk antibodies. Band 3 and catalase, as well as colloidal Coomassie-stained gels (see Figure S3a) in whole-cell
lysate (WCL), were used as loading controls. One representative gel from the other four with similar results is presented
(see also Figure S3a). Lower panel: densitometric analysis is presented as means ± SEM (n = 4); * p < 0.05 compared to
vehicle treated red cells.
To explore whether the membrane translocation of phospho-Prx2 was dependent on
Syk activation, we used specific inhibitors for either Syk or Src family kinases, such as PP1
and PP2. As shown in Figure 4a, Syk inhibitors I–II fully blocked Prx2 phosphorylation
and Prx2 membrane translocation. However, PP1 and PP2 did not modify the amount
of Tyr-phosphorylated Prx2 associated with the membrane of diamide-treated red cells
(Figure 4a). The oxidative dependent compartmentalization of Prx2 was further supported
by the observation that dithiotretol (DTT), a known thiol group donor, prevented the
membrane association of Tyr-phosphorylated Prx2 (Figure 4b) [15,21]. Noteworthily, Prx2
was associated with the membrane as both a monomer and dimer in diamide-treated red
cells, and DTT again prevented Prx2 dimer formation, as previously reported by us [13,36]
(Figure S3b). Taken together, our data suggest that Prx2 is Tyr-phosphorylated by Syk in
response to oxidation, binding to the membrane of diamide-treated red cells.
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3.2. Syk Phosphorylates Prx2, Resulting in an Increase in Prx2 Activity
To define the contribution of Syk in the phosphorylation of Prx2, recombinant Prx2
underwent in vitro phosphorylation assays in the presence of equal units of Syk or some of
members of the Src family (Src family kinases, or SFKs), which are known to be sensitive to
PP1/PP2s, such as Lyn, Fyn, or Fgr [37,38] (see Materials and Methods for experimental
details and the source of the enzymes). The mixture was then resolved by SDS-PAGE
and visualized by autoradiography. As shown in Figure 5a, Syk was able to abundantly
phosphorylate Prx2 (lane 1), whereas out of the SFKs added to the kinase mixture, Fyn
only phosphorylated Prx2 to a comparable extent (lane 5). On the other hand, the Prx2
phosphorylation by Lyn and Fgr was negligible (lanes 3 and 5). These results support
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the notion that the substrate specificity of SFKs can widely vary, as further highlighted
recently [36–38]. That the incorporation of 32P labels had occurred on tyrosine residues was
further confirmed by Western blot analysis of Prx2 with anti-phospho-tyrosine antibodies
(Figure 5b). Afterwards, to determine the level of incorporation of phosphate onto Prx2,
time-course phosphorylation in the presence of either enzyme was performed for one hour,
with single aliquots being drawn at discrete time points to be analyzed by autoradiography
after SDS-PAGE (data not shown). The bands corresponding to Prx2 were excised, and the
32P radioactivity was determined by Cerenkov counting (Figure 5c, upper panel), the molar
ratio of phosphate bound to Prx2 being found to be approximately 0.88:1.00. In addition, to
assess the role of phosphorylation on Prx2 by Syk, the peroxidase activity was determined
on Prx2 previously subjected to nearly exhaustive phosphorylation under the conditions
described above. Results shown in Figure 5c clearly highlight that the phosphorylation
of Prx2 increases its enzyme activity 2.3-fold, compared to the non-phosphorylated form
of the enzyme. Noteworthily, the Prx2-specific activity here reported is comparable to
that described for other Prx preparations with the same assay method, using DTT as a
reducing agent [39]. Whereas we used the Trx–TrxR reducing system in red cell preparation
(see Figure below). This method usually obtains more highly specific activities compared
to the DTT system [39]. Independent of the method, the main result to consider is the
increase of Prx2 activity, due to the phosphorylation of the enzyme compared to the
non-phosphorylated form.
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Figure 5. Prx2 activity is affected by Syk-mediated phosphor latio . (a) per panel: Prx2 (0.4 µg) was phosphorylated
in the presence or absence of eith (lanes 1–2), Lyn (lanes 3–4), Fyn (lanes 5–6), or Fgr (lanes 7–8) (see Materials
and Methods for further details) for 10 min, resolved by SDS-PAGE, and visualized by autoradiography. Lower panel:
densitometric analysis is presented as means ± SEM (n = 3); * p < 0.05 compared to vehicle-treated red cells. (b) Upper
panel: tyrosine phosphorylation of Prx2 and autophosphorylation of Syk or Fyn was assessed by Western blot analysis with
anti-phosphotyrosine antibody after separation on SDS-PAGE, transfer onto nitrocellulose, and reveal by ECL peroxidase
assay. Lower panel: densitometric analysis is resented s means ± SEM (n = 3); * p < 0.05 compared to vehicle-treated
red cells. (c) Time course of Prx2 phosph rylation by Syk and Fyn. Values are the mean ± SEM of four determinations
performed at each time point. (d) Enzymatic activity of Prx2 before (vehicle) and after phosphorylation by Syk. Values are
the mean ± SEM (n = 4; * p < 0.01 compared to control Prx2 by Student’s t-test).
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3.3. Syk Specifically Targets Tyr-193 Residues on Prx2
We then carried out phospho-proteomic analysis of recombinant Prx2 in vitro, phos-
phorylated by either Syk or Fyn, a Tyr-kinase of the Src family. Following Syk incubation,
Prx2 was digested with trypsin and AspN, and the resulting peptide mixture was directly
analyzed by LC-MS/MS. Mass spectral data showed the occurrence of a triply charged
mass signal at m/z 655.96, corresponding to the peptide DTIKPNVDDSKEYFSK, with a
mass increase of 80 Da, thus suggesting the presence of a phosphate group. Figure 6 shows
the partial MS/MS spectrum of the triply charged ion at m/z 655.96, showing the occur-
rence of both the y and b ion series that confirmed the peptide sequence. As highlighted in
the figure, the 243 Da mass difference between the y ions at m/z 624.25 (y4) and 381.20 (y3)
unambiguously located the phospho-Tyr residue at position 193. Noteworthily, Tyr-193
was also identified in immune-enriched Prx2 from diamide-treated red cells, supporting
the biologic importance of Tyr 193 in Prx2 function against oxidation.
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Figure 6. Identification of Tyr-193 on Syk-phosphorylated recombinant Prx2. Partial MS/MS spectrum of the triply charged
ion at m/z 655.96 from the tryptic and AspN double digest of Prx2 following Syk incubation. Manual inspection of the y
and b fragment i n serie confirmed the peptide sequence. The mass difference between the y4 and y3 ions unambiguously
indicate the occurrence of a phosphoTyr residue at position 193.
Similarly, the LC-MS/MS analysis of the tryptic peptides from Prx2 incubated with
Fyn revealed the occurrence of a mass signal at m/z 630.31 that was assigned to the doubly
charged phosphorylated peptide RLSEDYGVLK bearing a phosphate group. The corre-
sponding MS/MS spectrum reported in Figure S4 showed the occurrence of a phosphoTyr
residue at position 115, as demonstrated by the mass difference of 243 Da between the y
ions at m/z 844.32 and 601.30.
3.4. Tyr-193 Is Positioned in Proximity to the Active Site of Prx2
A structural inspection of Prx2 in its hyperoxidized (mimicking the reduced) state
shows that Tyr-193 is part of an extensive hydrogen bond network in place concurrent
with both the resolving Cys-172 (Figure 7a) and the buried catalytic Cys-51 (present in
this structure as hyperoxidated C-SPO2H)) (Figure 7b). In detail, Tyr-193 belongs to the
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important structural YF motif on the C-terminal helix interacting with Phe-194, and is
base-stacked to His-197 and on the same helix. His-197, in turn, stabilizes a loop containing
Trp-176 by subsequential interactions with Asp-181 and Ser-180. In this conformation,
Cys-51 and Cys-172 are ~13.4 Å distant, as visible in Figure 7b. Sulfinic Cys-51-SP-O2H
(mimicking Cys-SPH-51) is buried into the active site and stabilized by a network of
interactions with Arg-127, and with a water molecule that is coordinated also by Thr-48,
Phe-49, and Val-50. The formation of the inter-subunit disulfide bond (Cys-51–SP–SR–Cys-
172) leads to a local unfolding of the C-terminal region: the Trp-176 of one monomer moves
~18 Å apart and is packed in proximity of the GGLG motif of the second monomer, as
shown in Figure 7c. The rearrangement of the C-terminal coil causes a disruption of the
Tyr-193 interactions, and the YF motif completely loses its helical structure and electron
density. Arg-127 is displaced, and Phe-49 is shifted 5.4 Å.
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Based on our experimental data and the bioinformatic analysis, we argue that negative
charges introduced on the hydroxyl moiety of Tyr-193 upon phosphorylation would on
one side preserve the polar environment, and on the other impair the extensive network
of interactions of the C-terminal domain. It follows that phosphorylated Try-193 could
positively concur with the fully folded-to-locally unfolded conversion.
3.5. Red Cells from a Humanized Mouse Model of Sickle Cell Disease Display Tyr-Phosphorylated
Prx2 Associated with the Membrane
To understand the biologic importance of Prx2 Tyr-phosphorylation in pathologic red
cells, we studied eryt rocytes from a humanized mouse model of SCD [24,25].
SCD is a globall distributed hereditary red cell dis rder. is character-
ized by presence of the pathologic hemoglobin S (HbS), which polymerizes when
deoxyg nated [24,25,40–42]. This promotes a severe red cell membran oxidativ dam-
age, resulting in activation of Syk, agg gation of band 3, and membr ne transloca on of
Prx2 [14,22]. In red cells from humanized SCD mice, w observed increased membrane
translocati n of Prx2 when compared to healthy mice (Figure 8a). Prx2 was present as
both a mo omer nd dimer only in sickle red cells when compa d to healthy erythrocyt s.
Noteworthily, we observ high molecular polymers of band 3 again in SCD red ce ls
hen compared to healthy e ythrocyte , in agreement with previous r ports o me brane
oxidation of SCD red cells [22] (Figure 8a). Indeed, w f und sulfonate Prx in both the
cytosol and membrane compartments in SCD red cells, but not i healthy er thr cytes
(Figure S5a). We then evaluated th amount of phosp o-Prx2 in both healthy and CD
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erythrocytes. As shown in Figure 8b, we observed membrane translocation of both active
Syk and Tyr-phosphorylated Prx2 only in SCD red cells. The enzymatic activity of Prx2 was
increased by a factor of 3.6-fold in SCD red cells with respect to healthy erythrocytes, under-
lining the contribution of overactivation of Prx2 as phosphoPrx2 to face severe oxidation in
SCD red cells.
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4. Discussion
Here, we show for the first time that Prx2 is Tyr-phosphorylated in red cells in response
to either exogenous oxidation by diamide or endogenous oxidation, such as in sickle red
cells. We found that Syk specifically phosphorylates Prx2 at Tyr-193, resulting in increased
Prx2 activity. This is extremely interesting, since Prx2 is the third most abunda t protein
in red cells, playing a key role in the antioxidant syst m and as an atypical chaperone in
normal and diseased erythrocytes [17,36,40].
To date, Prx2 function has been mainly r lat d to th redox state of the sential
cysteine residues that are directly involved in the peroxid se activity of Prx2 in response
to oxidation. Our in vitro tudies with recombinan Prx2 have allowed us to identify
Syk and Fyn as candidate ki ases capable of phosphorylat ng Prx2. Indeed, we found
Syk to phosphorylate Tyr-193 and Fyn to phosphorylate Tyr-115 re idues on Prx2. Our
attention was captured by Syk, since the amount of Prx2 phosphor lated by this Tyr
kinase in vit o was large than that phosphorylated by Fyn (Figure 5). In addition, Tyr-
115 s ems less importan in relation to Prx2 fu ctio , si c this residue is located i a
hy rophobic cleft remote from the active site, its position remaining u changed b th
in the redu ed and oxidized form of Prx2 (Figure S6). On the other hand, Tyr-193 is
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situated in a key region, both for the catalytic activity and for the control of the oligomeric
structure. Indeed, Syk-mediated Tyr-phosphorylation of Prx2 enhances Prx2 activity, as
observed using recombinant Prx2 and confirmed by testing the activity of Prx2 from red
cells exposed to oxidation (diamide). Tyr-193 is highly mobile, shifting from the ordered,
fully folded, reduced state to the locally unfolded, disulfide-oxidized form, as shown
by the bioinformatic analyses; it is able to re-order at the end of the catalytic cycle. If
the sulfenic cysteine undergoes hyper-oxidation, Tyr-193 is responsible for an extensive
network of H bonds, which help to stabilize the decameric assembly, thus the chaperone
activity. It is possible that Tyr-193, when phosphorylated, contributes less to the rigid,
fully folded form, thus allowing catalysis to occur in a favorite manner. In this sense,
its post-translational, modified state helps to keep red cells more protected in highly
oxidative conditions, preventing hyper-oxidation by increasing the partition ratio towards
peroxidase rather than chaperone activity. In this sense, the oligomer-to-dimer equilibrium
is more easily achieved at each catalytic cycle, and high molecular weight aggregates are
unfavorably generated.
The biologic importance of Tyr-193, and of its neighboring residues Lys-196 or Phe-
194, located in the C-terminus of Prx2, has been also suggested by studies, both in the
recombinant form and in different cell lines. Although functional studies are limited,
Randall et al. have reported that Prx2 nitration on Tyr-193 results in increased Prx2
activity, associated with increased resistance of Prx2 to overoxidation [12,43]. In our model,
the effects of the phosphorylation of Tyr-193 on Prx2 activity are presented using both
native and recombinant Prx2. Interestingly, there is an increase in activity following the
phosphorylation of Tyr-193, analogous to nitration of the same residue [43], thus suggesting
that the modification of this residue, due to the addition of a negative moiety and the
related structural effect, could play a key role in strengthening the peroxidase activity.
Since red cells should survive 120 days in the peripheral circulation, an efficient
antioxidant and chaperone machinery is required. The functional link between Syk and
Prx2 ends in empowering Prx2 activity and contributes to ensure the survival of red cells
against exogenous or endogenous oxidation, respectively induced by oxidative agents,
such as diamide, or pathologic hemoglobin, such as in SCD.
In erythrocytes, Syk plays a crucial role in transduction cell signaling against oxidation.
We have previously shown that Syk overactivation favors band 3 clusterization, allowing
the release of erythroid microparticles and red cell membrane rearrangement. In addition,
oxidation might also affect band 3 function as an anion exchanger [27,44,45]. Exogenous
antioxidants, such as curcumin or melatonin, as well as the potentiation of endogenous
cytoprotectors like PEP-Prx2, might prevent or limit band 3 oxidative damage, preserving
band 3 structure and function [17,44,45]. Here, we observe that diamide strongly activates
Syk, whereas H2O2 slightly changes the amount of active Syk. Noteworthily, diamide
targets proteins thiol groups promoting S-thiolation, whereas H2O2 irreversibly oxidizes
sulfhydryl groups to sulfinic or sulfonic acid, leading to a peroxidase-incompetent Prx2.
Indeed, diamide promotes diamide cross-linking of band 3 with generation of oligomeric
structures that are Tyr-phophorylated by Syk [18,19]. This requires that phospho-Prx2, the
more active form of Prx2, is located at the red cell membrane. Indeed, our observations
suggest that Tyr-phosphorylated Prx2 translocates to the membrane. However, we cannot
exclude Tyr phosphorylation of the small amount of Prx2 already bound to the membrane,
as the method employed is not sensitive enough to dissect these events. The membrane
localization of more active Prx2 might represent a back-up mechanism to locally minimize
oxidative damage of membrane proteins, such as band 3. In agreement, band 3 was found
mainly in oligomeric state, as clusterized band 3, in sickle red cell membrane, which
showed increased phospho-Prx2 bound to the membrane (Figure 9).
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partmentalization of Prx2 to the red cell membrane and Prx2 activity, representing a back-up mechanism to locally mini-
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burden, the infected erythrocytes over-activate Syk that promotes band 3 clusterization 
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tri ers activation, resulting in increased tyrosine (Tyr) band 3 (B3) phosphorylation (PY). This modulates B3 interaction
with neighboring proteins, such as band 4.1, band 4.2, adducin, or ankyrin. These multiprotein complexes bridging the
m brane to the cytoskeleton contribute to the membrane’s mechanical instability. Diseased red cells, such as i i l
cell disease (SC ), are characterized by severe oxidation. This results in embrane damage and the overactivation of
Syk. The damaged, over-Tyr-phosphorylated B3 forms clusters, which favor erythroid vesicle release and the fast removal
of the damaged red cells by splenic macrophages. Under oxidative stress, Syk targets also Prx2. This affects both the
compartmentalization of Prx2 to the red cell membrane and Prx2 activity, representing a back-up mechanism to locally
minimize oxidative damage of the membrane proteins, such as band 3.
Our data are also important in the unique biologic context of malaria, when Plasmodium
imposes a strong oxidative stress on the host red cells [19,35,46]. To counteract this burden,
the infected erythrocytes over-activate Syk that promotes band 3 clusterization with the
release of erythroid microparticles. The erythrocyte ability to face oxidation is also vital
for parasite blood stage. Noteworthy, Plasmodium has been reported to recruit Prx2 from
red cells, most likely to potentiate its own defense [47,48]. The importance of Prx2 for
Plasmodium is further supported by the observation that parasite growth is prevented in red
cells with inhibited Prx2 [47,48]. Recently, we reported that pharmacologic Syk inhibitors,
such as imatinib, might represent a novel and interesting new therapeutic option for the
design of host-directed intervention strategies. Imatinib potentiates the action of standard
malaria treatment with artemisinin, allowing ore rapid parasite clearance [19,35,46]. Our
novel data on Syk-dependent Tyr phosphorylation of Prx2 add a new piece of knowledge
to the molecular mechanis s of malaria infestation, e phasizing at least two functional
targets of therapeutic Syk inhibition in malaria parasite red cells, namely band 3 and Prx2.
Due to the ever-increasing knowledge regarding this complex family of biological
sensors, the Prxs, endowed with both catalytical n regulation activities, this study might
offer new importa t information n Prx2 functio and regulation, as well a i s crosstalk
with red cell membra es in normal and diseased red cells, such as with SCD. However,
some other points in th progression of this inv stigation could be addressed, such as the
absence of mutagenesis experiments and the developme t f an anti-phspho-Tyr-193 Prx2
ntibody to be us d in different xperimental conditions, in order to furt er functionally
characterize the role of Tyr-193 Prx2 n different pathologic ed cells. In addition, it is
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possible that phosphorylated Prx2 is a small fraction of the total pool, and the site of
phosphorylation (cytosol or membrane) of Prx2 has not been identified. These points are
worth addressing in future investigations.
In fact, further studies are required to fully characterize phospho-Prx2 in both normal
and diseased red cells. In addition, the potentiation of endogenous antioxidant systems
by the modulation of intracellular signaling might represent an interesting new frontier of
investigation.
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(Wb) analysis with specific antibody against Prx2 of supernatant from immuno-precipitation assays,
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